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1.1 Abstract
Cancer is a complex disease, in which cells progressively accumulate mutations
disrupting their cellular processes. A fraction of these mutations drive tumourigen-
esis by affecting oncogenes or tumour suppressor genes, but many mutations are
passengers that do not actively contribute to tumour development. The advancement
of DNA/RNA sequencing technologies has enabled in-depth analysis of thousands of
human tumours from various tissues to perform systematic characterization of their
genomes/transcriptomes and to identify (epi)genetic changes associated with cancer.
Combined with appreciable progress in algorithmic development, this expansion in
scale has resulted in the identification of many cancer-associated mutations, genes
and pathways that are considered to be (potential) drivers of tumour development.
However, it remains challenging to systematically identify drivers in complex am-
plicons or deletions of copy number driven tumours, in non-coding regions of the
genome and drivers affected by complex structural rearrangements. Furthermore,
functional characterization of drivers, including their underlying biological mech-
anism and their effects on tumour evolution, is challenging in the human context
due to the lack of genetically tractable experimental model systems in which the
effects of drivers can be studied in the context of their tumour microenvironment.
In this respect, mouse models of human cancer provide unique opportunities for
pinpointing novel driver genes and detailed characterization of these genes. In this
review, we provide an overview of approaches for complementing human studies
with data from mouse models. We also discuss technological developments for
cancer gene discovery and validation in mice.
1.2 Introduction
Cancer is a disease in which normal cells are deregulated by disruption of their
cellular processes, resulting in increased proliferation, survival and invasion of
surrounding tissues. This disruption is generally attributed to mutations in so-
called ‘driver’ genes, which provide cells with a selective growth advantage and
thereby drive their malignant transformation. Broadly speaking, driver genes can be
divided into two classes of genes: oncogenes and tumour suppressor genes (TSGs)1.
Oncogenes drive tumour development when activated by their mutations and are
typically involved in processes related to proliferation2, whereas TSGs are inactivated
during tumourigenesis and are generally involved in processes protecting cells from
DNA damage and malignant transformation.
Tumours are however mostly not the product of single mutations, but develop
progressively over time through the accumulation of multiple mutations. Depending
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on the affected gene(s), these mutations can increase the fitness or tumourigenic
potential of cells (additional driver mutations), or have no effect on tumourigenesis
(passenger mutations). Over time, this accumulation gives rise to subpopulations
of cells (subclones) harbouring distinct sets of mutations, which are subject to
Darwinian competition (clonal evolution) within the tumour lesion3 (Figure 1.1).
This competition pressures cells to acquire further mutations, resulting in increased
fitness and the continued evolution of competing subclones within the tumour.
External influences such as the immune micro-environment or drug treatment can
also strongly influence the evolutionary process, either by selecting for specific
subclones that are intrinsically resistant to immune surveillance or treatment, or
by applying additional evolutionary pressure to acquire new mutations that confer
resistance4.
To effectively treat patients using precision medicine, in which treatments are
tailored to target specific mutations that are present in a patient’s tumour, it is crucial
to identify exactly which mutations contribute to tumourigenesis and how they
do so. However, although human sequencing studies have identified many genes
contributing to cancer development, they do not provide evidence for causality or
detailed insight into the biological mechanisms by which these genes drive tumour
development. These studies also do not reveal whether drivers are essential for
tumour maintenance and may therefore be of limited use for designing effective
therapeutic strategies. In contrast, preclinical model systems such as genetically
engineered mouse models (GEMMs) provide an experimentally tractable approach,
in which the biological effects of specific mutations can be studied in more detail in a
controlled genetic background. In this review, we describe several aspects of mouse
models and how these can ultimately be applied to improve treatment of cancer
patients. To this end, we first highlight several challenges in translating findings
from human sequencing studies to the clinical setting, before explaining how some
of these challenges can be addressed using complementary approaches in mouse
model systems.
1.3 Challenges in human tumour sequencing
studies
Several major human sequencing studies have been undertaken over the past years,
aiming to identify and catalogue potential driver mutations across many different
cancer types5–8. One of the key challenges in analyzing data from these efforts has
been the separation of driver mutations from passenger mutations. To address this
issue, many computational approaches have been developed to select driver genes
using signals of positive selection in the pattern of somatic mutations in genes across












Fig. 1.1. Darwinian evolution during tumour development. Tumourigenesis is a multi-
step process in which initially healthy cells progressively acquire multiple mu-
tations disrupting their cellular processes and increasing their tumourigenic
potential. Although many of these mutations are passengers that do not affect
the ability of cells to survive and proliferate, a few rare mutations are drivers that
will strongly increase the fitness of individual cells, allowing them to outcompete
other cells. Over time, this stochastic process gives rise to Darwinian competi-
tion between subclones of cells harbouring different sets of mutations, driving
selection towards subclones with increasing tumourigenic potential. External
interventions such as drug treatments can influence this process by eradicating
subclones that are sensitive to the given treatment. However, they can also drive
selection towards subclones that are resistant to the treatment, leading to the
emergence of therapy resistance that is seen in many cancer patients.
tumour samples. Examples include approaches based on mutation frequency9,10,
biases in the functional consequences of mutations11–14 and clustering of mutations
within genes15.
Although these approaches have proven successful in identifying many driver genes
affected by hotspot mutations, other types of mutations have proven more challeng-
ing. This is especially the case for DNA copy number driven diseases such as breast
cancer, in which approaches aimed at identifying recurrent copy number gains/losses
typically identify regions harbouring many genes16,17. Similarly, complex structural
rearrangements18 and mutations in non-coding regions19 can be difficult to pin-
point specific target genes, requiring further prioritization of candidate genes using
complementary approaches and/or exhaustive validation of potential drivers.
Another important challenge is the validation of putative driver genes and the
further characterization of their biological mechanism(s), as this insight is crucial for
understanding a driver’s role in tumourigenesis and identifying potential therapeutic
opportunities. Currently, most large-scale studies perform no or limited in vivo
validation of candidate genes20–24, as this additional follow-up is typically time- and
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labour-intensive. Furthermore, although some studies do perform in vitro validation
of candidate genes in human cell line models, this is likely to be of limited relevance25
as cancer cell lines harbour many additional mutations and are grown in a highly
artificial environment. Other in vitro models such as 3D tumour organoids26,27 may
provide an interesting alternative, but also lack a tumour microenvironment and
need to be grown in specific media28, which may limit the clinical translatability of
findings in these models.
Finally, many promising targeted therapies fail in the clinic due to the emergence
of treatment resistance. To understand why this is the case, it is important to
determine how different therapies impact the clonal evolution of a tumour and how
this leads to the development of treatment resistance. These insights can then be
used to develop new strategies that aim to prevent or overcome resistance. However,
detailed studies of clonal evolution and treatment resistance are challenging as
the development of resistance is often a stochastic process, as is evident from the
observation that patients can often develop multiple mechanisms of resistance to
the same treatment29–31. Combined with the limited availability of pre- and post-
treatment tumour samples from patients, this makes human studies less than ideal
for determining the range of potential resistance mechanisms. To identify and predict
these potential resistance mechanisms, we will therefore need experimental systems
that allow us to quantify the range of expected resistance mechanisms for a given
tumour and determine how these are impacted by different treatments or other
factors such as diverse genetic backgrounds.
1.4 Experimental models of human cancer
1.4.1 Patient-derived models
Experimental models of human cancer should be easy to manipulate and recapitulate
the genetic features and microenvironment of the original patient tumour as much
as possible. Human cancer cell lines have often been used for this purpose, as these
represent cell lines derived from patient tumours that are easy to manipulate in vitro.
However, cell lines are grown in a highly artificial environment and therefore undergo
a stringent selection process when being established, resulting in homogeneous
populations that no longer fully represent the genetic heterogeneity of the original
tumour32. More recently, 3D organoid models have been developed to overcome this
limitation by growing cells in three-dimensional media, which allows the formation
of more realistic organ-like structures33. This technique has enabled the development
of in vitro models for tissues that could not be established as cell lines28, suggesting
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that organoids are subject to less evolutionary pressure and are therefore more likely
to reflect the heterogeneity of the original patient tumours.
Human cell lines have been very popular in cancer research, as they remain relatively
close to the human setting, whilst providing a convenient platform for studying
cancer cell biology. As such, these in vitro models have proved instrumental in
delineating key biological signalling pathways and in preclinical drug screening34,35.
A drawback of human cell lines and organoids is however that they do not model
interactions with the tumour microenvironment and the effects of angiogenesis
and drug metabolism. To address these limitations, cell lines and organoids can be
injected into immune-deficient mice (Figure 1.2A) to create in vivo xenograft models.
However, although these xenograft models do capture interactions between tumour
cells and the (mouse) microenvironment, they do not recapitulate interactions with
the immune system due to the use of immunocompromised mice.
An alternative approach is to directly transplant tissue from human tissue into im-
munodeficient host mice, thereby creating patient-derived tumour xenograft (PDTX)
models. Compared to cell line- or organoid-based transplantation models, PDTX
tumours more faithfully retain the molecular, genetic, and histological heterogeneity
observed in the respective cancer patients, even after serial passaging in mice36,37.
As such, PDTX models have been a popular textitin vivo platform for preclinical drug
screening in a large variety of cancer types, such as breast cancer38,39, melanoma29,40
and colorectal cancer41–45. However, drawbacks of PDTX models are that certain
tumour types are much harder to establish in mice than others, and xenografts
may undergo mouse-specific tumour evolution46. Moreover, PDTX models still lack
an active immune system. Humanized mouse models aim to address this gap, by
introducing functional human immune systems into otherwise immunocompromised
mice47.
1.4.2 Genetically engineered mouse models (GEMMs)
A significant limitation of patient-derived models, is that they are typically estab-
lished using heavily mutated, end-stage tumours and can therefore not be used to
study the effects of individual mutations on tumour initiation and progression. In
contrast, genetically engineered mouse models (GEMMs) can be used to introduce
individual mutations identified from human sequencing projects into a clean genetic
background, allowing detailed characterization of these mutations and their effects
on cancer susceptibility, tumour formation, progression and maintenance.
The first GEMMs were developed by introducing cloned cancer genes into the genome
of transgenic mice (Figure 1.2B), providing the first conclusive evidence that mice
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Fig. 1.2. Schematic overview of different types of mouse models of human cancer.
(A) Patient-derived models are created by transplanting human material into
immune-deficient mice. This can be done by either injecting cell lines or organoids
which were previously derived from human tissue, or by directly grafting human
tumour pieces into mice. (B) In conventional GEMMs, de novo tumourigenesis
is induced either by tissue-specific expression of an oncogene or by germline
inactivation of a TSG. The engineered genes are typically selected based on
pre-existing data from (human) sequencing studies. (C) In conditional GEMMs,
de novo tumourigenesis is induced by tissue-specific inactivation of conditional
TSG alleles and/or activation of conditional oncogenes via Cre-loxP-mediated
recombination. (D) In somatic GEMMs, tumourigenesis is induced either by
injecting lentiviral vectors expressing specific oncogene(s) into the tissue of
interest, or by injecting Cas9 together with sgRNAs targeting specific TSGs. In
the latter approach, Cas9 can also be expressed conditionally in the host mouse.
could be made prone to developing tumours in a specific tissue by introducing
transgenic expression of an oncogene under control of a tissue-specific promoter48.
Later, with the rise of gene-targeting technology, the effects of mutations in tumour
suppressor genes (TSGs) on tumour formation could be studied in knockout mice49.
However, a significant limitation of these conventional GEMMs is that oncogenes
are expressed in all cells of a particular tissue in transgenic mice, whilst TSGs in
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knockout mice are inactivated in all cells. In this respect, conventional GEMMs fail
to mimic sporadic cancers, in which the accumulation of genetic events in a single
cell results in tumourigenesis in an otherwise healthy organ.
To address this issue, conditional GEMMs were developed by employing somatic acti-
vation of oncogenes and somatic inactivation of tumour suppressors50 (Figure 1.2C).
One of the most frequently used conditional strategies is the Cre/loxP recombinase
system51, in which parts of target genes are flanked by loxP recombinase recognition
sites that recombine in the presence of Cre-recombinase to delete intervening DNA
sequences. Using this system, oncogenes can be activated by removing engineered
stop sequences that prevent gene expression in the absence of the recombinase,
whereas TSGs can be inactivated by deleting exons that are crucial for gene function.
Conditional GEMMs have been developed for a large variety of different cancers,
generating a wealth of models that closely mimic the histopathological, molecular,
and clinical features of human tumours52,53.
A limitation of conditional GEMMs is that generating new models is still time-
consuming and expensive. Recent developments in somatic gene-editing techniques
provide incredible potential to speed-up this process by allowing mutations to
be introduced somatically into existing mouse models (Figure 1.2D). Using these
approaches, oncogenes can be introduced by injecting (viral) vectors expressing
these gene(s) into the tissue of interest54. Similarly, TSGs can be inactivated using
CRISPR-Cas9-mediated gene editing by injecting constructs containing Cas9 and
guide RNAs (sgRNAs) targeting the TSGs into Cas9-proficient mice55. Further
developments such as CRISPR interference/activation56 and CRISPR-mutagenesis
approaches57,58 promise to further expand this toolkit, enabling the use of somatic
engineering to rapidly model a wide variety of cancer-associated mutations.
1.5 Identifying cancer drivers in mouse models
1.5.1 Mouse tumour sequencing
Besides studying the effects of candidate cancer drivers, GEMMs can also be used to
identify additional driver mutations by sequencing mouse tumours and identifying
additional genes that are frequently mutated across tumours (Figure 1.3A). Follow-
ing this approach, driver mutations can be detected using various computational
approaches, in the same fashion as previously described for human tumours. One
of the main advantages of using mouse tumour sequencing to identify additional
drivers is that, by sequencing tumours from a specific and controlled genetic back-
ground, we can specifically identify drivers that collaborate with the pre-existing
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driver mutations. As such, whole-exome and whole-genome sequencing approaches
have been used to characterize the mutational landscapes of Kras-mutant mouse
skin squamous cell carcinoma59 and Egfr-, Myc- and Kras-driven lung cancers60,61.
Similarly, copy number-based approaches have identified several driver genes in
mouse models of Brca1- and Brca2-deficient breast cancer62. A potential drawback
of using mouse tumour sequencing to identify driver mutations is that (depending
on the pre-existing drivers) mouse tumours may harbour as many aberrations as
human tumours, complicating the identification of driver genes. This is, for exam-
ple, particularly the case for tumours with high copy number instability, such as
Brca1/Brca2-deficient breast cancer models62. Combined with the relatively low
numbers of tumours involved in mouse studies, this means that mouse sequencing
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Fig. 1.3. De novo driver gene identification in mice. (A) Driver genes can be identified
in mice in the same fashion as for human tumours by using DNA/RNA-sequencing
approaches aimed at identifying recurrent mutations, copy number aberrations,
gene fusions and complex structural rearrangements. (B) Comparative oncoge-
nomics approaches allow refinement of candidate driver gene lists by focusing on
genes that are recurrently mutated in both mouse and human tumours. In such
an approach, candidates are typically first identified for both species individually,
after which shared (orthologous) genes are selected and further prioritized based
on existing knowledge or other data sources.
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1.5.2 Comparative oncogenomics
A more powerful approach for identifying driver genes using sequencing approaches
is to combine insights from mouse and human datasets and prioritize genes that
are mutated in both species, as these are most likely to represent true driver genes.
This can be done in an ad hoc setting, by identifying drivers of mouse tumours
and comparing these with known mutations in human datasets, or as a deliberate
strategy using comparative oncogenomics. In the latter approach, sequencing data
from mouse and human tumours are typically first analyzed to identify candidate
driver genes for both species individually. These species-specific candidates are
then integrated by only selecting genes and/or networks that are aberrated in
both species (Figure 1.3B). Remaining candidates can optionally be filtered using
additional criteria, such as correlation with gene expression or prior knowledge from
literature.
This comparative strategy has proven particularly effective for distinguishing driver
genes from passengers in chromosomally unstable tumours. For example, in a mouse
model of hepatocellular carcinoma (HCC), Zender et al. identified a focal amplicon
on mouse chromosome 9qA1, which was syntenic with amplifications in human
HCCs on 11q2263. Further filtering based on expression identified two drivers on
this locus, cIAP1 and Yap, which were shown to act synergistically in tumourigenesis.
Similarly, copy number sequencing of metastases from an inducible Hras model of
a traditionally non-metastatic melanoma identified a focal amplification on mouse
chromosome 16, which contained only eight candidate driver genes64. Further
comparison with human RAS- and MET-driven melanomas identified a single gene,
NEDD9, as the driver of these metastases.
1.6 Identifying drivers using forward genetic
screening
Although additional driver genes can be identified by mouse tumour sequencing, this
approach is not always optimal as many mouse models have a long tumour latency
and may be more prone to acquire other types of mutations than those of interest (i.e.,
copy number aberrations rather than point mutations). Forward genetic screening
approaches can address these problems by using various mutagenesis strategies
to induce additional mutations and accelerate tumour formation, after which any
tumours that developed can be studied to identify new drivers. The type of mutations
that occur depends strongly on the used type of mutagenesis, meaning that different
mutagenesis strategies can used to specifically model different kinds of mutations.
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Fig. 1.4. Schematic overview of forward genetic screening approaches. (A) In chemi-
cal mutagenesis approaches, mice are treated with a mutagenic compound and
subsequently monitored for tumour formation. The resulting tumours can then
be sequenced using whole-genome or targeted sequencing to identify mutations
driving tumourigenesis. (B) In transposon-based insertional mutagenesis (TIM),
tissue-specific expression of a transposase enzyme induces the mobilization of
mobile elements called transposons, which can be re-integrated elsewhere in
the genome. By doing so, transposons can result in the activation of oncogenes
or inactivation of TSGs. (C) With in vivo CRISPR/shRNA screening, cells or
organoids are transduced with a library of sh/sgRNAs targeting a set of genes.
The transduced cells/organoids are injected in vivo, after which the mice are
monitored for tumour formation. Developed tumours are sequenced to determine
the abundance of individual sh/sgRNAs, which is contrasted to the starting popu-
lation to identify if sh/sgRNAs targeting specific genes are enriched (potential
TSGs) or depleted (potential oncogenes and/or drug targets).
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1.6.1 Screening using chemical mutagenesis
Chemical-based mutagenesis is one of the oldest mutagenesis strategies, in which
cells or animals are treated with a chemical substance that damages the DNA and
thereby induces mutations. The induced mutations are typically single nucleotide
changes; however, the spectrum of these mutations depends on the used substance
and can vary greatly between different chemicals. During in vivo chemical muta-
genesis screens, animals (typically zebrafish or mice) are treated with a controlled
dose of a chemical mutagen and subsequently monitored for tumour formation (Fig-
ure 1.4A). Developed tumours can be sequenced using whole-genome or targeted
sequencing strategies to identify mutations that may be driving tumourigenesis or
metastasis60,65.
An advantage of chemical mutagenesis compared to other mutagenesis approaches,
is that its bias towards single nucleotide changes makes it suitable for modelling
the effects of human variants, which are often single point mutations that result in
changes in the levels of expression or activity of a gene product. For this reason,
chemical mutagenesis approaches have been used to mimic human mutational
processes and to characterize the genomic landscapes of the mutational landscapes
of mouse skin squamous cell carcinoma59 and Kras-driven lung cancers60. However,
when designing screens, it is important to take the inherent mutational bias of
chemicals into account. Currently, N-ethyl-N-nitrosourea (ENU) is a popular choice
for chemical mutagenesis strategies aiming to model single-nucleotide variants
(SNVs), as it results in a range of point mutations that mirrors the range of mutations
observed in human tumours66.
1.6.2 Screening using insertional mutagenesis
A drawback of chemical mutagenesis strategies is that their bias towards point
mutations limits their utility for modelling other types of mutations, such as increased
gene expression resulting from gene amplifications. Insertional mutagenesis (IM)
strategies provide an alternative approach, in which viral or transposon sequences
are stochastically inserted into the genome, disrupting the expression of nearby
genes (Figure 1.4B). In transposon insertional mutagenesis (TIM) strategies, this
process is mediated by a transposase enzyme, which excises transposons from a
concatemer located in the genome of the mice and reintegrates them stochastically
elsewhere. By placing the expression of this transposase under a tissue-specific
promoter, mutagenesis can be restricted to specific tissues in the mouse.
The effects of insertions depend on the used transposon, but typically involve the
activation of oncogenes using promoter sequences and/or inactivation of tumour
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suppressors by truncating genes. For example, the T2Onc/2 transposon, which is
frequently used in Sleeping Beauty IM screens67,68, contains enhancer/promoter
(MSCV) and splice donor (SD) sequences that allow the transposon to initiate
transcription and drive the (over)expression of nearby genes. The transposon also
contains two splice acceptor sites (SA/En2SA) combined with a bi-directional polyA
sequence, which allow the transposon to truncate transcripts if integrated within
a gene. Depending on the gene and the relative location of the insertion, these
truncations can inactivate genes by resulting in an unstable transcript or inactive
protein, or activate genes by removing inhibitory protein domains69,70.
A considerable advantage of TIM strategies is that insertions can be specifically
targeted via PCR amplification before sequencing, enabling cheap and efficient
retrieval of the insertion sites compared to genome-wide sequencing. However, a
drawback of transposon-based systems is that they generally show bias in terms of
their insertion patterns, either due to sequence integration biases or biases towards
specific gene features (e.g., gene bodies or promoters)71. For this reason, screens
using different transposon systems (such as the Sleeping Beauty67,68 or piggyBac72,73
systems) may identify different candidate genes, even if screens are performed in
the same genetic background. Moreover, target genes are typically identified using
windows around the insertion sites71,74, which may lead to the identification of
many false positive candidate genes.
Despite these drawbacks, TIM has been valuable for identifying cancer-associated
driver genes in mouse models of a large variety of cancer types, including breast
cancer75–77, melanoma78, hepatocellular carcinoma79 and gastric cancer80. Addition-
ally, as mutagenesis remains constitutively active in these models, TIM has also been
used to identify drivers of metastasis formation81 and acquired resistance to drug
treatments82,83. Finally, new computational approaches based on RNA-sequencing
data have been developed to improve target gene prediction and offer additional
insight into the effects of insertions on the expression of the affected gene84,85.
1.6.3 shRNA screening
In contrast to the previously described genome-wide screening approaches, library-
based screening approaches, such as loss-of-function screens based on RNA inter-
ference (RNAi) technology, can be used to target specific sets of genes. In pooled
RNAi screening approaches, cells are transfected with short hairpin RNAs (shRNAs)
targeting specific genes that, when integrated into the genome, result in heritable
and long-term suppression of the corresponding gene86. To perform an in vivo RNAi
screen, the transfected cells can be injected orthotopically in animals87, which are
monitored for tumour growth (Figure 1.4C). Once developed, tumours are harvested
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and sequenced to quantify the frequency of each shRNA in the tumour cell popu-
lation. By contrasting these frequencies to those of the initial starting population,
this approach can identify which shRNAs are enriched in the tumour and are there-
fore likely targeting TSGs whose loss is beneficial for tumourigenesis. Conversely,
depleted shRNAs may identify potential oncogenes and/or genes that are crucial for
tumour maintenance.
The scope of shRNA screens depends entirely on the used library, meaning that
screens can be designed to target all genes in a genome-wide fashion or to test a
small number of pre-selected candidate genes. As such, shRNA screens can not
only be used to identify novel driver genes, but can also be used for narrowing
down lists of potential drivers or to validate putative driver genes. Compared to
in vitro approaches, in vivo shRNA screens provide the opportunity to expose the
vulnerabilities of tumour cells in the context of their microenvironment and can
be used to study drivers of metastasis and therapy resistance88–90. Drawbacks of
shRNA screening include variable efficiency between shRNAs in the knockdown of
their respective target genes91 and off-target effects92. Successful in vivo shRNA
screens have been reported for a variety of cancer types, including xenograft models
of hepatocellular carcinoma93, lymphoma94,95, leukemia96,97 and glioma98,99.
1.6.4 CRISPR screening
With the development of CRISPR–based technologies, it has also become possible to
perform pooled loss-of-function screens by knocking-out genes using CRISPR–Cas9-
mediated genome editing. CRISPR–Cas9 loss-of-function screens are generally
performed in the same fashion as shRNA screens by transducing cells with pools of
single guide RNAs (sgRNAs) targeting different genes, injecting the transduced cells
in vivo and contrasting the abundance of sgRNAs in tumours with their abundance
in the starting population100–102. However, in contrast to shRNA screening, gene
editing via CRISPR-Cas9 disrupts the genes by DNA cleavage and thereby intro-
ducing insertions/deletions in their genomic sequence, resulting in frameshifts that
induce heterozygous or homozygous knockout of genes rather than a reduction in
expression.
Compared to shRNA screens, CRISPR-based screens have been reported to be re-
markably efficient and suffer less from off-target effects than shRNA screens103,104.
The approach is less amenable to studying dosage-dependent effects as genes are
knocked-out rather than knocked-down, although dosage reduction can be achieved
if Cas9 only induces heterozygous loss of the gene, as we have previously observed
in the validation of candidates from a Sleeping Beauty IM screen77. With the devel-
opment of new technologies, CRISPR-based screening approaches are extending
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beyond loss-of-function screens by enabling gene activation using CRISPRa105, gene
inhibition using CRISPRi106 and the introduction of mutations with CAS9-AID or
CAS9-APOBEC base editors57,58.
1.7 Validating and characterizing candidate driver
genes
After identifying putative driver genes, it remains important to verify that these
genes actually contribute to tumourigenesis. In many studies, human tumour
cell lines are used for this purpose by either knocking-out/down candidate TSGs or
(over)expressing candidate oncogenes and studying the effects of these perturbations
on tumour cell growth. However, as previously described, these in vitro models
suffer from several drawbacks, including the presence of additional mutations
and/or the lack of a tumour microenvironment. An alternative approach is to
use GEMMs to validate driver genes by introducing the corresponding mutations
into a mouse model with a similar genetic background as in which the mutations
were identified, and studying their effect on tumourigenesis (Figure 1.5A). These
additional mutations can be introduced either using germline approaches (such
as the GEMM-ESC strategy)107 or somatic approaches (e.g., via injection of viral
vectors), as described in previous sections.
Once established, the resulting mouse model(s) can be studied to determine how
the added mutation(s) affect tumour formation compared to the baseline mouse
model. For validating putative driver genes, the key question is whether the new
model containing the additional mutation develops tumours with a higher incidence
and/or shorter latency, indicating that the extra mutation does indeed contribute
towards tumourigenesis. The new model can also be used to study the effects of
the extra mutation on tumour metastasis and therapy response. Any developed
tumours can be studied in detail to determine how the added mutation affects various
tumour characteristics, such as the morphology of the tumours and interactions
with the microenvironment and immune system. Additionally, by using sequencing
strategies or screening approaches to identify additional driver genes in these more
complex mouse models, mutational landscapes can be compared between models
with different drivers to determine how additional drivers affect the evolution of
tumours initiated by the engineered mutations, and if this provides clues to any
driver-specific vulnerabilities.
A key advantage of using mouse models to validate candidate driver genes is that they
can provide unambiguous proof of whether candidates are bona fide driver genes in a
given genetic background. Especially CRISPR-CAS9-based somatic cancer modelling







































Fig. 1.5. Validating candidate genes and studying treatment resistance.
(A) Candidate cancer driver genes can be validated in vivo by developing mouse
models containing the observed mutations and monitoring the mice for tumour
formation. Developed tumours can be characterized to determine if they reflect
the expected phenotype(s) and sequenced to identify additional candidate driver
genes. These additional candidates can be introduced into the same baseline
GEMM model to determine their effect on tumourigenesis. By applying this
process iteratively, this type of approach can be used to unravel the contribution
of different cancer genes during various stages of tumourigenesis. (B) Mouse
models can also be used to identify mechanisms of acquired therapy resistance by
transplanting cell lines, organoids or tumour pieces into multiple recipient mice
and subjecting these mice to different treatments. Tumours that become resistant
to treatment can then be sequenced and contrasted to vehicle-treated tumours to
identify acquired mutations driving the resistance phenotype.
enables rapid in vivo testing of (combinations of) candidate cancer genes and has
been used to validate driver genes for a wide range of cancer types, including breast
cancer55, colorectal cancer108, pancreatic cancer109 and liver cancer110. Additionally,
multiplexed somatic engineering approaches provide the opportunity to rapidly
validate multiple candidate genes at the same time, whilst simultaneously studying
Darwinian selection between the different candidates and how this selection is
influenced by cellular/tissue contexts and pre-existing mutations110,111. Finally,
using iterative approaches, drivers can be identified and introduced progressively
into mouse models of increasing complexity. This type of approach can be used to
study tumour formation and progression in detail and establish the contributions of
different driver genes at various stages of tumourigenesis112.
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1.8 Studying drug response and treatment
resistance
Ultimately, knowledge of driver genes and their effects is used to develop novel ther-
apeutic strategies that target specific vulnerabilities of the tumour, enabling effective
treatments with minimal side effects. Following this premise, personalized therapies
are generally designed by either targeting the identified driver genes directly (if
possible) or by targeting other genes in the same signalling pathway. A well-known
example is BRAF-mutant melanoma, which is targeted by inhibiting the mutant BRAF
kinase and/or MEK, which is downstream of BRAF in the RAS/MAPK signalling
pathway. Alternatively, tumours can be targeted therapeutically by exploiting a
synthetic lethality resulting from the driver mutation(s). A classic example of such a
synthetic lethality is PARP inhibition in BRCA-deficient tumours, which specifically
targets cells with defects in their homologous recombination (HR) pathway due to
loss HR-associated proteins such as BRCA1 and BRCA2.
Before moving to the clinic, drugs are generally first tested for efficacy in a preclin-
ical setting, either using in vitro models (cell lines, organoids) or in vitro models
(xenograft models, GEMMs, PDTXs). To identify which treatments are most effective
in different cancer types or tumours with different genetic backgrounds, several
efforts have been made to setup large biobanks of PDTX models for high-throughput
drug screening purposes39,42,113,114. By correlating treatment sensitivity with se-
quencing data from the same tumours, these approaches can also be used to identify
genetic markers of intrinsic (pre-existing) therapy resistance. A nice example of this
approach has been given by Bertotti et al., who identified HER2 amplification to be
driving resistance in a subset of cetuximab-resistant colorectal PDTX tumours and
showed that combined inhibition of HER2 and EGFR induced overt, long-lasting
tumour regression42.
Besides intrinsic therapy resistance, many targeted therapies fail in the clinic due
to the emergence of drug resistance which is acquired during treatment. As such,
a key challenge for improving the efficacy of these therapies is to identify (and
ideally pre-empt) (epi)genetic changes that underlie this acquired treatment resis-
tance. Both GEMMs and PDTXs can be used to identify potential in vivo resistance
mechanisms by grafting cell lines, organoids or tumour fragments into multiple
recipient mice; which are then subjected to different treatments (Figure 1.5B). Upon
relapse, resistant tumours can be sequenced and compared with tumours from
vehicle-treated mice to identify possible resistance mechanisms. Using this approach,
our lab identified several resistance mechanisms to PARP-inhibitor treatment in
mouse models of BRCA1- and BRCA2-deficient breast cancer115–117. This type of
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approach can also be combined with various mutagenesis strategies, for example by
using insertional mutagenesis to induce resistance and identify potential resistance
mechanisms82,83,118.
Besides identifying potential resistance mechanisms, an important challenge is to
determine how resistance actually arises and to design therapeutic strategies ac-
cordingly. For example, in cases where tumours acquire additional (epi)genetic
changes during treatment (as described above), therapies should ideally be designed
to pre-empt and prevent the most likely paths of resistance. On the other hand,
cases where resistance is driven by pre-existing sub-populations of intrinsically re-
sistant cells119 will require different treatment strategies. Traditionally, studying
intra-tumour heterogeneity has been challenging with bulk-sequencing technologies.
Single-cell sequencing approaches120,121 promise to revolutionize these analyses by
providing detailed insight into the (transcriptional) heterogeneity of tumour cells, en-
abling the identification of sub-populations of cells that may be driving resistance122.
Furthermore, approaches such as lineage tracing can be used to track the dynamics
of tumour evolution, providing detailed insight into which cell populations expand
and contract during treatment. As such, lineage tracing-based approaches have been
used to identify origins of resistance in mouse models of squamous cell carcinoma123,
prostate cancer124 and mouse intestinal adenomas125.
1.9 Conclusions and future perspectives
The success of personalized anti-cancer therapies hinges on how accurately we can
predict whether a given patient tumour will respond to a given treatment, allowing
clinicians to select the most effective therapeutic strategy for treating a patient.
Ideally such an approach would be implemented by feeding omics data and other
data types (e.g. imaging, pathology) from patient tumours into (computational)
models that predict which therapies are most likely to succeed based on specific
tumour biomarkers (Figure 1.6). Creating such models requires detailed insight
into which mutations are driving tumour development and how these affect therapy
response. Combined with high-throughput drug screening approaches, in vitro
and in vivo model systems provide crucial platforms for assessing sensitivity to
different therapies across multiple cell lines or tumours, enabling the construction
of correlative models that predict the efficacy of these treatments for new tumours.
More detailed genetic modelling in (mouse) model systems can further refine these
correlative models by providing causative evidence that (combinations of) mutations
drive cancer development and/or affect therapy response, and by enabling detailed
characterization of the effects of drivers on other tumour phenotypes, such as tumour
latency, morphology, mutational landscape and interactions with the (immune)




















































Fig. 1.6. The roles of model systems in designing personalized combination thera-
pies for effective cancer treatment. This figure illustrates how human/mouse
model systems are ultimately used to identify and characterize cancer driver
genes in different types of cancer, and how these insights can be used to in-
form patient treatment. This process can essentially be divided into two parts:
clinical application and fundamental research. On the clinical side, approaches
to personalized medicine sequence patient tumours to identify mutations and
potential cancer drivers. In parallel, tumour material can also be used to establish
patient-derived model systems, which can be used to screen for drug efficacy and
study treatment resistance. By combining this drug response data with mutations
identified through sequencing, this approach can be used to train computational
models predicting optimal therapies and identify biological features explaining
the observed drug response. On the fundamental side, mouse models can also be
used to identify cancer drivers (through sequencing and genetic screening) and
for drug screening. In contrast to patient-derived models, GEMMs can also be
used to conclusively validate cancer driver genes in vivo and to perform detailed
dissection of how different driver genes affect tumour development and progres-
sion. This information can be used for predictive models in the clinic, but can
also be used to formulate new hypotheses and additional experiments, fueling
further fundamental research into the molecular underpinnings of cancer.
microenvironment. Genetically engineered mouse models also provide a powerful
platform to critically evalutate new candidate drug targets126 and thereby improve
the robustness of preclinical cancer target identification127.
Modeling of human cancer using genetically engineered mice is complicated by
the observation that tumours generally contain multiple driver lesions, which can
strongly influence their sensitivity to treatments targeting specific drivers. As a result,
accurately assessing therapy response may require the generation of complex mouse
models containing multiple driver genes that are frequently encountered together in a
given type of cancer. Using germline engineering approaches, generating models with
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multiple driver lesions has been challenging due to the extensive breeding and animal
husbandry involved. Somatic approaches using CRISPR-CAS9 based gene editing
and overexpression vectors alleviate this bottleneck, by providing the technology to
quickly create new mouse models by introducing different combinations of mutations
into a pre-existing baseline mouse model. The rapidly ongoing refinement of these
tools will further expand the repetoire of mutations that can be modelled in this
manner, enabling the rapid creation of new models reflecting the mutations observed
in patient tumours, which can be used to test the effects of novel therapeutic
strategies targeting these mutations.
Besides designing novel therapies, other important clinical challenges include identi-
fying which patients are most at risk of developing cancer and should be screened for
preventative treatments. Although factors such as genetic background and lifestyle
have been shown to have a profound influence on cancer risk and survival, our
insights into how these factors influence cancer development is still limited. Due to
their tightly controlled genetics, mouse models are uniquely suited for examining
the effects of genetic backgrounds and how these interact with specific driver genes
in an in vivo setting. Similarly, mouse models can also be used to model the effects
of specific lifestyles (e.g. diet, gut microbiome, circadian rithm, exposure to muta-
gens) on cancer risk and development128. Combined, insights from such models
will hopefully allow us to incorporate knowledge of genetic modifiers and lifestyle
influences into clinical tests, improving the identification of individuals at high risk
for cancer and matching preventive therapies.
Improved screening imposes its own challenges, as population screening programmes
identify many lesions that will not necessarily progress to cancer and do therefore
not actually require treatment. Unfortunately, in many cases it is currently not
possible to distinguish which lesions are indolent and which will progress to invasive
cancer, leading to overdiagnosis and overtreatment129. Identifying which tumour
cell-intrinsic and -extrinsic factors contribute to tumour progression will hopefully
provide important insight into the tumourigenic process and allow us to develop
tests that distinguish between high- and low-risk lesions. These studies will require
models that allow us to study the early stages of cancer, which is not possible using
end-stage tumour material from patients. GEMMs can provide a powerful platform
for this type of research, as lesions in these models can be studied at any stage during
tumour progression. Moreover, by introducing mutations identified in pre-malignant
lesions from patients, mouse models can be used to determine the contributions of
these mutations to tumour progression and to screen for additional factors that may
be required for malignant transformation.
Tumour progression, metastasis and escape from therapy are phenomena which are
driven by intra-tumour heterogeneity130. Single-cell sequencing approaches provide
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a particularly promising approach for studying tumour progression by enabling
detailed characterization of distinct cell populations within a given tumour120,121.
For example, combined with (CRISPR-based) lineage tracing131,132, single-cell ap-
proaches in GEMM tumours can be used to study the early dynamics of pre-malignant
lesions and determine which cell populations play a role in driving eventual tu-
mourigenesis. Similarly, longtitudinal sampling of mouse tumours may be used to
determine how cell populations within tumours evolve during tumour progression
and under therapeutic pressure, providing insight into how certain (epi)genetic
changes may drive tumour evolution and the development of therapy resistance.
Finally, detailed characterization of non-tumour cells within the tumour can be used
to explore the interactions with the (immune) microenvironment133,134 and how
these interactions change during tumour progression or during therapy stress.
It is important to keep in mind is that tumours arising in GEMMs of human cancer
may not necessarily reflect all characteristics of human tumours. For example,
GEMM tumours may contain lower numbers of somatic mutations compared to
the cognate human tumours61 and fewer mutations seem to be required for cancer
formation in mice compared to humans135. As such, it remains important to establish
whether mouse tumours accurately reflect the aspects of the (sub)type of human
cancer that we wish to study, both in terms of morphology, genetic landscape and
transcriptional profile. Additionally, due to their limited genetic heterogeneity, it is
unrealistic to expect that mouse models will sufficiently represent the heterogeneity
of patient populations. It will therefore remain crucial to combine findings from
mouse models with information from other sources, including sequencing data
from patient populations and experimental data from other model systems, such as
(human) tumour organoids and PDTX models.
Finally, efforts to collect catalogue mouse sequencing data have been relatively
limited compared to efforts involving human sequencing studies. To fully exploit the
large compendium of mouse sequencing and screening data, it will be important
to collect these data in centralized repositories and create portals to query these
data, allowing researchers to quickly explore existing datasets and compare tumour
characteristics across different mouse models. Fortunately, several efforts are already
underway to collect data in application-specific databases136, to create portals
visualizing data from PDTX models and to adapt software like cBioPortal137 for
visualizing tumour data from non-human organisms. We expect that these initiatives
will play an important role in disseminating insights from mouse models and improve
accessibility for cross-pollination with human sequencing efforts.
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2Scope of this thesis
2.1 Introduction
Breast cancer is the most common malignancy affecting women in the Western
world, with more than 17,000 cases being diagnosed in the Netherlands alone each
year*. Overall treatment of breast cancer is relatively successful, however recurrence
of the disease remains a significant problem in clinical practice1. Breast cancer
is known to be a heterogeneous disease and has therefore been subdivided into
different subtypes, based on histological characteristics2, gene expression patterns3
and expression of different markers such as estrogen receptor-α (ER-α), progesterone
receptor (PR) and human epidermal growth factor receptor 2 (HER2, aka ERBB2),
which are known to drive expression of downstream signaling pathways and increase
cellular proliferation4–6. Genetic analyses have identified several common genetic
alterations associated with specific subtypes7–9, indicating that biological differences
between the subtypes strongly shape tumor development.
2.2 A tale of two breast cancer subtypes
In the remainder of this thesis, we focus on two particular subtypes of human breast
cancer: invasive lobular carcinoma and triple-negative breast cancer.
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer that
represents 8-14% of all breast cancer cases. The classical form of ILC is characterized
by rows of small discohesive cells, which invade into the surrounding stroma in a
single-file pattern10. This invasive phenotype is generally attributed to the functional
loss of E-cadherin (encoded by the CDH1 gene), a cell-cell adhesion molecule
that forms a key component of adherens junctions and plays an important role in
maintaining epithelial integrity11. Functional loss of E-cadherin occurs in 90% of
all ILCs and is mainly due to mutational inactivation, loss of heterozygosity (LOH)
or impaired integrity of the components of the E-cadherin–catenin complex9,12–14.
Besides this, ILCs are generally ER- and PR-positive and rarely show amplification of
HER2. However, long-term outcome of ILC is generally worse than stage-matched
invasive ductal carcinoma (IDC)15, suggesting that biological differences between
the two subtypes may be influencing treatment efficacy.
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that
is characterized by low expression of ER, PR and HER2. Altogether, TNBC accounts
for 10-17% of all breast cancer cases, depending on the methods and thresholds
used to assess the status of the three receptors16. At the mutational level, TNBCs
are enriched for mutations in TP537 and BRCA117, which plays a key role in the
*www.cijfersoverkanker.nl
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repair of DNA double-strand breaks (DSBs) via homologous recombination (HR). As
such, BRCA-deficient TNBCs generally show high levels of chromosomal instability,
which is attributed to the HR deficiency of these tumors18. Compared to other
subtypes, TNBCs occur more frequently in younger patients (<50 years) and are
significantly more aggressive19,20. Moreover, due to the lack of specialized therapies,
chemotherapy currently remains standard-of-care for patients with TNBC21, resulting
in a relatively poor prognosis.
2.3 Identifying drivers of human (breast) cancer
A common feature of ILC and TNBC, is that they respond more poorly to existing
therapies than other breast cancer subtypes. As such, both breast cancer subtypes
would be benefited by the development of novel therapies targeting specific vul-
nerabilities in these tumors. Efforts to identify such vulnerabilities have generally
focused on identifying genes driving tumor development and determining if these
drivers can be exploited to develop novel therapies, either by targeting the drivers
themselves or by exploiting other vulnerabilities stemming from the drivers.
Recently, several human sequencing studies have been undertaken to identify drivers
of human ILC besides functional loss of E-cadherin9,22. Together, these studies
have shed light on additional genetic alterations that are thought to be driver
events, including chromosomal gains of 1q and 16p23, loss of 16q24, activating
mutations in PIK3CA25,26 and inactivating mutations in TP5327. Further molecular
characterization has identified multiple aberrations in other components of the
PI3K-AKT pathway, indicating that PI3K-AKT signaling plays an important role in ILC
development9,22,28. However, a large fraction of human ILCs cannot be explained by
activated PI3K-AKT signaling and TP53 mutations, indicating that other aberrations
are likely to play additional roles in tumorigenesis. Therefore, to identify novel
genes and pathways driving ILC development, we used the Sleeping Beauty (SB)
transposon system to perform an insertional mutagenesis (IM) screen in female mice
with mammary-gland specific inactivation of Cdh1. The results of this screen are
described in Chapter 3.
One of the main challenges of identifying candidate cancer drivers using an IM-based
forward genetic screen, is that these screens can detect many potential cancer genes,
of which only a fraction is actually involved in driving tumorigenesis. Besides this, it
can be challenging to identify how genes are affected by their transposon insertions,
as the targeted DNA-sequencing approaches that are typically employed for detecting
insertion sites29–31 do not provide any evidence of how insertions affect gene expres-
sion. We reasoned RNA-sequencing-based insertion site detection approaches could
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alleviate these issues by focusing on detecting insertions that are actually expressed
(and therefore more likely to have an actual effect), whilst simultaneously providing
insight into how the expression of candidate genes is affected. To demonstrate this,
we developed a computational approach and accompanying software package called
IM-Fusion, which identifies transposon insertions from gene-transposon fusions in
RNA-sequencing data. Details of the approach, including a comparison with targeted
DNA-sequencing-based approaches, are described in Chapter 4.
As a result of their chromosomal instability, BRCA-deficient TNBCs develop character-
istic patterns of copy number aberrations32, suggesting that these aberrations harbor
additional genes driving tumorigenesis. Unfortunately, these aberrations generally
harbor tens-to-hundreds of genes, complicating the search for the true driver genes
in these regions. To address this issue, computational approaches (e.g. RUBIC,
GISTIC) have been developed to identify minimal recurrently aberrated regions and
thereby narrow down lists of potential drivers33,34. Besides this, comparative oncoge-
nomics approaches have also been used to restrict lists of candidate driver genes, by
focusing on genes that are recurrently aberrated in tumors from both mouse models
and human patients35. In Chapter 5, we explore the copy number landscape of
BRCA1-mutated TNBC using several mouse models containing previously identified
drivers such as Myc, Met and Rb1. By applying RUBIC in a comparative analysis
between both mouse and human tumors, we show that engineered MYC overexpres-
sion in BRCA1-deficient TNBC dramatically reshapes the copy number landscape
and identify MCL1 as a druggable driver in these tumors.
2.4 Preventing therapy resistance
Besides identifying druggable target genes, a significant challenge in the development
of targeted therapies is the emergence of (acquired) therapy resistance, which is
unfortunately frequently observed in patients after prolonged treatment with several
targeted therapies36. To prevent the development of therapy resistance, it is crucial
to gain an understanding of how tumors become resistant to therapies and use
these insights to develop new (combination) treatments that aim to prevent or
overcome resistance. Besides this, it is important to identify which patients are
likely to be intrinsically resistant to treatment, so that these patients can be treated
accordingly.
As part of the insertional mutagenesis screen described in Chapter 3, we identified
FGFR2 as a key driver of ILC, suggesting that FGFR inhibition would be a suit-
able therapeutic strategy for treating FGFR-driven ILC. Although no FGFR-targeting
therapies are currently approved for the treatment of human cancers, several thera-
36 Chapter 2 Scope of this thesis
peutics are currently being evaluated in phase I/II clinical trials for different types
of cancers37,38). Unfortunately, studies with some of these inhibitors have shown
that tumors can develop resistance to treatment, mainly via secondary mutations
in FGFRs39–41 and activation of alternative RTKs42–45. In Chapter 6, we explore
the effectiveness of FGFR inhibition in FGFR-driven ILCs by transplanting tumor
fragments into multiple recipient mice and treating them with the FGFR inhibitor
AZD4547. Besides this, we exploit the ongoing transposon mutagenesis in these
tumors to identify potential resistance mechanisms to AZD4547, which may be used
for developing novel (combination) therapies that prevent or overcome resistance.
In BRCA-deficient TNBC, the most promising targeted treatments have aimed to
exploit vulnerabilities resulting from the HR-deficiency incurred by BRCA1/BRCA2
loss18. This has led to the development of several PARP inhibitors, which indirectly
induce the accumulation of DSBs in the DNA46,47. These DSBs cannot be repaired in
an error-free fashion without BRCA1/2, leading to extensive DNA damage and cell
death in BRCA-mutant cells48,49. Unfortunately, the clinical effectiveness of PARP
inhibitors is limited by the emergence of therapy resistance50,51, typically due to
restoration of HR function via secondary mutations in BRCA1/252,53 or mutations
in the 53BP1-RIF1-REV7 pathway (reviewed by Annunziato et al.54). However, for
BRCA2-mutant tumors, there is no evidence that HR can be restored in the absence
of BRCA2, suggesting that other mechanisms must be driving therapy resistance. To
identify these additional resistance mechanisms, we combined in vitro screens in
BRCA2-deficient mammary tumor cells with multi-omics analysis of BRCA2-deficient
mouse mammary tumors that acquired PARPi resistance in vivo. The results of these
analyses are described in Chapter 7.
2.5 Future perspectives
Coming to the end of this thesis, in Chapter 8 we reflect on the methods and
results presented in this work and how they may be applied or extended in future
endeavours. Besides this, we also consider several technological advances and
important challenges that remain to be addressed in the field. Finally, we discuss
several limitations of mouse models in the light of expanding human datasets and
development of three-dimensional cell culture models, and what this means for the
future role of mouse models in cancer research.
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3.1 Abstract
Invasive lobular carcinoma (ILC) is the second most common breast cancer subtype
and accounts for 8-14% of all cases. Although the majority of human ILCs are
characterized by the functional loss of E-cadherin (encoded by CDH1), inactivation
of Cdh1 does not predispose mice to develop mammary tumors, implying that
mutations in additional genes are required for ILC formation in mice. To identify
these genes, we performed an insertional mutagenesis screen using the Sleeping
Beauty transposon system in mice with mammary-specific inactivation of Cdh1.
These mice developed multiple independent mammary tumors of which the majority
resembled human ILC in terms of morphology and gene expression. Recurrent
and mutually exclusive transposon insertions were identified in Myh9, Ppp1r12a,
Ppp1r12b and Trp53bp2, whose products have been implicated in the regulation of
the actin cytoskeleton. Notably, MYH9, PPP1R12B and TP53BP2 were also frequently
aberrated in human ILC, highlighting these genes as drivers of a novel oncogenic
pathway underlying ILC development.
3.2 Introduction
ILC belongs to the luminal subtype of breast cancer and accounts for 8-14% of all
breast cancer cases1–3. The majority of human ILCs (hILCs) are characterized by
functional loss of E-cadherin (CDH1), a cell-cell adhesion molecule that is a key
component of adherens junctions, where it associates with actin and the microtubule
cytoskeleton to maintain epithelial integrity4. Functional loss of E-cadherin in ILC
generally results from mutational inactivation, loss of heterozygosity (LOH), or
impaired integrity of the components of the E-cadherin-catenin complex5–8. Of note,
female mice with mammary-specific inactivation of E-cadherin are not prone to
developing mammary tumors9–11, indicating that additional mutations are required
for ILC development.
Several studies have shed light on genetic alterations that are thought to be driver
events in hILC, such as chromosomal gains of chromosomes 1q and 16p12, loss of
chromosome 16q13, activating mutations in PIK3CA14,15 and inactivating mutations
in TP5316. Molecular characterization of hILCs has further identified multiple
aberrations in genes encoding components of the PI3K-AKT signaling pathway and
increased AKT phosphorylation as compared to those in other breast cancer subtypes,
underscoring the importance of PI3K-AKT signaling in hILC7,17,18. However, only
50-60% of hILCs can be explained by PI3K-AKT activation and mutations in TP53,
and relatively little is known about the roles of other genes and signaling pathways
in hILC. To identify novel genes and pathways that drive ILC development, we
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performed a Sleeping Beauty (SB) insertional mutagenesis screen in mice that also
had mammary-specific inactivation of Cdh1.
3.3 Results
3.3.1 Sleeping Beauty-induced mammary tumors in
Wap-Cre;Cdh1F/F;SB mice
To generate mice with mammary-specific inactivation of E-cadherin and
concomitant activation of the Sleeping Beauty (SB) insertional mutagenesis
system, Wap-Cre;Cdh1F/F mice were crossed with T2/Onc;Rosa26Lox66SBLox71
mice, which contain the transgenic SB transposon concatemer (T2/Onc)
and the conditional SB11 transposase (Rosa26Lox66SBLox71), resulting in
Wap-Cre;Cdh1F/F;T2/Onc;Rosa26Lox66SBLox71/+ (hereafter referred to as Wap-
Cre;Cdh1F/F;SB) mice (Figure 3.1A)11,19,20. In these mice, the transgenic Cre re-
combinase was expressed from the promoter of the mammary-specific gene Wap,
resulting in the combined inactivation of Cdh1 and the mobilization of transposons
in mammary epithelial cells. To account for a potential bias toward transposition
events occurring in cis on the chromosome containing the transgenic SB transposon
concatemer, we used two different T2/Onc transgenic lines carrying the transposon
donor loci on chromosomes 1 and 15, respectively. Mice that lacked at least one of
the two SB components and mice that retained one wild-type allele of Cdh1 were
used as SB-inactive (Wap-Cre;Cdh1F/F) and Cdh1-proficient (Wap-Cre;Cdh1F/+;SB)
control mice, respectively.
Wap-Cre;Cdh1F/F;SB female mice developed multiple independent mammary tumors,
with a significantly decreased median mammary tumor-specific survival (537 d) than
in Wap-Cre;Cdh1F/F female mice (Figure 3.1B). No difference in median survival was
observed between Wap-Cre;Cdh1F/F;SB mice carrying the T2/Onc transposon donor
locus on chromosome 1 or 15 (Supplementary Figure S3.1A). Taken together, these
data indicate that mammary-specific SB transposition accelerates mammary tumor
formation in Wap-Cre;Cdh1F/F;SB mice, underscoring the idea that additional muta-
tions are required for malignant transformation of E-cadherin-deficient mammary
epithelial cells.
3.3.2 SB-induced mammary tumors reflect human ILC
Histopathological analysis of 123 mammary tumors from 89 Wap-Cre;Cdh1F/F;SB
mice showed that 80% of the tumors (99/123) showed an infiltrative growth pat-
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Fig. 3.1. SB insertional mutagenesis induces tumorigenesis in female mice with
mammary-gland-specific inactivation of E-cadherin. (A) Overview of the en-
gineered alleles in Wap–Cre;Cdh1F/F;SB mice. In this SB mutagenesis system,
genetically engineered transposons, which contain a 5’ long terminal repeat (LTR)
from the murine stem cell virus (MSCV) and two splice acceptor sites (SA/En2SA)
in opposite orientations, are excised from a transgene concatemer by the SB trans-
posase through indirect and direct repeats (IR/DR) and randomly reintegrated
elsewhere in the genome19. Depending on the location and orientation of their
insertion, these transposons can activate neighboring genes by inducing expres-
sion from the MSCV LTR or truncate gene transcripts using either of the splice
acceptor sites. Numbered boxes represent exons of the canonical gene transcript.
(B) Kaplan–Meier curve showing mammary tumor-specific survival (as defined in
the Online Methods) for the indicated genotypes. Wap–Cre;Cdh1F/F;SB (n = 268)
females show reduced survival as compared to Wap–Cre;Cdh1F/F (n = 91) (537
d versus >1,000 d; p < 0.0001, Mantel–Cox test) and Wap–Cre;Cdh1F/+;SB
(n = 20) (537 d versus >1,000 d; p = 0.0002) females. ∗p < 0.05 by Mantel–Cox
test. (C) Representative low- (left) and high-magnification (right) hematoxylin
and eosin (H&E)-stained images of cells with the different morphologies (ILC,
n = 99; spindle cell, n = 54; squamous metaplasia, n = 30). Scale bars, 50 µm.
tern with noncohesive E-cadherin-negative and cytokeratin 8 (CK8)-positive cells
invading the surrounding tissue in single-cell strands, thus resembling hILC (Fig-
ure 3.1C-D, Supplementary Figure S3.1B-C and Supplementary Table S3.1). Growth
patterns that were reminiscent of the alveolar or solid variants of ILC were also
occasionally observed, with nests and sheets of tumor cells, respectively. As such,
these tumors were classified as mouse ILC (mILC). Squamous metaplasia and tu-
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Fig. 3.1. Continued. (D) Histological classification of 123 tumors from 89
Wap–Cre;Cdh1F/F;SB females and the overlap with metastasis forma-
tion. (E) Overview of metastases to distant organs in metastasis-bearing
Wap–Cre;Cdh1F/F;SB females (30/89 mice).
mors with a spindle cell morphology were observed in 24% and 44% of all tumors,
respectively. Microscopic analysis showed metastasis in 34% of all tumor-bearing
Wap-Cre;Cdh1F/F;SB mice with predominant colonization of the lungs, lymph nodes,
kidneys, spleen and liver (Figure 3.1E). In conclusion, SB-mediated insertional mu-
tagenesis in Wap-Cre;Cdh1F/F;SB female mice results in an accelerated development
of mammary tumors, with the majority of tumors closely resembling hILC.
To establish whether the SB-induced mammary tumors modeled the luminal breast
cancer subtype of hILC, we used the PAM50 gene signature, which distinguishes in-
trinsic breast cancer subtypes, to cluster mouse tumors with human tumors from the
Cancer Genome Atlas (TCGA)21,22. For additional reference, two existing mouse mod-
els of luminal breast cancer (Wap-Cre;Cdh1F/F;PtenF/F)23 and basal-like breast cancer
(K14-Cre;Brca1F/F;Trp53F/F)24 were included in the clustering analysis. The resulting
unsupervised hierarchical clustering showed that the majority of the SB-induced tu-
mors coclustered with luminal breast cancers, confirming that these tumors reflected





































Fig. 3.2. Gene expression analysis of SB-induced tumors. (A) Unsupervised clustering
analysis (Euclidean distance, average linkage) of the SB-induced tumors (n =
123) with human breast cancer samples from TCGA (LumA, n = 231; LumB,
n = 127; basal-like, n = 95; HER2-enriched, n = 57 and normal-like, n = 29)
and tumors derived from mouse models of luminal (n = 20) and basal-like
(n = 22) breast cancer using the PAM50 gene signature. The clustering was
performed using 46 orthologous mouse genes from the PAM50 signature, but
only a representative subset of genes is shown. (B) Coefficient matrix from
the non-negative matrix factorization (NMF) analysis of the SB-induced tumors,
indicating the membership of each sample to each of the four subtypes (ILC-1,
n = 34; ILC-2, n = 33; spindle-cell-like, n = 30; squamous-like, n = 26). The
matrix is annotated with the morphological characteristics of samples and shows
a clear association between the clusters and the different morphologies.
3.3.3 SB-induced tumors comprise distinct molecular
subtypes
To determine whether the SB-induced mammary tumors consisted of distinct molec-
ular subtypes, we used a non-negative matrix factorization (NMF) procedure to
cluster tumors by their gene expression profiles. This analysis identified four sub-
types (Figure 3.2B), which were not associated with a specific T2/Onc transgenic line
(Supplementary Figure S3.3). Two of these subtypes (spindle-cell-like and squamous-
like) were associated with a spindle cell morphology and squamous metaplasia,
respectively (one-sided Fisher’s exact test with Benjamini-Hochberg correction, false
discovery rate (FDR) < 0.05). These morphological associations were supported
by the expression of corresponding marker genes (Supplementary Figure S3.2B-C).
The remaining two molecular subtypes consisted mainly of mILCs (FDR < 0.05),
suggesting that the Wap-Cre;Cdh1F/F;SB females developed two distinct subtypes of
mILC (which we refer to as mILC-1 and mILC-2).
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Fig. 3.2. Continued. (C,D) Heat map (C) and quantification (D) of the expression of four
key genes from the PAM50 gene signature for the different SB-induced subtypes
and the mouse reference models, highlighting differences in expression between
the different subtypes described in B. SC, spindle-cell-like; SQ, squamous-like.
Boxes extend from the third (Q3) to the first (Q1) quartile (interquartile range,
IQR), with the line at the median; whiskers extend to Q3 + 1.5 ∗ IQR and to
Q1− 1.5 ∗ IQR. Points beyond the ends of the whiskers are outliers. (E) Principal
component analysis (PCA) plot comparing the two mILC subtypes to the hILC
subtypes from TCGA (immune-related, n = 50; reactive-like, n = 50; proliferative,
n = 27) using orthologous genes from TCGA’s 60-gene subtype classifier. a.u.,
arbitrary units.
By projecting the gene expression profiles of these subtypes onto the PAM50 gene
signature, we found that mILC-1 tumors were characterized by high expression of
Esr1 (which encodes estrogen receptor (ER)-α) and the ER transcriptional modulator
Foxa1, as well as low expression of the proliferation marker Mki67 (Figure 3.2C-D
and Supplementary Figure S3.2D). Consequently, we found that mILC-1 tumors most
closely reflect the luminal A subtype of tumors25–27. As compared to mILC-1 tumors,
mILC-2 and spindle-cell-like tumors generally showed lower expression of Esr1 and
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higher expression of Mki67, indicating that these tumors are more proliferative.
Squamous-like tumors were mainly distinguished by the high expression of keratin-
encoding genes, such as Krt5.
To explore the potential links between our mILC subtypes and the three subtypes
(reactive-like, immune-related and proliferative) that were identified in hILC7,
we compared our mILCs with hILCs from the TCGA ILC study using the TCGA
60-gene subtype classifier. After translating this 60-gene signature into a mouse
signature using 49 orthologous mouse genes, we combined the two data sets and
compared the expression of the genes using principle component analysis (PCA).
This analysis showed that mILC-2 tumors are more similar to the proliferative human
subtype, which was also supported by the relatively higher expression of Mki67
in mILC-2, whereas mILC-1 tumors reflected the immune-related human subtype
(Figure 3.2E).
3.3.4 Identification of candidate genes involved in ILC
development via SB insertional mutagenesis
To identify the genes that were involved in ILC development, we sequenced the SB
transposon insertion sites of the 99 tumors with an ILC morphology by using the
ShearSplink protocol, which permits semiquantitative high-throughput analysis of
insertion sites28. This allowed us to determine both the location and the relative
clonality of the insertions within each tumor. We then used Gaussian kernel convolu-
tion (GKC) to identify common insertion sites (CISs)29, which represented genomic
loci that were more frequently occupied by SB insertions than those expected by
chance, and assigned CISs to putative target genes using a rule-based mapping
(RBM) approach30 (Figure 3.3A).
This analysis identified 3,230 insertions with a median of 29 insertions per tumor
(Supplementary Figure S3.4). From these insertions, we identified 58 CISs, which
could be assigned to 30 candidate genes that were potentially involved in ILC
development (hereafter referred to as candidate genes) (Figure 3.3B). A comparison
between the T2/Onc lines showed that, although line-specific biases were evident for
four candidate genes that were located in cis with the donor locus (Myh9, Ppp1r12b,
Trps1 and Trp53bp2), only Trp53bp2 showed significant bias toward one of the
lines (Supplementary Table S3.2). Furthermore, separate analyses on the individual
T2/Onc lines independently identified these genes as CISs, demonstrating that none
of these CIS-associated genes were unique to either line. We therefore decided
to include the chromosomes that contained the donor loci in the CIS analysis to
increase the power of the screen.
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Fig. 3.3. Insertion analysis of tumors from Wap–Cre;Cdh1F/F;SB females.
(A) Overview of the pipeline used to identify candidate genes. (B) Overview of
the insertions in candidate genes across all samples with an ILC morphology
(n = 99). The relative clonality of the insertions within each sample is depicted
in blue. (C) Orientation bias of the candidate genes, indicated by their fraction of
sense insertions. Genes with a strong bias toward sense insertions are expected
to be activated, whereas those biased toward antisense insertions are predicted
to be inactivated or to yield truncated products. The dashed red line (y = 0.5)
indicates an equal ratio of sense and antisense insertions. For clarity, only the
main candidates (which occur in six or more samples) are labeled.
To prioritize candidate genes, we ranked the genes by their frequency and the
median value of the clonality of their insertions (Supplementary Figure S3.5A).
Using this approach, we selected 19 main candidate genes that were mutated in
at least six samples, four of which were mutated in more than 25 samples (Fgfr2,
Trps1, Ppp1r12a and Myh9). The majority of these genes had a high median clonality
(≥ 0.5), which supported their role as drivers of ILC (Supplementary Figure S3.5B).
In contrast, a subset of genes (for example, Rasa1, Setd5 and Ywhae) had a lower



























































Fig. 3.3. Continued. (D) Venn diagram depicting the candidate genes involved in PI3K-
AKT signaling (according to KEGG, dashed circle), which is known to be associ-
ated with hILC, together with two significant pathways from the KEGG analysis.
(E) Overview of insertions in the four genes that were identified to be significantly
mutually exclusive (p < 10−3) using the DISCOVER algorithm. The relative clon-
ality of the insertions within each sample is depicted in blue. (F) Projection of all
candidate genes onto the STRING protein–protein interaction network (version
10). Only connected nodes are shown.
With regard to their associations with subtypes, insertions in Trps1 were enriched in
the combined mILC-1 and mILC-2 subtypes, whereas insertions in Eras and Tgfbr2
were enriched in the mILC-2 and squamous-like subtypes, respectively (one-sided
Fisher’s exact test with Benjamini-Hochberg correction, FDR < 0.1; Supplementary
Figure S3.6).
52 Chapter 3 Insertional mutagenesis identifies drivers of a novel oncogenic pathway in ILC
3.3.5 SB insertional mutagenesis identifies known ILC
drivers
To determine their biological relevance, we compared our candidate genes with
known drivers of ILC formation. This analysis showed that the SB screen was able to
identify known cancer genes such as Trp53, which has been shown to collaborate with
E-cadherin loss in the formation of mouse mammary tumors that resemble human
pleomorphic ILC10,11,16. Similarly, the screen identified several genes involved in
the PI3K-AKT signaling pathway (for example, Fgfr2 and Eras), which is mutated
in approximately 50% of hILC8,17,18. These results demonstrated that our screen
identified cancer driver genes and pathways that are known to be involved in hILC.
3.3.6 Candidate genes are biased toward inactivating
insertions
To determine how the SB insertions affected expression of the candidate genes, we
investigated orientation biases of the SB insertions in each candidate gene. This
analysis (Figure 3.3C) showed that four of the candidates (Trp53bp2, Gab1, Arfip1
and Eras) mainly contained insertions in the sense orientation, which indicated that
these genes were likely activated by their insertions (for example, Gab1; Supplemen-
tary Figure S3.7A). In support of this hypothesis, Trp53bp2, Gab1 and Eras showed
significantly (p < 10−3) increased expression of exons downstream of the insertion
site (Supplementary Figure S3.7B). In contrast, most of the candidate genes either
showed no orientation bias or were biased toward antisense insertions (for example,
Trps1; Supplementary Figure S3.7C), and their products were therefore likely inac-
tivated or truncated by the insertions. As expected, these genes typically showed
substantially decreased mRNA expression of exons downstream of the insertion site
(Supplementary Figure S3.7B).
3.3.7 SB insertion patterns identify oncogenic pathways in
mILC
To determine which processes or pathways were affected by the SB insertions, we
performed pathway enrichment analysis with all of the candidate genes using the
Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Figure 3.3D and
Table 3.1). This analysis identified several significantly enriched pathways with an
FDR of < 0.1, including the RAS-MAPK signaling pathway and that involved in the
regulation of the actin cytoskeleton. Consistent with this, several tumors showed
positive immunohistochemical staining for phosphorylated ERK1-ERK2, which are
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downstream effectors of RAS-MAPK signaling (Supplementary Figure S3.8). In
contrast to that seen in hILC, we did not find a significant enrichment for genes that
encoded the canonical components of the PI3K-AKT pathway (FDR = 0.44).
To identify further evidence that the insertions may be targeting a common biologi-
cal process or pathway, we used the DISCOVER31 algorithm to test for associations
of co-occurrence and mutual exclusivity between candidate genes. Although this
analysis did not identify any significant co-occurrences, it did identify a subgroup of
four genes (Myh9, Trp53bp2, Ppp1r12a and Ppp1r12b) that showed strong mutual
exclusivity (p < 10−3), suggesting that these genes were likely involved in a com-
mon pathway (Figure 3.3E). This hypothesis was supported by a projection of the
candidate genes onto the STRING protein-protein interaction network (Figure 3.3F),
which showed that three of these genes (Ppp1r12a, Ppp1r12b and Myh9) are in fact
known interactors in the STRING network.
Taken together, these analyses identified Myh9 (which encodes nonmuscle myosin
IIa heavy chain 9), Ppp1r12a and Ppp1r12b (also known as myosin phosphatase-
targeting subunit family members Mypt1 and Mypt2, respectively), and Trp53bp2
(also known as Aspp2) as potential drivers of a novel oncogenic pathway in ILC. The
mutual exclusivity, combined with the observation that Ppp1r12a, Ppp1r12b and
Trp53bp2 encode protein phosphatase 1 (PP1) targeting subunits32–34, supports the
idea that these genes function in a common pathway. According to the KEGG analysis,
this novel pathway may be involved in the regulation of the actin cytoskeleton,
suggesting that the disruption of this regulatory process could have a role in the
malignant transformation of E-cadherin-deficient mammary epithelial cells.
3.3.8 TP53BP2, PPP1R12B and MYH9 are frequently
aberrated in hILC
To establish the human relevance of the identified candidate genes, we assessed
their mutational status in human breast cancers from TCGA7 (Figure 3.4A and
Tab. 3.1. Overview of the significantly enriched pathways (hypergeometric test with
Benjamini–Hochberg correction, FDR < 0.1) according to KEGG pathway
enrichment analysis using all candidate genes.
Gene set p value FDR Overlapping genes
MAPK signaling pathway 5.17 ∗ 10−6 1.56 ∗ 10−3 Fgfr2, Nf1, Rasa1, Rasgrf1, Tgfbr2, Trp53
Chronic myeloid leukemia 1.08 ∗ 10−5 1.63 ∗ 10−3 Cblb, Runx1, Tgfbr2, Trp53
Proteoglycans in cancer 3.24 ∗ 10−5 3.26 ∗ 10−3 Cblb, Gab1, Ppp1r12a, Ppp1r12b, Trp53
Ras signaling pathway 5.70 ∗ 10−5 4.31 ∗ 10−3 Fgfr2, Gab1, Nf1, Rasa1, Rasgrf1
EGFR tyrosine kinase inhibitor resistance 4.98 ∗ 10−4 3.01 ∗ 10−2 Fgfr2, Gab1, Nf1
Regulation of actin cytoskeleton 7.24 ∗ 10−4 3.17 ∗ 10−2 Fgfr2, Myh9, Ppp1r12a, Ppp1r12b
Pathways in cancer 7.35 ∗ 10−4 3.17 ∗ 10−2 Cblb, Fgfr2, Runx1, Tgfbr2, Trp53
Neurotrophin signaling pathway 1.74 ∗ 10−3 6.57 ∗ 10−2 Gab1, Trp53, Ywhae
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Supplementary Figure S3.9). This analysis showed that TP53BP2, PPP1R12B and
MYH9 are commonly aberrated in the 127 hILCs. In particular, TP53BP2 and
PPP1R12B are both located within the human chromosome 1q locus, which is
frequently gained or amplified in hILC, and in breast cancer in general. In the breast
cancer samples in TCGA, expression of these genes was significantly correlated with
their copy number level (Figure 3.4B-C), indicating that gain or amplification of
TP53BP2 and PPP1R12B generally results in increased mRNA expression. In contrast,
MYH9 was mainly affected by truncating or missense mutations and heterozygous
copy number loss, the latter of which was correlated with reduced expression of
MYH9 mRNA (Figure 3.4D), which supported a haploinsufficient tumor suppressive
role of MYH9. Collectively, these data indicate that three of four mutually exclusive
genes are frequently mutated in hILC and that these aberrations result in altered
gene expression, supporting their role as potential drivers of hILC.
3.3.9 SB insertions show haploinsufficiency of Myh9 in ILC
SB insertions in Myh9 were mainly heterozygous and did not show any clustering,
indicating that they likely resulted in heterozygous loss of Myh9 (Figure 3.5A and
Supplementary Figure S3.10A). To assess the effects of SB insertions on Myh9 ex-
pression, we derived tumor cells from SB-induced tumors with or without insertions
in Myh9. PCR amplification of the transposon-Myh9 junction fragments confirmed
the presence of heterozygous Myh9 insertions in the isolated tumor cells, which
coincided with decreased levels of MYH9 protein (Figure 3.5B and Supplementary
Figure S3.10B). Notably, MYH9 expression was never completely lost, suggesting
that it may function as a haploinsufficient tumor suppressor in ILC development. To
rule out the possibility of a mixed cell population, heterozygous Myh9 insertions
were also confirmed by PCR in clones that were derived from the tumor cell lines
(Supplementary Figure S3.10C).
3.3.10 SB insertions cause truncation of PP1-targeting
subunits
In contrast to Myh9, SB insertions in the genes encoding PP1 targeting subunits
(Trp53bp2, Ppp1r12a and Ppp1r12b) were strongly clustered, which suggested the
expression of truncated transcripts (Figure 3.5C-E). To test this hypothesis, we
visualized the expression of samples with insertions in these genes at the exon level
to identify biases in read coverage before and after the insertion sites. This analysis
showed a relative increase in expression of the exons 5’ of the SB insertions in
Ppp1r12a and Ppp1r12b and the exons 3’ of the insertions in Trp53bp2, as compared
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Fig. 3.4. Overview of the candidate genes in hILC. (A) Overview of the mutations and
copy number events in 127 TCGA ILC samples for each of the main candidate
genes. Percentages indicate the fraction of tumors with alterations in the respec-
tive genes. (B–D) Correlation between the expression of TP53BP2 (B), PPP1R12B
(C) and MYH9 (D) and their respective copy number levels, using the entire
TCGA breast cancer data set (n = 1068) to ensure sufficient numbers for each
copy number level. Boxes extend from the third (Q3) to the first (Q1) quar-
tile (IQR), with the line at the median; whiskers extend to Q3 + 1.5 ∗ IQR and
to Q1 − 1.5 ∗ IQR. Correlation scores (ρ) and p values were calculated using
Spearman’s rank correlation. Het. loss, heterozygous loss; Ampl., amplification.
encoding the truncated PP1 targeting subunits was confirmed by northern blot
analysis (Supplementary Figure S3.11A-C) and by western blotting for PPP1R12A
(Supplementary Figure S3.11D).
Analysis of the predicted proteins showed that the truncated PP1 targeting subunits
lacked various regulatory domains but retained their PP1-binding domains (Fig-
ure 3.5F). To test whether the truncated proteins were still able to bind PP1, we
performed immunoprecipitation with a Flag-specific antibody followed by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) analysis in mouse mam-
mary epithelial HC11 cells expressing a Flag-tagged truncated PPP1R12A protein
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Fig. 3.5. Overview of the insertions and corresponding gene expression of the mu-
tually exclusive genes. (A) Visualization of SB insertions (arrows) in Myh9
(n = 33 tumors). Bars represent the exact genomic locations of the insertions. (B)
Immunoblot for MYH9 levels in SB-induced tumor-derived cells without (n = 5)
or with (n = 4) insertions in Myh9. β-actin was used as a loading control. (C–E)
Left, schematic representation of insertions in Trp53bp2 (C), Ppp1r12a (D) and
Ppp1r12b (E) (from 17, 52 and 9 tumors, respectively) showing strong clustering
of insertions within the genes. Right, heat maps of the exon-level expression
of the indicated genes in samples with an insertion, using a z-score measure to
normalize for overall expression differences between samples. The positions of
the insertions in each sample are indicated by black lines. Red indicates relatively
increased expression of an exon; blue signifies relatively decreased expression.
Increased expression toward the end of Ppp1r12a and Ppp1r12b is due to the use
























































































Fig. 3.5. Continued. (F) Overview of the binding domains of mouse TRP53BP2,
PPP1R12A and PPP1R12B, based on previously published work32,35. Colors
indicate the predicted proteins from the truncated genes. UBL, ubiquitin-like
domain; PRO, proline-rich domain; PP1, PP1-binding domain; ANK, ankyrin
repeats; SH3, Src homology 3 domain; CI, central insert; LZ, leucine zipper;
aa, amino acid. Asterisks indicate inhibitory or regulatory phosphorylation sites.
(G,H) Volcano plots showing protein interactors of truncated PPP1R12A (G) and
TRP53BP2 (H) in HC11 cells that were transduced with pBABE-Ppp1r12aex1-9
or pBABE-Trp53bp2ex13–18, respectively, as compared to that in cells that were
transduced with the pBABE empty vector control. p values were calculated using
a permutation-based FDR-corrected t-test. Proteins were considered interactors if
p < 0.01 and log2(abundance difference) > 1. LFQ, label-free quantification.
(encoded by Ppp1r12a exons 1-9) or TRP53BP2 protein (encoded by Trp53bp2
exons 13-18). This showed that both truncated proteins were still able to bind
specific PP1 isoforms, with PPP1R12A able to bind both PPP1CA and PPP1CB, and
TRP53BP2 preferentially able to bind PPP1CA (Figure 3.5G-H and Supplementary
Figure S3.11E). Taken together, these data suggest that truncated PPP1R12A and
TRP53BP2 are able to bind PP1 and that the loss of other regulatory domains could
affect their function.
3.3.11 Candidate ILC drivers enhance survival of Cdh1∆/∆
mouse mammary epithelial cells
To study the consequences of E-cadherin loss in primary mouse mammary epithelial
cells (MMECs), we used Cdh1F/F;Rosa26ACTB-tdTomato-EGFP MMECs, which contain, in
58 Chapter 3 Insertional mutagenesis identifies drivers of a novel oncogenic pathway in ILC
addition to floxed Cdh1 alleles, a Rosa26ACTB-tdTomato-EGFP reporter allele (termed
mT/mG) that expresses membrane-targeted mTomato before, and mGFP after, Cre
switching23,36. Transduction of Cdh1F/F;mT/mG MMECs with a Cre-encoding aden-
ovirus (AdCre) resulted in reduced proliferation and clonogenic survival, indicating
that E-cadherin loss alone is not sufficient for cellular transformation in vitro (Fig-
ure 3.6A-C). To test the effects of truncated PPP1R12A and TRP53BP2 in E-cadherin-
deficient MMECs, we transduced Cdh1F/F;mT/mG MMECs with lentiviruses encoding
Ppp1r12aex1-9 or Trp53bp2ex13-18 (Figure 3.6D). Simultaneous transduction of these
cells with AdCre showed that expression of truncated TRP53BP2 or PPP1R12A de-
creased cell death and increased clonogenic survival of E-cadherin-deficient MMECs,
without affecting canonical PI3K-AKT signaling (Figure 3.6A-C and Supplementary
Figure S3.12A-C). Similar results were obtained after reduction of MYH9 levels by
short hairpin RNA (shRNA)-mediated knockdown of Myh9 expression (Figure 3.6E-H
and Supplementary Figure S3.12D).
Previous work has shown that MYH9 is involved in regulating post-transcriptional
stabilization of the tumor suppressor p53, suggesting that an altered p53 response
in MYH9-deficient keratinocytes induces squamous cell carcinoma (SSC) in Tgfbr2
conditional-knockout mice37. In contrast, we and others38 have observed an intact
p53 response after DNA damage in cells with reduced MYH9 levels (Supplementary
Figure S3.12E-G), suggesting that an alternative mechanism of cellular transfor-
mation may be involved. Taken together, these data show that dosage reduction
of MYH9 or overexpression of truncated PP1 targeting subunits enhances survival
of E-cadherin-deficient MMECs and indicate deregulation of conventional actin-
related processes rather than loss of nuclear p53 retention or activation of canonical






























































































Fig. 3.6. Limited proliferation and survival of AdCre-transduced Cdh1F/F;mT/mG
mouse mammary epithelial cells (MMECs) that were rescued by expression
of truncated PPP1R12A and TRP53BP2 or by dosage reduction of MYH9. (A)
Cell survival analysis of AdCre-transduced Cdh1F/F;mT/mG MMECs that were
also transduced with lentiviruses encoding Ppp1r12aex1–9 or Trp53bp2ex13–18,
quantified using real-time IncuCyte imaging for 200 h. AdCre-transduced
Cdh1F/F;mT/mG MMECs also transduced with a GFP-expressing lentivirus (Lenti-
GFP) is shown as control. Data are mean ± s.d. of four independent experiments.
(B,C) Representative images (B) and quantification (C) of clonogenic assays (14
d after seeding the cells) of AdCre-transduced Cdh1F/F;mT/mG MMECs that were
also transduced with lentiviruses expressing the indicated constructs. Fold dif-
ference is relative to the GFP control. Data are mean ± s.d. of four independent
experiments. Scale bar, 1 cm. (D) Representative immunoblot (n = 3) for expres-
sion of Flag-tagged and truncated PPP1R12A and TRP53BP2 in AdCre-transduced
Cdh1F/F;mT/mG MMECs 7 d after transduction. β-actin was used as a loading
control.
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Fig. 3.6. Continued. (E) Cell survival analysis of AdCre-transduced Cdh1F/F;mT/mG
MMECs with simultaneous shRNA-mediated knockdown of Myh9 expression,
as quantified by real-time IncuCyte imaging for 200 h. Average survival of
AdCre-transduced Cdh1F/F;mT/mG MMECs of all shRNAs is shown. Independent
survival curves are depicted in Supplementary Figure S3.12D. Data are mean
± s.d. of three independent experiments. EV, empty vector. (F,G) Representa-
tive images (F) and quantification (G) of clonogenic assays of AdCre-transduced
Cdh1F/F;mT/mG MMECs with simultaneous shRNA-mediated knockdown of Myh9
expression 14 d after seeding the cells. Fold difference is relative to the value ob-
served in the EV control. Data are mean ± s.d. of three independent experiments.
Scale bar, 1 cm. (H) Representative immunoblot (n = 3) for the expression of
MYH9 in AdCre-transduced Cdh1F/F;mT/mG MMECs that also had simultaneous
shRNA-mediated knockdown of Myh9 expression (7 d after transduction). β-actin
was used as a loading control.
3.3.12 Truncated PPP1R12A and TRP53BP2 induce ILC
formation
Next we investigated whether expression of Ppp1r12aex1-9 and Trp53bp2ex13-18 in
Wap-Cre;Cdh1F/F mice could induce mammary tumor formation in vivo. To this
end, we introduced invCAG-Ppp1r12aex1-9-IRES-Luc and invCAG-Trp53bp2ex13-18-
IRES-Luc alleles for Cre-inducible expression of firefly luciferase and Ppp1r12a
exons 1-9 or Trp53bp2 exons 13-18, respectively, into the Col1a1 locus of
Wap-Cre;Cdh1F/F embryonic stem cells (ESCs) and subsequently generated
chimeric mice by blastocyst injection of the modified ESCs39 (Supplementary
Figure S3.13A). Male chimeras were mated with Cdh1F/F females to generate
Wap-Cre;Cdh1F/F;Col1a1invCAG-Ppp1r12a-ex1-9-IRES-Luc/+ (hereafter referred to as Wap-
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Cre;Cdh1F/F;Ppp1r12aex1-9) and Wap-Cre;Cdh1F/F;Col1a1invCAG-Trp53bp2-ex13-18-IRES-Luc/+
(hereafter referred to as Wap-Cre;Cdh1F/F;Trp53bp2ex13-18) mice, which showed
mammary-specific loss of E-cadherin expression and concomitant expression of
luciferase and truncated PPP1R12A or TRP53BP2, respectively (Figure 3.7A).
Wap-Cre;Cdh1F/F;Ppp1r12aex1-9 and Wap-Cre;Cdh1F/F;Trp53bp2ex13-18 female mice
showed mammary-specific bioluminescence signals that increased over time, which
indicated the development of mammary tumors (Figure 3.7B-C). Analysis of
the mammary glands from 15-week-old Wap-Cre;Cdh1F/F;Ppp1r12aex1-9 and Wap-
Cre;Cdh1F/F;Trp53bp2ex13-18 females showed multifocal tumor formation (in 27/29
and 30/30 of the analyzed glands, respectively), whereas no tumors were detected
in mammary glands from age-matched Wap-Cre;Cdh1F/F females (Figure 3.7D-E).
All of the tumors showed recombination of the conditional alleles (Supplementary
Figure S3.13B), which confirmed the inactivation of E-cadherin expression and the
activation of the expression of the truncated PP1 targeting subunits. Morphologically,
most of the tumors were CDH1-CK8+ and strongly invaded the surrounding tissue
(Supplementary Figure S3.13C). Taken together, these data confirm that loss of
expression of E-cadherin and concomitant expression of truncated PPP1R12A and
TRP53BP2 results in the development of mILCs that closely resemble hILC.



























































































































Fig. 3.7. Validation and characterization of candidate genes in genetically engi-
neered mice (GEMM). (A) Overview of the genetically engineered mice. ESC,
embryonic stem cell. (B) Representative images of in vivo bioluminescence
imaging of luciferase expression in Wap–Cre;Cdh1F/F;Ppp1r12aex1–9 (n = 3) and
Wap–Cre;Cdh1F/F;Trp53bp2ex13–18 (n = 3) females (at 100 d). Scale bar, 1 cm.
(C) Quantification of bioluminescence imaging of luciferase expression over time
in Wap–Cre;Cdh1F/F;Ppp1r12aex1–9 (n = 5) and Wap–Cre;Cdh1F/F;Trp53bp2ex13–18
(n = 5) females. Wap–Cre;Cdh1F/F females (n = 3) were used to show
background luminescence. (D) Representative images for H&E staining (left)
and for expression of E-cadherin (middle) and CK8 (right) by immunohis-
tochemistry in tumors of 15-week-old Wap–Cre;Cdh1F/F;Ppp1r12aex1–9 (n =
27 tumors) and Wap–Cre;Cdh1F/F;Trp53bp2ex13–18 (n = 30 tumors) females.
Scale bars, 50 µm. (E) Tumor burden in mammary glands of 15-week-old
Wap–Cre;Cdh1F/F (n = 34 glands), Wap–Cre;Cdh1F/F;Ppp1r12aex1–9 (n = 29
glands) and Wap–Cre;Cdh1F/F;Trp53bp2ex13–18 (n = 30 glands) females. Data are
mean ± s.d.
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Fig. 3.7. Continued. (F) Overview of intraductal injections performed in
Wap–Cre;Cdh1F/F;Cas9 females with high-titer lentivirus containing a vector
encoding Cas9, GFP and either a non-targeting (NT) single-guide RNA (sgRNA)
(Lenti-CRISPR-sgNT) or a sgRNA targeting the second exon of Myh9 (Lenti-
CRISPR-sgMyh9). (G) Representative images for H&E staining (left) and for
expression of E-cadherin (middle) and CK8 (right) in tumors (n = 11 tumors)
of Wap–Cre;Cdh1F/F;Cas9 females at 17 weeks after injection of Lenti-CRISPR-
sgMyh9. Scale bar, 50 µm. (H) Tumor burden of Wap–Cre;Cdh1F/F;Cas9 fe-
males 17 weeks after injection of Lenti-CRISPR-sgNT (n = 10 glands) or Lenti-
CRISPR-sgMyh9 (n = 26 glands). Data are mean ± s.d. (I) Representative
spectrum of insertions and deletions (indels) of targeted Myh9 alleles depicting
the CRISPR–Cas9-induced editing efficacy in the tumors (n = 3) as quantified
with the TIDE algorithm40. Fraction of unmodified alleles are depicted in pink;
red (p < 0.001) and black (p > 0.001) bars represent fractions of modified alleles.
(J,K) TIDE analysis of tumor cells cultured in vitro 5 d (J) and 50 d (K) after
isolation from a single tumor-bearing gland injected with Lenti-CRISPR-sgMyh9.
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3.3.13 Myh9 haploinsufficiency induces ILC formation
To determine whether loss of Myh9 also results in tumor formation in vivo, we
performed in situ gene editing of Myh9 in mammary epithelial cells using CRISPR-
Cas9 genome editing technology. We intraductally injected CRISPR-Cas9-encoding
lentiviruses that targeted the second exon of Myh9 (Lenti-CRISPR-sgMyh9) in Wap-
Cre;Cdh1F/F;Col1a1invCAG-Cas9-IRES-Luc/+ (Wap-Cre;Cdh1F/F;Cas9) female mice (Fig-
ure 3.7F). Analysis of the mammary glands 17 weeks after injection showed that 11
of 26 successfully injected glands contained mammary tumors that were CDH1-CK8+
and closely resembled hILC (Figure 3.7G-H and Supplementary Figure S3.13D).
Analysis of Myh9 target modification in these tumors showed equal levels of in-frame
and out-of-frame alterations (Figure 3.7I), suggesting that functional inactivation
of only one Myh9 allele had occurred, resulting in hemizygous expression of Myh9.
To substantiate this possibility, tumor cells from a successfully injected mammary
gland were isolated and cultured in vitro to remove stromal contaminants. Indeed,
DNA isolated from these tumor cells showed enrichment for in-frame and out-of-
frame genetic alterations in Myh9, supporting the idea of heterozygous loss of one
functional allele (Figure 3.7J-K). Collectively, these data provide additional support
for Myh9 as a haploinsufficient tumor suppressor in ILC development.
3.4 Discussion
Here we performed an SB-based insertional mutagenesis screen in mice to identify
novel genes and signaling pathways that are involved in ILC formation. SB-mediated
mutagenesis in Wap-Cre;Cdh1F/F;SB female mice resulted in the development of
multiple independent mammary tumors, which showed similarities to hILC in terms
of morphology and gene expression. CIS analysis identified multiple candidate
cancer genes, several of which have previously been implicated in hILC (such as
Arid1a, Nf1 and Runx1) and have also been shown to induce ILC formation in mice
(such as Trp53)7,16–18, demonstrating the relevance of the genes we identified.
In contrast to previous analyses of human data sets, we identified only a few
components of the canonical PI3K-AKT signaling pathway. Nevertheless, insertions
in Fgfr2 were observed in over half of the tumors, which could result in PI3K-AKT
pathway activation in the same manner as previously identified FGFR1 amplifications
in hILC41–43. Notably, mutations that can be linked to activated PI3K-AKT signaling
are found in only 50% of hILCs7,17,18, indicating that additional pathways are
involved in ILC formation. Consistent with this, our KEGG analysis of the candidate
genes in the SB-induced mILCs indicated a potential role for RAS-MAPK signaling,
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which was further supported by the presence of KRAS, NF1, MAP2K4, MAP3K1 and
ERBB2 mutations in hILC7,17,18,44. Additionally, we provided strong evidence that
genes involved in the regulation of the actin cytoskeleton (Ppp1r12a, Ppp1r12b,
Trp53bp2 and Myh9) effectively collaborated with E-cadherin loss in mILC formation
and were frequently mutated in hILCs. We therefore conclude that this process
constitutes a novel oncogenic pathway in ILC development.
An important advantage of cancer gene discovery using insertional mutagenesis
screens in mice is that these approaches can identify driver mutations that are not
readily apparent in humans. For example, MYH9 has not been identified as a tumor
suppressor in hILC because it is rarely mutated and mainly characterized by shallow
deletions. In contrast, our SB screen identified Myh9 as a haploinsufficient tumor
suppressor in ILC, as it was mainly affected by heterozygous inactivating insertions
that resulted in dosage reduction of MYH9. Haploinsufficiency of Myh9 has also
been observed for platelet development, resulting in macrothrombocytopenia in
human patients with heterozygous germline mutations in MYH945,46.
A second example involves the two candidate cancer genes Trp53bp2 and Ppp1r12b,
whose orthologs in humans are both located on the 1q locus. Although this locus
has already been described to be frequently amplified or gained in human breast
cancer7,12, the size of the amplicon makes it difficult to identify the relevant driver
gene(s). Notably, der(1;16)(q10;p10) unbalanced translocations, which result in a
chromosome 1q gain and chromosome 16q loss, are frequently observed in ILC47.
Although chromosome 16q loss is associated with LOH of CDH1, candidate driver
genes on chromosome 1q have remained elusive. Our screen pinpoints TP53BP2 and
PPP1R12B as potential drivers on this locus. Furthermore, we identified these genes
as part of a mutually exclusive group of four genes (Myh9, Ppp1r12a, Ppp1r12b and
Trp53bp2), indicating that these genes are targeting the same biological process.
Three of these genes (Myh9, Ppp1r12a and Ppp1r12b) are involved in the regulation
of the actin cytoskeleton, which implicates Trp53bp2 as an additional player in this
process.
Finally, three of the four genes in our mutually exclusive subgroup (Ppp1r12a,
Ppp1r12b and Trp53bp2) encode targeting subunits of PP1. Our data indicate that
strongly clustered SB insertions in these genes may be targeting specific domains,
thereby affecting PP1 functionality. Consistent with this, we observed that the
truncated PPP1R12A and TRP53BP2 proteins were still able to bind PP1 but lacked a
number of regulatory and/or inhibitory domains. Because these mutants rescued cell
survival of E-cadherin-deficient cells in vitro and collaborated with E-cadherin loss in
mammary tumorigenesis, our combined data suggest that rewiring of PP1 signaling
by dosage reduction of nonmuscle myosin IIa (MYH9) or by expression of truncated
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PPP1R12A or TRP53BP2 promotes malignant transformation of E-cadherin-deficient
mammary epithelial cells.
Although in vivo transposon mutagenesis is a powerful tool for cancer gene discovery,
there are a number of limitations of our screen. First, insertional mutagenesis does
not capture the full spectrum of hILC driver mutations (for example, PIK3CA point
mutations). Additionally, the bias toward gene inactivation or protein truncation
indicates that our screen might underestimate the number of oncogenes that are
involved in hILC. Complementary chemical or genetic mutagenesis strategies may be
used to identify additional ILC drivers. Second, Trp53bp2 and Ppp1r12b are affected
by mutually exclusive truncations in mILC, whereas both genes are co-amplified in
human breast cancers. It is, however, possible that these individual truncations may
have a similar effect on cellular transformation as the combined amplification of both
genes. Moreover, human breast cancers have been shown to express an N-terminally
truncated TP53BP2 isoform (∆N-ASPP2) that is similar to the truncated TRP53BP2
observed in mILCs48, warranting further investigation in future studies.
In summary, we show that our SB screen in mammary-specific E-cadherin-deficient
mice uncovers previously unidentified cancer genes whose orthologs are frequently
altered in hILC. This emphasizes the utility of in vivo insertional mutagenesis screens
in mice as a powerful genetic tool for unraveling biological processes underlying
human cancer development. Finally, our results identify a novel oncogenic pathway
involved in ILC formation, providing new opportunities for the development of
targeted therapies for hILC.
Acknowledgments We are grateful to E. Wientjens, J. Houthuijzen, M. van Mil-
tenburg, O. Bleijerveld, B. van Gerwen, B. Siteur, R. de Korte-Grimmerink, N. Proost,
U. Boon, C. Brambillasca, R. Mezzadra, S. Cornelissen and L. Braaf for providing
technical suggestions and/or help with the experiments, S. Canisius for critical
reading of the manuscript and N. Hynes (Friederich Miescher Institute, Basel) for
the HC11 cells. We thank the NKI animal facility, the animal pathology facility, the
mouse clinic transgenic and intervention unit, the core facility molecular pathology
and biobanking (CFMPB), and the genomics core facility for their expert technical
support. Financial support was provided by the Netherlands Organization for Sci-
entific Research (NWO: Cancer Genomics Netherlands, CGCNL), Cancer Systems
Biology Center (CSBC), the Netherlands Genomics Initiative (NGI) grants Zenith
93512009 (J.J.), VENI 016156012 (M.N.) and VICI 91814643 (J.J.), the EU Seventh
Framework Program (EurocanPlatform project 260791 (J.J.) and Infrafrontier-I3
project 312325 (J.J.)), the European Research Council (ERC Synergy project Com-
batCancer) (J.J.), and a National Roadmap grant for Large-Scale Research Facilities
from NWO (J.J.).
3.4 Discussion 67
Author contributions S.M.K., K.S., S.A., E.S., A.P.D. and E.v.d.B. performed labo-
ratory experiments; J.R.d.R. identified the insertion sites and CISs, analyzed the
RNA sequencing data sets and performed the other bioinformatic analyses; C.K. and
J.J.t.H. assisted in the initial bioinformatic analysis for the identification of insertion
sites and CISs; S.K. and J.W. assessed the histology of mouse tumors and quantified
the immunohistochemically stained images; D.J.A. was responsible for sequencing
the transposon insertions; M.J.K. initiated the breeding of the mouse lines; M.N.,
L.F.A.W. and J.J. supervised the experiments; and J.R.d.R., S.M.K., L.F.A.W. and J.J.
wrote the manuscript.




Generation of mice The generation of Wap-Cre;Cdh1F/F mice has previously been
described by Derksen et al.11. We used the transgenic SB transposon concatemer
(T2/Onc) mouse lines 68 and 76 with the transposon donor locus located on chromo-
somes 15 and 1, respectively19. The mice containing the conditional HSB5 variant
of the SB transposase in the Rosa26 locus has been described by March et al.20.
Wap–Cre;Cdh1F/F mice were crossed with T2/Onc and Rosa26Lox66SBLox71 mice to
generate Wap–Cre;Cdh1F/F;T2/Onc;Rosa26Lox66SBLox71/+ (Wap–Cre;Cdh1F/F;SB) mice.
All Wap–Cre;Cdh1F/F;SB mice were from a mixed genetic background (C57BL/6J and
FVB/N). The experimental cohort was monitored, and mice were sacrificed (mam-
mary tumor-specific survival) when the (total) mammary tumor burden reached
a size of 1500 mm3 (tumor volume = length ∗ width2 ∗ 0.5) or the mice suffered
from clinical signs of distress caused by the mammary tumor burden or metastatic
disease (such as respiratory distress, ascites, distended abdomen, rapid weight loss
and severe anemia). Lungs, heart, liver, spleen, intestines, mesenterium, kidneys,
mammary glands, pancreas and tumor-draining lymph nodes were collected and
analyzed microscopically for the presence of metastatic foci.
The Ppp1r12aex1–9 sequence (NM_027892.2) was isolated from the cDNA of mouse
tumor tissue using two subsequent Phusion Flash High-Fidelity (ThermoFisher Sci-
entific) PCRs and subsequently cloned in a zero TOPO blunt vector (ThermoFisher
Scientific). The Trp53bp2ex13–18 sequence (NM_173378.2) was commercially syn-
thesized by Genscript, and FseI-PmeI overhangs were added using Phusion Flash
High-Fidelity DNA Polymerase. The cDNAs were sequence-verified and inserted
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as FseI-PmeI fragments into the Frt-invCag-IRES-Luc vector, resulting in Frt-invCag-
Ppp1r12aex1–9-IRES-Luc and Frt-invCag-Trp53bp2ex13–18-IRES-Luc, respectively. Flp-
mediated integration of the shuttle vectors in Wap–Cre;Cdh1F/F;Col1a1frt/+ ESC
clones and subsequent blastocyst injections of the modified ESCs were performed
as previously described39. The resulting chimeric males were crossed with Cdh1F/F
(FVB) females to generate Wap–Cre;Cdh1F/F;Col1a1invCAG-Ppp1r12a-ex1-9-IRES-Luc/+
(Wap–Cre;Cdh1F/F;Ppp1r12aex1–9) and Wap–Cre;Cdh1F/F;Col1a1invCAG-Trp53bp2-ex13-18-IRES-Luc/+
(Wap–Cre;Cdh1F/F;Trp53bp2ex13–18) mice, respectively.
The generation of Wap–Cre;Cdh1F/F;Col1a1invCAG-Cas9-IRES-Luc/+ (Wap–Cre;Cdh1F/F;Cas9)
mice has been described by Annunziato et al.49. The Wap–Cre, Cdh1F,
T2/Onc, Rosa26Lox66SBLox71 and Col1a1invCAG-Cas9-IRES-Luc alleles were confirmed
by PCR as previously described10,11,19,39,50. Col1a1invCAG-Ppp1r12a-ex1-9-IRES-Luc,
Col1a1invCAG-Trp53bp2-ex13-18-IRES-Luc and wild-type alleles were detected by standard
PCR with an annealing temperature of 58 ◦C (product sizes of 433 bp, 351 bp and
234 bp, respectively). All of the primers are listed in Supplementary Table S3.3.
All mouse experiments were approved by the Animal Ethics Committee of the Nether-
lands Cancer Institute and performed in accordance with institutional, national and
European guidelines for animal care and use.
In vivo bioluminescence imaging In vivo bioluminescence imaging was performed
as previously described51. Signal intensity was measured over the region of interest
and quantified as flux (photons per s per cm2 per sr).
Intraductal injection Intraductal injections were performed as previously
described49,52. Lentiviral titers ranging from 2 ∗ 108 transducing units (TU) per
milliliter to 2.5 ∗ 109 TU/ml were used.
Histology and immunohistochemistry Tissues were formalin-fixed and paraffin-
embedded (FFPE) by routine procedures. Hematoxylin and eosin (H&E) staining
was performed as previously described53. All of the tissues were stained with H&E.
Mammary tumors were also stained for expression of E-cadherin, CK1, CK8 and/or
vimentin and were reviewed by a European College of Veterinary Pathologists (ECVP)
certified veterinary pathologist (S.K.) in a blinded manner, according to international
consensus of mammary pathology54, and by a consultant clinical pathologist with
expertise in breast cancer (J.W.). ILCs were characterized by small to moderately
sized neoplastic epithelial cells with a dominant ‘Indian file’ growth pattern in
tumor-associated stroma with moderately polymorphic nuclei, sporadic mitoses
and occasional intracytoplasmic vacuolization. The neoplastic cells were CK8+ and
lacked expression of E-cadherin (CDH1-), as confirmed by immunohistochemistry.
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Growth patterns reminiscent of the alveolar or solid variants of ILC were also
occasionally observed with nests and sheets of tumor cells, respectively. Tumors
with a spindle cell morphology were classified based on CK8-VIM+ neoplastic cells.
Squamous metaplasia was classified based on morphology as well as expression
of CK1. Tumor burden was calculated as the ratio between the total tumor area
and the area of the whole mammary gland, using ImageJ software version 1.4.3.67.
Immunohistochemical staining was processed as previously described51,53. Antibody
details and antigen retrieval methods are described in Supplementary Table S3.4.
The images on the slides were captured using an Axioskop 40 microscope and an
AxioCam MRc5 camera (Zeiss) and analyzed using the ZEN lite 2012 (Blue edition)
software, or the slides were digitally processed using the Aperio ScanScope (Aperio,
Vista, CA, USA) and captured using ImageScope software version 12.0.0 (Aperio).
3.5.2 Cell culture
Cell lines Purified primary MMECs were isolated from 10-to-15 week-old fe-
males as previously described23,55 and cultured in Dulbecco’s modified Eagle’s
medium (DMEM)-F12 containing 10 % fetal bovine serum (FBS), 100 IU/ml peni-
cillin, 100 µg ml−1 streptomycin, 5 ng ml−1 insulin, 5 ng ml−1 epidermal growth
factor (EGF) (all from Life Technologies) and 5 ng ml−1 cholera toxin (Gentaur).
HC11 cells56 were cultured in DMEM/F12-Glutamax medium containing 10 % FBS,
100 IU/ml penicillin, 100 µg ml−1 streptomycin, 5 ng ml−1 insulin, 5 ng ml−1 EGF
(all from Life Technologies). All cell lines were routinely tested for mycoplasma
contamination using the MycoAlert mycoplasma detection kit (Lonza).
For the isolation of primary tumor cells, whole mammary tissue or 50 mm3 to
100 mm3 tumor sample was finely chopped using a McIlwain tissue chopper (The
Mickle Laboratory Engineering Co.) and digested for 30 minutes shaking at 37 ◦C
with 3 mg ml−1 collagenase, 0.1 % trypsin and 0.5 µg ml−1 Fungizone in DMEM/F12-
glutamax medium containing 2 % FBS and 100 IU/ml penicillin (all Life Technolo-
gies). Enzyme activity was neutralized by addition of DMEM/F12-glutamax with
2 % FBS and suspension was dispersed through a 40 µm cell strainer. Cells were
washed twice and cultured in DMEM/F12-glutamax medium containing 10 % FBS,
100 IU/ml penicillin, 100 µg ml−1 streptomycin, 5 ng ml−1 insulin, 5 ng ml−1 EGF
(all Life Technologies), and 5 ng ml−1 cholera toxin (Gentaur). Single clones were
derived by seeding the polyclonal cell lines, which were first dispersed through a
40 µm cell strainer, at a concentration of 0.5 cells per 96-well. 293T and Phoenix
packaging cells were cultured in Iscove’s medium (Life Technologies) containing
10 % FBS, 100 IU/ml penicillin, and 100 µg ml−1 streptomycin.
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Retroviral vectors and virus production The Ppp1r12aex1-9 and Trp53bp2ex13-18 se-
quences were isolated with BamHI-SalI overhangs and a 3’ or 5’ FLAG-tag, re-
spectively using Phusion Flash High-Fidelity DNA Polymerase from Frt-invCag-
Ppp1r12aex1-9-IRES-Luc or Frt-invCag-Trp53bp2ex13-18-IRES-Luc and subsequently
cloned in zero TOPO blunt vectors. These cDNAs were inserted as BamHI-SalI
fragments into the pBABE-puro retroviral vector. Lenti-GFP, Lenti-Ppp1r12aex1-9 and
Lenti-Trp53bp2ex13-18 were constructed as follows. AgeI and SalI were used to remove
GFP from the SIN.LV.SF vector57, which was a gift of Eugenio Montini. T2A-puro was
isolated with AgeI-SalI overhangs using standard PCR from pSpCas9(BB)-2A-Puro
(PX459) V2.0, which was a gift from Feng Zhang (Addgene plasmid #62988)58.
T2A-puro was inserted as AgeI-SalI fragment into the SIN.LV.SF vector, resulting in
SIN.LV.SF-T2A-puro. GFP was isolated with BamHI-AgeI overhangs from the original
SIN.LV.SF vector. Ppp1r12aex1-9 and Trp53bp2ex13-18 were isolated with BamHI-AgeI
overhangs and a 3’ and 5’ FLAG-tag, respectively using Phusion Flash High-Fidelity
DNA Polymerase from pBABE-Ppp1r12aex1-9 and pBABE-Trp53bp2ex13-18. These cD-
NAs were inserted as BamHI-AgeI fragments into SIN.LV.SF- T2A-puro, resulting
in SIN.LV.SF-GFP-T2A-puro (Lenti-GFP), SIN.LV.SF-Ppp1r12aex1-9-T2A-puro (Lenti-
Ppp1r12aex1-9) and SIN.LV.SF-Trp53bp2ex13-18-T2A-puro (Lenti-Trp53bp2ex13-18). All
primers are listed in Supplementary Table S3.3.
The following Broad Institute’s Mission TRC-1 mouse library shRNAs targeting Myh9
are used #1: TRCN0000071503, #2: TRCN0000071504, #3: TRCN0000071506
and #4: TRCN0000071507. pL-CRISPR.EFS.GFP was a gift from Benjamin Ebert (Ad-
dgene plasmid #57818). The non-targeting sgRNA (TGATTGGGGGTCGTTCGCCA)
and sgRNA targeting Myh9 (CTCAAGGAGCGATACTACTC) were cloned in the pL-
CRISPR.EFS.GFP vector as previously described59. All vectors were validated by
Sanger sequencing. Concentrated lentiviral stocks were produced by transient co-
transfection of four plasmids in 293T cells as previously described60. Viral titers
were determined using the qPCR lentivirus titration kit from Abm (LV900).
Clonogenic assay MMECs were seeded in 6-well plates and 70 % to 90 % con-
fluent wells were transduced with viral Ad5-CMV-Cre particles (1 ∗ 109 transduc-
ing units [TU]; Gene Transfer Vector Core, University of Iowa) and Lenti-GFP,
Lenti-Ppp1r12aex1-9, Lenti-Trp53bp2ex13-18 or shRNAs (MOI>40) in the presence of
8 µg ml−1 polybrene (Sigma). Medium was refreshed 24 hours after transduction
and cells were selected with puromycin (1.8 µg ml−1) for 48 hrs. Confluent wells
were trypsinized and 50,000 cells were seeded in 6-well plates. Medium was re-
freshed 24 hours after seeding and the well confluency was recorded every 4 hours
with 36 images per 6-well for 200 hrs using an IncuCyte Zoom Live-Cell Analysis
System (Essen Bioscience). The images were analyzed using IncuCyte Zoom soft-
ware. The relative confluency was calculated as a ratio between the confluency at
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the indicated time point and t = 0. After 14 days, cells were fixed with 4 % formalin
in PBS and stained with 0.1 % crystal violet in demineralized water. Quantification
was performed by dissolving the crystal violet in 10 % acetic acid in demineralized
water and determining the absorbance at 590 nm. The experiments with the MMECs
were all performed at least three times, using independent MMECs isolations and
transductions of the cells.
DNA damage response in SB-induced tumor derived cell lines SB-induced tumor-
derived cell lines were seeded and allowed to grow till 80 % to 90 % confluency.
The cells were subsequently treated with vehicle (water) or doxorubicin (1 µmol; sc-
200923) for 6 hours and protein lysates were made using lysis buffer complemented
with protease inhibitors (Roche).
Flow cytometry MMECs were transduced as described previously and collected 72
hours after seeding 200.000 MMECs and stained using propidium iodide (556463,
BD Biosciences) and APC Annexin V (550474, BD Biosciences) according to man-
ufacturer’s protocols. For the analysis 20.000 cells were measured and single cells
were gated on size and shape using forward and side scatter. All experiments were
performed using a BD LSRFortessa Cell Analyzer with BD FACSDiva Software. Data
analysis was performed using FlowJo Software version 10. These experiments were
performed three times, using independent MMECs isolations.
3.5.3 Nucleic acid isolation and analysis
Genomic DNA isolation, PCR amplification and TIDE analysis Genomic DNA was
isolated from frozen mammary tumor pieces by proteinase K lysis and organic ex-
traction with phenol-chloroform. Genomic DNA from cell pellets was isolated
using the Gentra Puregene genomic DNA isolation kit (Qiagen 158767). Ge-
nomic DNA from FFPE mammary tissue was isolated using the Allprep DNA/RNA
FFPE kit (Qiagen) according to the manufacturer’s protocol. PCR amplification
of Myh9 exon 2 was performed with specific primers spanning the target site
(FW_Myh9: CCCGGATGATGCACTTACTT; RV_Myh9: GCAGGGAACAGAGGGTAATG,
product size 655 bp) and 1 µg DNA template, using the Q5 High-Fidelity PCR
kit (NEB M0492). Amplicons were run on 1.5 % agarose gel and gel purifica-
tion was performed using the Isolate II PCR and Gel kit (Bioline). PCR products
were Sanger sequenced using the FW primer and CRISPR/Cas9-induced editing
efficacy was quantified with the TIDE algorithm40,*. Cells isolated from non-
injected glands were used as a negative control in all genomic DNA amplifica-
tions and only TIDE outputs with R2 > 0.9 were considered. Transposon-gene
*https://tide.nki.nl
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(Myh9 and Trp53bp2) fusions were detected by standard PCR with two cell line
specific primers and a transposon specific primer. The following primer sequences
were used: Tumor 1 (11KOU35, Myh9) forward 5’-AAAGCCAAGTGACTCATATCC-
3’, reverse 5’-CAGTAGGCTTTCCCAGACC-3’ (wildtype band [WT] 244 bp and
transposon-gene junction band [TR] 408 bp); Tumor 2 (11KOU58, Myh9) for-
ward 5’-CTTGGCTATGTAAGAGTGCG-3’, reverse 5’-TCCTTTGCAACTTGTTCTGTC-
3’ (WT 190 bp and TR 402 bp); Tumor 3 (12SKA18, Myh9) forward 5’-
CTACACCCAAGACCCCTTC-3’, reverse 5’-ATCAATGCTGGGTATGGTG-3’ (WT 204 bp
and TR 327 bp); Tumor 4 (13SKA1, Myh9) forward 5’-TAGACCTAGCTACAGACACAG-
3’, reverse 5’- TACAGATCTGGGTACATGTTTG-3’ (WT 242 bp and TR 421 bp);
Tumor 1 (11KOU31-R5, Trp53bp2) forward 5;-CCTTCTCACTGTTTCATAGCAC-3’,
reverse 5’-GGTGCTGTTGTGGATTCTG-3’ (WT 295 bp and TR 452 bp); Tumor 2
(13SKA10-R2, Trp53bp2) forward 5’-GTTTCAGGGTATTGTCTTTGG-3’, reverse 5’-
GATGATAACATGCACTGTGTG-3’ (WT 201 bp and TR 394 bp) and transposon-specific
primer 5’-GCTTGTGGAAGGCTACTCGAA-3’. Inversion of the CAG promoter of the
Ppp1r12aex1-9 and Trp53bp2ex13-18 conditional alleles were detected as described
by Huijbers et al.39. Cdh1F and Cdh1∆ alleles were identified by PCR as previously
described10.
RNA preparation and sequencing Whole tumor pieces were processed as previously
described23. Illumina TruSeq mRNA libraries were sequenced with 50 base single
reads on a HiSeq2000 using V3 chemistry (Illumina Inc., San Diego). Sequence
reads were trimmed using Cutadapt61 (version 1.12), filtering any reads shorter
than 20 bp after trimming. The trimmed reads were aligned to the mm10 reference
genome using STAR62 (version 2.5.2b). Gene expression counts were generated by
featureCounts63 (version 1.5.0-post3) using gene definitions from Ensembl 76.
Northern blotting Tumor tissues were homogenized in TRIzol reagent (15596-018,
Ambion life technologies) using a polytron (DI 18 Disperser, IKA) according to
the manufacturer’s protocol. Polyadenylated RNA was purified from total RNA
using Dynabeads Oligo(dT)25 (61005, ThermoFisher scientific) according to the
manufacturer’s protocol. 500 ng of polyadenylated RNA was separated on 1 %
agarose formaldehyde gels and transferred to nitrocellulose membranes as described
by Sambrook et al.64. The primers used to obtain the cDNA probes are listed in
Supplementary Table S3.3.
Clustering with human TCGA breast cancers based on the PAM50 gene signature
To compare the expression of the mILCs to the human intrinsic breast cancer sub-
types, we integrated the SB tumor gene expression data with expression data from
mammary tumors from Wap-Cre;Cdh1F/F;PtenF/F and K14–Cre;Brca1F/F;Trp53F/F
mice and with expression data from the TCGA BRCA data set. For the mouse models,
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sequence reads were downloaded from the European Nucleotide Archive (accession
number PRJEB14147) and processed in the same manner as described for the SB-
induced tumor samples to obtain gene counts. For the TCGA data, normalized gene
expression counts were downloaded from Firehose (data set version 2016_01_28),
and the PAM50 subtype assignment of the TCGA breast tumors was obtained from
the TCGA BRCA publication22. The mouse read counts were normalized by correct-
ing for sequencing depth using the DESeq’s65 median-of-ratios approach and then
applying a log-transformation. The human expression data were log-transformed
and combined with the normalized mouse counts by concatenating the two data
sets on orthologous genes and then normalizing for batch effects using ComBat66,
as implemented in the sva R package (version 3.15.0). Unsupervised hierarchi-
cal clustering (Euclidean distance, average linkage) was performed using the 46
orthologous mouse genes from the PAM50 signature21.
Identification of molecular mILC subtypes The molecular mILC subtypes were iden-
tified using the NMF package67 (version 0.20.6) in R (version 3.3.1). The number
of subtypes was determined by performing the NMF analysis for 2–5 clusters (us-
ing 30 iterations) and selecting the optimal number of clusters according to the
consensus silhouette statistic and the consensus clustering results (Supplementary
Figure S3.14). The final clustering was determined by performing the NMF fac-
torization for four clusters and using 200 iterations. We tested for associations
between subtypes and morphological characteristics by using the Fisher’s exact test
(one-sided), correcting for multiple testing by using Benjamini–Hochberg correction.
Associations with an FDR < 0.05 were considered to be significant. The PAM50
expression of the different subtypes was compared by performing unsupervised
hierarchical clustering (Euclidean distance, average linkage) on the normalized
mouse expression data using the PAM50 genes.
The mouse molecular subtypes were compared with the hILC subtypes by combining
our mouse data set and the human TCGA ILC expression data set7 using ComBat
in the same manner as for the PAM50 analysis. The distribution of human/mouse
subtypes in the combined data set was visualized by performing a PCA analysis on 49
orthologous genes from TCGA’s 60-gene subtype classifier and plotting the samples
using the first two principal components.
Mapping of SB insertion sequences and identification of common insertion sites
Genomic DNA from the SB-containing tumors was processed using the ShearSplink
protocol, and transposon insertions were amplified as previously described28. Sam-
ples were sequenced in four sequencing runs on the 454-Titanium platform according
to the manufacturer’s protocol (Roche). The resulting reads were filtered for con-
taminant sequences, which represent non-hopped transposons, and were trimmed
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using Cutadapt61 (version 1.12) to remove the splinkerette adaptor and transposon
sequences (which require a minimum overlap of 10 bp with both sequences). Reads
without a valid adaptor and transposon sequence were discarded from the analysis,
as were reads shorter than 15 bp after trimming. The trimmed reads were aligned
to the mouse reference genome (mm10) using Bowtie2 (version 2.2.8)68. After
the alignment, redundant sequences that belonged to the same tumor and that
mapped to the same genomic location were collapsed into a single insertion. To
avoid issues with slight variations in the alignment, insertions from the same sample
that occurred within 5 bp of each other were collapsed into a single insertion.
To identify CISs, we analyzed the insertions using CIMPL (version 1.1), which uses a
Gaussian kernel convolution (GKC)-based approach to identify CISs29. The CIMPL
analysis was performed with the following options: scales of 10 kb and 30 kb,
10,000 iterations, the SB preset for correction of insertion bias and exclusion of local
hopping. The identified CISs were assigned to putative target genes using rule-based
mapping (RBM)30, using the SB preset and restricting assignments to the closest
gene in the event that multiple putative targets were identified. The final set of CIS
insertions was obtained by removing insertions that did not belong to at least one
CIS. CIS insertions were assigned to their putative target genes via their respective
CIS(s).
Insertion clonality and association with subtypes Clonality scores of insertions
were calculated using ShearSplink’s unique ligation point (ULP) score, which counts
the number of unique positions in the ligation point (LP) between the genomic
DNA and the splinkerette adaptor for a given insertion. These differing ligation
points are the result of ShearSplink’s stochastic shearing process, in which the
splinkerette adaptor is ligated to randomly fragmented DNA, effectively barcoding
tumor cells with a unique identifier. Using this ULP score we calculated a relative
clonality score by normalizing the ULP of each insertion by the highest ULP within
the corresponding tumor. This ensured that each insertion was assigned a score
between 0 (no insertion) and 1 (clonal insertion).
Identifying CIS insertion biases. The orientation insertion bias of a gene was calcu-
lated as the ratio of sense/antisense insertions in the gene, weighted by the clonality




I(i)wi with i ∈ Tg
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where bg is the bias of gene g, Tg is the collection of insertions in gene g, wi is the
clonality of insertion i and I is an indicator function that returns 1 if insertion i is
sense and 0 otherwise. Genes with bg close to 1 are biased toward sense insertions,
whereas genes with bg close to 0 are biased toward antisense insertions.
CIS differential expression analysis Genes were tested for differential expression
over their insertion sites by using the group-wise differential expression test imple-
mented in IM-Fusion (version 0.3.0)69. This test essentially divides the exons of a
given gene into two groups: exons before the insertion sites in the gene and exons
after the insertion sites. The expression counts of exons before the insertion sites are
then used to normalize expression differences between samples, as the expression of
these exons is not affected by the presence of insertions. The normalized expression
counts of exons after the insertion sites are then compared between samples with
and without an insertion to test for differential expression. Genes with p < 0.05
were considered to show a significant increase or decrease in expression as a result
of their insertions.
KEGG enrichment analysis To test whether insertions were enriched in genes
involved in specific pathways, we first downloaded KEGG pathway gene sets using
KEGGs REST API. We then tested for enrichment using the hypergeometric test,
applying Benjamini–Hochberg correction to correct for multiple testing. Pathways
with an FDR < 0.1 were considered to be significantly enriched.
Mutual exclusivity and co-occurrence analysis of CISs Mutual exclusivities and
co-occurrences between CISs were identified using DISCOVER31. Pairs of mutually
exclusive or co-occurring genes were identified by testing for significant pairwise
gene associations (FDR < 0.25). Co-occurrences were filtered to remove trivial
associations between overlapping genes. Pairwise mutual exclusivities were used to
assemble larger groups of genes, which were tested for significance using DISCOVER’s
group-wise test.
Candidate genes in hILC and human breast cancer Mutations and copy number
events in the TCGA ILC and BRCA data sets7 were visualized using cBioPortal70. The
correlation between copy number events and gene expression levels was determined
by using copy number and expression data from the TCGA BRCA provisional data
set (as downloaded from Firebrowse†, version 2016_01_28)22. After removing
normal samples and duplicate patient samples, correlation scores and p values were
calculated using Spearman’s rank correlation statistic.
†http://firebrowse.org
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Exon-level expression of Ppp1r12a, Ppp1r12b and Trp53bp2 Exon-level expression
was calculated as the average depth of coverage of the exons in each respective
sample to avoid biases due to differences in exon sizes. To obtain a relative measure
of exon expression within the gene for a given sample, these expression values were
transformed to z-scores for each combination of sample and gene. This effectively
provided a measure of the degree to which the expression of an exon is increased or
decreased relative to the mean expression of the gene in the corresponding sample.
The resulting z-scores were visualized as a heat map per gene, with black lines
indicating the position of insertions in the respective samples.
3.5.4 Protein isolation and analysis
Antibodies Primary antibodies to the following proteins were used: MYH9
(1:5,000, Sigma HPA 001644), Flag (1:1,000, Sigma F7425), PPP1R12A (1:1,000,
Cell Signaling Technology (CST) 2634), PP1 (1:200, Santa Cruz sc-7482), P21
(1:1,000, BD Bioscience 556430), p53 (1:1,000, Monosan MONX10194), ribosomal
protein S6 (1:1,000, CST 2217), phospho-S6 ribosomal protein (Ser235,Ser236)
(1:1,000, CST 2211), p44/42 MAP kinase (1:1,000, CST 4695), phospho-p44/42
MAPK ERK1/ERK2(Thr202/Tyr204) (1:1,000 CST 9101), AKT1 (1:1,000, CST 2938),
phospho-AKT(Ser473) (1:1,000, CST 4060) and β-actin (1:50,000, Sigma A5441).
Immunoblotting Protein lysates were made using lysis buffer (20 mmol Tris-HCl
8.0 pH, 150 mmol NaCl, 1 mmol EDTA, 1 mmol EGTA, 1 % Triton X-100, 0.5 % de-
oxycholate, 0.1 % SDS in milli-Q) complemented with protease and phosphatase
inhibitors (Roche) and quantified using the BCA protein assay kit (Pierce). Pro-
tein lysates were loaded on a 3 % to 8 % gel Tris-acetate gradient gel (Invitrogen)
and transferred overnight onto nitrocellulose membrane (Bio-Rad) in 1x transfer
buffer (25 mmol Tris, 2 mol Glycine, 20 % methanol in demineralized water). Mem-
branes were blocked in 5 % nonfat dry milk or 5 BSA in TBS-T (7.6 pH, 20 mmol Tris,
137 mmol NaCl, 0.005 % Tween-20 in demineralized water) and primary antibodies
were incubated overnight in 5 % nonfat dry milk or 5 % BSA in TBS-T. Membranes
were washed three times and incubated with the secondary antibodies goat anti-
rabbit-HRP (1:2000, Dako P0448), rabbit anti-mouse-HRP (1:5000, Dako P0260) or
donkey anti-mouse IRDye 680nm (1:5000, Li_COR 926 32222) in 5 % BSA in TBS-T.
Stained membranes were washed three times in TBS-T and then developed using
ECL (Pierce 32209) or captured using the Li-Cor Odyssey Infrared Imaging System
and analyzed using Odyssey Application software version 3.0.16.
Immunoprecipitation and LC/MS-MS analysis HC11 cells were transduced with
pBABE-puro, pBABE-Ppp1r12aex1-9 or pBABE-Trp53bp2ex13-18 as previously
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described10. Protein lysates were made using a NP40 lysis buffer (50 mmol Tris-HCl
(8.0 pH), 150 mmol NaCl, 1 % NP40 and 10 % Glycerol). Protein G Dynabeads (In-
vitrogen) were prepared according to manufacturer’s protocol and incubated for 2
hours at 4 degrees with 10 µg of rabbit anti-FLAG antibody (Sigma). The lysates
(200 mg) with beads were incubated overnight and washed five times with NP40
lysis buffer. Beads were reconstituted in 30 µL XT sample buffer (Bio-Rad) and
heated at 95 ◦C for 7 min. Bead eluates were subsequently cleared and concentrated
into a small protein band by short, partial SDS-PAGE separation71. The gel was
stained with GelCode Blue stain reagent, followed by excision of the gel bands,
reduction of the proteins with DTT and alkylation with iodoacetamide. Proteins
were digested with sequencing grade trypsin (3 ng µL−1) overnight at 37 ◦C. Pep-
tides were extracted with acetonitrile, dried down in a speed vacuum centrifuge and
reconstituted in 10 % formic acid prior to mass spectrometry analysis.
Peptides were separated in 65-min gradients using the Proxeon nLC 1000 system
(Thermo Scientific, Bremen) equipped with a 75 µm x 500 mm PicoFrit analytical
column fitted with a PicoTip Emitter (New Objective, Woburn, MA, USA), packed
in-house with ReproSil-Pur 120 C18-AQ 2.4 µm stationary phase (Dr. Maisch). The
outlet of the analytical column was coupled directly to a Thermo Orbitrap Fusion
(Q-OT-qIT, Thermo Scientific) using the Proxeon nanoflex source. Nanospray was
achieved using a liquid junction (Thermo) operated at 1.6 kV; additional settings
were as previously described72.
Raw data were analyzed by MaxQuant73 (version 1.5.0.30) in label-free quantitation
mode, using standard settings. MS/MS data were searched against the Mus Musculus
Swissprot database (16,719 entries, release 2015_10) complemented with a list of
common contaminants. Trypsin/P was chosen as cleavage specificity allowing two
missed cleavages. Carbamidomethylation (C) was set as a fixed modification, and
oxidation (M) was used as variable modification. For label-free quantitation (LFQ)
analysis, LFQ quantitation and ‘match between runs’ were enabled. LFQ intensities
(3 independent replicate values per sample) were log2-transformed in Perseus, after
which proteins were filtered for at least three valid values in one of the sample
groups. Missing values were replaced by imputation based on a normal distribution
using a width of 0.3 and a downshift of 1.874. Volcano plots were constructed for
each immunoprecipitation using a permutation-based FDR-corrected t-test. Proteins
were considered interactors when p < 0.01 and log2(Abundance difference) > 1.
3.5.5 Statistical analysis
For the mouse studies, no statistical tests were performed to determine the sample
size, and no blinding of investigators was performed. Survival probabilities were
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estimated using the Kaplan–Meier method and compared using the Mantel–Cox
test. Associations with the expression subtypes (concerning tumor morphology and
candidate genes) were identified by using a one-sided Fisher’s exact test (testing
for co-occurrence) with Benjamini–Hochberg correction. Biases of morphologies
or subtypes and candidate genes toward either of the T2/Onc lines were identified
by using a two-sided Fisher’s exact test with Benjamini–Hochberg correction. The
KEGG pathway enrichment analysis was performed using a hypergeometric test with
Benjamini–Hochberg correction. Correlation between copy number and expression
in the TCGA data set was calculated using Spearman’s rank correlation. Volcano plots
of the immunoprecipitations followed by LC-MS/MS analysis were constructed using
a permutation-based FDR-corrected t-test. Proteins were considered interactors
when p < 0.01 and log2(abundance difference) > 1. In the cell death assay, groups
were compared using Welch’s t-test. The investigators were not blinded to the sample
groups for all experiments. Graphs and error bars represent means ± s.d. Python
3.5, R 3.3.1 and GraphPad Prism 7.0 were used for the statistical analyses. p values
< 0.05 and FDR values < 0.1 were considered significant, unless stated otherwise.
3.5.6 Code availability
Jupyter notebooks containing the code and results of the various computational
analyses are available on GitHub‡. The software used for the insertion and CIS
analysis has been implemented in a Python package called PyIM, which is also
available on GitHub§. For these analyses, version 0.2.0 of this package was used.
3.5.7 Data availability
All sequence data that support the findings of this study are available in the European
Nucleotide Archive under accession number PRJEB14134. The ShearSplink sequenc-
ing data, together with additional files containing sample barcodes and other materi-
als, are available in Figshare under the identifier 10.6084/M9.FIGSHARE.4765111¶.
Processed expression and insertion data have also been deposited in Figshare under
the identifier 10.6084/M9.FIGSHARE.4929866||. All other data are available within
this paper and its supplementary information files, the Jupyter notebooks**, or are









Samples (n = 16)
Adenocarcinoma (n = 0)
Spindle cell (n = 12)
ILC (n = 8)















































Samples (n = 4)
Adenocarcinoma (n = 3)
Spindle cell (n = 1)
ILC (n = 0)
Tumor morphology of Wap-Cre;Cdh1F/+;SB mice
Fig. S3.1. Survival curves for the individual T2/Onc transgenic mouse lines, distri-
bution and immunohistochemical stainings of the different tumor mor-
phologies. (A) Survival curves Wap-Cre;Cdh1F/F;SB mice carrying the T2/Onc
transposon donor loci on chromosomes 1 and 15 (n = 142 and n = 126 mice,
respectively). ns, no significant difference (Mantel–Cox test). (B) Tumor mor-
phologies of Wap-Cre;Cdh1F/F (n = 16) and Wap-Cre;Cdh1F/+;SB (n = 4) female
mice. (C) Immunohistochemical detection of E-cadherin, cytokeratin 1, cytoker-
atin 8 and vimentin in the different tumor morphologies. Scale bar, 50 µm.








































































































































































Fig. S3.2. Additional plots accompanying the PAM50 gene expression analyses.
(A) Unsupervised clustering (Euclidean distance, average linkage) of the SB-
induced tumors with reference mouse models and human breast cancer samples
from TCGA, showing the expression of all 46 orthologous mouse genes from
the PAM50 gene signature. (B,C) Expression of known marker genes associated
with squamous and spindle cell tumors, showing high expression of the corre-
sponding markers in the associated molecular subtype. Boxes extend from the
third (Q3) to the first (Q1) quartile (IQR), with the line at the median; whiskers
extend to Q3 + 1.5 ∗ IQR and Q1 − 1.5 ∗ IQR. Points beyond the ends of the
whiskers are outliers. SC, spindle cell-like; SQ, squamous-like.











































































Fig. S3.2. Continued. (D) Unsupervised clustering (Euclidean distance, average linkage)
of the SB-induced molecular subtypes with the reference luminal and basal-like
mouse models.















































Fig. S3.3. Distribution of morphology and expression subtypes across the T2/Onc
transgenic mouse lines. (A) Distribution of morphology across the two T2/Onc
transgenic lines, showing that there is no significant bias between the two lines.
Lack of any significant bias was confirmed using pairwise Fisher’s exact tests
with Benjamini–Hochberg correction. (B) Distribution of subtypes across the
two T2/Onc transgenic lines, also showing no significant bias between the two
lines.
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Fig. S3.4. Histograms detailing various statistics of the identified insertions, both
for all insertions and for insertions within CISs. (A) Distribution of the
insertion depths (as indicated by ShearSplink’s ULP score) over all insertions.
(B) Distribution of insertion clonality scores. (C) Distribution of the maximum
insertion depth (maximum ULP score) per sample. (D) Distribution of the
number of insertions per sample, with a median of 29 insertions per sample.
(E-H) Same statistics as in A-D, but calculated for the CIS insertions, with a
median of 5 CIS insertions per sample.
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Distribution of insertion clonality per candidate gene
A
B
Fig. S3.5. Additional details on the clonality of the candidate genes. (A) Ranking of
genes by their overall frequency and the median clonality of their insertions.
For samples with multiple insertions in the same gene, we used the clonality of
the strongest insertion to avoid underestimating the median clonality due to
local hopping. For clarity, only the main candidates (occurring in six or more
samples) are labeled. (B) Clonality distribution of insertions in all candidate
genes, ranked (from left to right) by the frequency of each gene.
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Associations between CISs and subtypes (all samples)








































































































































































Associations between CISs and subtypes (ILC samples)A
B
Fig. S3.6. Distribution of the candidate genes over the identified molecular subtypes.
Bar plots indicating the distribution of all candidate genes over the molecular
subtypes. Red bars indicate significant associations between candidate genes
and the corresponding molecular subtype (FDR < 0.1, one-sided Fisher’s exact
test with Benjamini-Hochberg correction). This analysis was performed for both
the set of 99 tumors with an ILC morphology (A) and the full set of 123 tumor
samples (to increase statistical power) (B). The latter analysis identified an
additional enrichment for Trps1 in the combined mILC-1 and mILC-2 subtypes,
suggesting that Trps1 may play a role in the ILC morphology of these tumors.
Additionally, the mILC-2 subtype was further enriched for insertions in Arid1a
and Rasgrf1, indicating that expression differences between mILC-1 and mILC-2
may in part be driven by insertions in these genes.














































































































































































































































Fig. S3.7. Additional details on the insertion patterns and differential expression of
the candidate genes. (A) Insertion pattern in Gab1, showing bias toward
activating insertions. (B) Boxplots for the main candidate genes showing the
difference in expression after the insertion sites in the corresponding gene
between samples with and without an insertion. The boxplots and p values
were calculated using IM-Fusion’s differential expression test, which essentially
compares the expression of exons after the insertion sites in each gene between
samples with an insertion and samples without an insertion, after normalizing
for differences in overall expression between samples (see the Online Methods
for more details). Boxes extend from the third (Q3) to the first (Q1) quartile
(IQR), with the line at the median; whiskers extend to Q3 + 1.5 ∗ IQR and
Q1−1.5∗IQR. p values were calculated using the non-parametric Mann–Whitney
U test. Green/purple boxplots indicate significant increases and decreases in
expression (p < 0.05), respectively. (C) Insertion pattern in Trps1, showing bias
toward truncating/inactivating insertions.





































0-5% (negative) 10% positive tumor cells
25% positive tumor cells 50% positive tumor cells
Fig. S3.8. Representative images and quantification of immunohistochemical stain-
ing for phosphorylated ERK1/2, a downstream protein of the RAS/MAPK
signaling pathway. (A) Representative images of different percentages of
phosphorylated ERK1/2(Thr202/Tyr204) staining in SB-induced tumors. Scale bar,
50 µm. (B) Quantification of phosphorylated ERK1/2(Thr202/Tyr204) staining in
the different molecular subtypes. Mean ± s.d.
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Genetic Alteration









































Fig. S3.9. Overview of the mutations and copy number events in the TGCA breast
cancer data set (816 samples) for each of the main candidate genes and
CDH1. Percentages indicate the fraction of tumors with alterations in the
respective genes.
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Fig. S3.10. Myh9 haploinsufficiency in ILC formation in SB-induced tumor-derived
cell lines with or without Myh9 insertion. (A) Distribution of the number of
insertions per sample in Myh9, showing that the majority of the tumors show
single insertions in the gene. (B) PCR amplification of the transposon–Myh9
junction fragments in polyclonal SB-induced tumor-derived cell lines. (C)
Heterozygous Myh9 insertions by PCR in clones derived from two SB-induced
tumor cell lines. Green color indicates a correct clone; red color indicates an
incorrect clone.




























































Fig. S3.11. Expression of truncated Ppp1r12a/b and Trp53bp2 and PPP1R12A pro-
tein expression in SB-induced tumors. (A–C) Truncated Ppp1r12a/b and
Trp53bp2 in SB-induced tumors, as visualized by northern blot analysis. (D)
Expression of PPP1R12A in SB-induced tumors with and without insertions in
Ppp1r12a, as visualized by immunoblotting using an anti-PPP1R12A antibody.
β-actin is shown as a loading control. (E) Co-immunoprecipitation of PP1 in
HC11 cells expressing GFP, truncated PPP1R12A or TRP53BP2, as visualized
by immunoblotting using anti-FLAG and anti-PP1 antibodies.











































































































































1 2 1 2 1 2
Cdh1F/F  
mouse







































Fig. S3.12. Characterization of cell death, cell survival markers and activation
of a p53 response in E-cadherin-deficient cells expressing truncated
PPP1R12A or TRP53BP2 or showing reduced levels of MYH9. (A) Repre-
sentative dot plots depicting the proportions of Annexin V (AN)- and/or propid-
ium iodide (PI)-positive cells 72 h after seeding of AdCre-transduced Cdh1F/F
MMECs with simultaneous transduction of Lenti-GFP, Lenti-Ppp1r12aex1-9 or
Lenti-Trp53bp2ex13-18. (B) Quantification of Annexin V– and PI-positive cells
from AdCre-transduced Cdh1F/F MMECs with simultaneous transduction of
Lenti-GFP, Lenti-Ppp1r12aex1-9 or Lenti-Trp53bp2ex13-18. Asterisks indicate
p < 0.05 (Welch’s t-test). Mean ± s.d. of three independent experiments.
(C) Expression of total and phosphorylated AKT, ERK1/2 and S6 72 h after
seeding of AdCre-transduced Cdh1F/F MMECs with simultaneous transduction
of Lenti-GFP, Lenti-Ppp1r12aex1-9 or Lenti-Trp53bp2ex13-18, as visualized by
immunoblotting. β-actin is shown as a loading control.
92 Chapter 3 Insertional mutagenesis identifies drivers of a novel oncogenic pathway in ILC









































































































































































Fig. S3.12. Continued. (D) Cell survival of AdCre-transduced Cdh1F/F;mT/mG MMECs
with simultaneous shRNA- mediated knockdown of Myh9 with different
shRNAs, as quantified by using real-time IncuCyte imaging for 200 h. Mean
± s.d. of three independent experiments. (E) PCR amplification of the trans-
poson–Trp53bp2 and transposon–Myh9 junction fragments in polyclonal SB-
induced tumor-derived cell lines. (F) Expression of p53 and p21 in SB-induced
tumor-derived cell lines with insertions in Trp53bp2 or Myh9 as compared to
SB-induced tumor-derived cell line controls, as visualized by immunoblotting.
Cells were treated for 6 h with water (control) or doxorubicin (Dox;1 µmol).
β-actin is shown as a loading control. (G) Expression of p53 and p21 in
SB-induced tumor- derived clones with insertions in Myh9 as compared to
SB-induced tumor-derived control clones, as visualized by immunoblotting.
Cells were treated for 6 h with water (control) or doxorubicin (Dox; 1 µmol).
β-actin is shown as a loading control. Exp, exposure.
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+ Cre recombinase 
Fig. S3.13. Overview of Cre-conditional alleles and distribution of the tumor
morphology in the different genetically engineered mouse models.
(A) Depiction of Cre-conditional invCAG-Ppp1r12aex1-9-IRES-Luc and invCAG-
Trp53bp2ex13-18-IRES-Luc alleles in the Col1a1 locus. Cre-mediated recom-
bination allows inversion of the CAG promoter, resulting in expression of
PPP1R12A1-418aa or TRP53BP2766-1134aa accompanied by luciferase expression.
(B) Recombination status of the Cre-conditional alleles in tumors from Wap-
Cre;Cdh1F/F;Ppp1r12aex1-9 and Wap-Cre;Cdh1F/F;Trp53bp2ex13-18 mice, as visu-
alized by PCR. EcadF and EcadD are PCRs to detect the Cdh1F and Cdh1∆
alleles, respectively. ShuttleR detects the recombined (p1 and p3; 1,054 bp)
and non-recombined (p1 and p2; 897 bp) Cre-conditional alleles (primer
positions are shown in a).
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Samples (n = 11)
Squamous (n = 0)
Spindle cell (n = 0)
ILC (n = 11)
Tumor morphology of Wap-Cre;Cdh1F/F;Cas9 mice injected with Lenti-CRISPR-sgMyh9
Samples (n = 27)
Squamous (n = 0)
Spindle cell (n = 1)
ILC (n = 27)
Tumor morphology of Wap-Cre;Cdh1F/F;Ppp1r12aex1-9 miceC
D
Samples (n = 30)
Squamous (n = 0)
Spindle cell (n = 1)
ILC (n = 30)
Tumor morphology of Wap-Cre;Cdh1F/F;Trp53bp2ex13-18 mice
Fig. S3.13. Continued. (C) Histological classification of tumors from Wap-
Cre;Cdh1F/F;Ppp1r12aex1-9 (n = 27) and Wap-Cre;Cdh1F/F;Trp53bp2ex13-18
(n = 30) mice. (D) Histological classification of tumors (n = 11) from Wap-
Cre;Cdh1F/F;Cas9 mice injected with Lenti-CRISPR-sgMyh9.
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Fig. S3.14. Clustering statistics for different numbers of clusters in the NMF subtype
analysis. (A) Overview of various clustering statistics for different numbers of
clusters (2–5) in the NMF analysis of the SB-induced tumors. (B) Consensus
maps for the same cluster sizes, showing the consistency of cluster assignments
for the different numbers of clusters.
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3.6.2 Supplementary Tables (available online)
Tab. S3.1. Overview of sample information including sample IDs, mouse IDs, T2/Onc
lines, histopathology types, RNA-seq IDs, metastasis sites and subtypes.
Tab. S3.2. Overview of the identified candidate genes and various statistics for each
gene.
Tab. S3.3. Overview of all primers used in this study for genotyping, cloning and
northern blotting.
Tab. S3.4. Detailed information about antibodies and antigen retrieval methods
used in immunohistochemical experiments.
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4.1 Abstract
Insertional mutagenesis using engineered transposons is a potent forward genetic
screening technique used to identify cancer genes in mouse model systems. In the
analysis of these screens, transposon insertion sites are typically identified by targeted
DNA-sequencing and subsequently assigned to predicted target genes using heuristics.
As such, these approaches provide no direct evidence that insertions actually affect
their predicted targets or how transcripts of these genes are affected. To address
this, we developed IM-Fusion, an approach that identifies insertion sites from gene-
transposon fusions in standard single- and paired-end RNA-sequencing data. We
demonstrate IM-Fusion on two separate transposon screens of 123 mammary tumors
and 20 B-cell acute lymphoblastic leukemias, respectively. We show that IM-Fusion
accurately identifies transposon insertions and their true target genes. Furthermore,
by combining the identified insertion sites with expression quantification, we show
that we can determine the effect of a transposon insertion on its target gene(s)
and prioritize insertions that have a significant effect on expression. We expect
that IM-Fusion will significantly enhance the accuracy of cancer gene discovery
in forward genetic screens and provide initial insight into the biological effects of
insertions on candidate cancer genes.
4.2 Introduction
Transposon-based insertional mutagenesis (TIM) is a high-throughput method for
cancer gene discovery in mice1. In TIM, discrete DNA elements called transposons
can migrate throughout the genome by a cut-and-paste mechanism, in which they
are excised from their original location in the genome and randomly reintegrated
elsewhere2. Depending on the location and orientation of their reintegration, these
integrations can activate oncogenes or inactivate tumor suppressors, thereby in-
ducing tumor development and progression3. By identifying genomic loci that are
recurrently affected by transposon insertions in multiple independent tumors, this
approach can be used to identify candidate cancer genes1,3,4.
Transposon insertion sites are typically identified using targeted DNA-sequencing
approaches, in which junction fragments containing transposon and flanking ge-
nomic sequences are selectively amplified and sequenced5. The genomic parts of
these sequences are mapped to the reference genome to identify insertion sites and
their genomic locations6. These insertions are then assigned to their putative target
gene(s) using heuristics, typically picking genes in the direct vicinity of the inser-
tion. Examples of such heuristics are nearest gene6, fixed window7 and rule-based
mapping approaches8.
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A significant drawback of DNA-sequencing approaches is that they do not provide
any direct evidence that an insertion actually affects a gene. In ambiguous cases with
multiple genes in the vicinity of an insertion, heuristic approaches are frequently
unable to identify the true target(s) of the insertion. This typically leads to an
arbitrary selection of a single gene (nearest gene), potentially selecting the wrong
gene or missing other targets (false negatives). Alternatively, heuristics may select
many genes in the direct vicinity of the insertion (fixed window, rule-based mapping),
resulting in the selection of many non-target genes (false positives).
Additionally, DNA-sequencing approaches provide limited insight into how the
expression of a target gene is affected by a transposon insertion and which novel
transcripts may result from the insertion. This has two main drawbacks. First, it
prevents prioritizing insertions that have a strong effect on gene expression and are
therefore likely of more importance than insertions without an effect on expression.
This limits effective discrimination between driver and passenger insertions, resulting
in long lists of candidate loci which are likely to include a substantial fraction of
false positives that do not affect expression. Second, it limits our understanding
of how gene expression or the expression of (novel) gene transcripts is affected by
insertions. These insights may be key to ultimately understanding the biological
effect of insertions and how they may contribute to tumorigenesis.
In previous work, Temiz et al. have demonstrated that insertions can be identified in
paired-end RNA-sequencing data using their tool Fusion Finder9. In Fusion Finder,
insertions are detected from discordant mate pair alignments, in which one mate
aligns to a genomic sequence and the other to part of the transposon sequence.
A drawback of this approach is that it does not use information from chimeric
reads overlapping the fusion boundary between the gene and the transposon (split
reads), limiting the accuracy and sensitivity of insertion detection. Additionally, the
dependency on mate pair information prevents its use for analyzing datasets based
on single-end RNA-sequencing.
In this work, we present an approach called IM-Fusion, which uses fusion-aware
RNA-seq alignment to identify transposon insertions from splicing events between
endogenous genes and the transposon. Key advantages of this approach are that
it identifies exactly which gene(s) are affected by a transposon insertion and how
the transposon is incorporated into the resulting gene transcript. Additionally, by
using both split reads and discordant mate pairs to identify insertions, IM-Fusion is
more sensitive than existing approaches and can be used to analyze single-end RNA-
sequencing datasets. Finally, by combining insertions with exon-level expression
data, we are able to accurately predict the consequences of integrations on gene
transcripts.
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4.3 Materials and Methods
4.3.1 IM-Fusion
Insertion detection First, we create an augmented reference genome by adding the
transposon as an extra sequence in the reference genome. Then, for each sample,
we align sequence reads to the augmented reference genome using a fusion-aware
RNA-seq aligner such as STAR10 or Tophat-Fusion11. By default, STAR is used for
alignment, with the argument ‘--chimSegmentMin’ to ensure that chimeric read
alignments are produced. Chimeric alignments from STAR are filtered to select
alignments that represent fusions between the transposon and genomic sequences.
Alignments that overlap with the fusion junction (represented by split-read align-
ments) are grouped by the position of their breakpoints, as these reads precisely
identify the location of a fusion. Each such group is considered to represent a single
gene-transposon fusion. For paired-end sequencing data, alignments that do not
overlap with the fusion boundary are grouped if their mate positions fall within
a pre-defined distance, which depends on the insert size of the dataset. Where
possible, these ‘spanning’ read groups are assigned as additional support for fusions
identified from split-reads. For cases where no such fusion is found, approximate
locations for the corresponding fusions are predicted based on the bounds provided
by the spanning reads.
The identified fusions are annotated to identify which gene(s) and which transposon
feature(s) are involved in each fusion. Fusions that do not involve splice acceptor
(SA) or splice donor (SD) features of the transposon or fusions that represent
biologically implausible situations (such as fusions between transposon features and
gene exons in opposite orientations) are considered artifacts and removed from
the list of fusions. Optionally, fusions supported by less than a pre-defined number
of reads can be removed to avoid fusions with low support. For this filtering, we
provide two distinct measures: a support score and an FFPM (fusion fragments per
million) score. The support score simply indicates the number of reads/mates that
supports the corresponding fusion. The FFPM score is a scaled version of the support
score, which is normalized for differences in sequencing depth between samples.
This score is analogous to the FFPM score used by STAR-Fusion12. The list of filtered
fusions is used to predict approximate locations of the corresponding insertion sites,
based on the breakpoints of the fusions.
Transcript assembly To identify cases in which insertions lead to the expres-
sion of non-canonical transcripts, IM-Fusion provides an optional step which uses
StringTie13 to perform a reference-guided assembly of novel transcripts using the
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read alignment from STAR. The produced transcript annotation is used to assign any
previously unannotated insertions to any novel transcripts that overlap with the in-
sertion. If such a novel transcript overlaps with any known genes, the corresponding
insertion is also assigned to these known genes, as the transcript likely represents an
alternative transcript of these existing genes.
Commonly targeted gene selection Commonly targeted genes (CTGs) are selected
by testing if genes are affected by insertions more frequently than would be expected
by chance according to the Poisson distribution. The Poisson distribution expresses
the probability of a given number of events occurring in a fixed interval of time or
space, as long as the expected number of events in a fixed window is known and
events occur independently. Specifically,




where k is the number of events and λg is the expected number of events in a fixed
window. Here, each insertion represents an independent event and the fixed window
is the genomic region of the gene of interest, optionally expanded to include a
window around the gene. The expected number of insertions is calculated based on
the size of the gene window, the size of the transcriptome (the union of windows for
all genes) and the total number of insertions within the transcriptome windows.
In detail, we first count the number of insertions that were identified for a given
gene g (by the insertion identification step) and were located within a pre-defined
window (by default 20 kb) around the gene. This count is denoted as Ng. Second,
we calculate the expected number of insertions in gene g (λg) based on its window





in which Wg corresponds to the size of the window around gene g, Wt the size of the
transcriptome windows (the sum of windows for all genes in the genome, corrected
for overlap between gene windows) and Nt represents the total number of insertions
within the transcriptome windows. Using λg, we then calculate the probability of
observing Ng or more insertions in gene g as:
pg = Pg(K ≥ Ng;λg)
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After testing all genes of interest (by default all genes with at least one insertion in
the gene), calculated p values are corrected for multiple testing using Bonferroni
correction.
If the transposon employed in the screen is known to be biased toward integrating at
specific nucleotide sequences, λg can be calculated differently to take this integration
bias into account. In this case, instead of using the size of the gene windows, we use
the number of occurrences of the nucleotide sequence with the gene window (Sg)





To account for a potential bias in integrations on the chromosome on which the
transposon concatemer is located, insertions and genes on the donor chromosome
can be excluded from the analysis. In this case, genes on the donor chromosome are
also excluded when calculating the transcriptome size (Wt/St) and the number of
insertions (Nt).
Differential expression analysis To test for differential expression, we first generate
exon expression counts from the read alignments using featureCounts14. For this
count summarization, we use a flattened version of the reference GTF file, which
is similar to the flattened GTF files produced by DEXSeq15. This flattened GTF is
required to ensure that overlapping exons from different transcripts of the same
gene are only counted once by featureCounts.
Next, to test a given gene g for differential expression, we divide the exons of gene g
into two groups: those before the transposon insertions in the gene (EBg ) and those
after the insertions (EAg ). We assume that the expression counts of exons before the
insertions (EBg ) are not directly affected by the presence of an insertion and therefore
reflect differences in the overall expression of the gene between samples. Based on
this assumption, we normalize the counts of each sample for differences in overall
expression of the gene by dividing the counts by a sample-specific normalization
factor, which is calculated from the counts of the exons in EBg using DESeq2’s
median-of-ratios approach16. We then sum the normalized counts of exons in EAg
per sample, to get a single (normalized) count of expression after the insertion site
for each sample. Finally, to actually test for differential expression in the presence
of an insertion in gene g, we use a two-tailed Mann–Whitney U test to compare
the distribution of these counts between samples with an insertion in gene g and
samples without an insertion in the gene.
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In some cases, the above test is not possible because some samples do not have
at least one exon before and after their insertion sites. This mostly occurs when
insertions are located upstream of the first exon of the gene. To handle these cases,
we first try to remove these problematic samples and repeat the test using the
remaining samples. For cases where this does not leave us with any samples to
test, we provide an additional gene-level test, which compares the expression of the
overall gene between samples with/without insertions after normalizing for overall
differences in sequencing depth.
By default, we do not use multiple testing correction for the differential expression
test, as we primarily select CTGs using the Poisson-based test and use the differential
expression test as an extra test to determine whether to keep the CTG. Additionally,
not all CTGs may be subjected to the same test, as some genes may be tested using
the gene-level test if the exon-level version is not applicable.
Single-sample differential expression To test for differential expression in a single
sample (as opposed to the group-wise test described above), we provide an alter-
native approach that uses the same normalization procedure, but uses a negative
binomial distribution to compare the expression of the sample of interest to samples
without an insertion. In this approach, a negative binomial is fitted using the after
insertion counts of samples without an insertion in the gene. The after count of the
sample of interest is then compared to this distribution using a two-tailed test to
determine if the gene is differentially expressed.
Implementation For convenience and reusability, we implemented the different
steps of IM-Fusion in a Python package called imfusion, which is freely available
on GitHub*. Jupyter notebooks containing the code and results of the various
computational analyses are also available on GitHub†.
The Python package provides commands for each main step of IM-Fusion, including
the construction of the custom reference genome, identification of insertions from
RNA-seq reads, selection of CTGs and analysis of differential expression. The cur-
rent implementation supports the use of STAR or Tophat-Fusion to detect fusions,
although support for additional fusion-aware aligners may be added in the future.
For full functionality, working installations of STAR/Tophat2, StringTie and feature-
Counts are required; as STAR or Tophat2 (which implements Tophat-Fusion) are used
to align reads and detect fusions, StringTie is used to detect novel transcripts and
featureCounts is used to generate the expression counts. Optionally, STAR-Fusion12
*https://github.com/nki-ccb/imfusion
†https://github.com/jrderuiter/imfusion-analyses
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can also be used to detect endogenous gene fusions as part of the STAR insertion
detection pipeline.
4.3.2 Datasets
ILC dataset (RNA-seq) Single-end RNA-sequencing data from 123 tumors were
obtained from a dataset of a Sleeping Beauty (SB) transposon screen in a mouse
model of invasive lobular breast carcinoma (ILC)17. The RNA-seq data were down-
loaded from ENA in fastq format (accession number PRJEB14134) and analyzed
using IM-Fusion (version 0.3.1) to detect SB insertion sites in each sample, as well
as subsequently identify CTGs and their effects. For this analysis, we created an
augmented reference genome using the mm10 version of the mouse genome and
the T2/Onc transposon sequence18. STAR (version 2.5.2b) was used to perform the
alignment, StringTie (version 1.3.0) was used for transcript assembly and feature-
Counts (version 1.5.0-post3) was used to generate expression counts. Reference
genome features were downloaded from Ensembl 76.
ILC dataset (ShearSplink) DNA-sequencing data prepared using the ShearSplink
protocol19 for the same tumors as the ILC RNA-seq dataset were downloaded from
Figshare‡ and analyzed using the ShearSplink pipeline in PyIM§ (version 0.2.0) to
identify SB insertion sites. In essence, this pipeline first extracts genomic DNA from
reads by removing the transposon and linker sequences. The genomic sequences
are then aligned to the reference genome using Bowtie2 (version 2.2.8)20, and the
resulting alignments are grouped by sample and position to identify the location of
insertion sites. Finally, identified insertions are assigned to their predicted target
genes using the windows outlined in KC-RBM8. To reduce the number of identified
target genes for each insertion, we selected a single target gene for each insertion by
picking the closest gene identified by KC-RBM. In cases where this was not possible,
e.g. due to overlapping genes, we retained multiple target genes.
B-ALL dataset Insertion data and paired-end RNA-seq data from 20 B-cell acute
lymphoblastic leukemias (B-ALLs) were obtained from a previously published dataset
of a SB screen performed in a mouse model of B-ALL21. The RNA-seq data were
downloaded from ENA in fastq format (study ID: ERP005291, array expression ID: E-
ERAD-264). The insertion data were obtained from the Supplementary Materials of
the publication or through personal communication. Control samples were omitted
from the performed analyses.
‡DOI: 10.6084/m9.figshare.4765111
§https://github.com/jrderuiter/pyim
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4.3.3 Methods - ILC dataset
Gene-transposon fusion validation in RNA Tumor RNA was extracted as previously
described22 and 300 ng was converted to complementary DNA (cDNA) with a
Moloney murine leukemia virus reverse transcriptase using random hexamer primers
according to manufacturer’s protocol (Tetro cDNA synthesis kit, Bioline). Gene-
transposon fusions were detected by standard polymerase chain reaction (PCR) with
an annealing temperature of 58 ◦C. The following primer sequences were used:
• SA reverse 5’-TTCCCGCGAATCCATCTTTC-3’
• En2SA reverse 5’-GTCGACTGCAGAATTCGATGA-3’
• SD forward 5’-GCCCATCAAGCTTGCTACTA-3’
• Myh9 forward 5’-CTGTGTGGTCATCAACCCTTAT-3’
• Trp53bp2 reverse 5’-ATCGCTCTGGTTTCGATAAGG-3’
• Ctnnd1 forward 1 5’-GCTACATGCCTTGACAGATGA-3’
• Ctnnd1 forward 2 5’-GAGAGGAGAAAGGCAGGAAAG-3’
• Hprt forward 5’-CTGGTGAAAAGGACCTCTCG-3’
• Hprt reverse 5’-TGAAGTACTCATTATAGTCAAGGGCA-3’
To study the effects of individual SB insertions on expression, we visualized single
insertions together with the expression of each of their targets in the affected sample
and tested for differential expression over the insertion site in the sample. The
visualization was generated using the Python package geneviz, which is freely
available on GitHub¶. Gene annotations for the plot were obtained from Ensembl 76.
Expression profiles were generated from the RNA-seq alignment of the sample using
pysam23, by counting the number of reads overlapping each nucleotide position in
the plotted range. Junction strengths were derived from the junction files (SJ.out.tab)
generated by STAR during the alignment. To test for differential expression, we used
the single-sample exon-level test implemented by IM-Fusion.
Effects on CTGs To identify biases in SA/SD insertions for the various CTGs, we
counted the number of times each transposon feature (SD, SA, En2SA) was involved
in the insertions affecting each CTG. The results were visualized to show the different
distributions across CTGs. To test for differential expression, we applied IM-Fusions
group-wise DE test for each CTG.
Insertion comparison To compare the overlap in insertions between IM-Fusion
and ShearSplink, we matched two insertions between IM-Fusion and ShearSplink
¶https://github.com/jrderuiter/geneviz
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under the following conditions: both insertions were identified in the same sample,
had the same predicted target gene and their relative location and orientation was
compatible. The latter restriction was used to ensure that a ShearSplink insertion
was in the correct location to generate the fusion observed by IM-Fusion in the
RNA-seq data. Insertions matched between the two approaches were marked as
‘Shared’, unmatched insertions were designated ‘IM-Fusion only’ or ‘ShearSplink
only’ depending on the approach that identified them.
To identify features distinguishing shared insertions from insertions that were unique
to either approach, we compared the set of shared insertions to the IM-Fusion- and
ShearSplink-specific insertions. For both comparisons (Shared/ShearSplink and
Shared/IM-Fusion), we first defined a set of features that could potentially affect
insertion detection by either method. We then trained a logistic regression model
on these features to predict whether an insertion was matched or unique to the
corresponding approach. This model was used to determine the significance of
each feature. Finally, we visualized the distributions of significant features for both
the matched/unmatched insertions using kernel density estimation (KDE) plots for
interpretation.
Candidate gene comparison To compare the candidate genes identified by Shear-
Splink and IM-Fusion, we first identified significant common insertion sites (CISs)
and differentially expressed CTGs (DE CTGs) separately using the respective ap-
proaches. We then visualized the resulting gene rankings, linking genes that were
identified as candidate genes by both approaches. Candidate genes were colored
to distinguish whether they were (i) shared between both approaches (black), (ii)
were identified to have insertions but were not selected as a CTG/CIS by the other
approach (blue), (iii) were selected as a CTG/CIS but were not differential expressed
(green), (iv) were not selected as a CTG/CIS and were not differentially expressed
(purple) and (v) were omitted entirely by the other approach (red).
ShearSplink insertion validation in DNA Tumor DNA was isolated using a phe-
nol–chloroform extraction. Transposon insertions were detected in 500 ng DNA
by standard PCR with an annealing temperature of 58 ◦C. The following primer
sequences were used:
• En2SA forward 5’-GCTTGTGGAAGGCTACTCGAA-3’
• Nf1 11KOU029-R5.INS_12 reverse
5’-CTCACGTGAAGTGGGAAAGACA-3’
• Nf1 12SKA029-R3.INS_15 reverse
5’-GGCGCACACCTTTAATCCTAAC-3’
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• Nf1 12SKA033-R3.INS_10 reverse
5’-TAGCTCCCTGTGTGTTCCTTTG-3’
• Nf1 12SKA068-L3.INS_15 reverse
5’-AAGGGTGAAGCAGGAGGATTAC-3’
• Nf1 12SKA092-L2.INS_10 reverse
5’-ACGGAGAAGGAGAGAGGGAAA-3’
• Nf1 12SKA104-R3.INS_1 reverse
5’-CCAACATCCCTGTTGTGTGTATG-3’
• Hprt forward 5’-CTGGTGAAAAGGACCTCTCG-3’
• Hprt reverse 5’-TGAAGTACTCATTATAGTCAAGGGCA-3’
Endogenous fusion identification Endogenous gene fusions were identified by ap-
plying STAR-Fusion12 (version 0.5.4) to the raw RNA-seq data (fastq files) using
recommended settings. The resulting list of fusions were combined across samples
and filtered for fusions with breakpoints at known splice junctions, as these are most
likely to reflect proper gene fusions. The filtered fusions were prioritized by grouping
fusions on the involved genes and ranking by the recurrence of these gene pairs
across samples. The fusions involving Fgfr2 were validated using the same approach
as for the gene-transposon fusions, with the following additional primers:
• Fgfr2 forward 5’-TGGCCAGGGATATCAACAAC-3’
• Kif16b reverse 5’-CTTTCCTGAGGGCTAGAGTTTG-3’,
• Myh9 reverse 5’-GATAGCGCCTTTGTCTCCTT-3’,
• Tbc1d1 reverse 5’-CCAGGCTGTGAGAAGGATTT-3’
4.3.4 Methods - B-ALL dataset
Candidate gene comparison To compare IM-Fusion with the DNA-seq results from
the original publication, we applied IM-Fusion to the paired-end RNA-seq data and
compared the identified DE CTGs with the published candidate genes (DE CISs).
To avoid selecting CTGs with very low support in this relatively deeply sequenced
dataset (as these are more likely to represent false positives), we filtered insertions
with fewer than 10 supporting reads or mates from the CTG analysis.
Effect of sequencing depth The B-ALL samples were downsampled to depths of 15,
30, 50 and 70 million reads using Seqtk||. IM-Fusion was applied to each of these
downsampled datasets to identify DE CTGs, using the same settings as were used for
||https://github.com/lh3/seqtk
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the full dataset. The number of insertions and DE CTGs were compared between the
different depths, as well as the overlap in DE CTGs between depths.
Single- versus paired-end comparison A single-end version of the dataset was
simulated by supplying only the first pair as input to IM-Fusion. The results from
the paired-end and single-end analyses were compared by juxtaposing DE CTGs and
insertions in these genes between the two analyses.
Fusion Finder comparison We created an augmented version of the mm10 ref-
erence genome containing the T2/Onc transposon sequence in the same manner
as described by Temiz et al.9. This reference was modified to mask the En2 and
Foxf2 gene loci, which contain sequences homologous to parts of the transposon
sequence. Tophat224 (version 2.1.0) was used to align reads to this augmented
reference, after which the Fusion Finder script (version 3.1) was used to identify
insertions in each sample. The results were compared with IM-Fusions DE CTGs and
published candidate genes by analyzing the overlap between the identified insertions
and the CTGs/CISs. To determine why certain CTGs/candidates were not identified
by Fusion Finder, we visualized the distribution of the used transposon features
and compared the alignments of reads supporting insertions unique to IM-Fusion
between the Tophat2 and STAR alignments using pysam23.
Endogenous fusion identification Endogenous gene fusions were identified in the
same manner as for the ILC dataset.
4.4 Results
4.4.1 Identifying insertion sites from gene-transposon
fusions
Transposon insertions can affect the expression of nearby genes, potentially leading
to the activation of oncogenes or the inactivation of tumor suppressors. For example,
consider the T2/Onc transposon (Figure 4.1A) that is used in this work. When
integrated in the vicinity of a gene, this transposon can induce (over)expression of
nearby genes by initiating transcription from its promoter sequence (MSCV) and
then splicing into the gene using the SD sequence (Figure 4.1B). Alternatively, the
transposon can truncate transcripts using either of its SA sites (SA/En2SA) and
their corresponding polyA (pA) sites (Figure 4.1C). Depending on the gene and the
location of the transposon, these truncations can inactivate the gene by resulting in
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an unstable transcript or inactive protein, or activate the gene by removing inhibitory
protein domains.
In both of these cases, part of the transposon sequence is incorporated into the result-
ing mRNA transcript(s) via splicing between the affected gene and the transposon. As
such, these transcripts effectively represent fusions between the transposon sequence
and the affected gene. We therefore hypothesized that it should be possible to detect
transposon insertion sites from RNA-sequencing by identifying gene-transposon fu-
sions using existing gene fusion detection tools. By further analyzing the breakpoints
of each fusion, we could determine exactly which gene and which feature of the
transposon are involved in the fusion, and use this information to predict the location
of the corresponding insertion site.
A   Sleeping Beauty transposon (T2/Onc)
B   Activation of expression (oncogenes)
C   Transcript truncation (tumor suppressors and oncogenes)
Fig. 4.1. Overview of the T2/Onc transposon and its effects on gene expression.
(A) The transposon sequence contains two splice acceptor sequences (SA and
En2SA) with corresponding polyA sequences (pA), and a single promoter se-
quence (MSCV) combined with a splice donor (SD) sequence. (B) Sense inser-
tions of the transposon either within or upstream of a gene may drive overex-
pression of the downstream gene sequence by initiating expression from the
transposons promoter and SD sequence. (C) Insertions within genes (in either
orientation) may truncate gene transcripts by splicing to either of the SA sites (SA
or En2SA). The resulting truncations may inactive tumor suppressor genes, but




In this work, we developed a tool called IM-Fusion, that uses a three-step approach
to (i) identify insertions from gene-transposon fusions in RNA-sequencing data, (ii)
select genes that are more frequently affected by insertions than would be expected
by chance and (iii) test if the expression of these genes is significantly changed by
their insertions (Figure 4.2A). A brief description of each of the steps is provided
below, more details are available in the Materials and Methods section.
Identifying insertion sites
IM-Fusion identifies transposon insertion sites from gene-transposon fusions in the
RNA-seq data. To identify these fusions, IM-Fusion first creates an augmented version
of the host reference genome by adding the sequence of the transposon as an extra
sequence to the original reference sequence. Then, for each sample, IM-Fusion uses
a fusion-aware RNA-seq aligner to align RNA-seq reads to the augmented reference
and identify gene fusions. By default, STAR10 is used for this purpose, although
Tophat-Fusion11 is also supported. The identified fusions are filtered to only select
fusions between genes and the transposon sequence. These gene-transposon fusions
are then analyzed to identify the involved genes and transposon features, and to
infer the approximate locations of the insertions (Figure 4.2B). Optionally, the
RNA-seq alignment can be used to perform a reference-guided transcript assembly,
which allows IM-Fusion to detect insertions that result in the expression of novel
(unannotated) transcripts.
An important advantage of IM-Fusion over DNA-sequencing based approaches is
that, instead of focusing on deriving the exact location of insertion sites, it focuses
on determining which genes are affected by insertions. This gene-centric approach
allows us to select only those insertions that affect expressed genes and are therefore
most likely to have an actual biological effect. By doing so, IM-Fusion provides an
important filter that strongly enriches for biologically relevant insertions and avoids
selecting many extraneous insertions that are unlikely to affect gene expression.
This greatly increases the specificity of our results, providing more confidence in the
identified hits.
Selecting commonly targeted genes
To identify genes that are commonly targeted by insertions, we use the Poisson
distribution to test whether a given gene has more insertions than may be expected
by chance (see Materials and Methods). To correct for cases in which a single
insertion is detected multiple times in the same gene, either due to its involvement
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A   Overview of IM-Fusion  
Fig. 4.2. Overview of IM-Fusion. (A) The IM-Fusion pipeline. Samples are initially pro-
cessed individually to identify insertions and generate gene and exon expression
counts for each sample separately. The per-sample results are then combined to
identify genes that are recurrently affected across samples. For these genes, we
then combine the expression and insertion data to test for differential expression
over the insertion site. The results of this analysis are used to determine if inser-
tions have a significant effect on the expression of their target genes and exactly
how the insertions affect the resulting gene transcript.
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C   Differential expression analysis
B   Insertion site identification
Fig. 4.2. Continued. (B) Transposons that affect gene expression are included in gene
transcripts and are therefore detectable as fusion transcripts between genes and
the transposon. These fusions are detected by reads or mate-pairs that bridge
the fusion site. The breakpoints of the identified gene-transposon fusions are
analyzed to identify the involved gene(s) and predict an approximate location for
the corresponding insertion(s). (C) Insertion and expression data are combined
to test if an insertion significantly affects the expression of exons downstream of
the insertion site. Expression counts are calculated both before/after the insertion
site for a sample with an insertion and a set of background samples without an
insertion. The ‘before’ count is then used to normalize the sample counts, after
which the normalized ‘after’ counts are compared to the ‘before’ counts to test for
differential expression. Samples with a truncating insertion are expected to show
a lower level of expression after the insertion relative to the background, whilst
samples with an activating insertion are expected to show increased expression
after the insertion.
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in multiple gene isoforms or due to local hopping within the gene, insertions are by
default collapsed into a single insertion per gene per sample (taking the average
location of the insertions) before testing for enrichment. This ensures that selected
CTGs indeed represent recurrent insertions across multiple samples, and not just
multiple insertions within a single or few samples.
Testing for significant effects on expression
To establish whether the expression of a CTG is significantly altered by its insertions,
we test for differential expression over the insertion sites in the gene. The main goal
of this analysis is to determine if we see a significant increase in expression after
the insertion site, indicating that (partial) gene transcripts are (over)expressed by
the insertions, or observe a significant decrease in expression, indicating that gene
transcript(s) are truncated by the insertions.
To perform the test, we first normalize for differences in overall expression of the
gene across all samples based on the expression of exons before the insertion site,
which we assume are not directly affected by the presence of an insertion. After this
normalization, we compare the normalized expression levels after the insertion site
between samples with and without an insertion in the gene to test for differential
expression (Figure 4.2C). By default the test performs a group-wise comparison
using the Mann–Whitney U test, in which the expression of samples with an insertion
is compared to samples without insertions in the gene. Alternatively, we also provide
a single-sample test based on the negative binomial distribution, which determines
whether the gene is differentially expressed in a specific sample.
For cases without exons before the insertion site(s), which can occur if insertions
are located upstream of the gene, an additional gene-level test is provided. This
test compares the expression of the overall gene between samples with/without
insertions, after normalizing for overall differences in sequencing depth.
4.4.3 Applying IM-Fusion to a mouse model of breast
cancer
We tested our approach by using IM-Fusion to identify SB transposon insertions
in 123 tumors from a mouse model of invasive lobular breast cancer (ILC)17. On
average, 0.1% of the reads in each sample were chimeric reads supporting a potential
fusion, of which 0.42% represented a putative gene-transposon fusion (Supplemen-
tary Table S4.1). From these fusions, IM-Fusion identified a total of 2057 transposon
insertion sites across all tumors, with a median of 12 insertions per tumor (Supple-
mentary Table S4.2). A total of 1043 genes were affected by at least one insertion,
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14 of which were selected as differentially expressed (DE) CTGs (Supplementary Ta-
ble S4.3). To confirm the existence of the identified insertions, a subset of insertions
was validated using PCRs targeting the predicted gene-transposon fusion transcripts
(Supplementary Figure S4.1).
Effects of individual insertions
To evaluate the effect of individual insertions, we visualized single insertions together
with the expression of their target genes in the corresponding sample (Figure 4.3A-
D). A first example is shown in Figure 4.3A, which shows an antisense insertion in
the Trps1 gene. This insertion was identified from a fusion between the transposons
En2SA site and the fourth exon of the gene, indicating that the insertion truncated
the gene after this exon. This hypothesis was supported by the expression profile
of the gene in this sample, which showed a marked reduction in expression after
the insertion site. Using the single sample DE test, we confirmed that this reduction
in expression was indeed significant compared to background samples without an
insertion in the gene (Figure 4.3C).
A second example (Figure 4.3B) shows a sense insertion in the Trp53bp2 gene, which
was identified from two distinct gene-transposon fusions. The first fusion, between
the SA site of the transposon and exon 12 of the gene, indicated that the insertion
truncated gene transcription after this exon. However, the second fusion, between
the SD site and exon 13, indicated that the insertion also drove overexpression of
a partial gene transcript downstream of the insertion. Taken together, this showed
that the insertion simultaneously resulted in both the truncation of the original gene
transcript and overexpression of a C-terminal transcript containing exons 11–18.
This overexpression was clearly reflected in the expression levels of the gene, which
were significantly increased after the insertion site (Figure 4.3D). Finally, from the
shown splice junctions we saw that the full-length transcript of Trp53bp2 (and/or
the truncated N-terminal transcript) was still expressed in this sample, though at
lower levels than the partial transcript.
General effects of insertions on CTGs
To determine how each identified CTG was affected by its insertions, we first analyzed
the insertions in each CTG to identify if the gene was biased to SD or SA insertions. In
this analysis, a bias to SD insertions would indicate the gene is mainly overexpressed
by insertions in the gene (Figure 4.1B). Conversely, a bias toward the SA/En2SA
sites would indicate the gene is mainly truncated by its insertions (Figure 4.1C).
Second, we used IM-Fusion to test for differential expression across the insertion
site to determine if the insertions affect the expression of the gene and whether the
observed effect points to truncation or overexpression of the gene. For clarity we





Fig. 4.3. Examples of identified insertions, CTGs and their effects on gene expression.
(A) An example of an antisense insertion in Trps1 that results in truncation of the
gene transcript. The insertion (red arrow) is shown above the main transcript
of the gene, together with expression levels of the gene. The expression of the
exons is shown along the top in blue, which reflects the number of reads covering
the various exons. Similarly, the black arches below indicate the strength of
the splicing junctions between the different exons, with the height of the arch
indicating the number of reads supporting the splice junction. Taken together,
these expression profiles show a strong decrease in expression after the insertion
site, supporting the hypothesized truncation. (B) An example of a sense insertion
in Trp53bp2 (blue arrow). This insertion results in both truncation of the gene
and overexpression of a partial transcript. (C) Quantified expression levels
before/after the insertion site for the Trps1 insertion shown in (A). Compared
to the samples without an insertion (gray), the sample with this insertion (blue)
shows a significant decrease in expression after the insertion. (D) Quantified
expression levels for the Trp53bp2 insertion. Overexpression of the truncated
transcript is clearly reflected by the increase in expression after the insertion site.
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Fig. 4.3. Continued. (E) Frequencies of the transposon features involved in the insertions
of the top six identified CTGs. A bias toward SA/En2SA favors truncation of the
gene, whereas a bias toward SD favors overexpression. (F) Differential expression
across the insertion sites for each of the CTGs. An increase in the presence of an
insertion indicates overexpression, a decrease indicates truncation.
limited our analysis here to the top six candidate genes; similar results for the other
candidates are available in Supplementary Figure S4.2.
This analysis showed that most top CTGs (Ppp1r12a, Trps1, Myh9, Tgfbr2 and
Runx1) were clearly biased toward SA/En2SA insertions (Figure 4.3E), indicating
that transcripts of these genes were being truncated by the transposon insertions.
This hypothesis was further supported by the DE tests (Figure 4.3F), which confirmed
that each of these genes showed a significant decrease in expression after the
insertion site, indicating that genes are indeed truncated. Conversely, for one top
CTG, Trp53bp2, we saw a clear bias toward SD insertions, indicating that this gene
is overexpressed by its insertions. This was again supported by the DE analysis,
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which determined that Trp53bp2 showed a significant increase in expression after its
insertion sites.
Comparison with targeted DNA-sequencing
To assess if IM-Fusion identifies similar insertions to targeted DNA-sequencing
approaches, we compared our results to those obtained by targeted DNA-sequencing
of insertions using the ShearSplink protocol19. For this comparison, we matched
insertions between the two approaches (IM-Fusion and ShearSplink) if they identified
the same target gene and had compatible genomic locations and orientations. Note
that, using this approach, an insertion is counted multiple times if it is assigned to
multiple genes, thereby increasing the apparent total number of insertions.
Matched insertions were considered to be shared by both approaches, whereas un-
matched insertions were categorized as ‘ShearSplink-specific’ or ‘IM-Fusion-specific’
depending on their source. This analysis showed that the majority of the insertions
identified by IM-Fusion (578/818) were shared with ShearSplink (Figure 4.4A).
However, a substantial number of insertions were unique to either IM-Fusion (240)
or ShearSplink (2838), indicating a considerable disparity between the two ap-
proaches.
ShearSplink-specific insertions
To investigate why certain insertions were not identified by IM-Fusion, we compared
the ShearSplink-specific insertions to the insertions identified by both approaches.
The goal of this comparison was to identify features that distinguished the two sets
of insertions (see Materials and Methods) and might therefore provide insight into
the underlying reasons for the observed differences. Of the considered features, the
following were determined to be significantly predictive: the expression level of
the predicted target gene, the relative location of the insertion within its target, the
distance of an insertion to its target and the support of the ShearSplink insertion.
The first two of these features point toward biases in the sequencing coverage of the
RNA-seq data that affect the detection of insertions. The first feature, the expression
level of the target gene, indicates that IM-Fusion had trouble identifying insertions
in genes with no or low expression (Figure 4.4B). The lack of insertions in non-
expressed genes was expected, as these insertions are not represented in the RNA-seq
data. As these insertions are unlikely to have any biological effect, their omission is
expected to increase the specificity of IM-Fusion with regard to biologically relevant
insertions. The lack of insertions in genes with low expression reflects an inherent
bias of RNA-seq toward highly expressed genes, which results in less sequencing
coverage for genes with low expression.
4.4 Results 125



































































Shared, no CIS/CTG, not DE
Not shared
0.0 0.2 0.4 0.6 0.8 1.0















































Fig. 4.4. Comparison of insertions identified by IM-Fusion and ShearSplink. (A) Venn
diagram of the insertions identified by ShearSplink (red) and IM-Fusion (blue).
Many IM-Fusion insertions are shared with ShearSplink (green), but a consider-
able number of insertions are unique to either approach. (B and C) Distribution
of features reflecting biases of RNA-sequencing that affect the detection of in-
sertions by IM-Fusion. ShearSplink-specific insertions (red) typically have low
expression compared to shared insertions (green) and are therefore more difficult
to detect by RNA-seq. Similarly, insertions toward the start of the gene are more
frequently missed by IM-Fusion due to the 3’ bias of the polyA tail selection used
in the RNA-sequencing. (D and E) Distributions of support of DNA-seq insertions
and support of RNA-seq insertions. Insertions with low DNA-seq support are
more often missed by IM-Fusion, whilst insertions with low IM-Fusion support are
often not detected by ShearSplink. These differences likely reflect heterogeneity
of subclonal insertions present in the tumor tissue samples used for DNA-seq
and RNA-seq, respectively. (F) Comparison of the frequency-based ranking of
candidate genes identified by IM-Fusion and ShearSplink. Gray lines indicate
the relative rankings of genes that were identified by both approaches. Genes
missed by the other approach are marked red. Genes that were identified to have
insertions but not selected as CISs/CTGs by the other approach are colored blue
or purple, depending on their differential expression status. Genes that were
identified as CISs/CTGs but were not differentially expressed are marked green.
Similarly, the second feature, the relative position of an insertion within the gene,
showed that IM-Fusion misses more insertions at the 5’ end of genes (Figure 4.4C).
This is due to a well documented 3’ bias of the polyA-tail selection used to enrich
for mRNAs in RNA-sequencing, which results in decreasing coverage toward the
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5’ end of gene transcripts. Together, these two biases limit the ability of RNA-seq-
based approaches such as IM-Fusion to detect insertions in lowly expressed genes,
particularly at their 5’ end. This effect can be mitigated by deeper sequencing and
by using a different approach to enrich for mRNAs in the preparation for RNA-
sequencing (such as rRNA depletion).
Another significant feature, the support of an insertion (Figure 4.4D), showed that
IM-Fusion mainly missed ShearSplink insertions with a low support score. This bias
may be due to one or more of the following reasons. First, our RNA-seq data may
not be deep enough to detect very subclonal insertions that are only present in a
very small fraction of the tumor cells. Second, the observed differences may reflect
intratumoral heterogeneity, as we did not use the same tumor fragments for RNA
and DNA extraction and sequencing, but instead used two separate pieces of the
same tumor. For clonal insertions this is not an issue, but subclonal insertions might
be present in only one of the tumor pieces, therefore leading to some of the observed
differences between IM-Fusion and ShearSplink.
Finally, we found that the heuristic assignment of target genes by ShearSplink also
introduced biases. Even after restricting the assignment of target genes to the
closest gene, ShearSplink was unable to identify a unique target gene for some
insertions. For example, insertions within the Arfip1/Fbxw7 locus were frequently
assigned by ShearSplink to both Fbxw7 and Arfip1. Closer inspection of these
insertions indicated that these insertions are in fact closely clustered in Fbxw7 and
are therefore unlikely to affect the Arfip1 transcript that overlaps with Fbxw7. This
hypothesis was supported by the IM-Fusion results, which only identified insertions
in Fbxw7, indicating that Arfip1 is a false positive of the heuristic assignment by
ShearSplink. Similarly, the distance to target gene feature indicated that insertions
further away from their target genes are rarely matched by IM-Fusion. These hits are
also likely to be artifacts of the heuristic assignment of target genes by Shearsplink.
IM-Fusion-specific insertions
To determine why some insertions were only identified by IM-Fusion, we also
compared the set of insertions unique to IM-Fusion to the shared insertions. This
comparison identified the support score of an insertion as the most predictive
feature of IM-Fusion-specific insertions (Figure 4.4E). This feature, which reflects
the number of reads supporting the corresponding gene-transposon fusion, showed
that ShearSplink mainly misses insertions with a low IM-Fusion support score. As
these insertions are only supported by a few reads in the RNA-seq data, they are
likely either false positives of IM-Fusion or subclonal insertions that are present in a
small fraction of tumor cells or in specific parts of the tumor. In the latter case, the
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missed insertions are again likely attributable to heterogeneity between the DNA-
and RNA-seq samples, as previously explained for the ShearSplink support feature.
Comparison of identified candidate genes
To assess if IM-Fusion identified different candidate genes than ShearSplink, we
compared the DE CTGs from IM-Fusion to the genes associated with CISs from the
ShearSplink analysis. This comparison showed that IM-Fusion and ShearSplink iden-
tified 14 and 32 candidate genes respectively, of which 12 were shared between both
approaches. From a comparison of the rankings of the candidate genes (Figure 4.4F),
we saw the strongest concordance between the most frequently recurring candidate
genes, with more discrepancy among the less frequent candidates.
To determine why some ShearSplink candidate genes were not identified by IM-
Fusion, we examined them in more detail. Five genes (Arfip1, Gm26836, Gm14798,
Ppp2r2a and Bach2) were not identified at all by IM-Fusion, suggesting that these
are either false positives of the ShearSplink analysis, as we have already argued for
Arfip1, or are weak/subclonal insertions that were not picked up by IM-Fusion. For
Nf1, IM-Fusion did detect several weak insertions, which were only supported by
single reads and were therefore filtered from the CTG analysis. These insertions,
together with additional validation of several ShearSplink insertions (Figure S4.3
Supplementary Figure S4.3), demonstrated that Nf1 was not a false positive of the
ShearSplink analysis. However, closer inspection showed that Nf1 insertions were
generally supported by few reads in the ShearSplink data, thereby explaining their
omission by IM-Fusion.
Several other genes (Setd5, Gab1, Ppp1r12b, e.g.) were identified to have insertions
by IM-Fusion, but were not detected in enough samples to be selected as a CTG.
Further analysis showed that insertions in missing samples were supported by few
ShearSplink reads, indicating that these insertions are missed due to their low
clonality. This also explains why several of these genes (Ppp1r12b, Nfix, Rmb47, etc.)
are not differentially expressed in the presence of an insertion, as we are less likely
to pick up expression differences if the signal is weak due to subclonality.
A few candidate genes, including Fgfr2 – the top hit from the ShearSplink analysis,
were not selected as DE CTGs due to a lack of differential expression. Closer analysis
showed that Fgfr2 is affected by a mix of sense and antisense insertions. Whilst the
antisense insertions merely truncate the gene, the sense insertions both truncate the
gene and induce the overexpression of a partial C-terminal transcript (Supplementary
Figure S4.4). Together, this results in a mix of samples with increased and decreased
expression, thereby representing a more complex pattern of expression changes than
the overall changes that the DE test was designed to detect. This indicates that,
128 Chapter 4 Identifying transposon insertions and their effects from RNA-sequencing data
although the DE test is useful for prioritizing candidate genes, frequently recurring
CTGs that are not differentially expressed should be investigated in more detail
to avoid filtering out more complex cases of differential expression. This can, for
example, be done by grouping samples based on the orientation of their insertions
(as done here) or on the involved SD/SA sites if these are expected to have different
effects on expression.
Finally, besides the known candidates, IM-Fusion identified two novel candidates
that were not identified by ShearSplink. Interestingly, both of these genes were
identified in similar numbers of samples (two to three samples) by both ShearSplink
and IM-Fusion, indicating that IM-Fusion may have more power to identify rare
CTGs.
4.4.4 Application of IM-Fusion to paired-end
RNA-sequencing data from B-ALL tumors
To test IM-Fusion on paired-end RNA-sequencing data, we used an additional dataset
of SB-induced B-cell acute lymphoblastic leukemias (B-ALL) for which both tar-
geted DNA-sequencing and relatively deeply sequenced paired-end RNA-sequencing
(70–90 million reads) was available21. In the original analysis of this dataset, Van
der Weyden et al. first identified CISs from targeted DNA-sequencing data, and then
selected predicted target genes that showed significant differential expression in the
presence of an insertion (DE CISs). For our comparison, we applied IM-Fusion using
only the RNA-sequencing data and compared the identified insertions and CTGs
to the results of the DNA-seq analysis. In light of the higher sequencing depth of
the B-ALL dataset (relative to the ILC dataset), we removed insertions with fewer
than 10 supporting reads in the CTG analysis to avoid selecting genes that are
recurrently detected but have low support, as these are likely to represent false
positives (Supplementary Figure S4.5).
CTG comparison
On average, 0.72% of the mate pairs in each sample reflected chimeric alignments, of
which 0.45% supported potential gene-transposon fusions (Table S4.4). From these
fusions (Supplementary Table S4.5, IM-Fusion identified six CTGs (Jak1, Stat5b,
Cblb, Zfp423, Dlx3 and Bmi1), of which all except Bmi1 and Dlx3 coincided with the
six DE CISs identified by the DNA-seq analysis (Figure 4.5A-B). Two genes were only
identified by the DNA-seq analysis (Foxp1 and Il2rb). Closer inspection of the original
DNA-seq data showed that insertions in these genes were generally supported by
<10 reads (Supplementary Table S4.6), suggesting that these insertions are subclonal





Fig. 4.5. Comparison of candidate genes identified by IM-Fusion and the original
DNA-sequencing analysis in the B-ALL dataset. (A) Comparison of candidate
gene rankings between IM-Fusion (left) and the original DNA-seq-based analysis
(right). Colors are coded as in Figure 4.4F. (B) Overlap of IM-Fusions DE CTGs
and the published DE CISs. (C) Comparison of DE CTG rankings by IM-Fusion on
the single- and paired-end versions of the B-ALL dataset.
issues with sample heterogeneity. Interestingly, both of the novel CTGs (Bmi1, Dlx3)
have been reported to play a role in the development of B-ALL25,26, suggesting that
these are true hits that were missed by the DNA-based analysis.
Effect of sequencing depth
To determine how sequencing depth affects the detection of insertions and CTGs, we
made use of the high sequencing depth of the B-ALL dataset to repeat the analysis at
reduced depth by downsampling the original dataset to 15, 30, 50 and 70 million
reads per sample. These analyses showed that the number of detected insertions
increases linearly with the sequencing depth (Supplementary Figure S4.6A), indicat-
ing that additional sequencing depth provides more power to detect insertions. In
contrast, only one extra DE CTG (Dlx3) was detected at higher sequencing depths
(Supplementary Figure S4.6B-C), suggesting that deep sequencing may provide
limited returns when screening for candidate genes. However, less insertions were
detected in some of these CTGs at the lower depths (Supplementary Table S4.7),
demonstrating that a higher sequencing depth will provide more accuracy in the
detection of weak insertions.
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Single- versus paired-end sequencing
To study the added value of paired-end sequencing, we simulated a single-end
version of the dataset by applying IM-Fusion to only one of the paired-ends. Although
the analysis of the single-end dataset identified the same DE CTGs as the paired-
end analysis (Figure 4.5C), the paired-end data yielded on average two times
higher support scores for insertions due to the higher effective depth of paired-end
sequencing, and identified a number of insertions that were not detected in the
single-end sequencing data (Supplementary Table S4.8). Overall, this suggests that
paired-end sequencing data is not strictly necessary for detecting insertions, but is
beneficial for the detection of weak insertions.
Comparison with Fusion Finder
Finally, to compare IM-Fusion with existing approaches, we analyzed the B-ALL
dataset using Fusion Finder9, which uses Tophat224 to identify transposon insertions
from discordant mate pairs in paired-end RNA-sequencing data. Comparison of the
identified insertions showed that Fusion Finder identified recurrent insertions in
Cblb and Dlx3, but was only able to identify insertions in a single sample for Jak1
and Bmi1, and was unable to detect insertions in any of the other DE CTGs identified
by IM-Fusion (Supplementary Table S4.9).
More detailed analyses of the results showed that the insertions in CTGs missed
by Fusion Finder are (i) biased toward SD insertions and (ii) mainly supported
by chimeric reads overlapping the fusion boundary, rather than mate pairs that
span the fusion (with one mate on either side of the fusion). The latter explains
why the majority of these insertions were not detected by Fusion Finder, as Fusion
Finder does not incorporate split read information into its insertion detection. This
highlights an important advantage of using fusion-aware aligners such as STAR and
Tophat-Fusion, as these aligners explicitly account for chimeric fusion reads in their
alignment, resulting in increased sensitivity for the detection of these insertions.
Although Fusion Finder failed to detect insertions involving the SD site of the
transposon in this dataset, it did identify SD insertions in the original study by Temiz
et al.9. We expect that the differences between our result and theirs are due to
differences in read lengths, as the B-ALL dataset uses 100 bp reads compared to the
50 bp read length used in their dataset. The longer read length makes it more likely
that reads overlap the fusion boundary, making an approach that uses chimeric reads
preferable with longer read lengths.
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4.5 Discussion
We have presented IM-Fusion, a novel approach for identifying transposon insertion
sites from gene-transposon fusions in RNA-sequencing data. A key advantage of
this approach is that it focuses on identifying insertions that affect gene expression.
As such, IM-Fusion provides a significant filter that strongly enriches for insertions
that actually affect the expression of their target genes and are therefore most likely
to be biologically relevant. This greatly increases the specificity of the approach,
providing more confidence in detected insertions and genes and increasing our
power to identify rare candidate genes. Furthermore, by combining the insertions
with a differential expression analysis, IM-Fusion provides valuable insight into the
effect of insertions on the affected target genes.
An important advantage of using RNA-sequencing rather than targeted DNA-
sequencing for identification of transposon insertions, is that RNA-sequencing pro-
vides much more information than just the location of insertion sites. For example,
IM-Fusion uses RNA-expression information to determine how a gene is affected by
the presence of an insertion. The same expression data may also be used to identify
more global changes in gene expression associated with tumor subtypes or with
specific insertions17, or be used to detect single nucleotide variants and somatic
gene fusions that contribute to tumorigenesis. As an example of the latter, we have
identified several endogenous fusions in the ILC and B-ALL datasets (Supplementary
Figure S4.7 and Table S4.10), including several Fgfr2 fusions that reflect known
oncogenic fusions previously identified in human cancers27. Most importantly, these
extra analyses can be performed on the same RNA-seq sample, thereby inherently
avoiding potential discrepancies resulting from the use of different tumor material
for DNA- and RNA-sequencing, an issue that we encountered in the analyses of both
the ILC and the B-ALL datasets.
A potential limitation of IM-Fusion is that it requires splicing between the transposon
and the affected genes to identify the corresponding insertions. As a result, it will
not detect transposon insertions that affect expression via enhancer sequences, as
the effects of these insertions are not mediated via splicing. In our analyses, this
does not seem to be an issue, as DNA-sequencing approaches did not identify any
candidate genes that were perturbed via enhancer effects. This suggests that the
MSCV enhancer sequence present in the T2/Onc transposon is not particularly active
and that the transposon therefore mainly affects expression via splicing. This notion
is in agreement with previous studies reporting preferential intragenic insertion of
the T2/Onc transposon8, making it less likely to act as an enhancer. Enhancer effects
may however play a more important role in case other transposons are employed.
Similarly, IM-Fusion may be unable to detect insertions that result in transcript
132 Chapter 4 Identifying transposon insertions and their effects from RNA-sequencing data
instability or degradation, as these will be under-represented in the RNA-seq data.
Although we do not observe evidence pointing to transcript degradation in the
presence of (clonal) SB insertions (Supplementary Figure S4.8), other transposons
might have different effects on transcript stability.
A strategy to identify both insertions whose effects are mediated by transcriptional
enhancement and insertions that affect expression via splicing, would be to combine
DNA- and RNA-sequencing methods, ideally using RNA and DNA isolated from the
same sample. In such a combined approach, RNA-sequencing could be used to iden-
tify and characterize insertions that are mediated via splicing. For insertions that are
uniquely identified by DNA-sequencing, the RNA-seq data could be used to analyze
their effects on expression of the predicted target genes. Such a strategy would
effectively unite the advantages of both approaches, by combining the unbiased
identification of insertion sites by DNA-sequencing with the additional biological
information provided by RNA-sequencing in a single analysis.
Although Temiz et al.9 have provided a proof-of-concept showing that transposon
insertions can be identified via paired-end RNA-sequencing, our analysis was per-
formed on a much larger dataset (123 versus 20 samples), allowing us to determine
biases that affect insertion detection in DNA- and RNA-sequencing data and identify
potential limitations of either approach. Furthermore, IM-Fusion improves on Fusion
Finder by using a fusion-aware RNA-seq aligner to identify transposon insertions,
which enables the use of single-end RNA-sequencing data and increases the sensitiv-
ity and the accuracy of insertion detection by also using chimeric reads to identify
gene-transposon fusions. Finally, IM-Fusion is provided as comprehensive software
package that enables users to perform the entire analysis from start to finish, in-
cluding the generation of augmented reference genomes, identification of CTGs and
testing for differential expression.
In summary, IM-Fusion provides a convenient approach for the identification of
insertion sites and their effects on target gene expression from standard single- and
paired-end RNA-sequencing data. By combining the identification of insertion sites
with expression data, our approach provides valuable insight into the effect of an
insertion on its target gene(s) and helps prioritize insertions that are biologically
relevant. We expect that this approach will significantly enhance the accuracy of
cancer gene discovery in forward genetic screens and prioritization of the identified
candidate cancer genes for functional validation studies.
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# Sample Chrom. Position Strand Support Transposon feature Gene Type
1 13SKA014-R3 15 77807867 1 198 En2SA Myh9 Shared
2 12SKA029-R3 15 77807867 1 10 En2SA Myh9 IM-Fusion-specific
3 12SKA101-L3 15 77807867 -1 10 SA Myh9 Shared
4 12SKA102-R3 15 77807867 -1 2 SA Myh9 IM-Fusion-specific
1 182448400 1 7 SD Trp53bp2 Shared
5 11KOU051-R3 1 182448400 1 23 SD Trp53bp2 Shared
6 12SKA017 2 84615087 1 6 SA Ctnnd1 IM-Fusion-specific
7 12SKA108-R3 2 84650405 1 2 SA Ctnnd1 Shared
8 11KOU012-R5 2 84650405 1 9 SA Ctnnd1 Shared
B Validation results
Hprt
Ctnnd1 FW2 - En2SA 
Ctnnd1 FW1 - En2SA 
SD - Trp53bp2
Myh9 - SA
Myh9 - En2SA 
MQ1 2 3 4 5 6 7 8
Fig. S4.1. Validation of gene-transposon fusions from the ILC dataset via targeted
PCR on cDNA. A selection of predicted insertions from IM-Fusion were validated
using PCR primers targeting the corresponding fusions. (A) Overview of the
samples used in the validation. The Type column indicates whether the insertion
was shared or only identified by IM-Fusion. Samples were chosen to (i) include
a mix of SA/SD/En2SA insertions and (ii) span a range of low/high support
scores. (B) Results of the validation, showing that each of the expected fusions
is indeed detected in the cDNA of the corresponding sample. MQ (= MilliQ) is
a water control, which was used a negative control.
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A
B
Fig. S4.2. Feature bias and differential expression for all DE CTGs in the ILC dataset.
(A) Frequencies of the transposon features involved in the insertions for each
CTG. A bias towards SA/En2SA favors truncation of the gene, whereas a bias
towards SD favors overexpression. (B) Differential expression across the inser-
tion sites for each CTG. An increase in the presence of an insertion indicates
overexpression, a decrease indicates truncation.
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A Sample overview
# Insertion id Sample Chrom. Position Strand Support Gene Type
1 11KOU029-R5.INS_12 1566_15_11KOU029-R5 11 79461479 1 11 Nf1 Shared
2 12SKA029-R3.INS_15 2049_38_12SKA029_R3 11 79359162 -1 10 Nf1 ShearSplink-specific
3 12SKA033-R3.INS_10 2800_1_12SKA033-R3 11 79426158 -1 6 Nf1 ShearSplink-specific
4 12SKA068-L3.INS_15 2800_20_12SKA068-L3 11 79439837 1 2 Nf1 ShearSplink-specific
5 12SKA092-L2.INS_10 2800_36_12SKA092-L2 11 79446215 -1 15 Nf1 ShearSplink-specific
6 12SKA104-R3.INS_1 2800_44_12SKA104-R3 11 79382459 -1 58 Nf1 ShearSplink-specific
B Validation results








Fig. S4.3. Validation of ShearSplink insertions from the ILC dataset via targeted PCR
on DNA. Several ShearSplink insertions in Nf1 were validated using PCR primers
targeting the insertion sites. (A) Overview of the samples and insertions used in
the validation. The Type column indicates whether the insertion was shared or
only identified by ShearSplink. (B) Results of the validation, showing that each
of the expected insertions is indeed detected in the DNA of the corresponding
sample. MQ (= MilliQ) is a water control, which was used a negative control.
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B
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Fig. S4.4. Detailed analysis of insertion effects in Fgfr2 in the ILC dataset. (A) Strati-
fying the differential expression test for the orientation of insertions in samples
shows that samples with sense insertions (using the SA/SD sites) show sig-
nificant overexpression of the end of the gene, whilst samples with antisense
insertions (using the En2SA site) show a decrease in expression. (B) The major-
ity of samples with a sense insertion show both truncation of the transcript via
the SA site and overexpression via the SD site. This indicates that these samples
effectively have a truncated gene transcript, but that the remainder of the gene
is simultaneously overexpressed as a separate transcript.
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A
B
Fig. S4.5. Number of supporting mates in the B-ALL paired-end RNA-sequencing
data, before and after filtering by support scores. (A) Support for top genes
(ranked by insertion frequency) before filtering insertions for a minimum sup-
port of 10 reads. This shows that a number of genes (such as Pten, Gm6206 and
Ube2d2a) recur frequently, but have very low support and are therefore more
likely to represent false positives or weak/subclonal insertions. (B) Support for
the top genes after filtering for a minimum support of 10 mates. This shows
that the remaining genes all have a reasonable number of supporting reads. As
such, this filtering improves the confidence in any CTGs identified from this
filtered set of insertions and improves detection power by limiting the number
of tests (thereby reducing the multiple testing correction).
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Fig. S4.6. Effects of downsampling in the B-ALL dataset. (A) The number of detected
insertions as a function of sequencing depth, showing a linear relation between
sequencing depth and the number of insertions. (B) The number of DE CTGs
detected at different sequencing depths. (C) Overlap between DE CTGs detected
across the different sequencing depths.
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Sample Left gene Right gene Left breakpoint Right breakpoint Support (junction)
12SKA127-R3 Fgfr2 Kif16b 7:130167703:- 2:142834136:- 5
12SKA035-L3 Fgfr2 Myh9 7:130167703:- 15:77767663:- 3







Fig. S4.7. Validation of endogenous Fgfr2 fusions from the ILC dataset via targeted
PCR on cDNA. (A) Overview of endogenous fusions from STAR-Fusion (Supple-
mentary Table S4.10) involving Fgfr2, which reflect oncogenic fusions of FGFR2
identified in human breast cancers. (B) Validation results for these fusions,
showing that each of the expected fusions is indeed detected in the cDNA of
the corresponding sample. MQ (= MilliQ) is a water control, which was used a
negative control.























































































































12 rs = 0.38
p = 5.22e-03








































12 rs = 0.09
p = 6.29e-01






































7 rs = 0.09
p = 7.22e-01
Trp53bp2 expression vs. clonality
Fig. S4.8. Effects of ShearSplink insertions on transcript stability (quantified using
expression before the insertion sites) in the ILC dataset. Compares expres-
sion between samples with and without an insertion (left) and across samples
with varying levels of insertion clonality (right), showing that (clonal) insertions
do not result in reduced expression. Expression values were quantified using
the exons before the insertion sites (after normalizing for overall differences in
expression between samples), as the expression of these exons should not be
affected by the insertion(s). Correlations and p values were calculated using
Spearman’s Rank correlation (indicated as rs and p, respectively). For brevity,
results are shown for the top 10 ShearSplink candidate genes (continued on the
next page).







































9.0 rs = 0.27
p = 3.33e-01











































10.5 rs = 0.55
p = 4.95e-02







































9 rs = -0.42
p = 1.73e-01

















































































8 rs = 0.78
p = 4.68e-03
Nf1 expression vs. clonality
Fig. S4.8. Effects of ShearSplink insertions on transcript stability (continued).
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4.6.2 Supplementary Tables (available online)
Tab. S4.1. Quantification of fusion reads in the ILC dataset. Quantification of the
number of RNA-seq reads in each sample of the ILC dataset, together with the
number of reads supporting gene-fusions and how many of these fusion reads
support gene-transposon fusions. The two ratio columns indicate the fraction
of fusion reads relative to the total number of reads and the fraction of fusions
that support gene-transposon fusions.
Tab. S4.2. Fusions identified by IM-Fusion in the ILC dataset. Overview of all inser-
tions identified by IM-Fusion in the ILC dataset. The genomic breakpoints
of the corresponding fusions are described in the Chromosome, Position and
Strand columns. The Feature columns describe the transposon features that
are involved in the fusions and the position of the transposon breakpoints.
The Gene columns describe the genes involved in each fusion, whilst the Novel
transcript column indicates if a novel transcript is created by the fusion. Finally,
the Support and Ffpm columns indicate the degree of support for each fusion
(see Methods for more details).
Tab. S4.3. Overview of the CTGs identified by IM-Fusion in the ILC dataset. DE CTGs
were selected with a corrected CTG p value < 0.05 and a DE p value < 0.05.
The DE direction column indicates the direction of the differential expression
after the insertion site.
Tab. S4.4. Quantification of fusion reads in the B-ALL dataset. Quantification of the
number of RNA-seq reads in each sample of the B-ALL dataset, together with
the number of reads supporting gene-fusions and how many of these fusion
reads support gene-transposon fusions. The two ratio columns indicate the
fraction of fusion reads relative to the total number of reads and the fraction
of fusions that support gene-transposon fusions (same as for Supplementary
Table S4.1).
Tab. S4.5. Fusions identified by IM-Fusion in the B-ALL dataset. Overview of all inser-
tions identified by IM-Fusion in the B-ALL dataset. The table structure is the
same as described for Supplementary Table S4.2.
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Tab. S4.6. Overview of B-ALL insertions from the original DNA-sequencing analysis
for each of the published candidate genes. Due to lack of the original
annotation, insertions were selected for each gene if they occurred within 20kb
of the gene. The Support column indicates the number of reads supporting
the insertions. The RNAseq column states whether the insertion was also
identified in the (single-end) RNA-sequencing analysis performed using IM-
Fusion. Altogether, these tables show that the majority of the insertions not
identified by IM-Fusion had a relatively low depth in the DNA-sequencing data.
Additionally, Foxp1 and Ill2rb are generally only supported by insertions with
low depth.
Tab. S4.7. Number of samples with insertions in each DE CTG of the B-ALL dataset at
different sequencing depths, showing that additional insertions in Jak1,
Stat5b and Dlx3 are detected at the higher depths.
Tab. S4.8. Overview of single- and paired-end support scores for insertions identi-
fied by IM-Fusion for the DE CTGs in the B-ALL dataset. For brevity, the
table is limited to the strongest insertion for each gene in the corresponding
sample. This table highlights four insertions that were missed by the single-end
analysis, as well as differences in support scores between the single-end and
paired-end dataset, although the majority of the paired-end insertions are
identified from chimeric reads spanning the fusion junction.
Tab. S4.9. Overview of insertions identified by Fusion Finder in the B-ALL dataset.
For brevity, this table is limited to the published candidate genes and DE CTGs
from the IM-Fusion analysis, as these were the candidates of interest for the
comparison.
Tab. S4.10. Overview of the top endogenous fusions detected in the two RNA-seq
datasets. (A) Top 20 fusions identified in the ILC dataset. Fusions with En2
and Foxf2 were filtered from the results, as these genes contain sequences
that are homologous with the En2SA and SD sequences of the transposon.
These fusions therefore actually represent gene-transposon fusions, rather
than endogenous fusions, which is also evident from the observation that all
involved fusion partners coincide with candidate genes from the IM-Fusion
analyses. The three predicted Fgfr2 fusions were validated using a targeted
PCR (Supplementary Figure S4.7), thus confirming the presence of these
fusions. (B) Top 20 fusions identified in the B-ALL dataset, using the same
filtering. The engineered Etv6-Runx1 fusion was detected in most samples,
supporting the validity of the results. This fusion was likely missed in the
remaining four samples due to (i) differences in expression of the fusion
and/or (ii) differences between the mouse/human sequences of Runx1 (as the
reference used for STAR-Fusion contains the mouse Runx1 sequence, whilst
the engineered fusion was created using the human sequence).
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5.1 Abstract
BRCA1-mutated breast cancer is primarily driven by DNA copy number alterations
(CNAs) containing large numbers of candidate driver genes. Validation of these
candidates requires novel approaches for high-throughput in vivo perturbation of
gene function. Here we develop genetically engineered mouse models (GEMMs)
of BRCA1-deficient breast cancer that permit rapid introduction of putative drivers
by either retargeting of GEMM-derived embryonic stem cells, lentivirus-mediated
somatic overexpression or in situ CRISPR/Cas9-mediated gene disruption. We use
these approaches to validate Myc, Met, Pten and Rb1 as bona fide drivers in BRCA1-
associated mammary tumorigenesis. Iterative mouse modeling and comparative
oncogenomics analysis show that MYC-overexpression strongly reshapes the CNA
landscape of BRCA1-deficient mammary tumors and identifiy MCL1 as a collabo-
rating driver in these tumors. Moreover, MCL1 inhibition potentiates the in vivo
efficacy of PARP inhibition (PARPi), underscoring the therapeutic potential of this
combination for treatment of BRCA1-mutated cancer patients with poor response to
PARPi monotherapy.
5.2 Statement of significance
We demonstrate that engineering additional driver genes in progressively complex
mouse models of BRCA1-deficient triple-negative breast cancer can strongly influ-
ence their evolutionary trajectory. Comparative oncogenomics analysis of recurrent
copy number alterations in human and mouse tumors uncovered new culprits of
tumorigenesis and MCL1 as a novel therapeutic vulnerability.
5.3 Introduction
Triple-negative breast cancer (TNBC) accounts for 10%-15% of all breast cancers and
is characterized by lack of expression of the estrogen receptor (ER), the progesterone
receptor (PR) and the human epidermal growth factor receptor 2 (HER2). Due to
the lack of these receptors, TNBCs cannot be treated with targeted therapies that
have been effective in treating other breast cancer subtypes. As a result, TNBC has a
relatively poor clinical prognosis and chemotherapy remains its current standard-of-
care.
At the mutational level, TNBC is primarily a DNA copy number driven disease1,
harboring a multitude of copy number alterations (CNAs) containing various driver
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genes2. TNBCs are furthermore characterized by mutations in the TP53 tumor
suppressor gene, which occur in more than 80% of cases. Moreover, approximately
50% of TNBCs show loss of BRCA1 or BRCA2, either due to germline or somatic
mutations or because of promoter hypermethylation2. BRCA1 and BRCA2 are crucial
for error-free repair of DNA double-strand breaks via homologous recombination,
and loss of these genes results in high levels of chromosomal instability and a specific
mutator phenotype. This results in recurrent patterns of CNAs in BRCA-deficient
tumors, suggesting that these aberrations contain specific driver genes required for
tumorigenesis.
Unfortunately, the high degree of genomic instability in BRCA-deficient TNBCs
results in large numbers of CNAs harboring tens-to-thousands of genes, which com-
plicates the identification of putative cancer drivers. To address this issue, several
computational approaches have been developed to identify minimal regions that
are recurrently gained or lost across tumors3–6. Other approaches have comple-
mented these tools with comparative oncogenomic strategies, in which combined
analyses of human and mouse tumors are used to identify candidate driver genes
that are frequently altered in tumors from both species7–9. We have previously used
comparative oncogenomics analyses to identify driver genes that were frequently
aberrantly amplified or deleted in both mouse and human BRCA1-deficient TNBCs,
including the proto-oncogene MYC and the tumor suppressor RB110. However, it is
currently still unclear how exactly these putative drivers of BRCA1-deficient TNBC
contribute to tumorigenesis, and specifically how they may influence the muta-
tional landscape of the resulting tumors. To address these questions, we generate
additional mouse models of BRCA1-deficient TNBC harboring different candidate
genes. To overcome the time-consuming nature of generating these mouse models
via germline engineering, we develop somatic mouse models of BRCA1-deficient
TNBC and we show that these models accurately reflect their germline counterparts.
We analyze the resulting tumors to assess the contribution of candidate drivers to
BRCA1-associated mammary tumorigenesis and to determine their effect on the copy
number landscape. Finally, by applying comparative oncogenomics to a combined
set of germline and somatic BRCA1-deficient TNBCs with MYC overexpression, we
identify MCL1 as a key driver and a therapeutic target in these tumors.
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5.4 Results
5.4.1 Driver landscape in human BRCA1-deficient breast
cancer
To determine the mutational landscape of human BRCA1-mutated breast cancer, we
performed a meta-analysis by combining datasets from four large-scale breast cancer
sequencing studies and extracting the mutational data of all BRCA1-mutated tumors.
This analysis identified a total of 80 breast cancers (~1.5%) with a homozygous
deletion or an inactivating (putative) driver mutation in BRCA1 (Figure 5.1A, Sup-
plementary Table S5.1). For 18 of these cases (~23%) triple-negative (TN) status
could not be determined due to missing or inconclusive immunohistochemistry data.
Of the remaining 62 cases, 40 (~65%) were scored as TNBC. Association with TN
status was stronger in tumors from BRCA1 germline mutations carriers (27/30) than
in tumors with BRCA1 somatic mutations (13/32).
We next analyzed the mutational landscape of the 80 BRCA1-deficient breast cancer
cases, focusing on deleterious mutations, amplifications and homozygous deletions.
At the mutational level, these tumors were mainly characterized by mutations in
TP53 (52/80, ~65%) and PIK3CA (23/80, ~29%). At the copy number level, the
most prominent events included amplifications of MYC (35/80, ~44%) and several
co-amplified genes (e.g. RAD21, EXT1, RECQL4, RSPO2, EPPK1, PLEC) in the same
locus (30-34%). MYC is a particularly well-known transcription factor that lies
at the crossroad of several growth-promoting pathways and regulates global gene
expression, resulting in increased proliferation and influencing many other cellular
processes (reviewed by Meyer et al.11 and Kress et al.12). The MYC oncogene resides
in the 8q24 genomic locus, which is among the most frequently amplified regions
in breast cancer13, particularly in TNBC14. MYC expression and MYC signaling are
aberrantly elevated in TNBC15,16 and a MYC transcriptional gene signature has been
correlated with basal-like breast cancer (BLBC), a subtype typical for human BRCA1-
deficient breast cancer17–19. Altogether, this confirms that human BRCA1-deficient
breast cancers are enriched for TNBCs and are mainly characterized by inactivating
mutations in TP53 and amplification of MYC.
5.4.2 MYC is a potent driver in BRCA1-associated
tumorigenesis
To study the contribution of MYC overexpression to BRCA1-associated mammary
tumorigenesis, we initially employed the K14Cre;Brca1F/F;Trp53F/F (KB1P) mouse
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Fig. 5.1. Mutational landscape of human BRCA1-mutated TNBC and characterization
of the WB1P model. (A) Overview of the most common deleterious mutations
and copy number events in 80 BRCA1-mutated human breast tumor samples from
four large-scale tumor-sequencing studies. (B) Overview of the germline and
somatic mouse models for mammary gland-specific inactivation of conditional
Brca1 and Trp53 alleles. (C) Kaplan-Meier curve showing mammary tumor-
specific survival for WapCre;Brca1F/F;Trp53F/F (WB1P) female mice. (D) Repre-
sentative hematoxylin and eosin (HE) staining and immunohistochemical detec-
tion of E-cadherin, vimentin, ER and PR in WB1P tumors and in tumors from
Lenti-Cre injected Brca1F/F;Trp53F/F (B1P) mice. Bar, 400 µm. (E) Kaplan-Meier
curve showing mammary tumor-specific survival of B1P females injected with
Lenti-Cre. (F) Unsupervised clustering (Euclidean distance, average linkage) of
the WB1P tumors with tumors derived from published mouse models of lumi-
nal (WapCre;Cdh1F/F;PtenF/F, WEP20) and basal-like (K14Cre;Brca1F/F;Trp53F/F,
KB1P21) breast cancer, using a three-gene signature that distinguishes the PAM50
subtypes22.
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model21, in which epithelium-specific loss of BRCA1 and p53 leads to the forma-
tion of mammary tumors and, to a lesser extent, other epithelial tumors includ-
ing skin tumors. We used our previously established GEMM-ESC pipeline23 to
generate K14Cre;Brca1F/F;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+ (KB1P-Myc) mice with
epithelium-specific loss of BRCA1 and p53 and overexpression of MYC. Unfortunately,
these mice were more prone to developing non-mammary tumors than KB1P mice
and had to be sacrificed around 110 days for skin cancers and thymomas due to
expression of K14Cre in these tissues.
To avoid unwanted development of non-mammary tumors, we took a two-
pronged approach (Figure 5.1B). On one hand, we developed a novel GEMM
(WapCre;Brca1F/F;Trp53F/F, WB1P) in which mammary-specific expression of Cre is
driven by the whey acidic protein (Wap) gene promoter. In this WB1P model, female
mice spontaneously developed mammary tumors with a median latency of 198 days
(n = 35, Figure 5.1C), which is comparable to the latency of KB1P females (median
latency of 197 days, n = 41). Similar to KB1P mammary tumors, WB1P tumors
were either pure carcinomas (83%) or carcinosarcomas (17%). All tumors were
poorly differentiated, negative for ER and PR (Figure 5.1D) and showed recombina-
tion of the Brca1F and Trp53F alleles. On the other hand, we employed a somatic
strategy and performed intraductal injection of lentiviral vectors24–26 expressing the
Cre-recombinase (Lenti-Cre) in Brca1F/F;Trp53F/F (B1P) females. Tumors from B1P
mice injected with Lenti-Cre had a median latency of 238 days after injection (n = 7,
Figure 5.1E), and in terms of their morphology, they were indistinguishable from
WB1P tumors (Figure 5.1D).
To determine if tumors from these two new mouse models reflected the basal-
like subtype typical for human BRCA1-deficient breast cancer, we performed RNA-
sequencing on 22 WB1P tumors and 7 tumors from B1P mice injected with Lenti-Cre,
and compared their expression profile to tumors from the KB1P mouse model and
a mouse model of luminal breast cancer20 (WapCre;Cdh1F/F;PtenF/F, WEP), using a
three-gene signature that distinguishes the PAM50 subtypes22. This analysis showed
that all Brca1∆/∆;Trp53∆/∆ mouse mammary tumors from the three different mouse
models cluster together and are characterized by low expression of Esr1 and high
expression of the proliferation marker Aurka (Figure 5.1F), reflecting the expression
profile of human BLBC (Supplementary Figure S5.1).
To study the effects of Myc amplification in WB1P mice, we applied the
GEMM-ESC strategy23 to insert the conditional invCAG-Myc-IRES-Luc cassette
into the Col1a1 locus of WB1P embryonic stem cells. In the resulting
WapCre;Brca1F/F;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+ (WB1P-Myc) model, mammary-
specific expression of Cre induces inactivation of BRCA1 and p53 and concomitant
overexpression of the MYC oncogene accompanied by luciferase expression (Fig-
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ure 5.2A). WB1P-Myc female mice developed multifocal mammary tumors with a
median latency of 97 days (n = 35, Figure 5.2B). These tumors grew exponentially
(Supplementary Figure S5.2A) and animals had to be sacrificed 2-3 weeks after
detection of palpable tumors. In contrast to the KB1P-Myc mice, WB1P-Myc mice
developed only mammary tumors.
To test if somatic engineering could be used to overexpress MYC in
the mammary gland, we performed intraductal injections of Lenti-Cre in
Brca1F/F;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+ (B1P-Myc, n = 16) females (Fig-
ure 5.2A). Moreover, we also injected lentiviral vectors encoding both Cre and
Myc (Lenti-MycP2ACre, Supplementary Figure S5.3A) in B1P females (n = 13) and
lentiviral vectors encoding Myc (Lenti-Myc) in WB1P mice (n = 15). Mice from all
three groups developed mammary tumors with 100% penetrance and specifically
in the injected glands (Figure 5.2C). B1P-Myc mice injected with Lenti-Cre devel-
oped tumors much faster than B1P mice injected with Lenti-Cre (126 days after
injection vs 238 days after injection). B1P females injected with Lenti-MycP2ACre
and WB1P females injected with Lenti-Myc developed tumors even faster (median
latency of 92 and 61 days after injection, respectively), most likely due to higher Myc
expression from the viral constructs than from the knock-in allele (Supplementary
Figure S5.3B).
Histopathological analysis showed that, unlike the WB1P mouse model, WB1P-Myc
females developed multifocal tumors that were all carcinomas. However, similar to
WB1P tumors, WB1P-Myc tumors were poorly differentiated and ER-/PR-negative
(Figure 5.2D). Furthermore, they displayed recombined Brca1 and Trp53 alleles and
were sensitive to cisplatin and PARP inhibitors upon transplantation into nude mice
(Supplementary Figure S5.2B). WapCre;Brca1F/+;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+
females that were heterozygous for Brca1F alleles (n = 20) developed tumors slightly
but significantly slower than WapCre;Brca1F/F;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+
mice with homozygous Brca1F alleles (Supplementary Figure S5.2C). Histopatho-
logical analysis showed that mammary tumors from the somatic models were in-
distinguishable from the cognate tumors from the germline models (Figure 5.2D).
WB1P-Myc tumors showed similar expression levels of Esr1 and Aurka as the WB1P
tumors, indicating that they retained their basal-like subtype (Supplementary Fig-
ure S5.2D). Besides this, WB1P-Myc tumors showed high mRNA and protein levels
of MYC compared to WB1P tumors, demonstrating successful expression of the
knock-in allele (Supplementary Figure S5.2E-F). Unsupervised clustering of RNA-
seq data from tumors from the somatic models confirmed that they also retained
their basal-like phenotypes, and PCA analysis showed that these tumors also re-
semble their counterparts from the germline models in terms of their global gene
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Fig. 5.2. Validation of additional drivers in WB1P mice using germline and somatic
engineering. (A) Overview of the germline and somatic mouse models for
mammary gland-specific Myc overexpression in mice with conditional Brca1 and
Trp53 alleles. (B) Kaplan-Meier curves showing mammary tumor-specific survival
for the different genotypes. WapCre;Brca1F/F;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+
(WB1P-Myc) females showed a reduced mammary tumor-specific survival com-
pared to WB1P littermates (97 days vs 198 days; ∗∗∗∗p < 0.0001 by Mantel-Cox
test). (C) Kaplan-Meier curves showing mammary tumor-specific survival for
the different non-germline models. Brca1F/F;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+
(B1P-Myc) females injected with Lenti-Cre, B1P females injected with Lenti-
MycP2ACre and WB1P females injected with Lenti-Myc showed a reduced mam-
mary tumor-specific survival compared to B1P female mice injected with Lenti-
Cre (respectively 126, 92 and 61 days after injection vs 238 days after injection;
∗∗∗∗p < 0.0001 by Mantel-Cox test).
provide functional validation in germline and somatic models of the role of MYC in
BRCA1-associated mammary tumorigenesis.
5.4.3 Loss of PTEN and RB1 collaborates with MYC in
tumorigenesis
After MYC amplification, the next most common alterations in our analysis of the
human BRCA1-deficient TNBCs were mutations and/or amplifications of PIK3CA
(23/80 cases), indicating that activation of PI3K signaling is an important driver
in this breast cancer subtype (Figure 5.1A). Indeed, in addition to PIK3CA muta-
tion/amplification, heterozygous or homozygous loss of PTEN (a negative regulator
of PI3K signaling) was observed in 29/80 and 6/80 cases, respectively (Table S5.1).
Genetic alterations of PIK3CA/PTEN and MYC co-occurred in ~29% of all tumors
analyzed (23/80 cases), indicating that MYC overexpression and PI3K pathway
activation collaborate in BRCA1-related breast tumorigenesis.
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Fig. 5.2. Continued. (D) Representative hematoxylin and eosin (HE) staining and
immunohistochemical detection of E-cadherin, vimentin, ER and PR in tu-
mors from WB1P-Myc females and in tumors from Lenti-Cre injected B1P-Myc
mice, Lenti-MycP2ACre injected B1P mice and Lenti-Myc injected WB1P mice.
Scale bar, 400 µm. (E) Overview of the intraductal injections performed in
WapCre;Brca1F/F;Trp53F/F;Col1a1invCAG-Cas9-IRES-Luc/+ (WB1P-Cas9) females with
high-titer lentiviruses encoding Myc and either a non-targeting (NT) sgRNA
(Lenti-sgNT-Myc), a sgRNA targeting exon 2 of Rb1 (Lenti-sgRb1-Myc) or a sgRNA
targeting exon 7 of Pten. (F) Kaplan-Meier curves showing mammary tumor-
specific survival for the different models. WB1P-Cas9 females injected with Lenti-
sgPten-Myc and Lenti-sgRb1-Myc showed a reduced mammary tumor-specific
survival compared to WB1P-Cas9 female mice injected with Lenti-sgNT-Myc (re-
spectively 30 and 52 days after injection vs 70 days after injection, ∗∗∗∗p < 0.0001
and ∗∗∗p < 0.001 by Mantel-Cox test). (G) Boxplots depicting the fraction of
modified Rb1 and Pten alleles in tumors from WB1P-Cas9 mice injected with
Lenti-sgNT-Myc, Lenti-sgRb1-Myc and Lenti-sgPten-Myc. Boxes extend from the
third (Q3) to the first (Q1) quartile (interquartile range, IQR), with the line at
the median; whiskers extend to Q3 + 1.5 ∗ IQR and to Q1− 1.5 ∗ IQR.
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To assess if activation of PI3K signaling via loss of PTEN collabo-
rates with MYC overexpression in BRCA1-deficient TNBC, we developed
WapCre;Brca1F/F;Trp53F/F;Col1a1invCAG-Cas9-IRES-Luc/+ (WB1P-Cas9) mice with mammary-
specific loss of BRCA1 and p53 and concomitant expression of Cas9. We then
cloned and validated lentiviral vectors encoding a nontargeting sgRNA (sgNT) or
a sgRNA targeting the seventh exon of Pten (sgPten), in combination with a Myc-
overexpression cassette. Since also RB1 loss has been implicated in BRCA1-deficient
breast cancer27 and MYC-driven TNBC28, we also generated a similar lentiviral
vector encoding MYC and a sgRNA targeting the second exon of Rb1 (sgRb1). These
lentiviral vectors (Lenti-sgNT-Myc, Lenti-sgPten-Myc and Lenti-sgRb1-Myc) were
injected intraductally into WB1P-Cas9 females (Figure 5.2E) resulting in tumor
formation with high penetrance and very short latency (70, 30 and 52 days after
injection, respectively; n = 14, 12 and 14, respectively, Figure 5.2F). Genomic DNA of
mammary tumors from Lenti-sgPten-Myc and Lenti-sgRb1-Myc injected WB1P-Cas9
mice showed extensive modification of the target gene (Figure 5.2G; Supplementary
Figure S5.4A-B), with a strong bias towards indels resulting in frameshift mutations,
supporting homozygous inactivation of the tumor suppressor genes. Together, these
results demonstrate that activation of PI3K signaling and RB1 loss collaborate with
MYC in BRCA1-deficient TNBC.
5.4.4 MYC overexpression reshapes the copy number
landscape
To identify additional collaborating driver genes in BRCA1-deficient TNBC, we de-
cided to characterize the CNA landscape of WB1P and WB1P-Myc tumors, with
the assumption that recurrent CNAs in these tumors might underscore a conserved
selective pressure towards the specific gain or loss of cancer genes that collaborate
with loss of BRCA1 and p53 – alone or in combination with MYC overexpression –
during TNBC development. We therefore performed DNA copy number sequencing
(CNV-seq) on 39 WB1P tumors and identified recurrent CNAs using RUBIC6. This
analysis showed that WB1P tumors exhibit a high degree of genomic instability
and harbor a multitude of recurrent gains and losses (Figure 5.3A; Supplementary
Figure S5.5A). The most evident of these events was a focal amplification on chro-
mosome 6 containing the Met oncogene. Besides Met, we also identified a recurrent
loss on chromosome 14 (harboring Rb1) and several amplifications on chromosome
15 (containing Myc), in line with our previous studies in KB1P mice10.
Remarkably, CNV-seq of 19 WB1P-Myc tumors showed a dramatically reshaped
copy number landscape (Figure 5.3B), with significantly fewer CNAs compared
to the WB1P model (Figure 5.3C; p < 0.00001, two-sided Mann-Whitney U
test). To determine if the decreased number of CNAs observed in WB1P-Myc
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tumors was not simply a result of the shortened tumor latency, we generated
WapCre;Brca1F/F;Trp53F/F;Col1a1invCAG-Met-IRES-Luc/+ (WB1P-Met) mice containing
the Met oncogene, which we found frequently amplified in the WB1P tumors. Simi-
lar to WB1P-Myc females, WB1P-Met female mice developed multifocal mammary
tumors with a short latency of 89 days (n = 11, Supplementary Figure S5.6A). All
WB1P-Met tumors were classified as poorly differentiated ER/PR-negative ductal
carcinomas and showed MET overexpression and active MET signaling (Supplemen-
tary Figure S5.6B-E). These data confirm the previously reported role of MET in the
onset and progression of TNBC29. CNV-sequencing of WB1P-Met tumors (n = 20)
showed an intermediate number of CNAs (Supplementary Figure S5.6F), which was
lower than the WB1P tumors but significantly higher than the WB1P-Myc tumors
(p < 0.001, one-sided Mann-Whitney U test). This demonstrates that the observed
differences in CNA load are not merely a function of tumor latency but also of the
driver gene. Moreover, the validation of MET as a potent driver in BRCA1-associated
tumorigenesis underscores the potential of iterative analysis of CNAs in progressively
complex mouse models as an approach for identifying putative cancer genes that
promote tumorigenesis in specific genetic contexts.
5.4.5 Comparative oncogenomics identifies MCL1 as a driver
gene
Our RUBIC analyses showed that most of the CNAs identified in WB1P tumors
were no longer present in WB1P-Myc tumors, suggesting an increased evolutionary
pressure to acquire only specific driver mutations (Figure 5.3B). Interestingly, a small
number of losses were retained, including the Rb1-associated loss on chromosome
14, further supporting Rb1 as a collaborating driver in MYC-driven BRCA1-deficient
mammary tumors. Focusing on novel events, we identified a strongly recurrent
amplicon on chromosome 11 encompassing the Col1a1 locus in which we introduced
the invCAG-Myc-IRES-Luc cassette. The recurrent amplification of this locus suggests
that WB1P-Myc tumors underwent a selection for increased MYC expression via
amplification of the conditional Myc knock-in allele. Besides this, we also identified
novel recurrent amplifications on chromosome 3 and chromosome 15, which were
syntenic with human 1q and 22q loci, respectively, which are commonly amplified in
breast cancer patients.
To identify additional driver genes in MYC-driven BRCA1-deficient TNBC, we used a
comparative oncogenomics strategy to select candidate genes that are recurrently
aberrated in both WB1P-Myc tumors and human BLBCs from TCGA. In this approach
(outlined in Figure 5.3D), we first identified candidate drivers in both species
individually using RUBIC. For the mouse tumors, we combined CNV-seq data of














































































































Fig. 5.3. Identification of candidate drivers in WB1P-Myc tumors using comparative
oncogenomics. (A and B) Genome-wide RUBIC analysis of CNV profiles of
WB1P tumors (A) and WB1P-Myc tumors (B). Significant amplifications and
deletions are marked by light red and blue columns, respectively. (C) Genomic
instability of WB1P and WB1P-Myc tumors. Scores for spleen samples from WB1P
mice are shown as reference; ∗∗∗∗p < 0.0001 (two-sided Mann-Whitney U test).
Boxes extend from the third (Q3) to the first (Q1) quartile (interquartile range,
IQR), with the line at the median; whiskers extend to Q3 + 1.5 ∗ IQR and to Q1−
1.5 ∗ IQR. See Materials and Methods for more details. (D) Flowchart illustrating
the comparative oncogenomics analysis pipeline used for the identification of
additional cancer driver genes.
driven B1P models to increase our sample size, based on the observation that
these tumors share the same distinctive CNA profile (Supplementary Figure S5.5B-
C). Next, we mapped genes between species using mouse-human orthologs and
took the intersection of both candidate lists. Finally, to prioritize genes that show
differences in expression, we filtered the remaining candidates for genes with a
positive Spearman correlation (> 0.2) between their expression and copy number
status.
After applying this strategy, we focused on genes residing in the recurrent ampli-
fications on mouse chromosomes 3 and 15, as these were the most striking new
events in the WB1P-Myc model. The recurrent amplification on chromosome 11
containing the conditional Myc knock-in allele in the Col1a1 locus was excluded
from this analysis. While this did not identify any candidate genes in the peak
on chromosome 15 (mainly due to a lack of orthologous, recurrently aberrated
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Fig. 5.3. Continued. (E) Chromosome 3 RUBIC analysis of the combined CNV profiles
of the tumors from germline and somatic mouse models overexpressing Myc
in the mammary gland. Significant amplifications are marked by light red
columns. Genes residing in the minimal amplicon of chromosome 3 are shown.
Cross-species candidate genes surviving filter criteria are colored in red. (F)
Chromosome 1 RUBIC analysis of the CNV profiles of human TNBC. Significant
amplifications are marked by light red columns. Orthologs of the genes shown
in panel E are shown. Cross-species candidate genes surviving filter criteria are
colored in red.
genes), it did identify a list of 12 candidate genes residing in the peaks on mouse
chromosome 3 (Figure 5.3E) and human chromosome 1q (Figure 5.3F). To identify
potential drivers in this list of candidates, we derived organoids from a WB1P-Myc
mammary tumor using our recently established methodology30. We next performed
a fitness screen in these WB1P-Myc organoids with a focused lentiviral shRNA library
targeting candidate genes. This screen showed a marked depletion for shRNAs
targeting Mcl1 (Figure 5.4A), indicating that MCL1 expression is essential for growth
of WB1P-Myc tumor cells. In line with this, WB1P-Myc tumors showed strongly
elevated expression of MCL1 compared to WB1P tumors (Figure 5.4B).
To determine whether MCL1 cooperates with MYC in driving BRCA1-deficient TNBC,
we generated a lentiviral vector encoding both Cre and Mcl1 (Lenti-Mcl1P2ACre,
Supplementary Figure S5.7A) and injected this lentivirus intraductally into B1P
and B1P-Myc females (n = 7 and n = 11, respectively) to achieve simultaneous
Cre-mediated recombination of the conditional alleles and overexpression of Mcl1
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Fig. 5.4. Validation of MCL1 as a druggable driver in BRCA1-mutated TNBC. (A)
MAGeCK software was used to compute RRA scores for all genes included in
our focused shRNA library, showing depletion of Mcl1 shRNAs in WB1P-Myc
organoids. (B) Immunohistochemical detection of MCL1 in multiple independent
WB1P and WB1P-Myc tumors. (C) Overview of the non-germline mouse models
for mammary-specific Mcl1 overexpression. Scale bar, 400 µm. (D) Kaplan-Meier
curves showing mammary tumor-specific survival for the different models. B1P
and B1P-Myc females injected with Lenti-Mcl1P2ACre showed a reduced mam-
mary tumor-specific survival compared to B1P and B1P-Myc female mice injected
with Lenti-Cre, respectively (180 days after injection vs 238 days after injection;
∗∗p < 0.01 by Mantel-Cox test; 70 days after injection vs 126 days after injection;
∗∗∗∗p < 0.0001 by Mantel-Cox test).
(Figure 5.4C). Co-expression of MCL1 and Cre in B1P and B1P-Myc mice resulted in a
significant decrease in tumor latency compared to mice in which only Cre was deliv-
ered (180 vs 238 days and 70 vs 126 days, respectively; Figure 5.4D; Supplementary
Figure S5.7B). MCL1 overexpression appeared to relieve pressure for chromosome 3
amplification in the resulting tumors (Supplementary Figure S5.7C-D). Conversely,
MCL1 silencing in WB1P-Myc organoids resulted in Myc downregulation (Supplemen-
tary Figure S5.7E). Altogether, these analyses identify Mcl1 as an important driver
gene in the recurrent amplification on mouse chromosome 3 and demonstrate that
MCL1 effectively collaborates with MYC in BRCA1-associated breast tumorigenesis.
5.4.6 MCL1-inhibition synergizes with PARP-inhibition in
PDXs
Our focused shRNA library screen showed that knockdown of Mcl1 is detrimental
to WB1P-Myc organoids. To test whether WB1P-Myc tumors are also sensitive
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Fig. 5.4. Continued. (E) In vitro response of WB1P and WB1P-Myc organoids to MCL1
inhibitor S63845. Error bars represent standard error of the mean. (F) In
vivo response of organoid-derived WB1P and WB1P-Myc tumors to S63845,
as visualized by Kaplan-Meier curves. WB1P and WB1P-Myc organoid lines
were transplanted in the fourth mammary fat pad of nude mice. When tumors
had reached a size of 100 mm3, mice were treated with 25 mg kg−1 S63845
(i.v. once-weekly for 5 weeks) or vehicle. (G) Response of the BRCA1-mutated
TNBC PDX-110 xenograft model to S63845 and the PARP inhibitor olaparib, as
visualized by tumor volume curves (left) and Kaplan-Meier curves (right). Single-
cell suspensions of PDX-110 were transplanted in the fourth mammary fat pad of
NOD-SCID-IL2Rγc–/– mice. When tumors had reached a size of 100 mm3, mice
were treated with 25 mg kg−1 S63845 (i.v. once-weekly for 4 weeks), 50 mg kg−1
olaparib (i.p. 5 days out of 7 for 4 weeks), both drugs or vehicle. Combination
therapy with S63845 and olaparib prolonged survival compared to olaparib
monotherapy (∗∗∗∗p < 0.0001 by Mantel-Cox test). Error bars represent standard
error of the mean.
to pharmacological MCL1-inhibition, we tested the in vitro sensitivity of WB1P
and WB1P-Myc organoids to the selective MCL1 inhibitor S6384531, which was
recently shown to display activity in patient-derived xenograft (PDX) models of
breast cancer32. In contrast to other BH3 mimetics, S63845 binds to human MCL1
at sub-nanomolar concentrations whereas it does not display detectable binding to
other anti-apoptotic family members31. Proliferation assays indicated that WB1P-
Myc organoids were more sensitive to S63845 than WB1P organoids (Figure 5.4E).
To examine the response of WB1P and WB1P-Myc tumors to MCL1-inhibition, we
transplanted WB1P and WB1P-Myc organoids orthotopically into nude mice (n = 10
per line) and tested the response of the tumor outgrowths to S63845. However, in
this setting we did not observe a differential sensitivity to MCL1-inhibition, as none
of the tumors responded to S63845 at the tested dose (Figure 5.4F).
Based on the anti-apoptotic role of MCL1, we reasoned that MCL1-inhibition might
be most effective when combined with a pro-apoptotic drug, as previously demon-
strated in PDX models of HER2-amplified breast cancer and TNBC treated with
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trastuzumab and docetaxel, respectively32. We therefore investigated whether
S63845 could enhance the efficacy of the clinical PARP inhibitor (PARPi) olaparib,
which is currently used for treatment of BRCA1-mutated breast cancer patients. As
the olaparib-sensitivity of WB1P and WB1P-Myc tumors was too high to assess any
synergistic effect of MCL1-inhibition (Supplementary Figure S5.2B; Supplementary
Figure S5.8A-B), we turned to a PDX model of BRCA1-mutated TNBC (PDX-110),
which expresses relatively high levels of MYC and MCL1 and shows limited sensitivity
to PARPi32. To assess the effect of combined inhibition of PARP and MCL1 in this
model, PDX tumor cells were orthotopically injected into NOD-SCID-IL2Rγc–/– mice
(n = 48), which were randomly allocated to vehicle-, single- or double-treatment
arms once tumors reached a volume of 100 mm. Remarkably, while treatment with
S63845 or olaparib alone did not elicit a clinical response, tumor growth was consid-
erably inhibited upon treatment with both drugs and tumors relapsed only when
treatment was stopped after 4 weeks (Figure 5.4G).
5.5 Discussion
In this work, we have used both germline and somatic engineering approaches to
rapidly test candidate cancer drivers in the WB1P mouse model of BRCA1-deficient
TNBC. Using this approach, we validated MYC, MET, PTEN and RB1 as bona fide
drivers of BRCA1-associated tumorigenesis and showed that MYC overexpression
dramatically changes the mutational landscape of the resulting tumors. Finally, by
applying a comparative oncogenomics strategy to uncover additional culprits of
tumorigenesis, we identified MCL1 as a druggable cancer driver that collaborates
with MYC in BRCA1-deficient TNBC.
An important challenge of modeling cancer in mice, is that it requires technology
that allows rapid introduction of new driver mutations to quickly create a variety of
compound-mutant mouse models containing different combinations of candidate
genes. Such experiments are difficult to perform using germline engineering ap-
proaches, which generally involve extensive cross-breeding of single-mutant mice
to produce animals carrying the desired combination of mutations. Here, we have
shown that somatic engineering using lentiviral vectors for overexpression of cDNAs
and CRISPR-mediated in situ gene editing provides an effective alternative for rapid
generation of novel mouse models of BRCA1-deficient TNBC. The limitations of
cDNA-based overexpression systems – which may not fully recapitulate the desired
expression levels of candidate genes – might be alleviated by implementing novel
technologies for CRISPR-mediated transcriptional control (CRISPRi/CRISPRa) and
base-editing of endogenous genes. We therefore expect that our somatic engineer-
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ing methodology can ultimately be used to generate refined breast cancer models
containing a wide variety of fine-tuned (epi)genetic permutations.
One of the key advantages of this type of iterative mouse modeling, is that it
highlights the profound effect that additional driver genes can have on the mutational
landscape of a baseline tumor model. This indicates that the evolutionary pressure
that tumor cells experience depends strongly on the combination of driver mutations,
which push cells down a specific path to acquire additional aberrations that most
effectively collaborate with the pre-existing events. This notion has two important
implications. First, it means that it is crucial to study driver genes in the appropriate
genetic contexts as observed in human tumors, as they may have very different
effects in different backgrounds. Second, predominant changes in the mutational
landscape likely indicate that the pre-existing driver(s) push tumors down a relatively
restricted evolutionary path, which might be exploited therapeutically.
A clear example is provided by our study, showing that MYC-overexpression pushes
the evolution of BRCA1-deficient TNBC towards amplification of a druggable driver,
MCL1. Although MYC is a potent inducer of cell proliferation, supraphysiologic
overexpression of MYC also has pro-apoptotic effects and is generally not tolerated
in non-transformed cells33. This suggests that tumor cells need to acquire additional
alterations in other, collaborating cancer driver genes to counteract MYC-induced
apoptosis. MCL1 belongs to the Bcl-2 family and is involved in the inhibition of
apoptosis34. While it cannot be excluded that MYC overexpression reshapes evolu-
tion of BRCA1-deficient TNBCs via negative selection of tumor cell clones with high
levels of CNAs, amplifications of MCL1 might be particularly selected for as they may
counteract the pro-apoptotic effects of MYC overexpression. MCL1 amplifications
have been identified in a variety of tumor types, including breast cancer35), where
they correlate with poor survival36,37. Although the commonly amplified chromo-
some 1q region (where MCL1 resides) might harbor additional driver genes, MCL1
is the main pro-survival protein upregulated in TNBC38, and amplification of MCL1
has been implicated in resistance to multiple therapies used in patients with TNBC,
where it is often co-amplified with MYC39,40. We found amplification of MCL1 in
15% of the BRCA1-mutated TNBCs we analyzed (12/80 cases), and two-thirds of
these cases showed co-amplification of MYC (Supplementary Figure S5.8C). MCL1
and MYC were also shown to cooperate in mouse models of leukemia and non-
small cell lung cancer (NSCLC), and co-expression of these two factors correlates
with poor NSCLC patient survival41,42. This suggests that MCL1 inhibition might
be particularly effective against MYC-overexpressing tumors by exposing them to
MYC-induced apoptosis. MCL1 has only recently been recognized as an important
therapeutic target, and currently several MCL1 inhibitors are being tested in pre-
clinical trials, where they are showing promising activity, especially in combination
therapies32,43. Five phase-I clinical trials are currently ongoing for testing MCL1 in-
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hibitors in patients with hematopoietic malignancies (NCT02675452; NCT02992483;
NCT02979366; NCT03672695; NCT03465540). Our study demonstrates that MCL1
inhibition considerably enhances response of BRCA1-mutated TNBC to the clinical
PARPi olaparib and suggests that this combination should be prioritized for clinical
evaluation, especially in BRCA1-mutated cancer patients with poor response to PARPi
monotherapy.
Another example of identification of druggable drivers in mouse models of BRCA1-
deficient TNBC was recently provided by Liu et al.44, who analyzed transcriptional
and CNA profiles of mammary tumors from our previously published KB1P and
K14Cre;Trp53F/F (KP) models21. This analysis yielded a spectrum of somatic genetic
alterations putatively driving tumor evolution, including gene-fusions and chromoso-
mal amplifications and deletions (including recurrent amplification of Met and Myc
and deletion of Rb1). Interestingly, even though KB1P and KP tumors were following
diverse evolutionary trajectories, most tumors displayed enhanced activation of
MAPK and/or PI3K signaling and could be treated with inhibitors specific for the
aberrated drug target.
In summary, we applied novel germline and somatic technologies to functionally vali-
date the role of candidate drivers in BRCA1-deficient TNBC in vivo at unprecedented
speed. Our integrate approach revealed a profound effect of MYC overexpression
on tumor evolution and identified MCL1 as a critical and druggable dependency in
BRCA1-deficient TNBC with high expression of MYC. Combined inhibition of MCL1
and PARP might benefit a subset of BRCA1-mutated TNBC patients and warrants
further investigation.
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5.6 Materials and Methods
Lentiviral vectors The Lenti-Cre vector (pBOB-CAG-iCRE-SD, Addgene plasmid
#12336) was a kind gift of Lorenzo Bombardelli. Lenti-MycP2ACre and Lenti-Mcl1-
P2ACre were cloned as follows. AgeI and SalI were used to remove GFP-T2A-puro
from the SIN.LV.SF-GFP-T2A-puro45. P2ACre was synthesized with AgeI-SalI over-
hangs and inserted as AgeI-SalI fragment into the SIN.LV.SF-GFP-T2A-puro backbone,
resulting in SIN.LV.SF-P2ACre. Myc and Mcl1 murine cDNAs were isolated with
BamHI-AgeI overhangs using standard PCR from cDNA clones (Clone 8861953,
Source BioScience; Clone 3491015, Dharmacon) and inserted as BamHI-AgeI frag-
ments into the SIN.LV.SF-P2ACre vector. The Lenti-sgRb1-Myc, Lenti-sgPten-Myc and
Lenti-sgNT-Myc vectors were cloned as follows. Myc cDNA was isolated with XbaI-
XhoI overhangs using standard PCR from the Lenti-MycP2ACre vector, and inserted
as XbaI-XhoI fragment into pGIN, a lentiviral vector for sgRNA overexpression46.
The non-targeting sgRNA (TGATTGGGGGTCGTTCGCCA) and sgRNAs targeting
mouse Rb1 exon 2 (TCTTACCAGGATTCCATCCA) and mouse Pten exon 7 (CCTCAGC-
CATTGCCTGTGTG) were cloned as described47. All vectors were validated by Sanger
sequencing. Concentrated stocks of VSV-G pseudotyped lentivirus were produced
by transient co-transfection of four plasmids in 293T as previously described48.
Lentiviral titers were determined using the qPCR lentivirus titration kit from Abm
(LV900).
Cell culture 293T cells for lentiviral production and Cre-reporter 293T cells con-
taining a lox-STOP-lox-GFP cassette were cultured in Iscove’s medium (Invitrogen
Life Technologies) containing 10 % FBS, 100 IU ml−1 penicillin, and 100 µg ml−1
streptomycin. Transductions were performed by adding diluted viral supernatant to
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the cells in the presence of 8 µg ml−1polybrene (Sigma). Cells were transduced for
24h, after which medium was refreshed. Harvesting of cells for flow cytometry or
immunoblotting was performed 5 days after transduction.
Flow cytometry Cells were collected 5 days after transduction, washed in PBS,
fixed in Fixation Buffer (BD Biosciences) and permeabilized with Perm Buffer III
(BD Biosciences). They were then stained using the primary rabbit antibody anti-
Myc (1:1000, Abcam ab32072) or anti-Mcl1 (1:1000, Cell Signaling 94296S) for
30 minutes at 4 degrees, washed in PBS and incubated for 15 minutes with an
AlexaFluor647-conjugated secondary anti-rabbit antibody (1:1000, Thermofisher).
Stained cells were analyzed using a Becton Dickinson LSR FORTESSA. GFP and
AlexaFluor647 expression of viable cells was measured using a 488 nm and 640 nm
laser for excitation, respectively. Data analysis was performed using FlowJo software
version 7.6.5.
PCRs and TIDE analyses Amplification of Rb1 exon 2 and Pten exon 7 was per-
formed with specific primers spanning the target sites (FW_Rb1: TCACCATGC-
TAGCAGCTCTTC; RV_Rb1: AGCCAGTTCAATGGTTGTGGG; FW_Pten: TGTATTTAAC-
CACACAGATCCTCA; RV_Pten: AACAAACTAAGGGTCGGGGC) and 1 µg DNA tem-
plate using the Q5 high-fidelity PCR kit from NEB. Amplicons were run on 1%
agarose gel and gel-purified using the Isolate II PCR and Gel kit (Bioline). PCR
products were Sanger-sequenced using the FW primer and CRISPR/Cas9-induced
editing efficacy was predicted and quantified as described49. Untransduced cells
were taken along as a control in each gRNA amplification.
Immunoblotting Protein lysates were made using lysis buffer (20 mmol Tris 8.0 pH
, 300 mmol NaCl, 2 % NP40, 20 % glycerol, 10 mmol EDTA) complemented with
protease inhibitors (Roche) and quantified using the BCA Protein Assay Kit (Pierce).
Protein lysates were loaded onto a 3 % to 8 % Tris-Acetate gradient Gel (Invitrogen)
and transferred overnight onto PVDF membrane (Millipore, methanol pre-wetted)
in transfer buffer (38 mmol glycine, 5 mmol TRIS and 0.01 % SDS in PBS-T (0.5 %
Tween-20). Membranes were blocked in 5 % ELK in TBS-T after which they were
stained for four hours at room temperature using the primary antibody anti-Met
(1:1000, Cell Signaling 4560S), anti-phosphoMet (1:1000, Cell Signaling 3077S),
anti-Myc (1:1000, Abcam ab32072) or anti-Mcl1 (1:1000, Cell Signaling 94296S).
Membranes were washed three times with 1 % milk in PBS-T and incubated for 1 hr
with an HRP-conjugated secondary antibody (1:2000, DAKO). Stained membranes
were washed three times in 1 % milk in PBS-T and developed using SuperSignal ECL
(Pierce).
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Organoid culture WB1P and WB1P-Myc mammary tumor organoids were isolated
and cultured as described30. For cell viability assays, organoids were seeded (100,000
cells per well) in 40 µl complete mouse media/BME mixture on 24-well suspension
plates and cultured for 5 days in the presence of S63845 (ApEXBiO). Cell viability
was assessed using the resazurin-based Cell Titer Blue assay following manufacturer’s
protocol (Promega). Cell viability experiments were performed 3 times in triplicate
and data were analyzed with GraphPad Prism statistical software using nonlinear
regression and extra sum-of-squares F -test. For the focused shRNA library screen
in WB1P-Myc organoids30, a small library of shRNA targeting candidate genes was
built from the Mission shRNA collection (mouse TRC v1.0 collection) by pooling
shRNAs targeting candidate genes (Mcl1, Gabpb2, Arnt, Setdb1, Tars, Golph3l, Lass2
and Mllt11) and control genes (Plk1, Nlrp5, Crygb and Taar8a). Organoids were
transduced at MOI 0.3 and analyzed for shRNA representation at day 0, 7 and 14.
MAGeCK software was used to compute RRA scores for all genes to identify relative
shRNA depletion.
Meta-analysis of four human breast cancer datasets Curated copy number and mu-
tation data for the METABRIC, TCGA and MSK-impact datasets were downloaded
from cBioPortal*, after which the downloaded mutation data was filtered for dele-
terious mutations (Missense_Mutation, Nonsense_mutation, Frame_Shift_Del and
Frame_Shift_Ins). Similarly, copy number data were filtered for high-level ampli-
fications (amp) or homozygous deletions (homdel). Besides this, the MSK-impact
dataset was filtered to include only breast cancers. Mutation and copy number
data for the BASIS dataset were obtained from Supplementary Tables 4, 14 and 20
accompanying reference50 and filtered using similar criteria as the other datasets.
The resulting datasets were merged and, where possible, annotated with the ER, PR
and HER2 status of the corresponding samples. To select for samples with deleterious
missense mutations in BRCA1, BRCA1 missense mutations were annotated for their
expected pathogenicity using the Breast Cancer Information Core (BIC) database†
and Align-GVGD‡. We only selected samples with BRCA1 missense mutations that
were considered to be pathogenic (annotated as clinically important by BIC or Align-
GVGD assigned class C15, C25 and C65). The final dataset was visualized using a
custom script, focusing on cancer-associated genes, as defined by cBioPortal.
RNA Sequencing Illumina TruSeq mRNA libraries were generated and sequenced
with 50-65 base single reads on a HiSeq 2500 using V4 chemistry (Illumina Inc., San
Diego) as previously described51. The resulting reads were trimmed using Cutadapt
(version 1.15) to remove any remaining adapter sequences and to filter reads shorter




5.6 Materials and Methods 169
aligned to the GRCm38 reference genome using STAR (version 2.5.3a). QC statistics
from Fastqc (version 0.11.5) and the above-mentioned tools were collected and
summarized using Multiqc (version 1.1). Gene expression counts were generated by
featureCounts (version 1.5.2) using gene definitions from Ensembl GRCm38 version
89. Normalized expression values were obtained by correcting for differences in
sequencing depth between samples using DESeq’s median-of-ratios approach and
then log-transforming the normalized counts.
Generation of CNA profiles and data analysis Sequencing was performed using the
Illumina HiSeq 2500 with V4 chemistry (Illumina Inc., San Diego) as previously
described51. The resulting reads were trimmed using Cutadapt (version 1.15) to
remove any remaining adapter sequences and trim reads longer to a length of 50 bp
for QDNAseq. Additionally, reads shorter than 20 bp after trimming were removed
to ensure good mappability. The trimmed reads were aligned to the the GRCm38
reference genome using BWA aln (version 0.7.15). QC statistics from Fastqc (ver-
sion 0.11.5) and the above-mentioned tools were collected and summarized using
Multiqc (version 1.1). The resulting alignments were analyzed using QDNAseq
(version 1.14.0) using the mm10 reference genome (with a 50K bin size, 50 bp
read lengths and default settings for other parameters) to generate copy number
logratios, segmented profiles and calls. The segmented profiles were analyzed using
RUBIC6 (version 1.0.3) to identify recurrent CNAs regions (focal threshold = 1e+08,
min probes = 4 and FDR = 0.25). Genes with copy number values were identified
using a custom script, in which missing values were imputed from surrounding
bins (with window size = 11, requiring at least 5 non-missing values). Copy num-
ber instability was scored by calculating the fraction of bins with logratio values
above/below a threshold of ±0.5 in the segmented copy number data.
CNA analysis of BLBCs from TGCA Segmented copy number data for the TCGA
breast cancer samples were downloaded from firebrowse (version 2016_01_28).
These data were matched to subtype annotations from TCGA and filtered for BLBC
samples. This BLBC dataset was analyzed using RUBIC (version 1.0.3) to identify
recurrent CNAs (with focal threshold = 1e + 07, min probes = 260000 and FDR =
0.25).
Comparative oncogenomics analysis Candidate genes were initially selected by
identifying mouse genes that were recurrently amplified/deleted in the RUBIC anal-
ysis of the combined germline/somatic Myc-driven mouse tumors. These candidates
were subsequently annotated for their orthologous human genes using Ensembl
Biomart (GRCH37) and filtered for candidates whose orthologues were also recur-
rently aberrated in the RUBIC analysis of the human BLBCs. To filter for correlation
with expression, we calculated the Spearman correlation between copy number calls
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and gene expression values of the remaining candidate genes and selected genes
with an absolute correlation > 0.2, resulting in a list of cross-species candidates.
Mouse studies Myc murine cDNA was obtained from a cDNA clone (Clone 8861953,
Source BioScience), sequence-verified and inserted as FseI-PmeI fragment into
the Frt-invCag-IRES-Luc shuttle vector23, resulting in Frt-invCag-Myc-IRES-Luc. Frt-
invCag-Met-IRES-Luc and Frt-invCag-Cas9-IRES-Luc were described were described
by Henneman et al.51 and Annunziato et al.52. Flp-mediated knockin of the shuttle
vectors in the WapCre;Brca1F/F;Trp53F/F;Col1a1-frt GEMM-ESC was performed as
described23. Chimeric animals were crossed with WB1P or B1P mice to generate the
experimental cohorts. WapCre, Brca1F/F, Trp53F/F and knockin alleles were detected
using PCR as described21,23,53. In vivo bioluminescence imaging was performed
as described51 using a cooled CCD system (Xenogen Corp., CA, USA) coupled to
Living Image acquisition and analysis software (Xenogen). Intraductal injections
were performed as described24,52. Lentiviral titers ranging from 2× 108 TU/ml to
20× 108 TU/ml were used.
Orthotopic transplantation of WB1P and WB1P-Myc mammary tumors or organoids
was performed by implanting small tumor fragments or cells into the fourth right
mammary fat pad of nude mice as previously described30. Treatment was initiated
when tumors reached a size of ~100 mm (formula for tumor volume: 0.5 ∗ length ∗
width2). Cisplatin (6 mg kg−1 i.v.) was administered at day 0 and 14. Olaparib
(100 mg kg−1 i.p.) and AZD2461 (100 mg kg−1 per os) were administered daily
for 28 consecutive days. S63845 (25 mg kg−1 i.v.) was administered once-weekly
for 5 weeks32. For experiments with PDX-11032, thawed single cell suspensions
of the tumor were transplanted orthotopically into the fourth right mammary fat
pad of NOD-SCID-IL2Rγc–/– mice. Treatment was initiated when tumors reached
a size of ~100 mm. Olaparib (50 mg kg−1 i.p.) was administered 5 days out of 7
for 4 weeks. S63845 (25 mg kg−1 i.v.) was administered once-weekly for 4 weeks.
Vehicle was DMSO/10% (2-hydroxypropyl-b-cyclodextrin) for olaparib and 20%
(2-hydroxypropyl-b-cyclodextrin)/HCl for S63845.
Animal experiments were approved by the Animal Ethics Committees of the Nether-
lands Cancer Institute and the Walter and Eliza Hall Institute of Medical Research.
Mice were bred and maintained in accordance with institutional, national and
European guidelines for Animal Care and Use.
Histology and immunohistochemistry Tissues were formalin-fixed overnight and
paraffin-embedded by routine procedures. Haematoxylin and eosin staining was per-
formed as described54. Immunohistochemical stainings were processed as previously
described51,54. For MYC and MCL1 immunohistochemistry, primary rabbit antibody
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anti-Myc (1:1000, Abcam ab32072) or anti-Mcl1 (1:1000, Cell Signaling 94296S)
were used. All slides were digitally processed using the Aperio ScanScope (Aperio,
Vista, CA, USA) and captured using ImageScope software version 12.0.0 (Aperio).
Data availability The data that support the findings of this study are available from
the corresponding author upon reasonable request.
Code availability The analysis pipelines for the RNA-Seq and CNV-Seq data were
implemented using Snakemake (version 4.3.1) and are freely available on GitHub§,¶.





















Fig. S5.1. Gene expression analysis of human breast cancer samples. Unsupervised
clustering (Euclidean distance, average linkage) of the human breast cancer
samples from TCGA, using a three-gene signature that distinguishes the PAM50
subtypes22. LumA, luminal A; LumB, luminal B.
































































































































































































































































Fig. S5.2. Characterization of the WB1P-Myc mouse model. (A) Longitudinal in vivo
bioluminescence imaging of luciferase expression in a WB1P-Myc female, show-
ing signal build-up over time. (B) Response of WB1P and WB1P-Myc tumors
to cisplatin and PARP inhibitors, as visualized by tumor volume curves. Small
fragments of WB1P and WB1P-Myc tumors were transplanted in the fourth
mammary fat pad of nude mice. When tumors had reached a size of 100 mm,
mice were treated with 6 mg kg−1 cisplatin (administered i.v. on day 0 and
day 14), 100 mg kg−1 AZD2461 (administered daily by per os, for 28 con-
secutive days) or vehicle. Error bars represent standard error of the mean.
(C) Kaplan-Meier curves showing mammary tumor-specific survival for the
different genotypes. WapCre;Brca1F/F;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+ (WB1P-
Myc) females showed a reduced mammary tumor-specific survival compared to
WapCre;Brca1F/+;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+ littermates (97 days vs 105
days; ∗∗∗p < 0.001 by Mantel-Cox test).












































Fig. S5.2. Continued. (D) Unsupervised clustering (Euclidean distance, average link-
age) of WB1P and WB1P-Myc tumors with tumors derived from published
mouse models of luminal (WapCre;Cdh1F/F;PtenF/F, WEP) and basal-like
(K14Cre;Brca1F/F;Trp53F/F, KB1P) breast cancer, using a three-gene signature
that distinguishes the PAM50 subtypes22. (E) Myc expression levels in WB1P
and WB1P-Myc tumors; ∗∗∗∗p < 0.0001 (two-sided Mann-Whitney U test).
Boxes extend from the third (Q3) to the first (Q1) quartile (interquartile range,
IQR), with the line at the median; whiskers extend to Q3 + 1.5 ∗ IQR and to
Q1−1.5∗ IQR. Points beyond the ends of the whiskers are outliers. (F) Immuno-
histochemical detection of MYC in multiple independent WB1P and WB1P-Myc
tumors. Scale bar, 400 µm.
5.7 Supplementary Material 175













































































































































Fig. S5.3. Non-germline models with Myc overexpression. (A) In vitro validation of
Lenti-MycP2ACre in Cre-reporter cells (containing a lox-STOP-lox-GFP cassette)
5 days after transduction. Expression of MYC as visualized by FACS using an
anti-MYC antibody and FACS analysis of Cre-recombined GFP-positive cells
are shown. (B) Expression of MYC in independent tumors as visualized by
immunoblotting using anti-MYC antibody. Sample order: WB1P tumor without
chromosome 15 amplification; WB1P tumor with chromosome 15 amplification;
tumor from B1P mouse injected with Lenti-Cre; tumor from B1P mouse injected
with Lenti-MycP2ACre; tumor from B1P-Myc mouse injected with Lenti-Cre. (C)
Unsupervised clustering (Euclidean distance, average linkage) of the tumors
from germline and somatic models using the three-gene PAM50 signature22,
showing that tumors from the somatic models retain the basal expression
profiles observed in tumors from the germline models. (D) PCA plot comparing
WB1P and WB1P-Myc tumors to tumors from the non-germline models (Lenti-
Cre injected B1P and B1P-Myc mice) using global gene expression profiles.
(E) Myc expression levels in tumors from germline and non-germline models.
Boxes extend from the third (Q3) to the first (Q1) quartile (interquartile range,
IQR), with the line at the median; whiskers extend to Q3 + 1.5 ∗ IQR and to
Q1− 1.5 ∗ IQR. Points beyond the ends of the whiskers are outliers.
176 Chapter 5 Comparative oncogenomics and iterative mouse modeling identifies...
-10 -5 0 5 10

























-10 -5 0 5 10





























-20 -15 -10 -5 0 5 10 15 20




























-20 -15 -10 -5 0 5 10 15 20

























-20 -15 -10 -5 0 5 10 15 20




























-20 -15 -10 -5 0 5 10 15 20










































Fig. S5.4. CRISPR-mediated somatic gene disruption of Rb1 and Pten. TIDE analyses
showing the spectrum of insertions/deletions (indels) of the targeted Rb1 (A)
and Pten (B) alleles in multiple independent tumors from WB1P-Cas9 mice
injected with Lenti-sgRb1-Myc and Lenti-sgPten-Myc, respectively.
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Fig. S5.5. Genomic instability of WB1P and WB1P-Myc tumors. (A) Genomic instabil-
ity scores of WP, WB1P and KB1P tumors; ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001
(two-sided Mann-Whitney U test). Scores for spleen samples from WB1P mice
are shown as reference. Boxes extend from the third (Q3) to the first (Q1)
quartile (interquartile range, IQR), with the line at the median; whiskers extend
to Q3 + 1.5 ∗ IQR and to Q1− 1.5 ∗ IQR. Points beyond the ends of the whiskers
are outliers. (B) Unsupervised clustering (correlation distance, average linkage)
of the tumors from somatic and germline models based on their copy number
profiles. Tumors from the somatic models mainly cluster together with their
germline counterparts, demonstrating that these tumors have similar patterns
of copy number aberrations. (C) Overview of the recurrently aberrated re-
gions identified by RUBIC in the combined set of MYC-driven tumors from the
germline and somatic models.
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Fig. S5.6. Characterization of the WB1P-Met mouse model. (A) Kaplan-Meier
curves showing mammary tumor-specific survival for the different genotypes.
WapCre;Brca1F/F;Trp53F/F;Col1a1invCAG-Met-IRES-Luc/+ (WB1P-Met) females showed
a reduced mammary tumor-specific survival compared to WB1P littermates (89
days vs 188 days; ∗∗∗∗p < 0.0001 by Mantel-Cox test). (B) Representative
hematoxylin and eosin (HE) staining and immunohistochemical detection of
E-cadherin, vimentin, ER and PR in WB1P-Met tumors. (C) Expression and
activity of MET in independent tumors from WB1P and WB1P-Met mice, as
visualized by immunoblotting using anti-MET and anti-phosphoMET antibodies.
(D) Unsupervised clustering (Euclidean distance, average linkage) of WB1P and
WB1P-Met tumors with tumors derived from published mouse models of lumi-
nal (WapCre;Cdh1F/F;PtenF/F, WEP) and basal-like (K14Cre;Brca1F/F;Trp53F/F,
KB1P) breast cancer, using the three-gene signature that distinguishes the
PAM50 subtypes22. (E) Met expression levels in WB1P and WB1P-Met tumors;
∗∗p < 0.01 (two-sided Mann-Whitney U test). Boxes extend from the third (Q3)
to the first (Q1) quartile (interquartile range, IQR), with the line at the median;
whiskers extend to Q3 + 1.5∗ IQR and to Q1−1.5∗ IQR. (F) Genomic instability
of WB1P, WB1P-Met and WB1P-Myc tumors; ∗∗p < 0.01 and ∗∗∗∗p < 0.0001
(two-sided Mann-Whitney U test). Scores for spleen samples from WB1P mice
are shown as reference. (G) Genome-wide RUBIC analysis of the CNV profiles
of WB1P-Met tumors. Significant amplifications and deletions are marked by
light red and blue columns, respectively.
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Fig. S5.7. Validation of MCL1 as a driver in BRCA1-associated TNBC. (A) In vitro val-
idation of Lenti-Mcl1P2ACre in Cre-reporter cells 5 days after transduction.
Expression of MCL1 as visualized by FACS using an anti-MCL1 antibody and
FACS analysis of Cre-recombined GFP-positive cells are shown. (B) Longitudinal
in vivo bioluminescence imaging of luciferase expression in B1P-Myc animals
injected with Lenti-Cre (black lines) or Lenti-Mcl1P2ACre (red lines), showing
signal build-up over time. (C) Heatmap showing the copy number logratios
for tumors from B1P-Myc females injected with Lenti-Mcl1P2ACre, showing
that recurrent gains on chromosomes 11 and 15 are retained, whilst the gain
on chromosome 3 is less pronounced. (D) Unsupervised clustering (Euclidean
distance, average linkage) of MYC-driven tumors from germline and somatic
models (WB1P-Myc tumors and tumors from Lenti-Cre injected B1P-Myc mice)
together with tumors from B1P-Myc females injected with Lenti-Mcl1P2ACre.
The clustering shows that the focal gain surrounding Mcl1 is lost in the majority
of tumors from Lenti- Mcl1P2ACre injected B1P-Myc females. (E) Expression of
MYC and MCL1 in WB1P-Myc organoids transduced with a non-targeting shRNA
or with two independent shMcl1 vectors, as visualized by immunoblotting using
anti-MYC antibody 5 days after transduction.
180 Chapter 5 Comparative oncogenomics and iterative mouse modeling identifies...














































































































Amplification Homozygous deletion Missense mutationNonsense mutation Frameshift mutation
C
Fig. S5.8. Treatment of WB1P and WB1P-Myc tumors with MCL1 and PARP inhibitors.
(A-B) Response of organoid-derived WB1P and WB1P-Myc tumors to MCL1 and
PARP inhibitors, as visualized by tumor volume curves (A) and Kaplan Meier
curves (B). WB1P and WB1P-Myc organoid lines were transplanted in the fourth
mammary fat pad of nude mice. When tumors had reached a size of 100 mm,
mice were treated with 25 mg kg−1 S63845 (administered i.v. once weekly for 5
weeks), 100 mg kg−1 olaparib (administered i.p. daily for 28 consecutive days),
both drugs or vehicle. S63845 shows minimal additive efficacy over olaparib
alone in WB1P-Myc tumors (∗p < 0.05 by Mantel-Cox test). (C) Overview of the
mutations and copy number events in our panel of 80 BRCA1-mutated human
breast tumor samples for TP53, MYC and MCL1.
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5.7.2 Supplementary Tables (available online)
Tab. S5.1. Mutational landscape of human BRCA1-mutated TNBC. Deleterious muta-
tions and copy number events in 80 BRCA1-mutated human breast tumor
samples from four large-scale tumor-sequencing studies.
182 Chapter 5 Comparative oncogenomics and iterative mouse modeling identifies...
5.8 References
[1] Giovanni Ciriello, Martin L Miller, Bülent Arman Aksoy, et al. “Emerging landscape
of oncogenic signatures across human cancers”. In: Nature Genetics 45.10 (2013),
p. 1127 (cit. on p. 150).
[2] Cancer Genome Atlas Network et al. “Comprehensive molecular portraits of human
breast tumours”. In: Nature 490.7418 (2012), p. 61 (cit. on p. 151).
[3] Rameen Beroukhim, Gad Getz, Leia Nghiemphu, et al. “Assessing the significance of
chromosomal aberrations in cancer: methodology and application to glioma”. In:
Proceedings of the National Academy of Sciences 104.50 (2007), pp. 20007–20012
(cit. on p. 151).
[4] Christiaan Klijn, Henne Holstege, Jeroen de Ridder, et al. “Identification of cancer
genes using a statistical framework for multiexperiment analysis of nondiscretized
array CGH data”. In: Nucleic Acids Research 36.2 (2008), e13–e13 (cit. on p. 151).
[5] Ewald van Dyk, Marcel JT Reinders, and Lodewyk FA Wessels. “A scale-space method
for detecting recurrent DNA copy number changes with analytical false discovery
rate control”. In: Nucleic Acids Research 41.9 (2013), e100–e100 (cit. on p. 151).
[6] Ewald van Dyk, Marlous Hoogstraat, Jelle ten Hoeve, Marcel JT Reinders, and
Lodewyk FA Wessels. “RUBIC identifies driver genes by detecting recurrent DNA
copy number breaks”. In: Nature Communications 7 (2016), p. 12159 (cit. on pp. 151,
158, 170).
[7] Lars Zender, Mona S Spector, Wen Xue, et al. “Identification and validation of
oncogenes in liver cancer using an integrative oncogenomic approach”. In: Cell
125.7 (2006), pp. 1253–1267 (cit. on p. 151).
[8] Minjung Kim, Joseph D Gans, Cristina Nogueira, et al. “Comparative oncogenomics
identifies NEDD9 as a melanoma metastasis gene”. In: Cell 125.7 (2006), pp. 1269–
1281 (cit. on p. 151).
[9] Jenny Mattison, Jaap Kool, Anthony G Uren, et al. “Novel candidate cancer genes
identified by a large-scale cross-species comparative oncogenomics approach”. In:
Cancer Research 70.3 (2010), pp. 883–895 (cit. on p. 151).
[10] Henne Holstege, Erik van Beers, Arno Velds, et al. “Cross-species comparison of
aCGH data from mouse and human BRCA1-and BRCA2-mutated breast cancers”. In:
BMC Cancer 10.1 (2010), p. 455 (cit. on pp. 151, 158).
[11] Natalie Meyer and Linda Z Penn. “Reflecting on 25 years with MYC”. In: Nature
Reviews Cancer 8.12 (2008), p. 976 (cit. on p. 152).
[12] Theresia R Kress, Arianna Sabò, and Bruno Amati. “MYC: connecting selective
transcriptional control to global RNA production”. In: Nature Reviews Cancer 15.10
(2015), p. 593 (cit. on p. 152).
[13] Ajay N Jain, Koei Chin, Anne-Lise Børresen-Dale, et al. “Quantitative analysis of
chromosomal CGH in human breast tumors associates copy number abnormalities
with p53 status and patient survival”. In: Proceedings of the National Academy of
Sciences 98.14 (2001), pp. 7952–7957 (cit. on p. 152).
5.8 References 183
[14] JL Dillon, SM Mockus, Guruprasad Ananda, et al. “Somatic gene mutation analysis
of triple negative breast cancers”. In: The Breast 29 (2016), pp. 202–207 (cit. on
p. 152).
[15] Dai Horiuchi, Leonard Kusdra, Noelle E Huskey, et al. “MYC pathway activation in
triple-negative breast cancer is synthetic lethal with CDK inhibition”. In: Journal of
Experimental Medicine 209.4 (2012), pp. 679–696 (cit. on p. 152).
[16] Daniel C Koboldt, Qunyuan Zhang, David E Larson, et al. “VarScan 2: somatic
mutation and copy number alteration discovery in cancer by exome sequencing”. In:
Genome research 22.3 (2012), pp. 568–576 (cit. on p. 152).
[17] M Chehani Alles, Margaret Gardiner-Garden, David J Nott, et al. “Meta-analysis and
gene set enrichment relative to er status reveal elevated activity of MYC and E2F in
the “basal” breast cancer subgroup”. In: PloS One 4.3 (2009), e4710 (cit. on p. 152).
[18] Sanjay Chandriani, Eirik Frengen, Victoria H Cowling, et al. “A core MYC gene
expression signature is prominent in basal-like breast cancer but only partially
overlaps the core serum response”. In: PloS One 4.8 (2009), e6693 (cit. on p. 152).
[19] Michael L Gatza, Joseph E Lucas, William T Barry, et al. “A pathway-based classifi-
cation of human breast cancer”. In: Proceedings of the National Academy of Sciences
107.15 (2010), pp. 6994–6999 (cit. on p. 152).
[20] Mirjam C Boelens, Micha Nethe, Sjoerd Klarenbeek, et al. “PTEN loss in E-cadherin-
deficient mouse mammary epithelial cells rescues apoptosis and results in develop-
ment of classical invasive lobular carcinoma”. In: Cell Reports 16.8 (2016), pp. 2087–
2101 (cit. on pp. 153, 154).
[21] Xiaoling Liu, Henne Holstege, Hanneke van der Gulden, et al. “Somatic loss of
BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-
mutated basal-like breast cancer”. In: Proceedings of the National Academy of Sciences
104.29 (2007), pp. 12111–12116 (cit. on pp. 153, 154, 166, 171).
[22] Benjamin Haibe-Kains, Christine Desmedt, Sherene Loi, et al. “A three-gene model
to robustly identify breast cancer molecular subtypes”. In: Journal of the National
Cancer Institute 104.4 (2012), pp. 311–325 (cit. on pp. 153, 154, 173, 175, 176,
179).
[23] Ivo J Huijbers, Rahmen Bin Ali, Colin Pritchard, et al. “Rapid target gene validation
in complex cancer mouse models using re-derived embryonic stem cells”. In: EMBO
molecular medicine 6.2 (2014), pp. 212–225 (cit. on pp. 154, 171).
[24] Silva Krause, Amy Brock, and Donald E Ingber. “Intraductal injection for localized
drug delivery to the mouse mammary gland”. In: Journal of Visualized Experiments
80 (2013), e50692–e50692 (cit. on pp. 154, 171).
[25] Melanie R Rutkowski, Michael J Allegrezza, Nikolaos Svoronos, et al. “Initiation of
metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-
cre: a novel transgenic mouse model of breast cancer”. In: Journal of Visualized
Experiments: JoVE 85 (2014), p. 51171 (cit. on p. 154).
[26] Luwei Tao, Maaike PA van Bragt, Elizabeth Laudadio, and Zhe Li. “Lineage tracing
of mammary epithelial cells using cell-type-specific cre-expressing adenoviruses”. In:
Stem Cell Reports 2.6 (2014), pp. 770–779 (cit. on p. 154).
184 Chapter 5 Comparative oncogenomics and iterative mouse modeling identifies...
[27] Prashant Kumar, Malini Mukherjee, Jacob PS Johnson, et al. “Cooperativity of Rb,
Brca1, and p53 in malignant breast cancer evolution”. In: PLoS Genetics 8.11 (2012),
e1003027 (cit. on p. 158).
[28] Erik S Knudsen, A Kathleen McClendon, Jorge Franco, et al. “RB loss contributes to
aggressive tumor phenotypes in MYC-driven triple negative breast cancer”. In: Cell
Cycle 14.1 (2015), pp. 109–122 (cit. on p. 158).
[29] Jennifer F Knight, Robert Lesurf, Hong Zhao, et al. “Met synergizes with p53 loss
to induce mammary tumors that possess features of claudin-low breast cancer”.
In: Proceedings of the National Academy of Sciences 110.14 (2013), E1301–E1310
(cit. on p. 159).
[30] Alexandra A Duarte, Ewa Gogola, Norman Sachs, et al. “BRCA-deficient mouse
mammary tumor organoids to study cancer-drug resistance”. In: Nature Methods
15.2 (2018), p. 134 (cit. on pp. 161, 169, 171).
[31] András Kotschy, Zoltán Szlavik, James Murray, et al. “The MCL1 inhibitor S63845
is tolerable and effective in diverse cancer models”. In: Nature 538.7626 (2016),
p. 477 (cit. on p. 163).
[32] Delphine Merino, James R Whittle, François Vaillant, et al. “Synergistic action of
the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-
negative and HER2-amplified breast cancer”. In: Science Translational Medicine 9.401
(2017), eaam7049 (cit. on pp. 163–165, 171).
[33] Natalie Meyer, Sam S Kim, and Linda Z Penn. “The Oscar-worthy role of Myc in
apoptosis”. In: Seminars in Cancer Biology. Vol. 16. 4. Elsevier. 2006, pp. 275–287
(cit. on p. 165).
[34] John G Clohessy, Jianguo Zhuang, Jasper de Boer, Gabriel Gil-Gómez, and Hugh JM
Brady. “Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome
c release and its role in receptor-mediated apoptosis”. In: Journal of Biological
Chemistry 281.9 (2006), pp. 5750–5759 (cit. on p. 165).
[35] Rameen Beroukhim, Craig H Mermel, Dale Porter, et al. “The landscape of somatic
copy number alteration across human cancers”. In: Nature 463.7283 (2010), p. 899
(cit. on p. 165).
[36] Qingqing Ding, Xianghuo He, Weiya Xia, et al. “Myeloid cell leukemia-1 inversely
correlates with glycogen synthase kinase-3β activity and associates with poor prog-
nosis in human breast cancer”. In: Cancer Research 67.10 (2007), pp. 4564–4571
(cit. on p. 165).
[37] Kirsteen J Campbell, Sandeep Dhayade, Nicola Ferrari, et al. “MCL-1 is a prognostic
indicator and drug target in breast cancer”. In: Cell Death & Disease 9.2 (2018),
p. 19 (cit. on p. 165).
[38] CM Goodwin, OW Rossanese, ET Olejniczak, and SW Fesik. “Myeloid cell leukemia-1
is an important apoptotic survival factor in triple-negative breast cancer”. In: Cell
Death and Differentiation 22.12 (2015), p. 2098 (cit. on p. 165).
[39] Justin M Balko, Jennifer M Giltnane, Kai Wang, et al. “Molecular profiling of the
residual disease of triple-negative breast cancers after neoadjuvant chemotherapy
identifies actionable therapeutic targets”. In: Cancer Discovery 4.2 (2014), pp. 232–
245 (cit. on p. 165).
5.8 References 185
[40] Kyung-min Lee, Jennifer M Giltnane, Justin M Balko, et al. “MYC and MCL1 cooper-
atively promote chemotherapy-resistant breast cancer stem cells via regulation of
mitochondrial oxidative phosphorylation”. In: Cell Metabolism 26.4 (2017), pp. 633–
647 (cit. on p. 165).
[41] Zhifu Xiang, Hui Luo, Jacqueline E Payton, et al. “Mcl1 haploinsufficiency pro-
tects mice from Myc-induced acute myeloid leukemia”. In: The Journal of Clinical
Investigation 120.6 (2010), pp. 2109–2118 (cit. on p. 165).
[42] Thaddeus D Allen, Chang Qi Zhu, Kirk D Jones, et al. “Interaction between MYC
and MCL1 in the genesis and outcome of non–small-cell lung cancer”. In: Cancer
Research 71.6 (2011), pp. 2212–2221 (cit. on p. 165).
[43] Clint Mitchell, Adly Yacoub, Hamed Hossein, et al. “Inhibition of MCL-1 in breast
cancer cells promotes cell death in vitro and in vivo”. In: Cancer Biology & Therapy
10.9 (2010), pp. 903–917 (cit. on p. 165).
[44] Hui Liu, Charles J Murphy, Florian A Karreth, et al. “Identifying and targeting
sporadic oncogenic genetic aberrations in mouse models of triple-negative breast
cancer”. In: Cancer Discovery 8.3 (2018), pp. 354–369 (cit. on p. 166).
[45] Sjors M Kas, Julian R de Ruiter, Koen Schipper, et al. “Insertional mutagenesis
identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma”.
In: Nature Genetics 49.8 (2017), pp. 1219–1230 (cit. on p. 167).
[46] Bastiaan Evers, Katarzyna Jastrzebski, Jeroen PM Heijmans, et al. “CRISPR knockout
screening outperforms shRNA and CRISPRi in identifying essential genes”. In: Nature
Biotechnology 34.6 (2016), p. 631 (cit. on p. 167).
[47] Neville E Sanjana, Ophir Shalem, and Feng Zhang. “Improved vectors and genome-
wide libraries for CRISPR screening”. In: Nature Methods 11.8 (2014), pp. 783–784
(cit. on p. 167).
[48] Antonia Follenzi, Laurie E Ailles, Silvia Bakovic, Massimo Geuna, and Luigi Naldini.
“Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by
HIV-1 pol sequences”. In: Nature Genetics 25.2 (2000), pp. 217–222 (cit. on p. 167).
[49] Eva K Brinkman, Tao Chen, Mario Amendola, and Bas van Steensel. “Easy quantita-
tive assessment of genome editing by sequence trace decomposition”. In: Nucleic
Acids Research 42.22 (2014), e168–e168 (cit. on p. 168).
[50] Serena Nik-Zainal, Helen Davies, Johan Staaf, et al. “Landscape of somatic mutations
in 560 breast cancer whole-genome sequences”. In: Nature 534.7605 (2016), p. 47
(cit. on p. 169).
[51] Linda Henneman, Martine H van Miltenburg, Ewa M Michalak, et al. “Selective
resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient
metaplastic breast cancer”. In: Proceedings of the National Academy of Sciences 112.27
(2015), pp. 8409–8414 (cit. on pp. 169–171).
[52] Stefano Annunziato, Sjors M Kas, Micha Nethe, et al. “Modeling invasive lobular
breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mam-
mary gland”. In: Genes & Development 30 (2016), pp. 1470–1480 (cit. on p. 171).
186 Chapter 5 Comparative oncogenomics and iterative mouse modeling identifies...
[53] Patrick W B Derksen, Xiaoling Liu, Francis Saridin, et al. “Somatic inactivation
of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma
through induction of anoikis resistance and angiogenesis”. In: Cancer Cell 10.5
(2006), pp. 437–449 (cit. on p. 171).
[54] Chris W Doornebal, Sjoerd Klarenbeek, Tanya M Braumuller, et al. “A preclinical
mouse model of invasive lobular breast cancer metastasis”. In: Cancer Research 73.1




mutagenesis identify multiple in
vivo mechanisms of resistance to
the FGFR inhibitor AZD4547
Julian R. de Ruiter1,2,10,*, Sjors M. Kas1,10,*, Koen Schipper1,10, Eva Schut1,10,
Lorenzo Bombardelli3,10, Ellen Wientjens1,10, Anne Paulien Drenth1,10, Renske de
Korte-Grimmerink1,10, Sunny Mahakena4, Christopher Philips5, Paul D. Smith6, Sjoerd
Klarenbeek7, Koen van de Wetering4,8, Anton Berns3,10, Lodewyk F. A. Wessels2,9,10,
Jos Jonkers1,10
1 Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
2 Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands
3 Division of Molecular Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands
4 Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
5 Discovery Sciences, IMED Biotech Unit, Astrazeneca, Cambridge, UK
6 Bioscience, Oncology, IMED Biotech Unit, Astrazeneca, Cambridge, UK
7 Experimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
8 Present address: Department of Dermatology & Cutaneous Biology, Sidney Kimmel Medical College,
Philadelphia, USA
9 Department of EEMCS, Delft University of Technology, Delft, The Netherlands
10 Oncode Institute, Amsterdam, The Netherlands
∗ These authors contributed equally to this work
Published in Cancer Research, 16 August 2018
Volume 78, Issue 19, Pages 5668-5679
6.1 Abstract
In human cancers, FGFR signaling is frequently hyperactivated by deregulation of
FGF ligands or by activating mutations in the FGFR receptors such as gene amplifica-
tions, point mutations, and gene fusions. As such, FGFR inhibitors are considered an
attractive therapeutic strategy for patients with mutations in FGFR family members.
We previously identified Fgfr2 as a key driver of invasive lobular carcinoma (ILC)
in an in vivo insertional mutagenesis screen using the Sleeping Beauty transposon
system. Here we explore whether these FGFR-driven ILCs are sensitive to the FGFR
inhibitor AZD4547 and use transposon mutagenesis in these tumors to identify
potential mechanisms of resistance to therapy. Combined with RNA sequencing-
based analyses of AZD4547-resistant tumors, our in vivo approach identified several
known and novel potential resistance mechanisms to FGFR inhibition, most of which
converged on reactivation of the canonical MAPK–ERK signaling cascade. Observed
resistance mechanisms included mutations in the tyrosine kinase domain of FGFR2,
overexpression of MET, inactivation of RASA1, and activation of the drug-efflux
transporter ABCG2. ABCG2 and RASA1 were identified only from de novo transpo-
son insertions acquired during AZD4547 treatment, demonstrating that insertional
mutagenesis in mice is an effective tool for identifying potential mechanisms of
resistance to targeted cancer therapies.
6.2 Introduction
FGFRs are members of the receptor tyrosine kinase (RTK) family that bind to different
FGF family members and are upstream of both the MAPK–ERK and PI3K–AKT
signaling pathways. FGFRs dimerize upon FGF ligand binding, which results in
cross-phosphorylation of the receptors cognate kinase domains and allows the
binding of the adaptor protein FGFR substrate 2α (FRS2α), a key transducer of
FGFR signaling1. Once bound, subsequent phosphorylation of FRS2α induces the
recruitment of growth factor receptor-bound 2 (GRB2) and son of sevenless (SOS),
resulting in activation of the MAPK–ERK signaling pathway. In contrast, activation
of the PI3K–AKT signaling pathway is mediated by interactions between the FRS2α
complex and GRB2-associated binding protein 1 (GAB1)1.
In human cancers, FGFR signaling is frequently hyperactivated by deregulation
of FGF ligands or by activating mutations in the receptors, which predominantly
consist of gene amplifications, point mutations, and gene fusions2,3. As such, FGFR
inhibitors are considered to be an attractive therapeutic strategy for patients with
mutations in FGFR family members. Currently, no FGFR-targeted therapies are
approved for the treatment of human cancer, but multiple therapeutics targeting
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FGFR signaling are under investigation in several phase I/II clinical trials in different
types of cancer2,3. These encompass several different approaches for inhibiting
FGFR, including nonselective and selective FGFR small-molecule tyrosine kinase
inhibitors, monoclonal antibodies against FGFRs and FGF ligand traps.
Although these initial trials have shown promising results concerning tolerability
and antitumor activity of several FGFR inhibitors in a subset of patients2,4–9, more
research is required to determine the right criteria for patient selection and to tackle
potential resistance mechanisms to improve FGFR-targeted therapies. Several studies
have already identified resistance mechanisms to FGFR-targeting agents, including
polyclonal secondary FGFR mutations (including gatekeeper mutations)10–12, acti-
vation of alternative RTKs13–16, and paracrine signaling of the tumor stroma17,18.
However, because most of these mechanisms are identified in in vitro studies, they
may not encompass the complete spectrum of resistance mechanisms to FGFR in-
hibitors.
In a previous study, we identified Fgfr2 as a key driver of invasive lobular breast
carcinoma (ILC) using a Sleeping Beauty (SB)-based transposon insertional muta-
genesis screen in mice19. In this work, we explore how mouse ILCs (mILC) with
SB transposon insertions in Fgfr2 respond to treatment with the selective FGFR
inhibitor AZD4547, and by which mechanisms they acquire resistance to FGFR
inhibition. Our results show that the tumors exhibit increased FGFR signaling and
initially regress upon treatment with AZD4547, but eventually develop treatment
resistance. By performing a multiomics analysis focusing on the resistant tumors, we
identify several known and novel mechanisms by which tumors become resistant
to AZD4547 treatment. Two of these mechanisms were uniquely identified from
de novo transposon insertions that were acquired during treatment, demonstrating
that insertional mutagenesis in mice is an effective tool for identifying resistance
mechanisms to targeted cancer therapies.
6.3 Materials and methods
Orthotopic transplantations and AZD4547 intervention Orthotopic transplantations
of small tumor fragments were performed as previously described by Doornebal
and colleagues20. For the WESB-Fgfr2 tumor-derived cells, 200,000 cells were
injected orthotopically into the right fat pad of 8- to 15-week-old wild-type syngeneic
recipient FVB females in 20 µl Matrigel (Corning) and PBS (1:1). For the WESB-
Fgfr2-EV and WESB-Fgfr2-ABCG2 cells, 200,000 cells were injected orthotopically
into the right fat pad of 8-week-old NMRI-nude females (Janvier Labs) in 20 µl
Matrigel (Corning) and PBS (1:1). All the drug interventions were initiated as
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soon as the mammary tumors reached a size of 5 ∗ 5 mm (62.5 mm3; tumor volume:
length ∗width2 ∗ 0.5). The treatments were performed daily by oral gavage for the
indicated time with either the vehicle (1 %-Tween-80 in demineralized water) or
AZD4547 (AstraZeneca) at a dose of 12.5 mg kg−1 d−1. The experimental cohort was
monitored and mice were sacrificed (overall survival) when the (total) mammary
tumor burden reached a size of approximately 1500 mm3 (tumor volume: length ∗
width2 ∗ 0.5) or suffered from clinical signs of distress (respiratory distress, ascites,
distended abdomen, rapid weight loss, and severe anemia) caused by mammary
tumor burden or metastatic disease. One hour after the last dosing, mice were
sacrificed and the tumor, lungs, liver, spleen, and tumor-draining lymph nodes were
collected for further analysis. The mouse technicians were blinded to the sample
groups for the treatments of WESB-Fgfr2 and WESB-Fgfr2-ABCG2 established tumors
in mice. All animal experiments were approved by the Animal Ethics Committee of
the Netherlands Cancer Institute and performed in accordance with institutional,
national and European guidelines for Animal Care and Use.
Cell culture The isolation of primary tumor cells of the SB-induced mILCs (referred
to as WESB cells) was performed as previously described by Kas and colleagues19.
WESB cells were cultured in DMEM-F12 medium containing 10 % FBS, 100 IU ml−1
penicillin, 100 µg ml−1 streptomycin (all from Life Technologies). MEF3.8 cells
were cultured in DMEM-F12 medium containing 10 % FBS, 100 IU ml−1 penicillin,
100 µg ml−1 streptomycin (all from Life Technologies). Phoenix packaging cells were
cultured in Iscove’s medium (Life Technologies) containing 10 % FBS, 100 IU ml−1
penicillin, and 100 µg ml−1 streptomycin. WESB-Fgfr2 cells were transduced with
LZRS-IRES-GFP or LZRS-Bcrp1-IRES-GFP as previously described by Allen and
colleagues21. Single GFP+ cells were sorted and allowed to recover before they
were used in the experiments. Cell line authentication was not conducted. All cell
lines were kept at low passage and routinely tested for Mycoplasma contamination
using the MycoAlert Mycoplasma Detection Kit (Lonza).
Additional experimental details regarding the cell viability, clonogenic, and competi-
tion assays are described in the Supplementary Material.
Vesicular Transport Assays Vesicular transport assays were performed using the
rapid filtration method as previously described22,23. Additional experimental details
are described in the Supplementary Material.
Nucleic acid isolation DNA and RNA were isolated from whole tumor pieces using
the Allprep DNA/RNA Mini Kit (Qiagen) according to the manufacturer’s protocol.
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Additional experimental details regarding the detection of the endogenous
Fgfr2–Tbc1d1 fusion and the Met qPCR copy number analysis are described in
the Supplementary Material.
Amplification of SB transposon insertions Transposon insertions were amplified
and mapped following a previously described tagmentation-based DNA sequencing
protocol24. Additional experimental details and the analysis of the insertions sites
are described in the Supplementary Material.
Antibodies The primary antibodies to the following proteins were used: FGFR2
(1:1,000, GeneTex 10648), phospho-FGFR (1:1,000, CST 3471), FRS2 (1:1,000,
ProteinTech 11503-1-AP), phospho-FRS2 (Tyr436) (1:1,000, Abcam 193363), AKT1
(1:1000, CST 2938), phospho-AKT(Ser473; 1:1,000, CST 4060), p44/42 MAP kinase
(1:1,000, CST 4695), phospho-p44/42 MAPK ERK1/ERK2 (Thr202/Tyr204; 1:1,000
CST 9101), ABCG2 (1:400, Abcam 24115) and β-actin (1:50,000, Sigma A5441).
Additional details regarding immunoblotting and IHC are described in the Supple-
mentary Material.
In silico modeling of the FGFR2 kinase in complex with the inhibitor AZD4547 A
composite complex of AZD4547 bound to mutated FGFR2 was built using the crystal
structure of the FGFR1 kinase domain in complex with AZD4547 (PDB code V405)
as a template. A structural alignment of the FGFR2 kinase domain crystal structure
(PDB code 2PVF) was performed and the positions of the resistance mutations were
mapped onto this alignment. Molecular graphic images were prepared using the
CHIMERA package25.
Statistical analysis For the mouse studies, no statistical tests were performed to
determine the appropriate sample size. Survival probabilities were estimated using
the Kaplan–Meier method and compared using the Mantel–Cox test. The effect of
AZD4547 treatment on tumor growth of WESB-Fgfr2-EV and WESB-Fgfr2-ABCG2
established tumors was tested using mixed linear models (details in Supplementary
Material). To test for differential expression of Abcg2, Rasa1, and Pcdh15 over the
insertion sites across all SB-induced tumors, we used the group-wise differential
expression test implemented in IM-Fusion26. The investigators were not blinded to
the sample groups for all experiments. Graphs and error bars represent mean ± SD.
Python 3.5, R 3.3.1 and GraphPad Prism 7.03 were used for the statistical analyses.
p values < 0.05 were considered significant.
Data availability Raw tagmentation and RNA-sequencing data are available in ENA
under accession number PRJEB25507.
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6.4 Results
6.4.1 Activation of Fgfr2 induces mILC formation
In a previous study, we performed an SB insertional mutagenesis screen in mice
with mammary-specific inactivation of Cdh1 (encoding E-cadherin) to identify genes
and pathways driving the development of ILC19. Analysis of common insertion sites
(CIS) in the SB-induced mILCs showed that a majority (56 of 99) of these tumors
had SB insertions in Fgfr2, providing strong evidence that Fgfr2 is a driver of ILC.
To confirm active FGFR signaling in mILCs with SB insertions in Fgfr2, we estab-
lished cell lines from two SB-induced tumors, one with an insertion upstream of
Fgfr2 (WESB-Fgfr2) and one without an insertion in or near Fgfr2 (WESB). We next
compared the expression of FGFR2 and downstream signaling proteins between the
two tumor cell lines. Although immunoblot analysis with an anti-FGFR2 antibody
revealed no expression of native FGFR2 in either of the cell lines, we observed a
doublet of approximately 240 kDa that was only expressed in the WESB-Fgfr2 cell
line (Figure 6.1A). This size coincided with the predicted protein size of a gene fusion
between Fgfr2 and Tbc1d1 (Supplementary Figure S6.1A-B), which we previously
identified in RNAseq data from this SB-induced mILC26. Similar FGFR2 gene fusions
were previously identified in several other studies, which demonstrated that these
fusions result in increased FGFR signaling27. In line with this, comparison of signal-
ing proteins downstream of FGFR2 showed increased expression of phosphorylated
FRS2α in WESB-Fgfr2 tumor-derived cells compared with WESB cells.
These results demonstrate that WESB-Fgfr2 cells show increased expression of an
Fgfr2–Tbc1d1 fusion gene, which is driven by an SB insertion upstream of Fgfr2.
The increased expression of this fusion gene results in activation of FGFR signaling,
suggesting that FGFR inhibition could be an interesting therapeutic strategy in these
tumors.
6.4.2 Mouse ILCs with SB insertions in Fgfr2 are dependent
on FGFR signaling
To determine if WESB-Fgfr2 cells were indeed sensitive to FGFR inhibition, we
treated these cells with the selective FGFR inhibitor AZD4547, which is currently be-
ing evaluated in several early-phase clinical trials2. After treatment with 100 nmol l−1
AZD4547, WESB-Fgfr2 cells showed a decrease in expression of phosphorylated
FGFR, FRS2α, and ERK1/2 (Figure 6.1B), confirming inhibition of the FGFR signaling
pathway. Compared with WESB cells, the WESB-Fgfr2 cells also showed reduced
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Fig. 6.1. Intervention study with AZD4547 in mILCs with active FGFR signaling.
(A) Representative immunoblot (n = 3) for the expression of FGFR2 and its
downstream signaling proteins in WESB and WESB-Fgfr2 cells. β-Actin was used
as a loading control. (B) The effect of FGFR inhibition on FGFR signaling in
WESB-Fgfr2 cells after short-term treatment with the FGFR inhibitor AZD4547
(100 nmol l−1), as visualized by immunoblotting with antibodies detecting total
and phosphorylated FGFR, FRS2α, AKT, and ERK1/2. β-Actin was used as a
loading control. (C) Schematic overview depicting the orthotopic transplantation
of SB-induced mILC fragments into wild-type syngeneic recipient mice and the
subsequent drug intervention with AZD4547. (D and E) Tumor growth kinetics
of orthotopically transplanted WESB-Fgfr2 tumors under the continuous (D)
and intermittent (E) treatment schedules with vehicle (blue) or AZD4547 (red).
(F and G) Kaplan–Meier curves showing the overall survival of tumor-bearing
mice under continuous (F) and intermittent (G) treatment with vehicle (blue) or
AZD4547 (red). p values were calculated using a Mantel–Cox test.
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viability upon exposure to increasing concentrations of AZD4547 (Supplementary
Figure S6.1C), indicating that WESB-Fgfr2 cells are dependent on FGFR signaling
for their survival in vitro.
To determine the efficacy of AZD4547 in vivo, we orthotopically transplanted WESB-
Fgfr2 tumor fragments into multiple wild-type syngeneic recipient FVB animals and
treated these animals with vehicle or AZD4547 (12.5 mg kg−1 d−1) daily via oral
gavage (Figure 6.1C). To reduce the potential toxicity of prolonged treatment and to
test the effect of a ‘drug holiday’ on tumor growth, the animals were treated using ei-
ther a continuous or an intermittent dosing schedule (Supplementary Figure S6.1D).
In both dosing schedules, tumors treated with AZD4547 showed decreased expres-
sion of downstream FGFR signaling and increased expression of cleaved caspase-3
(Supplementary Figure S6.1E–G), which resulted in tumor regression within 10 to
20 days after start of the treatment (Figure 6.1D-E). Furthermore, the majority of
the AZD4547-treated tumors (9 of 10 continuous-treated and 13 of 14 intermittent-
treated tumors) did not show any regrowth within the first treatment cycle of 24
days.
In the majority of mice, continuous treatment with AZD4547 resulted in tumor
control for at least 40 days after start of the treatment, resulting in an increased
overall survival compared with the vehicle-treated animals (Figure 6.1F). Notably,
2 of 10 sacrificed animals did not show any remaining tumor cells. In contrast, all
intermittently treated mice showed tumor regrowth after the first treatment cycle of
24 days. However, these tumors remained sensitive to multiple additional cycles of
AZD4547 treatment (Supplementary Figure S6.2A), resulting in an increased overall
survival compared with the vehicle-treated animals (Figure 6.1G). Similar results
were obtained with continuous AZD4547 treatment of mice after the orthotopic
injection of WESB-Fgfr2 tumor-derived cells (Supplementary Figure S6.2B-C).
Although the overall survival of AZD4547-treated mice was increased compared
with vehicle-treated animals, there was no significant difference in survival between
the continuous dosing (107 days) and the intermittent dosing (126 days) groups.
However, in the continuous dosing group an increased number of animals succumbed
due to clinical signs of distress (respiratory distress, ascites, distended abdomen,
rapid weight loss, and severe anemia), suggesting that the intermittent treatment
schedule is less toxic for the animals (Supplementary Figure S6.2D). In spite of the
potent anticancer activity of AZD4547, both treatment schedules failed to deliver
long-term tumor control, most likely due to the emergence of acquired therapy
resistance. This reflects the major problem observed in patients with cancer treated
with targeted anticancer therapies.
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6.4.3 Transcriptome analysis identifies known and novel
secondary FGFR2 mutations and increased MET
expression in AZD4547-resistant tumors
To explore potential resistance mechanisms to FGFR inhibition, we performed RNA-
sequencing of AZD4547-sensitive and -resistant tumors obtained from vehicle-treated
and AZD4547-treated animals (Supplementary Table S6.1), respectively, and com-
pared their mutational spectra to identify mutations that were acquired during
AZD4547 treatment. In this approach, we initially focused on known resistance
mechanisms to FGFR-targeting therapeutics10–16, which include upregulation of
alternative RTKs and secondary FGFR mutations.
To assess if upregulation of other RTKs could explain the resistance of these tumors,
we used RNA-sequencing data to determine changes in gene expression for Kit, Met,
and all FGFR-, EGFR-, and IGF-related RTKs. For this purpose, we used DIDS, an
algorithm that is specifically designed to identify differentially expressed genes in
heterogeneous populations28. Although this analysis did not identify any RTKs that
were significantly differentially expressed across multiple samples, it did identify
two AZD4547-resistant tumors with increased expression of Met [also known as
hepatocyte growth factor receptor (HGFR)] and one AZD4547-resistant tumor with
increased expression of insulin-like growth factor 1 receptor (Igf1r), compared with
vehicle-treated tumors (Figure 6.2A; Supplementary Figure S6.3A). Subsequent
analysis of IGF1R and MET protein expression by IHC did not support IGF1R as
a potential resistance mechanism, because no correlation was observed between
expression levels of Igf1r mRNA and IGF1R protein (Figure 6.2B). In contrast, both
AZD4547-resistant tumors with high Met mRNA expression showed amplification of
Met (Supplementary Figure S6.3B) and overexpression of MET protein (Figure 6.2C),
whereas vehicle-, AZD4547-treated, and other AZD4547-resistant tumors were
negative for MET expression (Supplementary Figure S6.3C). These in vivo results are
in line with previous in vitro studies showing that upregulation of MET attenuates
the efficacy of FGFR inhibition in tumor cells14,15, indicating that upregulation of
MET may also counteract the therapeutic efficacy of AZD4547 in vivo. In contrast
to previous in vitro studies13,16, we did not observe an obvious increase in mRNA
expression of the Egfr or other EGFR-family members in any of the AZD4547-resistant
tumors.
Next, to determine if any mutations in RTKs or members of the MAPK–ERK pathway
could explain the resistance of these tumors, we used the RNA-sequencing data
to identify mutations in the above-mentioned RTKs and genes involved in the
MAPK–ERK signaling pathway (Supplementary Table S6.2). Using this approach,
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Fig. 6.2. Transcriptome analysis of AZD4547-resistant tumors. (A) Differential expres-
sion analysis of Met and Igf1r in AZD4547-sensitive (n = 15) and -resistant
(n = 27) tumors using DIDS, showing outliers for Met (n = 2) and Igf1r (n = 1).
(B) Quantification of IGF1R expression in AZD4547-sensitive (n = 4) and -
resistant (n = 8) tumors. AU, arbitrary unit. (C) Representative immunohisto-
chemical stainings of MET in AZD4547-sensitive (vehicle) and -resistant tumors.
Scale bar, 50 µm. (D) Schematic overview showing the locations of mutations
identified for Fgfr2 in the AZD4547-resistant tumors. Red mutations have been
previously reported in patients with FGFR2 fusion–positive cholangiocarcinoma,
whose tumors acquired resistance to the selective FGFR inhibitor NVP-BGJ398.
Numbers indicate amino acid residue positions (mouse). Ig, immunoglobulin-like
domain; TM, transmembrane domain; TK, tyrosine kinase domain. (E) In silico
modeling of AZD4547 (middle) in the ATP-binding pocket of FGFR2. The FGFR2
kinase domain is depicted as a sky-blue ribbon with residues of interest colored
by atom type: carbon, pink; nitrogen, blue; oxygen, red. AZD4547 is colored by
atom type: carbon, gray; nitrogen, blue; oxygen, red.
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which four were located in the third immunoglobulin (Ig)-like domain (IgIII) and
seven were located in the tyrosine kinase domain (Figure 6.2D).
To predict the effects of the mutations in the FGFR2 kinase domain on AZD4547
binding, we mapped the seven missense mutations onto the FGFR2 protein structure
and observed that residues I567, N568, V581, E584, S587 reside in the ATP-binding
pocket of FGFR2 (Figure 6.2E). As a consequence, these mutated residues directly
perturb the binding site of AZD4547. In addition, the E584G mutation is located in
the kinase hinge and introduces flexibility at the key recognition motif for AZD4547.
The K660R mutation is adjacent to the binding site, which suggests that the binding
of AZD4547 is indirectly perturbed. Finally, the K678M mutation is located in the
kinase activation loop, suggesting that this mutation alters the dynamics of the
activation loop and favors the active conformation.
Interestingly, four out of the seven missense mutations in the tyrosine kinase domain
reflected recurrent point mutations that were previously reported in patients with
FGFR2 fusion–positive cholangiocarcinoma, whose tumors acquired resistance to
the selective FGFR inhibitor NVP-BGJ39810. In this previous work, structural charac-
terization combined with functional in vitro studies showed that these FGFR2 kinase
mutations either induce a steric clash with NVP-BGJ398 in the ATP-binding pocket
or destabilize the inactive conformation of the kinase. Together, these data indicate
that the seven mutations in the ATP-binding pocket of FGFR2 disrupt the binding
of selective FGFR tyrosine kinase inhibitors and therefore hamper their therapeutic
efficacy.
6.4.4 AZD4547-resistant SB-induced tumors show de novo
insertions in candidate resistance genes
Because of the presence of a constitutively active SB transposase, the SB-induced
mILCs could be capable of developing resistance by acquiring de novo transposon
insertions in or near resistance genes during AZD4547 treatment. To determine
if SB-mediated mutagenesis might indeed be driving resistance in some of these
tumors, we performed an insertion analysis of 27 AZD4547-resistant SB-induced
tumors and compared the identified SB insertions to those found in the donor tumor
and 15 vehicle-treated tumors. Globally, this analysis showed that the majority
of the clonal insertions in the donor tumor (e.g., Fgfr2, Ppp1r12a, Slc16a9, and
Trps1) were maintained after orthotopic transplantation and long-term treatment of
the tumor-bearing mice (Supplementary Figure S6.4A; Supplementary Tables S6.1
and S6.3). Interestingly, additional SB insertions were observed in both vehicle- and
AZD4547-treated tumors, indicating that mobilization of transposons still occurs
after transplantation of SB-induced tumors.
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To specifically identify de novo insertions that might be driving resistance to AZD4547,
we filtered for genes that contained SB insertions in the AZD4547-resistant tumors
but not in the donor or vehicle-treated tumors (Supplementary Figure S6.4B). This
analysis revealed three candidate resistance genes (Abcg2, Rasa1, and Pcdh15) with
insertions in at least three AZD4547-resistant tumors (Figure 6.3A). Of these three
genes, Abcg2 contained several independent insertions that were mainly in the sense
orientation and located upstream of the transcription start site (Figure 6.3B), indi-
cating that these insertions result in increased Abcg2 expression. In support of this,
these insertions coincided with increased mRNA and protein expression of ABCG2
(Figure 6.3C; Supplementary Figure S6.5A–C). Variable ABCG2 expression highlights
intratumor heterogeneity in mechanisms of AZD4547 resistance. In contrast to Abcg2,
Rasa1, and Pcdh15 contained either a mix of sense/antisense insertions or purely
antisense insertions, suggesting that these genes are inactivated (Figure 6.3D–G).
Further analysis revealed decreased expression of exons downstream of the insertion
sites in Rasa1, supporting inactivation of Rasa1 via truncation of the gene, whereas
expression of Pcdh15 was not markedly affected.
To investigate whether insertions from the donor tumor might contribute to intrinsic
treatment resistance, we compared the relative support scores of insertions between
untreated tumors (vehicle-treated tumors and the donor tumor) and AZD4547-
resistant tumors to determine if insertions in specific genes were enriched after
AZD4547 treatment. This analysis identified six genes (Arid1a, Myh9, Fbxw7, Matr3,
Slc16a9, and Map4k4) with increased support scores in AZD4547-resistant tumors,
indicating that subclones with insertions in these genes are selected for during
treatment (Supplementary Figure S6.5D). These genes might therefore be involved in
intrinsic resistance to AZD4547. Interestingly, the top three genes (Arid1a, Myh9, and
Fbxw7) were previously identified as candidate driver genes in ILC formation19.
Collectively, these results show that persistent mobilization of transposons in SB-
induced mILCs allows them to acquire new insertions during treatment and that
this approach can be used to identify novel resistance mechanisms. Our analysis
implicates upregulation of Abcg2 and inactivation of Rasa1 as additional resistance
mechanisms to AZD4547, which were not previously identified with our mutational
analyses. This demonstrates that combining insertional mutagenesis with drug
treatments poses an effective strategy for identifying resistance mechanisms to
targeted therapies in mice.
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Fig. 6.3. Overview of insertions and corresponding gene expression of candidate re-
sistance genes. (A) Overview of insertions in candidate resistance genes that
were mutated in at least three AZD4547-resistant tumors (n = 27) and were not
mutated in any of the donor (two technical replicates) or vehicle-treated (n = 15)
tumors. Relative clonality of insertions is indicated by relative support scores
(blue), which were calculated by counting the number of mate pairs supporting
an insertion and normalizing these support scores to the highest score of the
corresponding sample. (B–G) Left, visualization of SB insertions (arrows) in
Abcg2 (B), Rasa1 (D), and Pcdh15 (F). Right, normalized gene expression values
after the insertion sites of Abcg2 (C), Rasa1 (E), and Pcdh15 (G) in all SB-induced
tumors with and without insertions in the respective genes. p values were calcu-
lated using a Mann–Whitney U test, as implemented in IM-Fusion. (H) Schematic
overview of the in vitro competition assay performed with WESB-Fgfr2 cells trans-
fected with modified pX330 vectors containing sgRNAs targeting Rasa1 (sgRasa1)
or a nontargeting sgRNA (sgNT). I, Competition assay of WESB-Fgfr2-sgNT and
WESB-Fgfr2-sgRasa1 cells mixed in a 1:1 ratio at day 0. After 7, 10, and 12
days of vehicle or AZD4547-treatment (2 µmol l−1), the allele distributions of the
polyclonal populations were quantified by the percentage of frameshift mutations
in Rasa1 using the TIDE algorithm29. The percentages of gene modifications are
mean ± SD of at least four replicates.
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6.4.5 Loss of RASA1 reduces sensitivity of WESB-Fgfr2
tumor cells to AZD4547
To test whether inactivation of Rasa1 induces resistance to AZD4547 treatment, we
transfected WESB-Fgfr2 tumor-derived cells with modified pX330 vectors containing
single guide RNAs (sgRNA) targeting three different genomic regions of Rasa1 or
a nontargeting sgRNA (sgNT). All the Rasa1 targeting sgRNAs induced efficient
modification of the Rasa1 target sites in the transfected cell populations (Supplemen-
tary Figure S6.5E–G), as determined by tracking of insertions or deletions [indels]
by decomposition (TIDE) analysis29. To test for drug sensitivity, we performed an
in vitro competition assay with a mixture of WESB-Fgfr2-sgNT and WESB-Fgfr2-
sgRasa1 cells (1:1 ratio) in the presence or absence of 2 µmol l−1 AZD4547 and
subsequently quantified the allele distribution of the polyclonal population using the
frequency of frameshift mutations in Rasa1 (Figure 6.3H). After prolonged AZD4547
treatment, the polyclonal population was enriched for Rasa1 frameshift mutations
for all three Rasa1-targeted regions (Figure 6.3I), indicating that Rasa1-depleted
cells were less sensitive to AZD4547 treatment compared with control cells. In
contrast, the allele distributions were not affected when cells were cultured without
AZD4547, demonstrating that the observed effect was not due to a difference in
proliferation between WESB-Fgfr2-sgNT and WESB-Fgfr2-sgRasa1 cells. Altogether,
these data show that inactivation of Rasa1 reduces the sensitivity of WESB-Fgfr2
cells to AZD4547 treatment.
Abcg2 is an ATP-binding cassette (ABC) efflux transporter, suggesting that overex-
pression of this gene may induce resistance through increased extrusion of AZD4547
from the tumor cells. To determine if this is indeed the case, we first sought to
confirm that AZD4547 is a substrate for the ABCG2 transporter. To this end, we per-
formed a vesicular transport assay (Figure 6.4A), in which we measured the uptake
of tritium-labeled methotrexate ([3H]-MTX) in inside-out Sf9-membrane vesicles
expressing ABCG2 (Sf9-ABCG2), both in the presence and absence of increasing
concentrations of AZD4547, and compared the results to the uptake of [3H]-MTX
in control Sf9-membrane vesicles (Sf9-control). This showed that ATP-dependent
uptake of [3H]-MTX by ABCG2 was inhibited by AZD4547 (Figure 6.4B), indicating
that AZD4547 is indeed a substrate of ABCG2.
6.4.6 Overexpression of ABCG2 reduces sensitivity to
AZD4547
To further explore whether increased expression of Abcg2 reduces the sensitivity
of cells to AZD4547, we used mouse embryonic fibroblasts (MEF) derived from
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Fig. 6.4. AZD4547 is a substrate for ABCG2. (A) Schematic overview of the vesicular
transport assay. Control or ABCG2-containing inside-out membrane vesicles were
incubated with [3H]-MTX (blue) and increasing concentrations of AZD4547 (red)
in the presence or absence of ATP. After 10 minutes incubation, the membrane
vesicles were captured using rapid filtration and the filters were washed to
eliminate the excess of [3H]-MTX that was not transported into the vesicles. The
retained radioactivity inside the membrane vesicles was measured using liquid
scintillation counting. (B) Inhibition of ABCG2-mediated [3H]-MTX transport by
increasing concentrations of AZD4547 (red). Values are corrected for transport
in the absence of ATP. Data are mean ± SD of three independent experiments,
which were each performed in triplicate.
Abcb1a-/-;Abcb1b-/-;Abcc1-/- mice (hereafter referred to as MEF3.8), which have
very low background expression of endogenous ABCG221. Furthermore, these
MEFs lack both P-glycoprotein (P-gp, encoded by Abcb1a and Abcb1b), and the
multidrug resistance-associated protein 1 (MRP1, encoded by Abcc1), allowing us to
exclude confounding influences of these other drug efflux transporters. To test for
drug sensitivity, MEF3.8 cells were transduced with an empty retroviral expression
vector (MEF3.8-EV) or a vector containing Abcg2 (MEF3.8-ABCG2) and subsequently
exposed to increasing concentrations of AZD4547 in long-term clonogenic assays
(Figure 6.5A). Compared with MEF3.8 cells, MEF3.8-ABCG2 cells were able to
survive higher concentrations of AZD4547 (Figure 6.5B-C), indicating that increased
ABCG2 expression reduces the efficacy of AZD4547.
To confirm that increased expression of ABCG2 also reduces the sensitivity of
treatment-naive WESB-Fgfr2 cells to AZD4547, we transduced these cells with
an empty retroviral expression vector (WESB-Fgfr2-EV) or a vector containing
Abcg2 (WESB-Fgfr2-ABCG2) and treated the transduced cells with AZD4547. Short-
term treatment of WESB-Fgfr2-EV cells with AZD4547 resulted in decreased phos-
phorylation of FGFR, FRS2α, and ERK1/2, whereas the phosphorylation levels of
these proteins were less affected in AZD4547-treated WESB-Fgfr2-ABCG2 cells
(Figure 6.5D).
To test the effect of ABCG2 overexpression on the responsiveness of established
tumors to AZD4547, we injected WESB-Fgfr2-EV and WESB-Fgfr2-ABCG2 cells into
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Fig. 6.5. ABCG2 reduces sensitivity to AZD4547 in vitro and in vivo. (A) Represen-
tative immunoblot (n = 3) for the expression of ABCG2 in MEF3.8-EV and
MEF3.8-ABCG2 cells. β-Actin was used as a loading control. (B and C) Repre-
sentative images (B) and quantification (C) of the clonogenic assays (11 days
after seeding the cells) of MEF3.8 cells treated with increasing concentrations of
AZD4547. Data are mean ± SD of three independent experiments. (D) Represen-
tative immunoblot (n = 3) showing the effect of short-term AZD4547 treatment
(100 nmol l−1) in WESB-Fgfr2 cells with and without ABCG2 expression. β-actin
was used as a loading control.
were treated with either vehicle or AZD4547 (12.5 mg kg−1 d−1) daily for 30 days
when the tumors reached the size of 62.5 mm. Interestingly, the NMRI-nude mice
did not show tumor regression upon treatment with AZD4547, in contrast to the
previously used FVB syngeneic animals (Supplementary Figure S6.2B), suggesting
that an intact immune system might enhance the therapeutic efficacy of AZD4547.
Nonetheless, mice with WESB-Fgfr2-EV tumors did show stable disease, whereas
WESB-Fgfr2-ABCG2 tumors progressed during treatment (Figure 6.5E–G). These
results show that increased ABCG2 expression also reduces the sensitivity of FGFR2-
activated tumors to AZD4547 in vivo, confirming that upregulation of this drug efflux
transporter can drive resistance to AZD4547.
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Fig. 6.5. Continued. (E and F) Tumor growth kinetics of WESB-Fgfr2-EV (E) and
WESB-Fgfr2-ABCG2 (F) cells in NMRI-nude female mice under vehicle (blue) or
AZD4547 (red) treatment (for 30 consecutive days). Datapoints are mean ± SD
and p values were calculated using mixed linear models (details are described in
the Supplementary Material). Vehicle-treated WESB-Fgfr2-EV versus WESB-Fgfr2-
ABCG2 tumors, p = 0.5511, not significant; AZD4547-treated WESB-Fgfr2-EV
versus WESB-Fgfr2-ABCG2 tumors, p = 3.983e− 05. (G) IHC detection of ABCG2
in sections of WESB-Fgfr2-EV and WESB-Fgfr2-ABCG2 tumors. Scale bar, 50 µm.
6.5 Discussion
In this work, we performed an SB-based insertional mutagenesis screen in a mouse
model of ILC to identify genes that are involved in the development of resistance to
FGFR-targeting therapies. As a starting point for this screen, we used SB-induced
mILCs, in which we previously identified Fgfr2 as the most frequently mutated
candidate gene19. By orthotopically transplanting an SB-induced mILC with activated
FGFR signaling into multiple recipient mice, we showed that treatment with the
FGFR inhibitor AZD4547 initially results in tumor regression and provides long-
term tumor control, but eventually results in acquired treatment resistance. Our
mutational analysis of the AZD4547-resistant tumors identified several potential
resistance mechanisms, including secondary mutations in FGFR2, inactivation of
RASA1, a negative regulator of RAS signaling, and overexpression of MET and
the drug-efflux transporter ABCG2. Together, these mechanisms explain acquired
resistance to AZD4547 in (21 of 27) tumors (Figure 6.6A). Resistance mechanisms
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Fig. 6.6. Schematic overview of the resistance mechanisms in AZD4547-resistant tu-
mors identified in this study. (A) Overview of the genetic alterations and gene
expression changes in the respective genes identified in the AZD4547-resistant
tumors. Red bars, amplification of the respective gene. Blue and red triangles
indicate insertions in sense or antisense orientation relative to the gene, respec-
tively. Bars with a red outline indicate the upregulation of the respective genes.
Green and black squares represent missense mutations in the IgIII-like domain or
the tyrosine kinase domain of FGFR2, respectively. (B) Schematic representation
of the identified resistance mechanisms in the FGFR signaling pathway. Activating
and inactivating events resulting in resistance to AZD4547 are depicted in green
and red, respectively.
In line with previous studies in a mouse model of melanoma30 and Arf-/- mice31, we
show that transposon mutagenesis in mice cannot only be used to identify candidate
cancer genes, but is also an effective strategy to identify genes involved in in vivo
drug resistance. In our mutational analysis of the AZD4547-resistant tumors, we
exploited the constitutive activity of the SB-mediated insertional mutagenesis system
in SB-induced mILCs to identify potential resistance mechanisms in an unbiased,
genome-wide fashion. This allowed us to identify two resistance mechanisms (acti-
vation of ABCG2 and inactivation of RASA1), which might not have been identified
without SB mutagenesis. However, resistance mechanisms that involve specific
amino acid substitutions may not be uncovered by transposon mutagenesis, but only
arise from spontaneous mutations. A comprehensive characterization of the various
206 Chapter 6 Transcriptomics and transposon mutagenesis identify multiple in vivo...
mechanisms of resistance to targeted anticancer therapeutics may therefore require
a multipronged approach, combining transposon mutagenesis with other sequenc-
ing modalities to identify spontaneous mutations and/or transcriptional changes
that may be driving resistance. Given enough sequencing depth, RNA-sequencing
based approaches for identifying transposon insertions may be able to provide the
most comprehensive analysis from a single dataset26,32, by allowing detection of
transposon insertions, mutations, gene-fusions, and transcriptional changes in RNA-
sequencing data. However, targeted DNA-sequencing approaches (as we have used
here to detect SB transposon insertions) are likely to yield more detailed detection
of insertions and/or mutations with a low frequency, by effectively providing deeper
sequencing at a lower cost.
The diverse spectrum of identified resistance mechanisms illustrates the major
challenge that (intra-)tumor heterogeneity poses for the prevention of therapy re-
sistance, as we observe multiple resistance mechanisms arising from and within
a single (donor) tumor. All of the identified mechanisms center on reactivation
of the canonical MAPK–ERK signaling pathway, suggesting that this is a dominant
mechanism for overcoming vulnerability to FGFR inhibition (Figure 6.6B). Reactiva-
tion of MAPK–ERK signaling has also been identified as a predominant resistance
mechanism to EGFR inhibitors33. In our analysis of AZD4547-resistant tumors, we
observed recurrent alterations in several components of the MAP–ERK pathway,
including secondary mutations in FGFR2, overexpression of the MET receptor and
inactivation of RASA1. MET overexpression can induce resistance by driving reacti-
vation of signaling pathways downstream of FGFR2, as has previously been shown in
the context of FGFR and other RTK inhibitors2,14,15,34. Also loss of RASA1, which is
a negative regulator of RAS, may cause resistance to FGFR inhibition via reactivation
of the MAPK–ERK pathway35.
Our analysis of the secondary mutations in FGFR2 showed that the majority of
these mutations occurred in the tyrosine kinase domain, suggesting that they mainly
provide resistance by preventing the inhibitor from binding to the ATP-binding pocket
and thereby reactivating the FGFR signaling pathway. This finding agrees with
previous studies with other FGFR inhibitors, which identified polyclonal secondary
FGFR mutations (including gatekeeper mutations) as a main resistance mechanism
to FGFR-targeting treatments10–12. Our observations are further supported by studies
with other RTK inhibitors, which also describe secondary mutations in the receptor
as one of the main resistance mechanisms to tyrosine kinase inhibitors34.
Our validation of the drug efflux transporter Abcg2 showed that increased ABCG2
expression can induce resistance by reducing the concentration of AZD4547 within
tumor cells, which results in decreased inhibition of FGFR and reactivation of the
FGFR signaling pathway. In patients, overexpression of the drug efflux pump MDR1
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(encoded by ABCB1) has been observed in chemotherapy-resistant ovarian cancer36.
Our results suggest that drug efflux transporters such as ABCG2 cannot only drive
therapy resistance in hematologic malignancies37, but may also have similar effects
on therapy efficacy in solid tumors.
Recent approaches have aimed to overcome resistance to FGFR-targeting therapies
either by combining multiple existing RTK inhibitors14,15, or by designing irreversibly
binding inhibitors such as FIIN-2, FIIN-3, and PRN137138,39, which cannot be
disrupted as easily by secondary mutations in the receptor. However, our results
suggest that combining FGFR and MEK/ERK inhibitors might be a more effective
strategy, as this prevents reactivation of MAPK–ERK signaling. In addition, to
avoid resistance resulting from drug efflux transporters, novel inhibitors should be
specifically designed to be poor substrates for common transporters. Alternatively,
CRISPR/Cas9 genetic screens could be used to identify synthetic lethal interactions
with FGFR inhibitors in the context of FGFR inhibitor-resistant tumors to design
rational and more effective combination therapies to overcome drug resistance40.
In summary, SB insertional mutagenesis in mice is an effective tool to identify
mechanisms of drug resistance. A comprehensive analysis of AZD4547-resistant
mILCs, in which SB-based mutagenesis is combined with targeted DNA- and RNA-
sequencing, allowed us to explain the mechanism of resistance in 78% of the resistant
tumors, of which all converged to the reactivation of the canonical MAPK–ERK
signaling cascade. Altogether, our findings suggest that FGFR-targeting drugs might
be improved by designing FGFR inhibitors that are poor substrates of drug efflux
transporters and irreversibly bind to the ATP-binding pocket of the receptor to prevent
secondary mutations in the tyrosine kinase domain. In addition, combining these
novel FGFR inhibitors with MEK/ERK inhibitors might be an even more effective
strategy for preventing resistance to FGFR-targeted therapies.
Acknowledgments We are grateful to Els Wagenaar, Sander Canisius, Chris
Doornebal, Eline van der Burg, and Ute Boon for providing technical suggestions
and/or assistance with the experiments. We thank Alfred Schinkel (The Netherlands
Cancer Institute, Amsterdam) for the MEF3.8 and MEF3.8-ABCG2 cells. We thank
Elaine Kilgour, Lindsay Bridgett, and Paul Smith (Oncology IMED, IMED Biotech Unit,
AstraZeneca) for providing the AZD4547. We thank the NKI animal facility, RHPC
computing facility, the animal pathology facility, the mouse clinic transgenic and
intervention unit, the core facility molecular pathology and biobanking (CFMPB),
and the genomics core facility for their expert technical support. Financial support
was provided by the Netherlands Organization for Scientific Research [NWO: Cancer
Genomics Netherlands (CGCNL), Cancer Systems Biology Center (CSBC), Nether-
lands Genomics Initiative (NGI) grant Zenith 93512009 (J. Jonkers), infrastructural
208 Chapter 6 Transcriptomics and transposon mutagenesis identify multiple in vivo...
grant from the National Roadmap for Large-Scale Research Facilities], the EU Sev-
enth Framework Program (Infrafrontier-I3 project 312325 to J. Jonkers), and the
European Research Council (ERC Synergy project CombatCancer to J. Jonkers). This
work was carried out on the Dutch national e-infrastructure with the support of SURF
Cooperative (e-infra160136 to J. Jonkers). This work is part of the Oncode Institute,
which is partly financed by the Dutch Cancer Society (KWF; to J. Jonkers).
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
Disclosure of potential conflicts of interest C. Phillips and P.D. Smith have owner-
ship interest (including patents) in AstraZeneca PLC. L.F.A. Wessels reports receiving
a commercial research grant from Genmab. No potential conflicts of interest were
disclosed by the other authors.
Author contributions
Conception and design: S.M. Kas, J.R. de Ruiter, J. Jonkers.
Development of methodology: S.M. Kas, J.R. de Ruiter, K. Schipper, L. Bombardelli, A.
Berns, J. Jonkers.
Acquisition of data (provided animals, acquired and managed patients, provided facili-
ties, etc.): S.M. Kas, K. Schipper, A.P. Drenth, R. de Korte-Grimmerink, S. Mahakena,
K. van de Wetering.
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computa-
tional analysis): S.M. Kas, J.R. de Ruiter, K. Schipper, C. Phillips, P.D. Smith, S.
Klarenbeek, K. van de Wetering, L.F.A. Wessels, J. Jonkers.
Writing, review, and/or revision of the manuscript: S.M. Kas, J.R. de Ruiter, C. Phillips,
P.D. Smith, K. van de Wetering, L.F.A. Wessels, J. Jonkers.
Administrative, technical, or material support (i.e., reporting or organizing data, con-
structing databases): E. Schut, L. Bombardelli, E. Wientjens, A.P. Drenth, R. de
Korte-Grimmerink, A. Berns.
Study supervision: J. Jonkers.
6.5 Discussion 209
6.6 Supplementary Material
6.6.1 Supplementary experimental details
Cell viability assay WESB cells were seeded in triplicate with 500 cells per well in
96-well plates. After 24 hours, the medium was refreshed with either DMSO (as
a control) or AZD4547 with the indicated concentrations. Three days later, cell
viability was assayed in an Envision plate reader (Perkin Elmer) using resazurin (cell
titer blue; Promega).
Clonogenic assay MEFs were trypsinized and 2000 cells were seeded in 6-well
plates. After 24 hours, the medium was refreshed with either DMSO (as a control) or
AZD4547 with the indicated concentrations. Eleven days later, the cells were fixed
with 4 % formalin in PBS and stained with 0.1 % crystal violet in demineralized water.
Quantification was performed by dissolving the crystal violet with 10 % acetic acid
in demineralized water and determining the absorbance at 590 nm. The experiment
was performed three times.
Competition assay WESB-Fgfr2 cells were transfected with pX330.pgkpur con-
structs containing three independent sgRNAs targeting Rasa1 (sgRasa1) or a non-
targeting as control (sgNT) using Lipofectamine 2000 (ThermoFisher Scientific
11668027) according to manufacturer’s protocol. Transfected cells were selected
using puromycin (4 µg ml−1) for 48 hours. The pX330.pgkpur construct is a modified
version of the pX330 backbone41, which contains a puromycin resistance ORF under
the hPGK promoter42. The pX330-U6-Chimeric_BB-CBh-hSpCas9 construct was a
gift from Dr Feng Zhang (Addgene plasmid #42230). WESB-Fgfr2 cells containing
sgNT or sgRasa1 were mixed and seeded at a one-to-one ratio on 6-well plates in
medium supplemented with 5 % FBS and either DMSO or 2 µmol AZD4547. The
medium was refreshed every 4 days and DNA was isolated at days 0, 7, 10 and 12
using the Gentra Puregene genomic DNA isolation kit (Qiagen). PCR amplifications
of Rasa1 exon 2, 6 and 8 were performed with specific primers spanning the target
sites and 100 ng to 200 ng DNA template, using the Q5 High-Fidelity PCR kit (NEB
M0492). Amplification PCR reactions were diluted 20 times with Milli-Q and sub-
sequently Sanger sequenced using the FW primers. CRISPR/Cas9-induced editing
efficacy was quantified using the TIDE algorithm29. Cells with only sgNT were used
as a negative control in all genomic DNA amplifications and only TIDE outputs with
R2 > 0.9 were considered.
sgRNA sequence Rasa1-1: 5’-TTATAAGAGAGAGTGATCGG-3’
sgRNA sequence Rasa1-2: 5’-CGAGAAGAAGATCCACACGA -3’
210 Chapter 6 Transcriptomics and transposon mutagenesis identify multiple in vivo...
sgRNA sequence Rasa1-3: 5’-ATCTCCAGGAGTATTATCTG-3’
Rasa1 sgRNA1 PCR FW 5’-TTGTGTTCTCACAGACCTGAAT-3’ (557 bp)
Rasa1 sgRNA1 PCR RV 5’-TCAATCTGTGATCTCCAAGCC-3’ (557 bp)
Rasa1 sgRNA2 PCR FW 5’-TGTAGGCAAGAGAGCCAAATTA-3’ (697 bp)
Rasa1 sgRNA2 PCR RV 5’-GTTCAAGGCCAGTCTGATCTAC-3’ (697 bp)
Rasa1 sgRNA3 PCR FW 5’-GAGTTCTTTCAGAGAGCGAAGG-3’ (406 bp)
Rasa1 sgRNA3 PCR RV 5’-GAGTTCTTTCAGAGAGCGAAGG-3’ (406 bp)
Preparation of membrane vesicles and vesicular transport assays Membrane vesi-
cles from Sf9 cells were obtained after infection with a control or a human ABCG2-
containing baculovirus at a multiplicity of infection of 122. After incubation at 27 ◦C
for 3 days, cells were harvested by centrifugation at 500xg for 5 min. Cells were
then resuspended in ice-cold hypotonic buffer (0.5 mmol sodium phosphate and
0.1 mmol EDTA, 7.4 pH) supplemented with a protease inhibitor cocktail (Roche,
Basel, Switzerland) and incubated at 4 ◦C for 90 min under constant agitation.
Thereafter, the cell lysate was homogenized using a tight-fitting Dounce homoge-
nizer. Next, cell debris and nuclei were removed by slow-speed centrifugation at
500xg (4 ◦C for 10 min). The supernatant was collected and centrifuged at 4 ◦C at
100, 000xg for 40 min. The membrane pellet was resuspended in TS buffer (50 mmol
Tris-HCl and 250 mmol sucrose, 7.4 pH) and passed through a 27-gauge needle 25
times. The vesicles were dispensed in aliquots, snap-frozen in liquid nitrogen, and
stored at −80 ◦C until use. Vesicular transport assays were performed using the rapid
filtration method as previously described22,23. Briefly, ABCG2 or control Sf9 mem-
brane vesicles containing 20 µg of protein were incubated with 1 mmol [3H]-MTX in
50 µl of TS buffer in the presence of 4 mmol ATP or AMP, 10 mmol MgCl2, 10 mmol
creatine phosphate, and 100 g of creatine kinase/ml. After 10 minutes, 40 µl of the
reaction mixture was diluted in 200 µl of ice-cold TS buffer and immediately filtrated
using a MultiScreenHTS vacuum manifold in combination with MultiscreenHTS FB
96-well filter plates (Millipore, Bedford, MA). Membranes were washed four times
with 200 µl of ice-cold phosphate-buffered saline and the radioactivity retained on
the membranes was counted by liquid scintillation counting.
Immunohistochemistry Tissues were formalin-fixed and paraffin-embedded (FFPE)
by routine procedures. Immunohistochemical stainings of MET, ABCG2 (BCRP)
and cleaved Caspase-3 were processed as previously described20,43. The following
primary antibodies were used for the respective proteins: MET (1:100, R&D Systems
AF527), BCRP (1:400, Abcam 24115) and cleaved Caspase-3 (1:400, CST 9661).
Citrate buffer was used as antigen retrieval for MET and BCRP. TRIS/EDTA 9.0 pH
was used for cleaved Caspase-3. Immunohistochemical staining of IGF1R was
performed on a Discovery Ultra autostainer (Ventana Medical Systems). Briefly,
paraffin sections were cut at 3 µm, heated at 75 ◦C for 28 minutes and deparaffinised
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in the instrument with EZ prep solution (Ventana Medical Systems). Heat-induced
antigen retrieval was carried out using Cell Conditioning 1 (CC1, Ventana Medical
Systems) for 64 minutes at 95 ◦C. IGF1R was detected using clone G11 (Ready-to-
use, 16 minutes at 37 ◦C, Ventana Medical Systems), bound antibody was detected
using the OMap anti-Rb HRP (Ventana Medical Systems) for 12 minutes after
which the ChromoMap DAB Kit (Ventana Medical Systems) was applied. Slides were
counterstained with Hematoxylin and Bluing Reagent (Ventana Medical Systems). All
slides were digitally processed using the Aperio ScanScope (Aperio, Vista, CA, USA)
and captured using ImageScope software version 12.3.2.8013 (Aperio). Cleaved
Caspase-3 and ABCG2 immunohistochemical stainings were reviewed and scored
by a veterinary pathologist (Sjoerd Klarenbeek) in a blinded manner. The images
on the slides were captured using an Axioskop 40 microscope and an AxioCam
MRc5 camera (Zeiss) and analyzed using the ZEN lite 2012 (Blue edition) software.
The number of cleaved Caspase-3 positive cells were counted in four independent
fields (0.34 mm2) per tumor and the average number of positive cells per mm2 was
calculated. Necrotic areas in these tumors were excluded from the analysis.
Immunoblotting Protein lysates were made using lysis buffer (25 mmol Tris-HCl
7.6 pH, 150 mmol NaCl, 1 % NP-40, 1 % sodium deoxycholate, 0.1 % SDS in Milli-Q)
complemented with protease and phosphatase inhibitors (Roche) and quantified
using the BCA protein assay kit (Pierce). Equal amounts of proteins were sepa-
rated on a 4 % to 12 % Bis-Tris gradient gel (Invitrogen) and transferred overnight
onto nitrocellulose membrane (Bio-Rad) in 1x transfer buffer (25 mmol Tris, 2 mol
Glycine, 20 % methanol in demineralized water). Membranes were blocked in 5 %
w/v bovine serum albumin (BSA) in PBS-T (7.5 pH, 0.005 % Tween-20 in deminer-
alized water) and incubated overnight with the primary antibodies in 5 % w/v BSA
in PBS-T. Membranes were washed three times and incubated with the secondary
antibodies goat anti-rabbit-HRP (1:2000, Dako P0448), rabbit anti-mouse-HRP
(1:5000, Dako P0260), rabbit anti-rat-HRP (1:2000, Invitrogen 61-9520) or donkey
anti-mouse IRDye 680nm (1:5000, Li_COR 926-32222) in 5 % w/v BSA in PBS-T.
Stained membranes were washed three times in PBS-T and then developed using
ECL (Pierce 32209), ECL 2 Substrate (Pierce 80196) or captured using the Li-Cor
Odyssey Infrared Imaging System and analyzed using Odyssey Application software
version 3.0.16. The intensities of the bands were quantified using ImageJ software
version 2.0.0-rc-65/1.52b.
RNA sequencing and analysis Illumina TruSeq mRNA libraries were generated
and sequenced with 50-65 base single reads on a HiSeq 2500 using V4 chemistry
(Illumina Inc., San Diego) as previously described by Boelens et al.44. The resulting
reads were trimmed using Cutadapt45 (version 1.13) to remove any remaining
adapter sequences, filtering reads shorter than 20 bp after trimming to ensure good
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mappability. The trimmed reads were aligned to the GRCm38 reference genome
using STAR46 (version 2.5.3a). QC statistics from Fastqc47 (version 0.11.5) and the
above-mentioned tools were collected and summarized using Multiqc48 (version
1.1). Gene expression counts were generated by featureCounts49 (version 1.5.2)
using gene definitions from Ensembl GRCm38 version 89. Normalized expression
values were obtained by correcting for differences in sequencing depth between
samples using DESeq’s median-of-ratios approach and then log-transforming the
normalized counts50. Differentially expressed genes were identified using DIDS28
(version 0.10.1), using a threshold of p < 0.05 for statistical significance. Variants in
RTKs and genes involved in downstream FGFR signaling were called using Vardict51
(version 2017.04.18) and annotated using Ensembl VEP52 (version 90.7). The entire
analysis pipeline (including the alignment, expression estimation and variant calling)
was implemented using Snakemake53 and is freely available on GitHub*.
Amplification of SB transposon insertions Transposon insertions were amplified
following a previously described tagmentation-based DNA sequencing protocol24.
Briefly, recombinant Tn5 transposase was prepared as previously described by Picelli
et al.54, and diluted in glycerol buffer to a final concentration of 3.7 µmol. The
Tn5-adapter complex was prepared by incubating 30 minutes at 37 ◦C equimolar
amounts of Tn5 and separately annealed adapters pairs Tn5ME-A+ 3’dT5P-oligo
and Tn5ME-B+3’dT5P-oligo as previously described by David L. Stern24. Each
tagmentation reaction was prepared by combining 2 µl of genomic DNA (100 ng in
total), 4 µl of 5x TAPS-PEG buffer54, 1 µl of Tn5-adapters complex and 13 µl water
and incubated for 10 minutes at 55 ◦C. Tn5 was stripped off from DNA by adding
4 µl of 0.2 % SDS and incubating the reaction 5 min at 55 ◦C. The enrichment PCR
was performed by combining 3 µl of tagmented DNA, 1 µl of enrichment primer at
1 µmol, 6 µl water and 10 µl Phusion Flash 2x mix (cat. #F548L, Thermo Scientific,
Waltham, MA USA). PCR1 was performed by combining 5 µl of enrichment PCR
reaction, 8 µl water, 1 µl of P5-indexed primer and 1 µl of transposon-specific primer
SB-PCR1 and 10 µl Phusion Flash 2x mix. PCR2 was performed by combining 2 µl
of PCR1 reaction, 8 µl water, 1 µl of P7-indexed primer + 1 µl FC2 primer and 10 µl
Phusion Flash 2x mix. Equal amounts of PCR2 products were pooled and run on an
agarose gel. Fragments above 600 basepairs were excised from the gel, purified on
Qiagen columns and eluted in water. The pool of tagmented DNA was sequenced
with 150 base paired-end reads on a MiSeq 300 using the micro kit v2 reagents









3’dT5P-oligo: CTGTCTCTTATACACATCTGAC (must be 5’ phosphorylated and 3’ OH blocked






























Enrichment PCR (2-step): 98 ◦C 30 s; 45 cycles of (98 ◦C 8 s, 72 ◦C 35 s)
PCR1: 98 ◦C 30 s; 15-18 cycles of (98 ◦C 8 s, 63 ◦C 5 s, 72 ◦C 30 s)
PCR2: 98 ◦C 30 s; 15-18 cycles of (98 ◦C 8 s, 63 ◦C 5 s, 72 ◦C 30 s)
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Insertion site analysis Insertion sites were identified using the taqmap pipeline in
PyIM† (version 0.3.0). Briefly, this analysis pipeline first trimmed the TaqMap paired-
end reads using Cutadapt45 (version 1.12) to remove any matepairs not containing
the transposon and to remove any Nextera transposase sequences. The remaining
mate pairs were aligned to the mm10 reference genome using Bowtie255 (version
2.3.0). After the alignment, redundant sequences mapping to the same genomic
location and belonging to the same tumor were collapsed into a single insertion. To
avoid issues with slight variations in the alignment, insertions from the same sample
that occurred within 10 bp of each other were collapsed into a single insertion.
Insertions were assigned to genes using the rule-based mapping approach56 with
the ‘SB’ preset and gene definitions from Ensembl GRCm38 89. Support scores were
calculated as the number of unique mate pairs supporting a given insertion. Relative
support scores (used as a proxy for clonality) were calculated by normalizing support
scores to the highest support score of the corresponding sample.
Genes associated with de novo resistance were identified by selecting genes that
did not have any insertions in untreated tumors (vehicle-treated tumors and the
donor tumor) and had insertions in at least two AZD4547-resistant samples. The
de novo candidate genes were then ranked by their frequency of occurrence. Genes
associated with intrinsic resistance were selected by performing a Welch’s t-test
between the clonality scores of insertions in the AZD4547-resistant tumors and the
vehicle treated tumors, as well as determining the difference between the means of
both groups (to ensure a minimum effect size). Candidate genes were selected by
filtering for genes with a difference in means > 0.1 and a t-test p value < 0.25, after
which the candidates were ranked by their mean differences.
Validation of the endogenous Fgfr2-Tbc1d1 fusion The Fgfr2-Tbc1d1 fusion was
detected in WESB-Fgfr2 cells as previously described26. WESB cells were used as
negative control. The following primer sequences were used:
Fgfr2 FW: 5’-TGGCCAGGGATATCAACAAC-3’
Tbc1d1 RV: 5’-CCAGGCTGTGAGAAGGATTT-3’
Met qPCR copy number analysis DNA was isolated from AZD4547-resistant tumors
and wild-type FVB spleen as a control. The qPCR was performed on a Quantstudio 6
flex Real-Time PCR system (Applied Biosystems) using low ROX SYBR green (Bioline)
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Ctnnb1 FW: 5’-TCAGGGCAGGTGAAACTGTA-3’
Ctnnb1 RV: 5’-GACTCCCAGCACACTGAACTTA-3’
The relative copy number levels of Met and Ctnnb1 were quantified using a five-point
standard curve. The Met relative copy number was normalized to the Ctnnb1 relative
copy number for each sample and subsequently normalized to the normalized
relative abundance of wild-type FVB spleen.
Statistical analysis The effect of AZD4547 treatment on tumor growth of WESB-
Fgfr2-EV and WESB-Fgfr2-ABCG2 established tumors was tested using mixed linear
models. Prior to this analysis, the tumor size measurements were scaled so that each
tumor’s size at the first time point was equal to 1. Inspection of the individual tumor
growth curves suggested an approximately linear increase in tumor size over time.
The exact growth rate, i.e. the slope of the growth curve, showed some inter-tumor
variability. Therefore, we modeled growth rate using a fixed effect population-level
slope β, a random effect tumor-level slope bi to account for inter-tumor variability,
and a fixed effect term γ for the interaction of time and treatment to model the
effect of treatment on tumor growth. Additional inter-tumor variability is allowed
by random intercepts ai, which complement the fixed effect intercept α. This leads
to the following model formulation for the size of tumor i as a function of time and
treatment:
Tumor sizei = α+ ai + (β + bi) ∗ time + γ ∗ time ∗ treatmenti
The significance of the treatment effect was established using an ANOVA comparing
the models with and without the interaction term γ.
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6.6.2 Supplementary Figures
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Fig. S6.1. Validation of the Fgfr2-Tbc1d1 gene fusion and the effects of AZD4547
treatment on viability and downstream FGFR signaling in WESB cells.
(A) Schematic overview of the Fgfr2-Tbc1d1 gene fusion showing the genomic
and amino acid sequences of Fgfr2 (red) and Tbc1d1 (black). (B) Validation
of the Fgfr2-Tbc1d1 fusion using targeted PCR on cDNA of WESB-Fgfr2 tumor-
derived cells. WESB cells and MQ (= Milli-Q) were used as negative controls.
(C) The viability of WESB and WESB-Fgfr2 cells after 72 hours of AZD4547
treatment. Data are mean ± s.d. of three independent experiments in which the
cells were seeded in triplicate. (D) Schematic representation of the treatment
schedules with AZD4547 in tumor-bearing mice. (E) Immunoblot showing
the effect of a single vehicle/AZD4547 treatment on total and phosphorylated
AKT and ERK1/2 in established WESB-Fgfr2 tumors. β-actin was used as a
loading control. (F and G) Representative images (F) and quantification (G) of
immunohistochemical detection of cleaved Caspase-3 in tumors after a single
vehicle (n = 5) or AZD4547 treatment (n = 3 for each indicated time point
after administration of AZD4547). Scale bar, 50 µm.
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Fig. S6.2. Tumor growth kinetics of established tumors during treatment and causes
of death observed under the different treatment schedules. (A) Tumor
growth kinetics of vehicle (blue) and four different AZD4547-treated (red)
tumors. The black arrows indicate the start of a treatment cycle of 24 days.
(B) Tumor growth kinetics of WESB-Fgfr2 cells injected into the mammary
gland of wild-type syngeneic recipient female mice under continuous treatment
with vehicle (blue) or AZD4547 (red). (C) Kaplan-Meier curve showing the
overall survival of tumor-bearing mice upon continuous dosing with vehicle
(blue) or AZD4547 (red). p value was calculated using a Mantel–Cox test. (D)
Comparison of the causes of death observed in the different treatment schedules.
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Fig. S6.3. Differential gene expression analysis of multiple RTK family members and
the status of MET in vehicle-treated, AZD4547-sensitive and resistant tu-
mors. (A) Differential gene expression analysis of all FGFR-, EGFR-, IGF-related
family members and Kit in AZD4547-sensitive (n = 15) and resistant (n = 27)
tumors using DIDS. (B) Quantitative PCR (qPCR) of Met copy number variation
(CNV) in AZD4547-resistant tumors with high (n = 2) or low (n = 10) MET
expression. Met CNV is normalized to Ctnnb1 (control). (C) Representative
images of MET immunohistochemical stainings of WESB-Fgfr2 tumors after a
single vehicle- or AZD4547-treatment. Scale bar, 25 µm.
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Fig. S6.4. Overview of insertions in genes across donor, vehicle-treated and
AZD4547-resistant tumors. (A) Overview of insertions in genes across donor
(two technical replicates), vehicle-treated (n = 15) and AZD4547-resistant
(n = 27) tumors. Relative support scores of insertions (depicted in blue) were
calculated by counting the number of mate pairs supporting the insertion and
normalizing these support scores to the highest score of the corresponding
sample. (B) Overview of insertions in genes that were mutated in two or more
AZD4547-resistant (n = 27) tumors but were not mutated in any of the donor
or vehicle tumors. The relative support of the insertions within each sample is
depicted in blue.
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Fig. S6.5. Immunohistochemical stainings of ABCG2 in correlation to mRNA expres-
sion in AZD4547-resistant tumors, boxplots of genes that show intrinsic
resistance to AZD4547 and efficacy of Rasa1 gene editing in WESB-Fgfr2
cells. (A) Representative immunohistochemical stainings of ABCG2 in the
WESB-Fgfr2 donor tumor and an AZD4547-resistant tumor. Scale bar, 50 µm.
(B) Correlation plot of mRNA and protein expression of ABCG2 in AZD4547-
resistant tumors (n = 27) with and without insertions in Abcg2. (C) Immunohis-
tochemical stainings of ABCG2 in the three AZD4547-resistant tumors with the
highest Abcg2 mRNA expression as depicted in (B). Scale bar, 1 mm. (D) Boxplot
showing the relative support scores for genes that show enriched support in
AZD4547-resistant compared to vehicle-treated tumors (differential support
score > 0.1 and p < 0.25, t-test). (E-G) Representative spectrum of insertions
and deletions (indels) for each sgRNA targeting Rasa1 in WESB-Fgfr2 cells as
quantified using the TIDE algorithm.
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6.6.3 Supplementary Tables (available online)
Tab. S6.1. Overview of the sequenced tumor samples, including sample IDs, treat-
ment information and the type of transplanted material.
Tab. S6.2. Mutations (SNVs) identified for RTKs and genes involved in the MAPK-
ERK signaling pathway in the donor, vehicle- and AZD4547-treated tu-
mors.
Tab. S6.3. Overview of insertions identified in the donor, vehicle- and AZD4547-
treated tumors.
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7.1 Summary
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered
the clinic for the treatment of homologous recombination (HR)-deficient cancers.
Despite the success of this approach, drug resistance is a clinical hurdle, and we
poorly understand how cancer cells escape the deadly effects of PARPi without
restoring the HR pathway. By combining genetic screens with multi-omics analysis
of matched PARPi-sensitive and -resistant Brca2-mutated mouse mammary tumors,
we identified loss of PAR glycohydrolase (PARG) as a major resistance mechanism.
We also found the presence of PARG-negative clones in a subset of human serous
ovarian and triple-negative breast cancers. PARG depletion restores PAR formation
and partially rescues PARP1 signaling. Importantly, PARG inactivation exposes
vulnerabilities that can be exploited therapeutically.
7.2 Significance
To explore defects in the DNA damage response in cancer therapy, exciting opportu-
nities have been achieved using the ‘synthetic lethal’ approach. A successful example
is the development of PARP inhibitors to kill cancer cells that are defective in HR;
e.g., due to lack of function of BRCA1 or BRCA2. Thus, there is a real opportunity to
cure patients with HR-deficient cancers if we overcome the hurdle of drug resistance.
At present, it is largely unknown how tumor cells escape PARP inhibition without
restoring BRCA2-mediated HR. Here, we show that loss of PARG governs PARPi resis-
tance in HR-deficient tumors by restoring PARP1 signaling. Importantly, inactivation
of PARG results in vulnerabilities that can be exploited to combat resistance.
7.3 Introduction
Defects in the DNA damage response (DDR) result in genomic instability and are
implicated in many types of cancer1. DDR alterations are responsible for the ac-
cumulation of mutations that result in tumorigenesis, and they can be specifically
exploited for targeted cancer therapy. A prime example of such a tailored approach
is the application of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) in the
treatment of tumors defective in homology-directed DNA repair due to BRCA1 or
BRCA2 inactivation2,3. PARP1, a founding member of the PARP family, is a nuclear
protein functioning in various cellular processes, including chromatin remodeling
and DNA damage repair4. Upon DNA damage, PARP1 is rapidly recruited to DNA
nicks where it induces the synthesis of protein-conjugated polymers of ADP-ribose
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(poly(ADP-ribose) [PAR]). PARP1 itself is a prime target of PARylation and the result-
ing PAR chains serve as a platform for the recruitment of downstream repair factors.
PARylation is a transient and reversible modification, as it is counteracted by the
activity of PAR glycohydrolase (PARG), which degrades PAR5. Inhibition of PARP1
leads to the accumulation of unresolved single-strand breaks (SSBs)6. Moreover,
several PARPi trap PARP1 onto chromatin7,8, resulting in the collapse of replication
forks (RF) that hit trapped PARP1. This leads to DNA double-strand breaks (DSBs)
and cells depend on BRCA1/2-mediated repair to resolve these DSBs in an error-free
way. Hence, PARP1 inhibition causes synthetic lethality in tumors with defects in
homologous recombination (HR)2,3. Indeed, this lethality was also observed in
mouse models for BRCA1/2-mutated breast cancer9,10 as well as in patients with
BRCA1/2 mutations who developed breast or ovarian cancer11–13. On the basis of
these positive clinical results, three different PARPi were recently approved as a
monotherapy for the treatment of BRCA1/2-mutated ovarian cancers14.
Drug resistance often follows the introduction of therapeutics in the clinic, and
unfortunately PARPi are no exception11,12. Using cell lines and mouse models,
several mechanisms of PARPi resistance have been identified, including upregulation
of the P-glycoprotein (P-gp; also known as ABCB1) drug efflux transporter9,10 and
restoration of HR activity (reviewed by Annunziato et al.15). While the clinical
significance of P-gp-driven resistance remains controversial, HR restoration has been
observed in human tumors that re-established BRCA1/2 function16,17. Nevertheless,
secondary BRCA1/2 mutations explain only some of the cases of PARPi resistance18.
The requirement of BRCA1 for HR activity can be bypassed by the loss of the 53BP1-
RIF1-REV7 pathway, as shown by various studies15. In contrast, there is no evidence
that HR can be rescued in the absence of BRCA2, suggesting that BRCA2-deficient
tumors employ distinct, HR-independent pathways to overcome PARPi toxicity.
Little is known thus far about HR-independent resistance to PARPi. Loss of the
drug target PARP1 has been described as a mechanism of resistance in HR-proficient
cells19, but this cannot explain resistance in the PARPi target group, since PARP1
loss causes synthetic lethality of BRCA1/2-mutated cells2,3. In this study, we set out




7.4.1 Functional genetic screens identify loss of PARG as a
PARPi resistance factor
To identify HR-independent mechanisms of PARPi resistance, we carried out func-
tional genetic screens in two types of in vitro cultures that we derived from
Brca2-/-;p53-/- mouse mammary tumors from K14cre;p53F/F;Brca2F/F (KB2P) mice:
two-dimensional (2D) tumor cell lines (KB2P1.21, KB2P3.4) and three-dimensional
(3D) cancer organoids (ORG-KB2P26S.1)9,20,21. In these cells we introduced a li-
brary of 1,976 short hairpin RNA (shRNA) constructs targeting 391 DDR-related
genes (on average five shRNAs/gene)22. The cells were then selected for 3 weeks
with the PARPi olaparib or AZD2461 (Figure 7.1A) at a concentration lethal to the
parental cells (data not shown). Sequencing of PARPi-surviving populations revealed
a reproducible enrichment of multiple hairpins targeting PARG. The strong effect
of PARG depletion is reflected by the overall top score of Parg among all positively
selected genes, as determined by the MAGeCK (Model-based Analysis of Genome-
wide CRISPR-Cas9 Knockout) algorithm23 (Figure 7.1B-C; Table S7.1). We applied
the same screening approach to a cell line isolated from BRCA-proficient mouse
mammary tumors from K14cre;p53F/F (KP) mice9 and also identified Parg among
the top outliers. In fact, Parg was the only common hit in both BRCA-deficient and
-proficient screens (Figure 7.1D-E). In contrast, shRNAs targeting PARP1 were only
enriched in the BRCA-proficient KP3.33 cells (Figure 7.1C-E), providing functional
evidence that PARP1 loss confers PARPi resistance in BRCA-proficient cells, presum-
ably by preventing PARP1 trapping, but not in BRCA2-deficient cells that depend on
PARP1 for survival.
7.4.2 PARG is frequently lost in PARPi-Resistant KB2P
mouse mammary tumors
Although high-throughput genetic screens are powerful tools for the identification
of gene candidates, in vitro conditions do not fully recapitulate the complexity of
drug response observed in real tumors. We therefore generated a panel of KB2P
mouse mammary tumors that had acquired PARPi resistance in vivo. For this purpose,
21 individual spontaneous KB2P carcinomas were orthotopically transplanted into
multiple syngeneic mice to allow differential treatment of the original donor tumor.
Upon outgrowth, the tumors were either treated with vehicle control or with the
PARPi AZD2461 (Figure 7.2A). As expected, KB2P tumors were initially highly
sensitive to PARPi treatment but eventually developed drug resistance (Figure 7.2B-
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Fig. 7.1. Functional shRNA-based screens in BRCA2-deficient and -proficient cells
identify PARG as PARPi resistance factor. (A) Outline of the functional shRNA
screen. (B) Log ratio (fold change) versus abundance (mean of norm counts)
plot representing the screening outcome in KB2P1.21 cells treated with AZD2461.
(C-D) Distribution of the one-sided p value (gene enrichment) for all 391 genes
targeted by the shRNA-based library in KB2P1.21 cells (C) and KP3.33 (D) cells
upon PARPi treatment. (E) Comparison of the screening outcome between in-
dicated cell lines; dotted grid line indicates p value = 0.05. All p values were
generated per gene with MAGeCK software; each screen was performed and
analyzed in triplicate. See also Table S7.1.
C). The observed resistance cannot be explained by BRCA2 restoration, which is
prevented by the irreversible intragenic deletion in Brca2, nor by upregulation of P-gp
(Figure S7.1A), because of the low affinity of AZD4261 to this transporter24,25.
Our extensive in vivo studies yielded a unique collection of matched PARPi-naive
(n = 21) and PARPi-resistant tumors (n = 34; for some of the donors more than
one resistant tumor was generated). We have recently shown that the resistance
phenotype is stable upon transplantation into allografts21,26. We now used this
collection of tumors to identify genetic factors contributing to PARPi resistance.
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Fig. 7.2. PARG is frequently lost in KB2P Tumors that acquired PARPi resistance in
vivo. (A) Generation of matched PARPi-naive and -resistant KB2P tumors. (B)
Treatment response of individual KB2P tumor treated with either vehicle or
AZD2461, orally for 28 consecutive days. Treatment was resumed when the
tumors reached a size of 100% (initial volume at the start of the treatment)
and the treatment cycles were repeated until acquired resistance (black arrows
mark the beginning of repeated cycles). Graph shows relative tumor volume as a
function of time. (C) Kaplan-Meier curve showing overall survival of mice bearing
KB2P tumors treated with either vehicle or AZD2461. Log rank (Mantel-Cox) p
value is indicated. (D) Flowchart illustrating the steps of multi-omics approach
used for the discovery of resistance factors in a panel of KB2P tumors. (E) Venn
diagram showing overlap of potential gene candidates identified within indicated
datasets.
DNA copy number variation (CNV) sequencing (CNV-seq) data for all tumors and
carried out an integrative analysis of naive versus resistant samples (Figure 7.2D-
E). First, we identified differentially expressed genes using the DIDS (detection of
imbalanced differential signal) algorithm (cutoff p < 0.05), which is specifically
designed for the detection of subgroup markers in heterogeneous populations27. In
parallel, we selected acquired copy number events, present only in resistant, but
not in naive, samples. Since KB2P tumors exhibit high levels of genomic instability
and accumulate many genetic alterations, we decided to focus on DDR-related
genes, as their contribution to the PARPi response is most plausible. We generated
a list of approximately 1,800 genes that have been implicated in DDR processes
(Table S7.2) and combined it with the significant hits from the DIDS and CNV
analyses. The 82 genes that survived these selection criteria were ranked based
on their recurrence or correlation between expression and CNV data. To integrate
these rankings, we used three different aggregation statistics: mean aggregation,
Stuart aggregation, and robust rank aggregation (RRA)28. Consistent with our
in vitro screens, all three algorithms placed Parg at the top of the list of gene
candidates (Table S7.3). Parg also ranked among the top outliers in a non-curated,
























































































































































Fig. 7.2. Continued. (F) Overview of genomic alterations in Parg acquired by a panel
of 34 KB2P PARPi-resistant tumors (KB2Px-Ry: x, original donor identification
[ID] number; y, ID of individual resistant tumors derived from the same donor
tumor). (G) Correlation between Parg expression and copy number estimation
for the whole panel of KB2P tumors. Spearman correlation coefficient (ρ), p
value, and expression threshold generated by DIDS algorithm (gray line) are
indicated. (H) Representative images of PARG IHC staining in KB2P tumors; scale
bar, 100 µm. (I) ELISA-based PARG activity assay in tumor organoids (N, naive;
R, resistant); **p < 0.01, ****p < 0.0001 (two-tailed t-test); experiment repeated
three times, data presented as mean ± SD of replicates. (J) Western blot analysis
of PAR in tumor-derived organoids; data representative of two independent
experiments. (K) Enrichment analysis of the secondary genetic screen in KB2P
cells: comparison of the p values for all genes targeted, shown for the cell lines
indicated; one-sided p value was determined by the MAGeCK algorithm; the
screen was performed in triplicate. See also Figure S7.1 and Tables S7.1 to S7.4.
genome-wide comparison (Table S7.3). In our panel of 34 PARPi-resistant tumors,
we observed decreased expression of Parg in 17 tumors, and acquired copy number
loss of the Parg locus in 22 tumors (11 deletions, 11 heterozygous loss events), with
a substantial overlap between both datasets (Figure 7.2F-G and S1B). The difference
in PARG levels between PARPi-naive and -resistant tumors was also confirmed by
immunohistochemistry (IHC) (Figure 7.2H). Blinded semi-quantitative analysis of
the PARG staining revealed a significant difference between resistant versus naive
samples (p < 0.015, Mann-Whitney U test). This was further validated using an
ELISA assay in which we monitored the loss of biotinylated PAR from immobilized
histones and thereby directly measured the relative activity of endogenous PARG in
3D cancer organoids derived from PARG-deficient PARPi-resistant tumors and PARPi-
sensitive controls (Figure 7.2I). As expected, PARPi-resistant organoids showed
reduced ability to degrade synthetic PAR (Figure 7.2I) and overall exhibited elevated
levels of endogenous PAR (Figure 7.2J).
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To investigate the contribution of the other candidate genes to PARPi resistance,
we performed a secondary genetic loss-of-function screen using an shRNA library
targeting the identified candidates and 32 non-essential genes as internal controls
(Table S7.4). Parg was again identified as a top outlier by the enrichment analysis in
both KB2P cell lines (Figure 7.2K and Table S7.1), suggesting that loss of PARG is
one of the strongest mechanisms involved in PARPi resistance in our model.
To test whether PARPi-induced loss of PARG is specific to KB2P tumors, we also stud-
ied genetic alterations in Parg in our previously described collection of PARPi-naive
and -resistant BRCA1-deficient mammary tumors from K14cre;Brca1F/F;Trp53F/F
(KB1P) mice24. Also in this cohort, combined RNA-seq and CNV-seq analysis identi-
fied several PARPi-resistant tumors with significantly lower expression and acquired
copy number loss of Parg (Figure S7.1C). Taken together, our in vivo data confirm
and extend the results from the in vitro screens and suggest that PARG depletion
alleviates PARPi toxicity.
7.4.3 PARG downregulation causes PARPi resistance in
vitro
To validate the role of PARG depletion in PARPi resistance, we introduced two indi-
vidual shRNAs against PARG (PARG sh1, PARG sh4) in KB2P1.21 and KB2P3.4 cells,
resulting in substantial decrease of Parg mRNA levels (Figure 7.3A and Figure S7.2A)
and reduced PARG activity (Figure 7.3B and Figure S7.2B) Consistently, genetic de-
pletion of PARG in KB2P cells led to the accumulation of PAR under genotoxic stress
induced by the alkylating agent methyl methanesulfonate (MMS) (Figure S7.2C-D)
but did not affect Parp1 expression levels (Figure S7.2E).
The shRNA-mediated loss of PARG resulted in increased resistance to the PARPi
olaparib and AZD2461 in long-term clonogenic survival assays. This effect was
observed in cell lines derived from both KB2P and KB1P tumor models, in which
PARPi-induced loss of PARG was observed in vivo (Figure 7.3C and Figure S7.3A-
C). To exclude off-target effects of the shRNAs, we also targeted the Parg locus in
KB2P cells using CRISPR-Cas9 technology (Figure 7.3D and Figure S7.3D-F). In
contrast to the control cells, Parg-targeted cells formed many resistant colonies
after 14 days of PARPi selection. This effect was specific to Parg inactivation, as
shown by the TIDE (Tracking of Indels by Decomposition) analysis29. In the initial
tumor cell population, roughly half of the alleles carried frameshift mutations,
and vehicle (DMSO) treatment did not significantly affect allele composition. In
contrast, PARPi selection resulted in a substantial increase in frameshift disruptions
(> 90%), showing that the surviving populations are predominantly PARG deficient
(Figure 7.3D and Figure S7.3D-F, Table S7.5).
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We obtained further evidence for the role of PARG in PARPi resistance with a re-
cently developed small-molecule PARG inhibitor (PARGi) PDDX-004 (PDD00017272),
which is very active against mouse PARG30. In line with this, PDDX-004 caused a
dose-dependent accumulation of nuclear PAR upon MMS-induced DNA damage in
our cell lines (Figure S7.3G-H). Consistent with our genetic inhibition experiments,
the clonogenic assays in KB2P cells also showed an increased PARPi survival upon
chemical inhibition of PARG (Figure 7.3E and Figure S7.3I). Moreover, the viability
of cells exposed to the combination of PARPi and PARGi correlated with the degree
of PARG inhibition, while PDDX-004 alone did not affect cell growth nor PARPi re-
sponse of PARG-depleted cells (Figure S7.3J). In conclusion, both genetic depletion
or inactivation and chemical inhibition of PARG lead to PARPi resistance in KB2P
cells, confirming an important functional role of PARG in mediating PARPi toxicity.
7.4.4 PARG-Depleted KB2P cells remain HR deficient and
fail to protect stalled RFs
The sequence of events that leads to PARPi-induced death of BRCA-deficient cells
includes the inhibition of PAR synthesis, RF collapse, and the formation of DSBs.
In collaboration with the Nussenzweig laboratory, we have recently shown that
RF protection can explain resistance in some of the PARPi-resistant KB2P mouse
mammary tumors26. Given its role in PAR catabolism, however, we did not expect
that the tumors in which we find PARG downregulation would correct the BRCA2
defect by protecting stalled RFs or by BRCA2-independent restoration of HR. To
verify this, we measured the capacity of PARG-depleted KB2P cells to protect stalled
RF using DNA fiber assays. In both control and PARG knockdown KB2P cells,
the induction of replication stress resulted in the degradation of nascent tracts
(Figure S7.4A), suggesting that PARG loss cannot bypass the requirement of BRCA2
for RF stabilization. Next, we assessed the capability of KB2P cells to form RAD51
ionizing radiation (IR)-induced foci (IRIF), a hallmark of HR activity. As expected,
we did not detect any RAD51 IRIF in KB2P cells, regardless of Parg expression levels
(Figure S7.4B-C). Moreover, the same phenotype was observed in PARPi-resistant
KB2P tumors, in which PARG loss was confirmed at the genomic level (Figure S7.4D).
These results demonstrate that loss of PARG causes PARPi resistance independently of
BRCA2 and that resistance cannot be explained by HR restoration or RF protection.
7.4.5 PARG downregulation rescues PARylation upon PARPi
treatment
To assess how PARG depletion causes PARPi resistance, we studied its effect on
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Fig. 7.3. Downregulation of PARG causes PARPi resistance in BRCA2-deficient cells
in vitro. (A) RT-qPCR analysis of Parg expression levels in KB2P1.21 cell lines ex-
pressing indicated shRNAs; data represent mean ± SD of triplicate; ∗∗∗∗p < 0.001
(two-tailed t-test). (B) PAR ELISA assay in KB2P1.21 cells; data shown as mean
± SD of triplicate, ∗∗∗∗p < 0.001 (two-tailed t-test). (C) Representative images
(left) and quantification (right) of long-term clonogenic assay with KB2P1.21
cells, treated with PARPi or untreated (DMSO). Data represent mean ± SD of
three independent repeats; ∗∗p < 0.01 (t-test). (D) Representative images (left)
and TIDE quantification (right) of long-term clonogenic assay with KB2P1.21
cells expressing indicated guide RNAs. (E) Representative images (left) and
quantification (right) of long-term clonogenic assay with KB2P1.21 cells treated
as indicated. The experiment was repeated three times; data plotted as mean ±
SD; p < 0.001 (ANOVA). See also Figures S7.2 and S7.3 and Table S7.5.
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barrier to PAR formation, but this is reinforced by the PARG-mediated degradation
of PAR, which acts in the same direction as PARPi. We therefore hypothesized that
PARPi alone does not fully inhibit PARP and loss of PARG would allow sufficient
PAR formation in the presence of PARPi. We tested this hypothesis by measuring
endogenous PAR levels in KB2P cells treated with the PARPi olaparib and the PARGi
PDDX-004 (Figure 7.4A). To discriminate between stabilization of pre-existing and
de novo synthesized PAR, we first incubated cells with the inhibitors for 1 hr and then
exposed them to MMS to stimulate PARP activity. As predicted, olaparib treatment
resulted in a strong reduction of PAR, already at nanomolar doses. Inhibition of
PARG overcame this reduction and MMS treatment led to a further increase of the
PAR signal. These data indicate that olaparib concentrations sufficient to kill cells
do not completely inhibit PARP and that this residual activity is sufficient for PAR
formation if PARG activity is suppressed. We conclude that endogenous PARG activity
is required for efficient inhibition of PAR signaling by PARPi.
We next investigated the effect of different PARP family members on the PARPi
response using BRCA-proficient KP3.33 cells, in which CRISPR/Cas9-mediated dis-
ruption of Parp1, Parp2, or Parp3 was well tolerated (Figure S7.5A-C). While the
PARPi sensitivity of Parp2-/- and Parp3-/- KP3.33 cells was significantly reduced by
PARG inhibition, Parp1 depletion resulted in partial resistance to olaparib (con-
sistent with Murai et al.7), which was not further increased by PARGi treatment
(Figure S7.5D). This result is in line with a previous report suggesting that up to 90%
of cellular PAR results from PARP1 activity31 and shows that PARG-related PARPi
resistance is mainly mediated by PARP1 signaling.
7.4.6 PARG inhibition reduces PARP1-DNA complexes
induced by PARPi treatment
It has been shown that PARP1 association to and dissociation from chromatin is
regulated by its PARylation5 and persistent PARP1-DNA complexes, induced by
clinical PARPi, are toxic to cells7. We therefore measured the levels of chromatin-
bound PARP1 in KB2P cells using a previously described trapping assay7. Immunoblot
analysis showed olaparib-dependent accumulation of PARP1 in chromatin fractions,
which was reduced in cells expressing PARG-targeting shRNAs (Figure 7.4B). Since
stable PARG depletion could result in a substantial proportion of free PARP1 in
a PARylated state, and therefore lower its affinity to chromatin, we repeated the
PARP1 trapping assay in cells exposed to short-time inhibition of PARG (Figure 7.4C).
Although single treatment with PDDX-004 led to decreased levels of chromatin-
associated PARP1, simultaneous inhibition of both PARP1 and PARG resulted in
PARP1 trapping comparable with olaparib alone. We further corroborated this finding
by measuring PARP1 association kinetics at multi-photon laser-induced DNA damage
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Fig. 7.4. PARG deficiency partially rescues PARylation and reduces the accumulation
of PARP1-DNA complexes. (A) ELISA PAR assay in KB2P3.4 cells treated as
indicated; data shown as mean ± SD of triplicate (t-test). ∗∗∗∗p < 0.0001. (B-C)
Immunoblot analysis of PARP1 in chromatin-bound fractions upon genetic (B)
and chemical (C) inhibition of PARG in KB2P cells, treated as indicated; data
representative for two independent experiments. (D-E) Representative images
(left) and quantification (right) of analysis of PARP1 recruitment kinetics to
multiphoton tracks in U2OS PARP1-GFP cells, following the indicated treatments.
∗∗p < 0.01; n.s., not significant; two-tailed t-test, data represented as mean ±
SEM. Scale bar, 10 µm. (F) Representative images of stained wells (right) and
quantification (left) of clonogenic assay in KB2P cells expressing the indicated
shRNAs and treated with talazoparib; data presented as mean ± SD of two
experiments; ∗∗∗p < 0.001 (two-tailed t-test). See also Figures S7.4 and S7.5.
sites in U2OS cells (Figure 7.4D-E). Cells were exposed to 0.5 µmol olaparib and/or
the PARGi PDDX-001/PDD00017273 (1 µmol)30, which alone efficiently inhibited
downstream signaling of both proteins (Figure S7.5E-G). We utilized U2OS GFP-
PARP1 cells and quantified the intensities of laser tracks; first, 1 min post irradiation,
when under native conditions PARP1 accumulation reached a maximum, and then
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15 min after the induction of DNA damage, when most of the chromatin had evicted
PARP1 (Figure S7.5H). Both olaparib treatment alone and the combination with
PDDX-001 resulted in a slight increase of chromatin-associated PARP1 15 min post
irradiation (Figure 7.4D-E). Of note, even more PARP1 protein remained associated
with damaged sites in cells exposed to PARGi only. The results, however, do not show
any evidence that PARG depletion results in more rapid release of chromatin-bound
PARP1. Taken together, our data demonstrate that PARG depletion does not enhance
PARP1 dissociation from chromatin and therefore do not diminish PARP1 trapping
per se. Instead, long-term suppression of PARG prevents excessive PARP1 binding
and thus reduces PARPi-dependent accumulation of toxic PARP1-DNA complexes.
The relevance of this finding is further supported by the fact that PARG depletion
also results in resistance to talazoparib, a highly potent PARP1-DNA trapping agent
in clinical use (Figure 7.4F).
7.4.7 PARG depletion alleviates PARPi-induced DNA
damage
Following different forms of genotoxic stress, PARP1 activity has recently been
shown to limit the rate of RF progression32,33 by modulating fork reversal and
preventing premature restart of reversed RF34,35. Deregulated RF remodeling by
PARP inhibition was suggested to contribute to the synthetic lethality of PARPi with
HR defects, as it increases the fraction of SSBs being processed into DSBs36. As
shown in Figure 7.5A, we confirmed that PARPi treatment increases the DNA fiber
track length upon induction of DNA damage with MMS or camptothecin (CPT).
When PARG was also inhibited in these cells, the track length was significantly
decreased, suggesting that PARG depletion prevents unrestrained RF progression in
PARPi-treated cells (Figure 7.5A and Figure 7.5I). Concomitantly, PARG inhibition
reduced the formation of DSBs in these cells, as measured by the neutral comet assay
(Figure 7.5B and Figure 7.5J).
Given the role of PARP1 in DNA repair, we next investigated the PARP1-mediated
recruitment of the scaffold protein XRCC1, a PAR interactor and a key player in the
BER pathway37. To study the effects of PARPi and/or PARGi on XRCC1 recruitment,
we applied the laser micro-irradiation assay to U2OS cells expressing a XRCC1-GFP
fusion protein. We found that under drug-free conditions XRCC1-GFP was rapidly
recruited to sites of laser-induced DNA damage (Figure 7.5C-D). Although a large
proportion of the protein dissociated from chromatin within 60 min after irradiation,
a substantial amount of XRCC1-GFP remained at the sites of DNA damage. In line
with previous reports38, treatment of cells with the PARPi olaparib abrogated XRCC1-
GFP localization to laser-inflicted damage (Figure 7.5C-D). Inhibition of PARG
mitigated the inhibitory effect of olaparib, however, and partially rescued XRCC1-GFP
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recruitment. Importantly, the quantitative analysis of laser track intensities showed
that the restored accumulation, although delayed in time, resulted in a similar
retention of XRCC1-GFP at 1 hr post irradiation as in the control cells (Figure 7.5C-
D). This effect of PARGi is specific to PARylation-induced recruitment of DNA repair
factors, as we did not observe any differences in chromatin association of MDC1,
which localizes to damaged sites in a PARP1-independent manner39 (Figure 7.5E).
As a readout for PARP1 function in the repair of SSBs, we employed the previously
described Fast Micro-method SSB assay40. Consistent with our previous results,
Parg-depleted cells exhibited increased capacity to repair SSBs in comparison with
control cells (Figure 7.5F). This was further confirmed in cells exposed to olaparib for
24 hr. Immunofluorescence (IF) analysis of γH2AX foci revealed that Parg-depleted
cells accumulated less olaparib-induced DNA damage (Figure 7.5G).
Based on our data, we conclude that PARG suppression not only reduces PARP1-DNA
complexes but also rescues controlled RF progression and promotes the recruitment
of DNA repair enzymes to sites of damage in cells exposed to PARPi. Altogether, this
leads to a reduction of PARPi-induced DNA damage and improved PARPi survival
(Figure 7.5H).
7.4.8 PARG deficiency overcomes PARPi toxicity in human
cancer cells
The anticancer efficacy of PARPi has been validated in various clinical studies and
several PARPi were recently approved for the treatment of patients with BRCA1/2-
mutated tumors. We therefore determined whether PARG depletion confers PARPi
resistance in human cancer cells by introducing two individual shRNAs targeting
PARG in BRCA1-mutated SUM149PT (carrying a protein-truncating 2288delT muta-
tion) and BRCA2-deficient DLD-1 cells. Both shRNAs efficiently suppressed PARG
expression and conferred resistance to olaparib (Figure 7.6A-B and Figure S7.6A).
Similarly, chemical inhibition of PARG led to increased survival of both cell lines in
the presence of PARPi (Figure S7.6B-C).
Given that PARG loss causes PARPi resistance independently of BRCA1/2, we ex-
tended our analysis to a recently published pharmacogenomics dataset of 1,001
human cancer cell lines41. In particular, we assessed the correlation between half
maximal inhibitory concentration (IC50) values of PARPi and gene expression levels
of 1,800 DDR-related factors (Table S7.2). Gene expression data and drug responses
to four different PARPi (olaparib, veliparib, rucaparib, and talazoparib) were avail-
able for 935 cell lines from this panel. Statistical analysis revealed a significant
negative association between PARG expression and IC50 values of all four PARPi
(Figure 7.6C and Figure S7.6D); i.e., higher PARG RNA levels were related to in-
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10 min 15 min 60 min
Fig. 7.5. PARG inhibition alleviates PARPi-induced DNA damage. (A) RF progression
assay in U2OS cells exposed to indicated treatments; the experiment was repeated
twice; box extends from 25th to 75th percentile, with a middle line representing
the median and whiskers drawn down to the 10th percentile and up to the 90th;
Mann-Whitney U test; ∗∗∗∗p < 0.001; n.s., not significant. (B) Neutral comet
assay in U2OS cells treated as in (A); Mann-Whitney U test, ∗∗∗∗p < 0.001, data
shown as mean ± SD of a replicate; the experiment was repeated twice. (C-
D) Representative images (C) and quantification (D) of time course analysis
of GFP-XRCC1 recruitment in U2OS cells treated as indicated; ∗∗p < 0.01; n.s.,
not significant; two-tailed unpaired t-test; data represent mean ± SEM of three
independent experiments. Scale bar, 10 µm. (E) Quantification of MDC1 tracks
following immunostaining; statistical analysis as in (D).
creased sensitivity to these drugs. A similar negative association was also observed
for PARP1 gene expression, in agreement with the concept that more PARP1 leads to
more trapping of PARP1 onto DNA in the presence of PARPi.
7.4.9 PARG depletion occurs in triple-negative breast and
serous ovarian cancer
To further assess the clinical relevance of PARG depletion, we measured the hetero-
geneity of PARG expression in large sections of 56 treatment-naive triple-negative
human breast cancer (TNBC) biopsies from high-risk women eligible for PARPi
treatment42,43. IHC analysis (Figure 7.6D-E, and Figure S7.6E) revealed that, al-
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Fig. 7.5. Continued. (F) SSB assay in KB2P cells, treated as indicated; SSF, strand scission
factor; data representative for two independent experiments, shown as mean ±
SD of a replicate; two-tailed unpaired t-test; ∗p < 0.05; n.s., not significant. (G)
IF analysis of gH2AX foci in KB2P cells, treated as indicated; statistical analysis
as in (F); ∗∗p < 0.01; ∗p < 0.05. (H) Proposed model: in the presence of PARPi,
PARP1 maintains residual activity but is counteracted by PARG. Loss of PARG
leads to stabilization of PAR chains and, consequently, limits accumulation of
toxic PARP-DNA complexes, prevents unrestrained RF progression, and promotes
the recruitment of the downstream factors. Together, this results in reduced
PARPi-induced DNA damage and improves PARPi survival. See also Figure S7.5.
areas were found in a sizable proportion of samples. Specifically, 29 (52%) and
14 (25%) out of 56 cancers showed lack of PARG in areas corresponding to >10%
and >20% of the tumor, respectively. Moreover, PARG-negative cells were positive
for PAR, and in some of the samples PAR levels were substantially increased (Fig-
ure 7.6E). Of note, the variable degree of PAR could also reflect the degree of the
endogenous DNA damage among the cases, as PARP enzymes are activated by DNA
damage and these patients did not receive any genotoxic therapy. A similar PARG
expression spectrum was also found in a cohort of serous ovarian carcinomas44, a
cancer type that has been recently approved for PARPi treatment (Figure 7.6D and
Figure S7.6F). Taken together, our data show that PARG-depleted cells pre-exist in a
substantial proportion of clinically relevant tumors and could potentially be selected
by PARPi treatment.
7.4.10 PARG suppression results in acquired vulnerabilities
Molecular alterations that render cells resistant to targeted therapies may also cause
synthetic dependencies, which in turn could be exploited therapeutically to prevent
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Fig. 7.6. PARG depletion in human cancer cells leads to PARPi resistance but results
in acquired vulnerabilities. (A-B) Long-term clonogenic assay with SUM149PT
(A) and DLD-1 BRCA2-deficient (B) cells expressing indicated shRNAs and treated
with olaparib; PARG expression levels were determined by qRT-PCR (left; mean
± SD of triplicate, ∗∗∗∗p < 0.001, t-test) and representative images of stained
wells (right) are shown. (C) Correlation between IC50 of olaparib or rucaparib
and expression of DDR genes; PARP1 and PARG are highlighted; p values were
determined using the relation between estimated coefficient and Student’s t
distribution. (D) Summary of IHC analysis of PARG expression in TNBCs and
ovarian serous carcinomas. (E) Representative images of PARG and PAR IHC of
TNBC biopsies. Scale bar, 100 µm.
cancer progression. Perturbed PAR signaling due to downregulation of PARG has
been shown to increase the sensitivity to IR45. Susceptibility to IR is also one of
the characteristics of cells with dysfunctional BRCA1/2 proteins46. We therefore
set out to determine whether PARG suppression could potentiate IR toxicity in
BRCA1/2-mutated cells. For this purpose, SUM149PT cells with shRNA-mediated
PARG knockdown were exposed to a range of IR doses and grown for another 7
days. Viability measures showed increased IR sensitivity of PARG-depleted cells in
comparison with control populations (Figure 7.6F). Furthermore, dose-dependent
sensitization was also achieved by chemical inhibition of PARG in SUM149PT, BRCA2-
deficient DLD-1, and KB2P cells (Figure 7.6G-H and Figure S7.6G). Notably, we also













































































Fig. 7.6. Continued. (F-G) Response to irradiation of SUM149PT cells, expressing in-
dicated shRNAs (F) or treated with PARGi (G). (H) Response to irradiation of
DLD-1 BRCA2-deficient cells treated as indicated. (I) Response to temozolomide
of SUM149PT cells treated as indicated. In (F)-(I) data are presented as mean ±
SD of triplicates. See also Figure S7.6.
mide (Figure 7.6I and Figure S7.6H), an alkylating agent that has been previously
shown to potentiate PARPi toxicity8.
Together, these results illustrate that PARG suppression, although detrimental to
PARPi efficacy, provides therapeutic vulnerabilities that could be used to target
resistant tumors.
7.5 Discussion
In this study, we show that loss of PARG is a frequent mechanism of PARPi resistance
in Brca2-mutated tumors. Our data provide an HR-independent mechanism for
tumor cells to adapt their DDR in order to escape the lethal effects of PARPi. PARG is
the main enzyme responsible for degrading nuclear PAR and thereby counteracting
the action of PARP enzymes. Hence, PARG works in the same direction as PARPi and
prevents PAR accumulation. Our finding that PARG depletion causes PARPi resistance
in BRCA2-deficient tumors highlights an important aspect of PARPi therapy: the
endogenous PARG activity in tumor cells is crucial for therapy success. As PARPi
do not fully block PARP activity, loss of PARG activity is sufficient to restore PAR
formation and rescue downstream signaling of PARP1.
Within the PARP family of ADP-ribosyltransferases, three family members, PARP1,
PARP2, and PARP3, have been linked to DNA repair47. PARP1 is the most abundant
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of these and has been shown to play critical roles in the DDR48. Upon DNA damage,
RFs are rapidly and globally reversed and are maintained in the reversed state
by transient PARP-mediated inhibitory ADP ribosylation of RECQ1 helicase, the
enzymatic activity specifically required for restart of reversed RFs34,35. In this way,
PARP1 represents a molecular switch to control transient fork reversal and RF restart
following genotoxic stress35. Neelsen and Lopes36 therefore suggested that the
synthetic lethality of PARPi with HR defects results not only from an increasing load
of SSBs but also from a greater fraction of these lesions being processed into DSBs.
Whereas untreated cells gain extra time to repair DNA damage through RF reversal,
PARPi-treated cells are unable to reverse forks efficiently, resulting in increased
DNA breakage and the requirement for HR-mediated DSB repair. In line with this
hypothesis, we found that PARG depletion restores controlled RF progression in
the presence of PARPi and reduces subsequent DNA damage. We also found a
mechanism at the level of DNA repair that contributes to PARPi resistance induced by
PARG loss: PAR stabilization rescues the recruitment of the downstream scaffolding
protein XRCC1, which is known to bring together a variety of components required
for efficient SSB repair49.
In BRCA-proficient tumors, the toxic effect of PARPi can also be counteracted by the
loss of the drug target PARP1. Consistent with the data of Pettitt et al.19, we found a
significant enrichment for Parp1-targeting shRNAs in our drug resistance screen in
BRCA-proficient mammary tumor cells. In accordance with the concept of synthetic
lethality, however, this hit did not show up when we screened BRCA2-deficient
mammary tumor cells. Previous screens in BRCA1-deficient tumor cells also did not
yield Parp1 as a hit22.
Most PARPi do not only block the catalytic activity of PARP1 but also induce toxic
PARP1-DNA complexes. Our study shows that PARG inhibition reduces the amount
of trapped PARP1 by preventing its excessive binding. This result underscores the
delicate balance between enzymatic PARP1 activity and its toxicity when trapped on
DNA.
Since PAR synthesis and degradation go hand in hand in orchestrating the DNA
damage response, the use of PARGi has been put forward for the treatment of
cancers with DDR defects50, and the possibility of a synthetic lethal interaction
between PARG and BRCA proteins has received considerable interest. However,
several studies that addressed this question have produced contradictory results51–53,
which suggest that sensitivity to PARG depletion may depend on the cell line and the
degree of PARG suppression. Importantly, Koh et al.54 showed that PARG depletion,
although embryonically lethal, can be tolerated in embryonic stem cells cultured
in the presence of PARPi. In our cell lines, both genetic depletion and chemical
inhibition of PARG were well tolerated and did not affect cellular viability. Moreover,
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homozygous loss of Parg was acquired in vivo in a substantial fraction of KB2P
tumors.
PARG-negative clones were also found in a sizable proportion of human high-risk
TNBCs or serous ovarian cancers, potential target groups for PARPi treatment due to
the increased presence of HR-deficient cancers. Taken together, these data suggest
that PARG-negative clones can be specifically selected by PARPi treatment and
modulate therapy response.
While the clinical application of PARPi has initially focused on BRCA1/2-mutated
tumors, the therapeutic scope of these drugs is now being extended to other molec-
ular defects (reviewed by Lord and Ashworth55). Since PARG acts directly at PAR
structures and independently of the HR pathway, stabilization of PARylation via
PARG suppression might represent a generic mechanism of PARPi resistance, relevant
for a broad spectrum of cancers. Although this is bad news for the clinical use of
PARPi, loss of PARG can also be exploited as a potential Achilles’ heel for cancer treat-
ment, as it confers sensitivity to IR45. Our data indeed show that PARG suppression
potentiates the toxicity of radiation therapy in BRCA-deficient cells. Additionally, we
show that PARG inhibition synergizes with temozolomide, a chemotherapeutic agent
that is now being evaluated in the clinic in combination with PARPi56.
Our research has yielded a collection of matched PARPi-naive and -resistant Brca2-/-
mouse mammary tumors, which can be further utilized in a search for additional
resistance mechanisms. Although PARG loss was observed in the majority of the
PARPi-resistant KB2P tumors, it cannot explain resistance in all cases. Three other
candidates, Rps6ka6, Socs4, and Pbrm1, were validated as additional significant hits
in a secondary screen. Since all three of these genes are connected to chromatin,
it will be interesting to understand the underlying mechanism of how they affect
PARPi response in a follow-up study.
In collaboration with the Durocher and Lord laboratories, we have recently identified
that PARPi resistance can also be caused by loss of the Shieldin (SHLD) complex,
which acts downstream of 53BP1 in blocking DNA end resection (Noordermeer et
al., manuscript submitted). Importantly, loss of the SHLD complex is not a generic
PARPi resistance mechanism, since it causes PARPi resistance specifically in BRCA1-
but not in BRCA2-deficient cells. In contrast, loss of PARG explains PARPi resistance
in both BRCA1- and BRCA2-mutated tumors, as it operates independently of the HR
pathway.
Taken together, our findings suggest that PARG is an important mediator of PARPi
response. The presence of PARG-negative cells in treatment-naive tumors from the
clinically relevant groups of high-risk women suggests that PARG loss should be
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assessed as a potential cause of clinical PARPi resistance. In this case, measurement
of PARG activity should further improve clinical decision making for patients with
tumors that lack homology-directed DNA repair.
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7.6 STAR Methods
7.6.1 Contact for reagent and resource sharing
Further information and requests for resources and reagents should be di-
rected to and will be fulfilled by the Lead Contact, Sven Rottenberg
(sven.rottenberg@vetsuisse.unibe.ch).
7.6.2 Experimental model and subject details
Mice All animal experiments were approved by the Animal Ethics Committee of
The Netherlands Cancer Institute (Amsterdam, the Netherlands) and performed
in accordance with the Dutch Act on Animal Experimentation (November 2014).
Brca2-/-;p53-/- mammary tumors were generated in K14cre;Brca2F/F;p53F/F(KB2P) fe-
male mice, described previously20. Tumor implantation experiments were performed
in syngeneic, wild-type F1 (first filial generation) FVB:129/Ola females, at the age
of 6 weeks. Parental FVB (FVB/NRj) and 129/Ola animals were purchased from
Janvier Labs and Harlan Olac, respectively, and crossed at the NKI Animal Facility.
Animals were assigned randomly to the treatment groups and the treatments were
supported by animal technicians who were blinded regarding the hypothesis of the
treatment outcome. Collection of Brca1-/-;p53-/- (KB1P) PARPi-naive and -resistant
mouse mammary tumors was described before24.
Human samples of triple-negative breast and serous ovarian cancer Retrospective
Triple Negative Breast Cancer (TNBCs) biopsies from 56 clinical high-risk patients
(high-risk definition according to the Danish Breast Cooperative Group; www.dbcg.dk
accessed 22.10.2009) that underwent mastectomy between 2003 and 2015 were
selected and classified as being triple negative according to the criteria set in the
ASCO/CAP guidelines (ER < 1%, PR < 1%, HER2 0, 1+ or 2+ but FISH/ CISH
negative). The patients presented a unifocal tumor of an estimated size of more
than 20 mm. None of the patients had previous surgery to the breast and did not
receive preoperative treatment42,43. This study was conducted in compliance with
the Helsinki II Declaration and written informed consent was obtained from all
participants and approved by the Copenhagen and Frederiksberg regional division of
the Danish National Committee on Biomedical Research Ethics (KF 01-069/03).
Paraffin-embedded material from the cohort of ovarian tumors was collected at the
Department of Pathology, University Hospital, Las Palmas, Gran Canaria, Spain, from
surgical operations performed in the period 1995-2005. For the purpose of the
present study, only samples from serous ovarian carcinoma (the type approved for
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treatment by PARP inhibitors) were used from a larger cohort that was reported
previously44, and included also other histological types of ovarian tumors. The use
of long-term stored tissue samples in this study was in accordance with the Spanish
codes of conduct (Ley de Investigación Biomédica) and was approved by the review
board of the participating institution. Patients were informed that samples may be
used for research purposes under the premise of anonymity.
Cell lines All 2D cell lines used in this study were described previously:
KB2P1.21, KB2P3.4, KP3.339, KB1P-G324, U2OS (RRID:CVCL_0042), SUM149PT
(RRID:CVCL_3422), DLD-1 BRCA2(-/-) (Horizon Discovery, #HD 105-007;
RRID:CVCL_HD57), HEK293FT (RRID:CVCL_6911).
For these lines, cell growth media were supplemented with 10 % (v/v) fetal calf
serum (FCS, Sigma) and 50 units ml−1 penicillin-streptomycin (Gibco). KB2P1.21,
KB2P3.4, KB1P-G3 and KP3.33 cells were grown in Dulbecco’s Modified Eagle
Medium/Nutrient Mixture F-12 (DMEM/F12; Gibco) containing 5 µg ml−1 Insulin
(Sigma, #I0516), 5 ng ml−1 cholera toxin (Sigma, #C8052) and 5 ng ml−1 murine
epidermal growth-factor (EGF, Sigma, #E4127). U2OS cells were cultured in DMEM
(Gibco) media supplemented with GlutaMAX (Gibco, #35050-061). SUM149PT
cells were grown in RPMI1640 (Gibco) media, similarly to DLD-1 BRCA2(-/-) cells
for which growth media was additionally enriched with 2 mmol L-glutamine and
25 mmol sodium bicarbonate. HEK293FT cells were cultured in Iscove’s Modified
Dulbecco’s Media (IMDM, Gibco) supplemented with 2 mmol glutamine.
Tissue culture was carried out under standard conditions (37 ◦C, 5 % CO2), except
for KB2P1.21, KB2P3.4 and KB1P-G3 cells which were cultured under low oxygen
conditions (3 % O2). All cell lines used in this study are of female origin, except
for DLD-1 BRCA2(-/-) cells (male). Testing for mycoplasma contamination was
performed on a regular basis.
Tumor-derived organoids KB2P26S.1, KB2P17 and KB2P12 tumor organoids were
derived from a mammary KB2P PARPi-naive tumor (female donor), genotyped and
cultured as described before21. Briefly, cultures were embedded in Culturex Re-
duced Growth Factor Basement Membrane Extract Type 2 (BME, Trevigen; 40 µl
BME:growth media 1:1 drop in a single well of 24-well plate) and grown in Advanced
DMEM/F12 (AdDMEM/F12, Gibco) supplemented with 1 mol HEPES (Sigma), Gluta-
MAX (Gibco) 50 units ml−1 penicillin-streptomycin (Gibco), B27 (Gibco), 125 mmol
N-acetyl-L-cysteine (Sigma), 50 ng ml−1 murine epidermal growth factor (Sigma),
10 % (v/v) Rspo1-conditioned medium (kindly provided by Calvin Kuo, Stanford
University) and 10 % (v/v) Noggin-conditioned medium57. Organoids were cultured
7.6 STAR Methods 251
under standard conditions (37 ◦C, 5 % CO2) and regularly tested for mycoplasma
contamination.
7.6.3 Method details
Generation of PARPi-naive and -resistant KB2P tumors
Spontaneous mammary tumors that arouse in KB2P (K14cre;Brca2F/F;p53F/F) mice
were harvested, genotyped, sampled and cryopreserved (DMEM/F12, 10 % (v/v)
FCS, antibiotics-free), as described before20,58. To obtain matched PARPi-naive
and -resistant tumor panel, 21 individual spontaneous tumors were engrafted as
tumor fragments in the fourth right mammary fat pad of wild-type FVB:129/Ola
female mice (F1). Each tumor donor was transplanted into multiple animals (at
least 2, 1 for control and 1 for PARPi treatment) and starting from 2 weeks after
transplantation, tumor size was monitored at least three times a week. Tumor
volume was determined by caliper measurements (length and width in mm) and
calculated by using the following formula: 0.5 ∗ length ∗width2. All treatments were
initiated when tumors reached approx. 200 mm (100 % relative tumor volume). For
PARPi treatment, AZD2461 powder was reconstituted in deionized water solution
of 0.5 % (w/v) hydroxypropyl methylcellulose (HPMC) to a final concentration
of 10 mg ml−1. AZD2461 solution (100 mg kg−1) or vehicle control (0.5 % HPMC)
were administered to animals orally for 28 consecutive days. Upon tumor relapse to
100 % relative tumor volume, the treatment was repeated and continued for another
28 days, until acquired resistance. Animals were sacrificed when the tumors reached
a volume of 1.500 mm. Tumor sampling included cryopreserved tumor pieces, fresh
frozen tissue and formalin-fixed material (4 % (w/v) formaldehyde in PBS).
Generation of deep sequencing data and analysis
RNA preparation, sequencing and DIDS analysis Fresh-frozen tumor tissues were
subjected to high-speed shaking in 2 ml microcentrifuge tubes containing 1 ml of
TRIsure reagent (Bioline) and stainless steel beads (TissueLyser LT, Qiagen; 10 min,
50 Hz, room temperature). Homogenized lysates were further processed for RNA
isolation following TRIsure manufacturer’s protocol. Quality and quantity of the total
RNA was assessed by the 2100 Bioanalyzer using a Nano chip (Agilent, Santa Clara,
CA). Total RNA samples having RIN > 8 were subjected to library generation.
Strand-specific libraries were generated using the TruSeq Stranded mRNA sample
preparation kit (Illumina Inc., San Diego, RS122-2101/2) according to the manufac-
turer’s instructions (Illumina, Part #15031047 Rev. E). Briefly, polyadenylated RNA
from intact total RNA was purified using oligo-dT beads. Following purification, the
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RNA was fragmented, random primed and reverse transcribed using SuperScript II
Reverse Transcriptase (Invitrogen, part #18064-014) with the addition of Actino-
mycin D. Second strand synthesis was performed using Polymerase I and RNaseH
with replacement of dTTP for dUTP. The generated cDNA fragments were 30 end
adenylated and ligated to Illumina Paired-end sequencing adapters and subsequently
amplified by 12 cycles of PCR. The libraries were analyzed on a 2100 Bioanalyzer
using a 7500 chip (Agilent, Santa Clara, CA), diluted and pooled equimolar into a
10 nmol sequencing stock solution.
Illumina TruSeq mRNA libraries were sequenced with 50 base single reads on a
HiSeq2000 using V3 chemistry (Illumina Inc., San Diego). The resulting reads
were trimmed using Cutadapt59 (version 1.12) to remove any remaining adapter
sequences, filtering reads shorter than 30 bp after trimming to ensure good map-
pability. The trimmed reads were aligned to the GRCm38 reference genome using
STAR60 (version 2.5.2b). QC statistics from Fastqc61 (version 0.11.5) and the above-
mentioned tools were collected and summarized using Multiqc62. Gene expression
counts were generated by featureCounts63 (version 1.5.0-post3) using gene def-
initions from Ensembl GRCm38 version 76. Normalized expression values were
obtained by correcting for differences in sequencing depth between samples using
DESeq’s median-of-ratios approach64 and then log-transforming the normalized
counts. Differentially expressed genes were identified using DIDS27, using a thresh-
old of p < 0.05 for statistical significance. Given that generated p value was a very
conservative estimate of the true p value and was only used as a heuristic filter, we
did not apply multiple testing correction (in accordance with de Ronde et al.27).
Selected genes were subsequently ranked by the number of (resistant) samples that
were considered to show differential expression according to the DIDS criteria.
Genomic DNA extraction and CNV sequencing Genomic DNA was isolated from
fresh-frozen tumor material using standard phenol:chloroform extraction. CNV-
Seq was performed using double stranded DNA (dsDNA), quantified with the
QubitO®dsDNA HS Assay Kit (Invitrogen, #Q32851). To obtain fragment sizes
of 160-180 bp, 2 µg of dsDNA were fragmented by Covaris shearing and purified
using 1.8X Agencourt AMPure XP PCR Purfication beads according to manufac-
turer’s protocol (Beckman Coulter, #A63881). Next, sheared DNA was quantified
and qualified on a BioAnalyzer system with the DNA7500 assay kit (Agilent Tech-
nologies, #5067-1506). Library preparation for Illumina sequencing was carried
out with 1 µg of DNA and KAPA HTP Library Preparation Kit (KAPA Biosystems,
#KK8234). To obtain a sufficient yield for sequencing, 4-6 PCR cycles were per-
formed during the library enrichment step. Prepared libraries were cleaned up using
1X AMPure XP beads and analyzed on a BioAnalyzer system using the DNA7500
chips to determine the molarity. Finally, up to 11 uniquely indexed samples were
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pooled (equimolar pooling) in a final concentration of 10 nmol and sequenced on
an Illlumina HiSeq2500 machine in one lane of a single read 65 bp run, according
to manufacturer’s instructions. The resulting reads were trimmed using Cutadapt59
(version 1.12) to ensure a uniform length of 50 bp reads between samples and to
remove any remaining adapter sequences. After trimming, reads shorter than 30
bp were removed to ensure good mappability. The trimmed reads were aligned to
the GRCm38 reference genome using BWA aln65 (version 0.7.15). The resulting
alignmentswere sorted and marked for duplicates using Picard tools (version 2.5.0).
QC statistics from Fastqc61, Samtools66 (version 1.2) and the above-mentioned tools
were collected and summarized using Multiqc62. Copy number calls were generated
using the QDNAseq67 and QDNAseq.mm10 packages from Bioconductor (versions
1.8.0 and 1.4.0, respectively). To select for acquired copy number events, the CNV
calls from resistant samples were filtered to remove any calls that were already
present in the matched sensitive sample. After this filtering, genes were ranked by
their recurrence (number of resistant samples with a loss/gain), dropping any genes
that were only aberrant in a single sample.
DDR-related gene list The DDR gene set was generated based on the gene list
from Thanos Halazonetis (Geneve University) and the NCBI search (terms: ‘DNA
repair’, ‘DNA damage response’, ‘DNA replication’, ‘telomere-associated genes’). See
Table S7.2 for the complete gene list.
Final ranking of gene candidates To obtain a final ranking for the 82 candidate
genes, we first created two new DIDS and CNV rankings, containing only these
candidate genes. Next, to prioritize candidates with a strong correlation between
copy number and expression, we created a third ranking by calculating the spearman
correlation between the copy number values and expression of each gene across all
samples, and sorting the genes by decreasing correlation. These three ranks were
aggregated using the R package RobustRankAggreg68 (version 1.1) to obtain the
final rankings using three different aggregation methods (Stuart, RRA and Mean).
To handle ties within the DIDS/CNV ranks (due to the discrete nature of these ranks),
genes with the same values in these ranks were assigned the same rank value before
the aggregation.
Immunohistochemistry analysis
PARG IHC analysis in KB2P tumor panel Immunohistochemical staining was per-
formed on formalin-fixed paraffin embedded (FFPE) material of the KB2P tumor
panel. First, antigen retrieval was performed by cooking the samples in citrate buffer
6.0 pH (ScyTek Laboratories) for 15 min in pressure cooker (110 ◦C).
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Next, endogenous peroxidase activity was blocked by incubation a with methanol
solution of 3 % (v/v) H2O2 for 20 min. 10 % (v/v) milk solution in PBS was used as
a blocking buffer (30 min, room temperature) and PBS containing 1 % (w/v) bovine
serum albumin and 1.25 % (v/v) normal goat serum was used as antibody diluent.
Incubation with primary PARG antibody (Thermo Fisher Scientific; #PA5-14158;
diluted 1:100, final concentration 20 µg ml−1) was carried out overnight at 4 ◦C and
followed by 30 min incubation with secondary Goat-a-Rabbit-Bio antibody (DAKO,
#E0432; 1:1000) at room temperature. For detection, samples were exposed to
PBS solution containing DAB substrate (Sigma, #D5905) and 0.025 % (v/v) H2O2
(Sigma, #A31642) for 20 min and hematoxylin counterstaining. Semi-quantitative
(scoring: 1-low signal, 2-high signal) PARG expression analysis was carried out by a
pathologist who was blinded regarding the identity of the samples.
PARG/PAR analysis in TNBC and serous ovarian carcinoma cohorts Five-mm tis-
sue sections were cut from the formalin-fixed, paraffin-embedded tissue blocks and
mounted on Super Frost Plus slides (Menzel-Gläser, Braunschweig, Germany), baked
at 60 ◦C for 60 min, deparaffinized, and rehydrated through graded alcohol rinses.
Heat induced antigen retrieval was performed by immersing the slides in citrate pH
6.0 buffer and heating them in a 750 W microwave oven for 15 min followed by
immunohistochemistry staining with the primary antibodies as follows: anti-PARG
antibody from Thermo Scientific (PA5 14158; diluted 1:2000) and anti-PAR antibody
from GeneTex (10H, GTX75054, diluted 1:2500. The sections were incubated with
the primary antibodies overnight in a cold-room, followed by subsequent processing
by the indirect streptavidin-biotin-peroxidase method using the Vectastain Elite kit
(Vector Laboratories, Burlingame, CA, USA) and nickel-sulphate-based chromogen
enhancement detection as previously described69, without nuclear counterstaining.
For negative controls, sections were incubated with non-immune sera. The results
were evaluated by two experienced researchers, including a senior oncopathologist,
and the data expressed as percentage of positive tumor cells within each lesion.
Constructs, lentiviral transductions and genome editing
Constructs A collection of 1,976 lentiviral hairpins targeting 391 DDR-related
mouse genes (pLKO.1; DDR library) were derived from the Sigma Mission library
(TRCMm1.0) as described before22. Custom-made shRNA library (pLKO.1) targeting
82 candidate genes (identified by the multi-omics analysis of KB2P tumors) and 32
non-essential genes (552 shRNAs in total, on average 5 shRNAs/gene) was obtained
from the Sigma Mission collection (TRCMm1.0) (see also Table S7.4). Non-essential
genes were used as negative controls for the enrichment analysis, and were selected
based on the work of Hart and colleagues70 and RNA-Seq data from KB2P tumors
(non-expressed genes).
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Individual hairpin constructs used in the validation studies were selected from
the TRC library: mouse PARG - sh1: TRCN0000126559, sh4: TRCN0000126562;
human PARG - sh1: TRCN0000051303, sh2: TRCN0000051305) (see also Ta-
ble S7.6). For CRISPR/Cas9-based genome editing two different systems were
used: (1) for targeting Parg locus (Figure 7.3D and Figure S7.3D-F) the Cas9 ex-
pressing pGSC_Cas9_Neo vector (kind gift from Bastiaan Evers, NKI) was used
and individual gRNAs (see Table S7.6) were cloned into the iKRUNC-Puro system
described previously71; (2) for targeting Parp1, Parp2, Parp3 loci (Figure S7.5A-
D) lentiCRISPRv2 vector was used and individual gRNAs (see Table S7.6) were
cloned as described previously72. For laser micro-irradiation experiments, pEGFP-
C1-XRCC1 (gift from Simon Bekker-Jensen) and pEGFP-c3-PARP1 (gift from Valerie
Schreiber) vectors were used. pEGFP-N1-CHD2 vector has been described before73.
All constructs were verified by Sanger sequencing.
Lentiviral transductions Lentiviral stocks, pseudotyped with the VSV-G envelope,
were generated by transient transfection of HEK293FT cells, as described before74.
Lentiviral titers were determined using the qPCR Lentivirus Titration Kit (Applied
Biological Materials), following the manufacturer’s instructions. For all experiments
the amount of lentiviral supernatant used was calculated to achieve the MOI (multi-
plicity of infection) of 50, except for the transduction of the lentiviral library (genetic
screens) for which an MOI of 1.5 was used. To ensure efficient transduction, cells
were incubated with lentiviral supernatants overnight in the presence of polybrene
(8 µg ml−1). Antibiotic selection was initiated 24 hr post-transduction and was car-
ried out for 5 consecutive days. Tumor-derived organoids were transduced according
to a previously established protocol21.
Genome editing For CRISPR/Cas9-mediated genome editing with the iKRUNC sys-
tem, KB2P1.21 or KB2P3.4 cells were first transduced with the lentiviral pGS-Cas9
(Neo) construct (MOI 50) and grown under G418 selection (500 µg ml−1) for 5
days. Next, neomycin-selected cells were incubated with lentiviral supernatants of
iKRUNC-Puro vectors (gRNA-encoding constructs, MOI 50) and exposed to 3 µg ml−1
puromycin for 5 days. To induce gRNA expression, puromycin-surviving cells were
treated for another 5 days with 3 µg ml−1 doxycycline (Sigma). For CRISPR/Cas9-
mediated genome editing with lentiCRISPRv2 system, KP3.33 cells were transduced
with the lentiviral supernatant (MOI 50) and grown under Puromycin (3 µg ml−1)
selection for 5 days. To assess the modification rate, genomic DNA was extracted
(Puregene Core Kit A, Qiagen) and 100 µg was used as an input for the PCR am-
plification of the targeted sequence. PCR reaction was performed with Thermo
Scientific Phusion High-Fidelity PCR Master Mix (Thermo Scientific), according to
manufacturer’s instructions (3-step protocol: annealing - 60 ◦C for 5 s, extension
time 15 s) and using primers listed in Table S7.6. Resulting PCR products were
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purified using the MinElute PCR Purification Kit (Qiagen) and eluted in 50 µl of
water. Finally, 2 µl of purified DNA served as a template for the BigDye Terminator
v3.1 reaction (Thermo Fisher). BigDye PCR reactions were performed with the same
forward primers as in the preceding PCR reactions (no reverse primer used) and
according to the BigDye manufacturer’s protocol. Allele composition was deter-
mined with the TIDE analysis29 by comparing sequences from modified and parental
(non-transduced control) cells.
Functional genetic screens
The DDR shRNA library and the shRNA library targeting candidate genes (secondary
screen) were stably introduced into 2D lines (KP3.33, KB2P1.21, KB2P3.4) and
organoids (ORG-KB2P26S.1) by lentiviral transduction (MOI 1.5). After antibiotic
selection (puromycin, 3 µl ml−1, 5 days) cells were seeded for the clonogenic assay
with PARPi or pelleted for the genomic DNA isolation (day 0; control samples for
the enrichment analysis). The total number of cells used in a single screen was
calculated as following: library complexity ∗ coverage (1000x). Cells were seeded
at low confluency to avoid contact inhibition between single clones (2D cells -
30,000 cells per 10 cm dish; organoids - 50,000 cells/well, 24-well format) and in
the presence of PARPi (KB2P1.21/KB2P3.4: 200 nmol olaparib, 300 nmol AZD2461;
KP3.33: olaparib 10 µmol; ORG-KB2P26S.1: 25 nmol AZD2461). Cells were selected
with PARPi for 3 weeks, and media was refreshed at least twice per week. PARPi-
surviving clones were pooled and genomic DNA was extracted (QIAmp DNA Mini
Kit, Qiagen). shRNA sequences were retrieved by a two-step PCR amplification, as
described before22. To maintain screening coverage, the amount of genomic DNA
used as an input for the first PCR reaction was taken into account (6 µg of genomic
DNA per 106 genomes, 1 µg per PCR reaction). Resulting PCR products were purified
using MinElute PCR Purification Kit (Qiagen) and submitted for Illumina sequencing.
Sequence alignment and enrichment analysis (day 0 vs PARPi-treated population)
was carried out using MaGECK software23.
Long-term clonogenic assays
Long-term clonogenic assays were performed in 6-well (KB2P1.21, KB2P3.4, KB1P-
G3, KP3.33) or 12-well plates (SUM149PT, DLD-1 BRCA2(-/-)). Cells were seeded
at low density to avoid contact inhibition between the clones (KB2P1.21 - 3,000
cells/well, KB2P3.4 and KP3.33 - 2,000 cells/well, KB1P-G3 - 5,000 cells/well,
SUM149PT and DLD-1 BRCA2(-/-) - 3,000 cells/well) and cultured for 2 weeks,
except for control (DMSO-treated) KB2P1.21, KB2P3.4, KB1P-G3 and KP3.33 cells,
which were stopped after 7 days. Media was refreshed at least twice a week. For the
quantification, cells were incubated with Cell-Titer Blue (Promega) reagent and later
fixed with 2 % formaldehyde and stained with 0.1 % crystal violet. Clonogenic assays
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with cells with CRISPR/Cas9-based genome editing were quantified with TIDE, simi-
larly to a previously described method75. Drug treatments: cells were grown in the
continuous presence of temozolomide, PARPi (olaparib, talazoparib or AZD2461),
and/or PARGi (PDDX-004), at the indicated concentrations. All compounds were re-
constituted in DMSO (PARP/PARG inhibitors: 10 mmol, temozolomide: 5 mg ml−1).
For the ioninizing irradiation studies, cells received single irradiation doses 24 hr
after seeding. IR treatments were carried out using Gammacell 40 Extractor (Best
Theratronics Ltd.).
RT-qPCR
To determine gene expression levels, total RNA was extracted from cultured cells
using ISOLATE II RNA Mini Kit (Bioline) and used as a template to generate cDNA
with Tetro cDNA Synthesis Kit (Bioline; oligo (dT)18 mix). Quantitative RT-PCR
was performed using SensiMix SYBR Low-ROX Kit (Bioline; annealing temperature -
60 ◦C) in a Lightcycler 480 384-well plate (Roche), and analyzed using Lightcycler
480 Software v1.5 (Roche). Mouse Hrtp and human HPRT were used as house-
keeping genes (control). The primer sequences used in this study are listed in
Table S7.6.
PAR immunoblotting
Tumor-derived organoids or 2D cells were washed with PBS, trypsinized and then
lysed for 30 min in RIPA buffer supplemented with protease inhibitors (cOmplete
Mini EDTA-free, Roche) and 1 µmol PARG inhibitor ADP-HPD (Merck). The protein
concentration was determined using Pierce BCA Protein Assay Kit (Thermo Scien-
tific). SDS-Page was carried out with the Invitrogen NuPAGE SDS-PAGE Gel System
(Thermo Fisher; gel: 4 % to 12 % Bis-Tris, buffer: MOPS, input: 50 µg protein),
according to the manufacturer’s protocol. Next, proteins were electrophoretically
transferred to a nitrocellulose membrane (Biorad) and then the membrane was
blocked in 5 % (w/v) milk (PAR) solution in Tris-buffered saline Triton X-100 buffer
(TBS-T; 100 mmol Tris, 7.4 pH, 500 mmol NaCl, 0.1 % (v/v) Triton X-100). Mem-
branes were incubated overnight with primary antibodies in blocking buffer, at 4 ◦C.
Horseradish peroxidase (HRP)-conjugated secondary antibody incubation was per-
formed for 1 hr at room temperature in blocking buffer and signals were visualized
by ECL (Pierce ECL Western Blotting Substrate, Thermo Scientific). Primary antibod-
ies used in this study: mouse monoclonal anti-PAR (H10) (Millipore), 1:1000; rabbit
polyclonal anti-PARP1 (#9542, Cell Signaling), 1:1000; rabbit polyclonal anti-PARP3
(#ALX-210-541- R100, Enzo Life Sciences), 1:500; rabbit polyclonal anti-Histone H3
(#ab1791, Abcam), 1:5000; mouse monoclonal anti-GADPH (6C5) antibody (Santa
Cruz), 1:5000 dilution. Secondary antibody used in this study: rabbit polyclonal
anti-mouse immunoglobulins/HRP (Dako), diluted 1:5000.
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PARP1 trapping assay
The PARP1 trapping assay was adapted from Murai et al.7. In brief, 24 hr prior
the assay, KB2P cells were seeded on 10 cm dishes to achieve ~90 % confluency.
Drug treatments: (1) KB2P cells with genetic depletion of PARG (Figure 7.4B)
were treated with olaparib (0, 0.1 or 1 µmol) and 0.01 % MMS for 2 hr; (2) KB2P
cells with chemical inhibition of PARG (time-course experiment, Figure 7.4C) were
first pre-incubated with 0.5 µmol olaparib and/or1 µmol PDDX-004 for 1 hr, and
then exposed to the same treatments but in a presence of 0.01 % MMS for 30 min;
following incubation with MMS cells were further incubated with olaparib and/or
PDDX-004 for 0.5 or 2 hr, as shown on Figure 7.4C. After indicated treatments
cells were trypsinized and subsequently lysed to isolate chromatin-bound fractions.
Fractionation was performed with Subcellular Protein Fractionation Kit from Thermo
Scientific (#78840, Rockford, IL, USA), following the manufacturer’s instructions
and in the presence of 1 mM of PARGi ADP-HPD (#118415, Calbiochem) in the
lysis buffers. Immunoblotting was carried out as described in previous section
(Immunoblotting). Experiments were repeated three times.
PARG activity assay
Enzymatic activity of endogenous PARG was measured using HT Colorimetric PARG
Assay Kit (#4683-096-K, Trevigen), following the manufacturer’s instructions. Ex-
periments were repeated three times.
PAR ELISA assay
To measure endogenous PAR levels cells were seeded on 6-well plate 24 hr prior to
PARPi, PARGi or combined PARPi/PARGi treatment to achieve ~90 % confluency
at the day of the assay. Cells were treated with different doses of inhibitors for
2 hr, and additionally some of the samples were exposed to 0.01 % MMS for the
last 60 min. Cell lysis, protein isolation and PAR ELISA were carried out using HT
PARP In Vivo Pharmacodynamic Assay II kit (#4520-096-K, Trevigen), according to
the manufacturer’s protocol. Protein concentration was measured with Pierce BCA
Protein Assay kit (Thermo Scientific).
PAR immunofluorescence analysis
PAR levels were measured using the adapted immunofluorescent PAR cell assay
described before76. Briefly, cells were seeded on Corning 96-well special optics
plates (#CLS3720, Sigma) 24 hr prior the assay to achieve ~90 % confluency. Next,
cells were treated with a range of PARGi doses for 2 hr, and for the last 60 min
cells were additionally exposed to 0.01 % MMS. After incubation with drugs, plates
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were fixed with ice-cold 95 % (v/v) methanol/PBS (100 ml/well) for 15 min at
−20 ◦C. Plates were then washed twice with PBS and cells were permeabilized by
adding 100 µl per well of 0.1 % (v/v) Triton X-100 in PBS and incubating for 20
min at room temperature. Incubation with the primary mouse monoclonal anti-PAR
(H10) antibody (Millipore), diluted 1:4000 in PBS solution containing 5 % (v/v)
FBS and 0.05 % (v/v) Tween-20, was carried out overnight at 4 ◦C. After three
washes with PBS, cells were incubated for 1 hr (room temperature) with polyclonal
AlexaFluor488 goat anti-mouse immunoglobulins (1:1000) and Hoechst (1:5000;
Thermo Scientific) diluted in 5 % (v/v) FBS/0.1 % (v/v) Triton X-100 in PBS. PAR
immunofluorescent signal was detected with a Leica TCS SP8 confocal system (Leica
Microsystems), using a HC PL APO 40x/1.10 W objective. Total nuclear intensities
were measured per nuclei with ImageJ software. For each well, four different areas
(200 cells on average) were imaged and analyzed. Each experiment was repeated
three times.
RAD51/53BP1 IRIF analysis
Cultured cells Cells were seeded on Millicell EZ slides (#PEZGS0816, Millipore) 24
hr prior the assay to achieve ~90 % confluency. Cells were then irradiated using the
Gammacell 40 Extractor (Best Theratronics Ltd.) at the dose of 10 Gy and allowed
to recover for 4 hr. Next, cells were fixed with 4 % (w/v) solution of formaldehyde
in PBS for 30 min and permeabilized in 0.2 % (v/v) Triton X-100 in PBS++ (PBS
solution containing 1 mmol CaCl2 and 0.5 mmol MgCl2) for 20 min. To minimize the
background, cells were further incubated for 30 min in staining buffer (1 % (w/v)
BSA, 0.15 % (w/v) glycine and 0.1 % (v/v) Triton X-100 in PBS++). Staining buffer
was also used as a solvent for antibodies - primary antibodies: rabbit anti-RAD51 (gift
from Roland Kanaar, Erasmus MC, Rotterdam), diluted 1:5000, rabbit polyclonal
anti-53BP1 (Abcam), diluted 1:1000, secondary antibody - goat polyclonal anti-
rabbit, Alexa FluorO®658-conjugated, diluted 1:1000. Incubation with primary
and secondary antibodies was done for 2 hr and 1 hr, respectively. All incubations
were performed at room temperature. Samples were mounted with VECTASHIELD
Hard Set Mounting Media with DAPI (#H-1500; Vector Laboratories). Images
were captured with Leica SP5 (Leica Microsystems) confocal system and analyzed
using an in-house developed macro to automatically and objectively evaluate the
DNA damage-induced foci22. Fraction of positive cells was determined for each
sample using following criteria: RAD51 > 5 foci/nucleus, 53BP1 > 10 foci/nucleus.
Experiment was performed in triplicate (on average 100 cells/replicate). As a
positive control for RAD51 staining, BRCA-proficient KP3.33 cells were used.
In situ analysis of GEMM tumors Matched PARPi-naive and -resistant KB2P tumors,
and KP (K14cre;p53F/F) tumor (positive control) were re-transplanted into wild-type
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syngeneic mice. Upon tumor outgrowth to 500 mm tumors were locally irradiated
(dose: 15 Gy) using CT-guided high precision cone beam micro-irradiator (X-RAD
225Cx) or left untreated (control). Two hr post-irradiation tumors were isolated
and fixed in 4 % (w/v) solution of formaldehyde in PBS. FFPE material was then
used for immunofluorescent staining. First, samples were deparaffinized and antigen
retrieval was done by cooking samples in DAKO Target Retrieval Solution pH 9
(#S236784, DAKO) for 20 min in microwave at ~600 W. Next, samples were
permeabilized in 0.2 % (v/v) Triton X-100 in PBS for 20 min and further incubated
with DNase (1000 u ml−1; #04536282001, Roche) in humidified chamber for 1 hr
at 37 ◦C. Incubation with antibodies, mounting, imaging and analysis were carried
out as described for cultured cells. At least five different areas were imaged and
analyzed for each sample. All incubations were performed at room temperature,
unless otherwise stated.
Immunofluorescent staining of Olaparib-Induced γH2AX foci Cells were seeded on
Corning 96-well special optics plates (#CLS3720, Sigma) 24 hr prior the olaparib
treatment to achieve ~60 %. Next, cells were incubated with olaparib for the next
24 hr and subsequently fixed and stained following the same protocol as described
for RAD51/53BP1 IRIF assay (cultured cells). Primary antibody used in this assay:
Phospho-Histone H2A.X (Ser139) rabbit monoclonal antibody, Cell Signaling, #2577
(1:200 in staining buffer). Immunofluorescent signal was detected with a Leica
TCS SP8 confocal system (Leica Microsystems), using a HC PL APO 40x/1.10 W
objective. Foci were quantified using in-house developed macro to automatically
and objectively evaluate the DNA damage-induced foci22. For each condition, four
different areas (200 cells on average) were imaged and analyzed. Experiment was
performed in triplicate and repeated twice.
DNA fiber assay
Replication fork progression assay Fork progression was measured using an
adapted method described previously in Zellweger et al.35. Briefly, asynchronously
growing U2OS cells were first incubated with 0.5 µmol PARPi (olaparib or AZD2461)
for 1 hr and further treated with 0.5 µmol PARPi alone, or in combination with
1 µmol PDDX-001, for another 60 min. Next, cells were labeled with 30 µmol CIdU
(Sigma-Aldrich) for 30 min, washed twice with PBS, and labeled with 250 µmol IdU
in the presence of genotoxic agents - 50 µmol MMS or 25 nmol CPT for another 30
min. Following pulse labelling, cells were quickly trypsinized and resuspended in
PBS at 2.5 ∗ 105 cells per ml. Next, labeled cells were diluted 1:8 with unlabeled
cells, and 2.5 ml of cells were mixed with 7.5 ml of lysis buffer (200 mmol Tris-HCl,
7.5 pH, 50 mmol EDTA, and 0.5 % (w/v) SDS) on a glass slide. After 9 min, the
slides were tilted at 15-45, and the resulting DNA spreads were air dried, fixed in 3:1
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methanol/acetic acid, and refrigerated overnight. The DNA fibers were denatured
with 2.5 mol HCl for 1 hr, washed with PBS, and blocked with 2 % (w/v) BSA in
PBST (PBS and Tween 20) for 40 min. The newly replicated CldU and IdU tracks
were labeled (for 2.5 hr in the dark, at RT) with anti-BrdU antibodies recognizing
CldU (rat; Abcam) and IdU mouse (BD), respectively. After washing for 533 min in
0.2 % (v/v) PBS-T, the following secondary antibodies were used (1 hr incubation,
in the dark, at RT): anti-mouse Alexa Fluor 488 (Molecular Probes) and anti-rat
Cy3 (Jackson ImmunoResearch Laboratories, Inc.). After washing for 533 min in
PBS-T (0.2 % (v/v)), the slides were air dried completely, mounted with 20 µl per
slide Antifade gold (Invitrogen), and sealed to a coverslip by transparent nail polish.
Microscopy was performed with a fluorescence microscope (IX81; Olympus; objec-
tive lenses: LC Plan Fluor 603, 1.42 NA oil) and acquired with a charge-coupled
device camera (Orca AG; Hamamatsu Photonics). The images were processed with
CellR software (version 2.6; Olympus). On average 120 fibers were quantified per
condition; experiment was repeated twice.
Replication fork protection assay KB2P cells were seeded 24 hr prior the assay to
achieve ~75 % confluency. On the next day, cells were pulse-labeled with CldU
(25 µmol) for 20 min, washed with warm medium and pulse-labeled with IdU
(250 µmol) for another 20 min. Next, cells were incubated for 3 hr with 0.9 µmol
MMS to induce replication stress. After MMS incubation, cells were trypsinized,
washed and lysed on microscopy slides in lysis buffer (0.5 % (w/v) sodium dode-
cyl sulfate (SDS), 200 mmol Tris 7.4 pH, 50 mmol EDTA). DNA fibers were spread
by tilting the slide, air-dried and fixed in methanol/acetic acid (3:1) for 10 min.
Fixed DNA spreads were treated with 2.5 mol HCl for 75 min. Immunofluorescent
staining was performed as described in the previous section (RF progression assay).
Images were acquired on a Leica DM-6000RXA fluorescence microscope, with Leica
Application Suite software. CldU and IdU track lengths were measured using ImageJ
software. At least 100 IdU and CldU ratios per condition were analyzed.
Neutral comet assay Asynchronously growing U2OS cells were first incubated with
0.5 µmol olaparib for 1 hr and further treated with 0.5 µmol olaparib alone, or in
combination with 1 µmol PDDX-001, for another 60 min. Next, DNA damage was
induced by 30 min incubation with 25 nmol CPT in the presence of PARPi and/or
PARGi. Cells were then collected by trypsinization and resuspended in PBS at the
concentration of 106 cells per ml. 20 µl of cell suspension was then loaded onto
600 µl of 0.8 % (w/v) Low Melting Point (LMP) agarose (Lonza) in PBS, previously
equilibrated to 37 ◦C (for 60 min). Next, 60 µl of cells resuspended in LMP was
spread on the comet slide (CometAssay®Kit, Trevigen). Slides were incubated at
4 ◦C for 15 min to allow solidification of the cells-LMP mixture and further incubated
in a lysis buffer (CometAssayO®Lysis Solution, Trevigen) overnight at 4 ◦C. On the
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next day, slides were first incubated in electrophoresis buffer (300 mmol sodium
acetate, 100 mmol Tris, 8.3 pH) for 1 hr and then electrophoresis was performed
using the comet chamber at 21 Volt for 30 min, at 300 mA and 4 ◦C. Next, slides were
rinsed twice in water, placed in 70 % ethanol at 4 ◦C for 20 min and incubated at
37 ◦C until dry. Slides were than stained with SYBR®Gold (Thermo Fisher Scientific)
diluted at 1:30,000 in Tris-EDTA (10 mmol Tris-HCl 7.5 pH, 1 mmol EDTA) for 30
min in dark. Images were recorded on a Leica DM6 B upright digital research
microscope at 10x magnification. The images were analyzed using the Open Comet
plugin (http://www.cometbio.org/) for Fiji. At least 95 cells were analyzed per
sample and plotted using GraphPad PRISM 7.0c. The experiment was repeated
twice.
Fast micromethod DNA single-strand break assay The assay was performed as
described before40. Briefly, KB2P1.21 cells were seeded on Corning 96-well special
optics plates (#CLS3720, Sigma) 24 hr prior the assay (10,000 cells/well). On the
next day, cells were first treated with olaparib and 0.01% MMS for 30 min to induce
base damage. After that incubation plates were either processed (time point 0) or
further incubated with olaparib for 3 hr (time point 3 hr). Following incubation
with drugs, media was removed and cells were incubated for 1 hr in dark with 50
ml of 1 % (v/v) solution of PicoGreen (Thermofisher) in PBS. This incubation was
performed at 4 ◦C to avoid additional DNA repair. After 1 hr 250 µl of NaOH solution,
adjusted to a final pH of 12.45 with EDTA, was added to cells and the measurement
of the fluorescence signal (485 nm/538 nm) was immediately started using Tecan
Infinite 200 PRO (Tecan) plate reader. Measurements were taken every 60 s for 25
min. The data were analyzed as described before40. BCA protein measurements
were taken to assure equal amount of cells per condition. The experiment was
performed in triplicate and repeated twice.
Laser Micro-Irradiation Assays
PARP1-GFP: Multiphoton Laser Mico-Irradiation U2OS cells were transiently trans-
fected (using Lipofectamine 2000, Invitrogen; according to the manufacturer’s
protocol) with pEGFP-c3-PARP1 (kind gift from Valerie Schreiber) vector. Cells
grown on 18 mm coverslips were placed in a Chamlide CMB magnetic chamber
and the growth medium was replaced by CO2-independent Leibovitz’s L15 medium
supplemented with 10 % (v/v) FCS and penicillin-streptomycin. Cells were treated
with DMSO (control), 0.5 µmol olaparib, 1 µmol PDDX-001 or olaparib/PDDX-001
combination for 1 hr prior to micro-irradiation. Laser micro-irradiation was carried
out on a Leica SP5 confocal microscope equipped with an environmental chamber
set to 37 ◦C. DSB-containing tracks (1.5 µm width) were generated with a Mira
modelocked titanium-sapphire (Ti:Sapphire) laser (l = 800 nm, pulse length =
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200 fs, repetition rate = 76 MHz, output power = 80 mW) using a UV-transmitting
633 1.4 NA oil immersion objective (HCX PL APO; Leica). Confocal images were
recorded before and after laser irradiation at 5 s or 10 s time intervals over a period
of 2-3 min. Images recorded after multi-photon micro-irradiation of living cells
were analyzed using ImageJ software. The average pixel intensity of laser tracks
was measured within the locally irradiated area function (Idamage), in the nucleo-
plasm outside the locally irradiated area (Inucleoplasm) and in a region not containing
cells in the same field of view (Ibackground). The relative level of accumulation ex-
pressed relative to the protein level in the nucleoplasm was calculated as follows:
(Idamage − Ibackground)− (Inucleoplasm − Ibackground).
XRCC1-GFP: UV-A Laser Micro-Irradiation The laser micro-irradiation assay was
performed as described before73. Briefly, U2OS cells were transiently transfected
(using Lipofectamine 2000, Invitrogen; according to the manufacturer’s protocol)
with pEGFP-C1-XRCC1 (gift from Simon Bekker-Jensen). Cells were grown on
18 mm coverslips and sensitized with 10 µmol 50-bromo-2-deoxyuridine (BrdU) for
24 hr. On the next day, the growth medium was replaced with CO2-independent
Leibovitz’s L15 medium supplemented with 10 % FCS and penicillin-streptomycin
and cells were kept at 37 ◦C. Cells were treated with DMSO (control), 0.5 umol
olaparib, 1 µmol PDDX-001 or olaparib/PDDX-001 combination for 1 hr prior to
micro-irradiation. For micro-irradiation, the cells were placed in a Chamlide TC-
A live-cell imaging chamber that was mounted on the stage of a Leica DM IRBE
widefield microscope stand (Leica) integrated with a pulsed nitrogen laser (Micro-
point Ablation Laser System; Andor). The pulsed nitrogen laser (16 Hz, 364 nm)
was directly coupled to the epifluorescence path of the microscope and focused
through a Leica 403 HCX PLAN APO 1.25-0.75 oil-immersion objective. The laser
output power was set to 60 to generate strictly localized subnuclear DNA damage,
resulting in XRCC1, but not in XRCC4 accumulation73. Following micro-irradiation,
cells were incubated for the indicated time points at 37 ◦C in Leibovitz’s L15 and
subsequently fixed with 4 % formaldehyde before immunostaining. Typically, an
average of five cells was micro-irradiated (2 iterations per pixel) within 1 min using
Andor IQ software (Andor). For each condition, 20-25 cells were micro-irradiated,
and experiments were repeated three times (60-75 cells in total). Following DNA
damage, cells were further incubated for 5, 10, 15 or 60 min. Next, cells were fixed
with 2 % formaldehyde in PBS for 20 min. Cells were post-extracted with 0.5 %
Triton-X100 (Sigma) in PBS, and blocked with 20 mmol glycine and 0.5 % BSA in
PBS for 15 min and used for antibody incubations. Samples were incubated with
primary antibodies overnight at 4 ◦C and with secondary antibodies supplemented
with 0.1 mg ml−1 DAPI for 1 hr at room temperature. Samples were subsequently
mounted in Polymount (Polysciences). Antibodies used in this study are: primary
rabbit polyclonal anti-MDC1 (#ab11171-50, Abcam), diluted 1:1000 and secondary
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goat anti-rabbit AlexaFluor-555-conjugated, diluted 1:1500 (#A-21429, Thermo
Fisher). The MDC1 (AF-555), XRCC1-GFP (GFP) and CHD2-GFP (GFP) signal was
detected using Zeiss AxioImager D2 widefield fluorescence microscope equipped
with 403, 633 and 1003 PLAN APO (1.4 NA) oil-immersion objectives (Zeiss) and
an HXP 120 metal-halide lamp used for excitation. Images were recorded using the
ZEN 2012 software. Tracks were evaluated in ImageJ, by calculating the ratio of
track to background (nuclear) intensities for each channel.
PARPi toxicity analysis in a panel of 1,001 cancer cell lines
The pharmacogenomics dataset of 1,001 human cancer cell lines, published
recently41, was used to assess the corelation between PARG or PARP1 expression and
IC50 values of PARPi. For this purpose, expression data for DDR-related genes (see
Table S7.2) and drug response data to olaparib, veliparib, rucaparib and talazoparib
was extracted, resulting in a smaller dataset for 935 out of 1,001 cell lines. For sta-
tistical analysis Pearson correlation was estimated for each gene and the correlation
p values were computed using the relation between the estimated coefficient and
the student-t distribution. Negative correlation means that a lower IC50 associates
with higher expression (= more sensitive).
7.6.4 Quantification and statistical analysis
Statistical parameters including sample size, precision measures and statistical
significance are reported in the figures, corresponding figure legends and Method
Details sections.
Genetic screens See Figure 7.1, Figure 7.2K and Table S7.1. Genetic screens were
performed in triplicate and statistical analysis was carried out using the MAGeCK
software.
In vivo studies See Figure 7.2.
Survival analysis The effect of PARPi treatment in mice carrying KB2P tumors
was measured by survival analysis of control (n = 21) vs AZD2461-treated group
(n = 34). Data are presented as Kaplan-Meier curves and the p value was computed
using Log-Rank (Mantel Cox) statistics (Figure 7.2C).
Statistical analysis of deep-sequencing data See Figure 7.2D, Figure 7.2G, and
Figure S7.1. Detailed description of the bioinformatics analysis is reported in the
Method Details section.
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Immunohistochemistry analysis of PARG expression Semi-quantitative compari-
son of the PARG staining of resistant (n = 34) versus naive (n = 21) KB2P tumors
was carried out by a trained pathologist who was blinded regarding the sample iden-
tity. Group comparison was performed using Mann-Whitney U test. Representative
images are shown (Figure 7.2H).
qRT-PCR analysis Gene expression measurements were performed in triplicate,
normalized to expression of house keeping genes, and presented as mean ± SD of
replicates. Statistical significance was estimated with the two-tailed unpaired t-test.
See Figure 7.3A, Figure 7.6A-B, Figure S7.2A, Figure S7.2E, and Figure S7.3B.
PARG activity assays and PAR ELISA assay Experiments were performed in trip-
licate, repeated three times and presented as mean ± SD of repeats. Statistical
significance was estimated with the two-tailed unpaired t-test. See Figure 7.2I,
Figure 7.3B, and Figure S7.2B for the PARG activity assays and Figure 7.4A for the
PAR ELISA assay.
PAR immunofluorescence assay Intensities of PAR signal were measured per nu-
clei, for four different imaging areas per condition, each containing on average 200
cells; the experiment was repeated three times. Results were presented as a mean
for each area (12 areas in total) ± SD. Statistical analysis was performed using the
two-tailed unpaired t-test. See Figure S7.2D.
Long-term clonogenic assays See Figures 7.3C, 7.3E, 7.4F, 7.6F-I, S7.3A, S7.3C,
S7.3I, S7.3J, S7.5D, S7.6A, S7.6C, S7.6G, and S7.6H. All experiments were repeated
three times, unless otherwise stated, and data are presented as mean ± SD of
replicates. For statistical analysis the two-tailed unpaired t-test (Figures 7.3C, 7.4F,
S7.3A, S7.3C, S7.3H, S7.5D, and S7.6A) or ANOVA (Figures 7.3E, S7.6G-J, S7.3G,
S7.6B, S7.5F, and S7.6G) test was used.
Analysis of DNA damage-induced foci See Figures S7.5G, S7.4B, and S7.4D. For
the analysis of γH2A foci (Figure 7.5G), foci were counted per nuclei, in four
different imaging areas per condition, each containing on average 200 cells. Results
were presented as a mean ± SD of the three replicates. Statistical analysis was
performed using the two-tailed unpaired t-test. For the analysis of RAD51/53BP1
irradiation-induced foci (Figures S7.4B and S7.4D), foci were counted per nuclei
and data are presented as mean ± SD of replicates (triplicate for cultured cells and
five replicates for GEMM samples) and group comparison was performed using the
two-tailed unpaired t-test. On average 100 cells were analyzed per replicate.
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Fast micromethod SSB assay See Figure 7.5F. Assay was performed in triplicate
and repeated twice, data are shown as mean ± SD of the two repeats. Statistical
significance was assessed using two-tailed unpaired t-test.
DNA fiber assays See Figures 7.5A, S7.5A, and S7.5I. For the fork protection assay
(Figure S7.4A), at least 100 fibers were measured per condition and statistical
significance was assessed with the Mann-Whitney U test. For fork progression
analysis (Figures 7.4C and S7.5I), on average 120 fibers were quantified and group
comparison was performed with the two-tailed unpaired t-test. Experiments were
repeated twice.
Neutral comet assay On average 100 comets (cells) were analyzed per condition
and each data point represents tail moment (Figure 7.5B) or olive moment (Fig-
ure S7.5J) of a single comet, together with a mean ± SD of all cells per condition.
Statistical significance was assessed using Mann-Whitney U test. Experiments were
repeated twice.
Micro-irradiation assays See Figures 7.4E, 7.5D-E, and S7.5F-G. In each exper-
iment on average 15-20 cells were micro-irradiated and analyzed per condition.
Experiments were repeated three times and data are presented as mean ± SEM
of independent experiments. Statistical analysis was performed using two-tailed
unpaired t-test.
Immunoblotting See Figures 7.2J, 47.4B-C, and S7.5A-B. Immunoblotting experi-
ments were repeated three times. Representative images are shown.
PARPi Toxicity Analysis in a Panel of 1,001 Cancer Cell Lines See Figures 7.6C and
S7.6D. Correlation between gene expression and IC50 values for PARPi was assessed
using Pearson correlation, which was estimated for each gene and the correlation p
values were computed using the relation between the estimated coefficient and the
student-t distribution.
7.6.5 Data and software availability
The deep sequencing data generated in this study is available in the European
Nucleotide Archive (ENA) under accession number PRJEB20535. Raw data from
this manuscript: https://doi.org/10.17632/r9cm2kh8mt.1.





























Fig. S7.1. Multi-omics analysis of PARPi-resistant mouse mammary tumors. Related
to Figure 7.2. (A) Expression (RNA-seq) of Pgp drug efflux transporter in KB2P
PARPi-naive and resistant tumors; p value: two-tailed t-test. The box extends
from the lower to upper quartile values of the data, with a line at the median;
whiskers (whis) are a function of the inner quartile range, they extend to the
most extreme data point within (whis ∗ (75% − 25%)) data range. (B) Copy
number log2 ratios of chromosome 14 shown for all KB2P tumors; the Parg locus
is indicated by the red dashed line. KB2Px-R/Ny: x - original donor ID number,
y - ID of individual resistant tumors derived from the same donor tumor, R -
resistant, N - naive. (C) Correlation between Parg expression and copy number
estimation for a panel of KB1P tumors. Spearman correlation coefficient (ρ)
and p value (DIDS algorithm) are indicated.









































Fig. S7.2. Suppression of PARG in KB2P cells. Related to Figure 7.3. (A) RT-qPCR
analysis of Parg expression in KB2P3.4 cells expressing indicated shRNAs;
∗∗∗∗p < 0.001 (two-tailed t-test), data shown as mean ± SD of triplicate. (B)
ELISA-based PARG activity assay in the cell lines indicated; data represent mean
± SD of triplicate, ∗∗∗∗p < 0.001 (two-tailed t-test). (C-D)Immunofluorescence-
based PAR detection in the indicated cell lines upon MMS (0.01 %) treatment.
Representative microscopic images (C) and quantification of the assay (D) are
shown; ∗∗∗∗p < 0.001 (two-tailed t-test), data are presented as mean ± SD of
single areas imaged (experiment repeated three times, four areas/experiment,
average 300 cells/area); scale bar, 100 µm. (E) RT-qPCR analysis of Parp1 gene
expression in KB2P PARG kd cells; n.s. - not significant (two tailed t-test), data
are shown as mean ± SD of triplicate experiments.
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Fig. S7.3. Downregulation of PARG drives PARPi resistance in KB2P cell lines. Re-
lated to Figure 7.3. (A) Long-term clonogenic assay using KB2P3.4-scr sh
(scramble shRNA, control), -PARG sh1 and -PARG sh4 cells and the PARPi
AZD2461 or olaparib. Representative images of stained wells (left) and quantifi-
cation of the assay (right; mean ± SD of three repeats) are shown; ∗∗p < 0.01
(two-tailed t-test). (B) qRT-PCR analysis of Parg expression in KB1P-G3 cells
expressing the hairpins indicated; ∗∗∗∗p < 0.001 (two-tailed t-test), data shown
as mean ± SD of triplicate. (C) Clonogenic assay in KB1P-G3 cells expressing the
hairpins indicated and treated with olaparib; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001
(two-tailed t-test); data represents mean ± SD of two repeats. (D) Outline of
the long-term clonogenic assays in KB2P cells expressing control (NT) or gRNAs
targeting Parg. (E) Example of the TIDE analysis: spectrum of alleles identified
by the algorithm in the samples indicated.
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Fig. S7.3. Continued. (F) Long-term clonogenic assay using KB2P3.4 cells expressing the
indicated gRNAs. Representative images (left) and TIDE quantification of allele
composition (right) are shown. (G-H) Chemical inhibition of PARG using PDDX-
004 in the cell lines indicated. Representative images of PAR immunofluorescent
staining (G) and quantification (H) are shown; data represent mean ± SD
of three repeats; scale bar, 100 µm. (I) Long-term clonogenic assay using
KB2P3.4 cells treated with the PARPi olaparib and PARGi PDDX-004 alone or in
combination. Representative images of stained cells (left) and quantification of
the assay (right) are shown. Data on the graph represent experiments repeated
three times (mean ± SD); p value (ANOVA) is indicated. (J) Clonogenic assay
in KB2P cells expressing the shRNAs indicated, and treated with olaparib;
∗∗p < 0.01, n.s. - not significant (two-tailed t-test); data shown as mean ± SD
of triplicate.
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Fig. S7.4. PARG loss causes PARPi resistance independently of HR and RF protection.
Related to Figure 7.4. (A) DNA fiber assay using KB2P3.4 cells treated with
MMS (0.9 µmol); ∗∗∗p < 0.001, n.s. - not significant (Mann-Whitney U test). Er-
ror bars represent SD and red lines represent mean values. (B-C) RAD51/53BP1
IRIF formation assay in the given cell lines; KP3.33 (p53-/-) cells were used as
HR-proficient control in this assay; 53BP1 served as DNA damage marker. Quan-
tification (B) and representative images (C) are shown. A cell was considered
positive when: RAD51 ≥ 5 foci/nuclei, 53BP1 ≥ 10 foci/nuclei. Data represent
mean ± SD; ∗∗∗∗p < 0.0001, n.s. - not significant (two-tailed t-test); scale bar,
10 µm.
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Fig. S7.4. Continued. (D) Example of RAD51 foci formation analysis in a KB2P2 tumor
pair, representative for all PARPi-resistant tumors for which alterations in the
Parg gene were identified by DeepSeq analysis. Matched naive samples, as
well as KP (p53-/-) tumor (positive control) were taken along for the analysis.
Microscopy images (upper panels) and foci quantification (lower panels) are
shown. For quantification, a fraction of positive cells (≥ 5 foci/nuclei for RAD51
and ≥ 10 foci/nuclei for 53BP1) was calculated for five different areas of each
tumor (shown as single data point on the graph, error bars represent SD).
∗∗∗p < 0.0001, ∗∗∗∗p < 0.0001, n.s. - not significant (two-tailed t-test). 53BP1
was used as a marker of DNA damage. Scale bar, 25 µm.
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Fig. S7.5. PARG depletion partially restores downstream signaling of PARP1. Related
to Figures 7.4 and 7.5. (A-B) Immunoblot analysis of PAR (A), PARP1 and
PARP3 (B) cellular levels in KP3.33 expressing the gRNAs indicated. Red arrow
(B) indicates band specific for PARP3. Histone 3 (H3) was used as a loading
control. Data representative of experiments repeated twice. (C) TIDE analysis
of allele modification rates in KP3.33 cells expressing the gRNAs indicated;
data representative for experiment repeated twice. (D) Clonogenic assay with
KP3.33 cells expressing the gRNAs indicated, treated with olaparib; ∗∗p < 0.01,
∗∗∗∗p < 0.0001, n.s. - not significant; data shown as mean ± SD of two repeats.
(E) PARG inhibition in U2OS cells by PDDX-001; data presented as mean ± SD
of two repeats.
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Fig. S7.5. Continued. (F) GFP-XRCC1 recruitment analysis in DMSO (control) or olaparib-
treated GFP-XRCC1 U2OS cells; representative images (right) and quantification
(left) are shown. XRCC1 recruitment was used as a readout for PARP1 inhibition.
(G) GFP-CHD2 binding to the site of DNA damage in GFP-CHD2 U2OS cells
treated with DMSO (control) or PDDX-001; representative images (right) and
quantification (left panel) are shown. CHD2 association to chromatin was used
as a positive control for PARG inhibition. (H) Time-course recruitment analysis
of GFP-PARP1 to laser tracks in control cells (DMSO). For experiments shown
in (F-H) data are represented as mean ± SEM of two independent repeats;
∗∗∗∗p < 0.0001 (t-test); in all images scale bar, 10 µm. (I) Fork progression
assay in U2OS cells exposed to the treatments indicated. Box extends from 25th
to 75th percentile, with a middle line representing the median and whiskers
drawn down to the 10th percentile and up to the 90th. (J) Neutral comet assay
in U2OS cells treated as indicated. Data shown as mean ± SD of a replicate.
Experiments shown in (I-J) were repeated twice; ∗∗∗∗p < 0.001, n.s. - not
significant, Mann-Whitney U test.






























































































Fig. S7.6. PARPi response of PARG-depleted human cancer cells. Related to Fig-
ure 7.6. (A) Quantification of long-term clonogenic assays shown in Figure 7.5A.
Graph represents mean ± SD values of triplicates; ∗∗p < 0.01 (two-tailed t-test).
(B) Chemical inhibition of PARG with PDDX-004 in indicated cells. Data repre-
sent mean ± SD of three repeats. (C) Quantification of a long-term clonogenic
assay in SUM149PT (upper panel) and DLD-1 BRCA2(-/-) (lower panel) cells
treated with the PARPi olaparib and the PARGi PDDX-004 alone or in combina-
tion. Data presented as mean ± SD values of three repeats.
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Fig. S7.6. Continued. (D) Correlation analysis between IC50 values of PARPi (veliparib
and talazoparib) and expression of DDR genes in a panel of 935 human cancer
cell lines; PARP1 and PARG are highlighted; Pearson correlation was computed
and p values were determined using the relation between estimated coefficient
and the student-t distribution. (E) Validation of PARG antibody used in IHC
analyses; representative images of SUM149PT cells expressing indicated shRNAs
are shown; scale bar, 100 µm. (F) Example of PARG IHC staining in two ovarian
serous carcinomas; scale bar, 100 µm. (G-H) Response of KB2P1.21 cells to
ionizing radiation (IR) and temozolomide (TMZ), treated with PARGi PDDX-004.
Data is presented as mean ± SD.
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7.7.2 Supplementary Tables (available online)
Tab. S7.1. Genetic screens identify Parg as a PARPi-resistance factor. Related to Figures 7.1
and 7.2.
Tab. S7.2. DDR-related genes. Related to Figures 7.2 and 7.6.
Tab. S7.3. Overview of candidate genes identified in multi-omics analysis of matched
KB2P PARPi-naive and -resistant tumors. Related to Figure 7.2.
Tab. S7.4. Custom-made shRNA library targeting candidate genes (identified by multi-
omics analysis of KB2P tumors) and additional 32 non-essential genes (con-
trols). Related to Figure 7.2.
Tab. S7.5. TIDE analysis of clonogenic assays using KB2P cells expressing gRNAs targeting
Parg. Related to Figure 7.3.
Tab. S7.6. Oligonucleotides used in this study. Related to STAR methods.
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8General discussion
8.1 Introduction
In this work, we have made extensive use of several mouse models for studying tumor
development and therapy resistance in two different types of breast cancer: invasive
lobular carcinoma (ILC) and BRCA1-deficient triple-negative breast cancer (TNBC).
This allowed us to identify several known and novel drivers of ILC (Chapters 3 and 4)
and BRCA1-deficient TNBC (Chapter 5), which were also shown to be frequently
aberrated in human tumors. Besides this, we also demonstrated how mouse models
can be used to identify resistance mechanisms in both ILC (Chapter 6) and BRCA-
deficient TNBC (Chapter 7), by treating mice with transplanted tumor fragments
with targeted treatments and comparing therapy-sensitive and -resistant tumors.
In the following sections, we focus on some of the concepts that underlie the work
presented in this thesis. Specifically, we will first elaborate on our approaches used
to identify cancer genes and therapy resistance mechanisms and reflect on several
advantages and shortcomings of the presented approaches. Next, we touch on
several recent advances in sequencing technologies and challenges in increasing the
accessibility of sequencing data for future studies. Finally, we reflect on the current
role(s) of mouse models in cancer research and how this is impacted by increased
human sequencing efforts and the developments of organoid technologies.
8.2 Strengths and weaknesses of insertional
mutagenesis strategies
One of the major goals/challenges in cancer research involves identifying which
genes are driving tumor development, based on the idea that these genes can be
targeted specifically in new therapies. In this work, we have shown how transposon-
based insertional mutagenesis (IM) can be used to screen for candidate cancer genes,
allowing us to identify driver genes in a mouse model of invasive lobular carcinoma
(ILC) (Chapter 3). Moreover, we also have demonstrated how transposon insertions
can be identified from RNA-sequencing data, and how this approach provides an
important biological filter that focuses on transposon insertions that are actually
expressed in the tumors, and therefore most likely to be relevant for tumor formation
(4)
One of the main advantages of IM strategies, compared to other mutagenesis ap-
proaches, is that they provide a relatively unbiased genome-wide approach to
forward genetic screening, whilst allowing efficient retrieval of transposon insertions
via targeted sequencing. Moreover, depending on the used transposon, IM-based
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screens can be used to simultaneously identify both candidate oncogenes and tumor
suppressors in a single screen. As such, IM-based screening approaches have been
successfully used to identify cancer driver genes in a wide variety of cancer types1–7.
In these settings, IM has been particularly effective in identifying cancer drivers that
are not readily apparent in human sequencing data, due to complex amplicons or
more subtle events such as alternative splicing. A clear example is given by our
transposon mutagenesis screen, which identified several ILC driver genes that were
located in an amplicon on human chromosome 1q. Due to the size of this amplicon,
these genes would have been difficult to identify without our screening results.
An important limitation of IM strategies is that different transposon systems have
specific biases8, which can lead to different results depending on the used transposon.
Part of these biases are inherent to the used transposon systems (e.g., piggyBac9,10,
Sleeping Beauty11,12), which have been shown to have integration biases towards
specific genetic sequences and/or certain gene features (e.g., integration within or
upstream of genes)13. Other biases stem from the sequences used to construct the
transposon, which may affect the mutagenicity of the transposon in certain types of
cells. For example, the T2/Onc2 transposon used in our screen contains an MSCV
promoter, which is likely to drive oncogene expression in hematopoietic cells at
a higher rate than in other cell types. For this reason, other transposons such as
the T2/Onc314 transposon have been developed for targeting different cell types by
including different promoter sequences.
These biases may explain to some extent why our screen identified a relatively concise
set of candidate genes, compared to other recent IM screens1,4,7. For instance, SB
transposons generally have a lower integration rate than other, more aggressive
transposon systems such as piggyBac15. This might explain why we identify fewer
integration sites than studies with other transposons7, but it does not explain
differences with SB-based studies1,4. Similarly, the used transposon (T2Onc/2) may
not be particularly active in mammary gland epithelium, due to limited activity of the
MSCV promoter in this tissue. Alternatively, biological constraints might be limiting
the number of potential ILC driver genes, as is suggested by the limited number
of driver mutations associated with ILC16. Finally, sequencing issues (e.g. limited
sequencing depth) might have reduced the sensitivity of our insertion detection.
However, orthogonal analyses using different sequencing approaches (IM-Fusion17,
Tagmap18) identified similar patterns of insertions, indicating that this is unlikely to
be the case.
Another limitation of IM strategies is that targeted sequencing approaches aimed at
identifying transposon insertions are unlikely to identify other types of mutations
generated by competing, spontaneous mutational processes occurring in tumors. As
such, naive IM screening approaches may miss additional candidate genes that are,
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for example, aberrated by spontaneous point-mutations or copy number changes.
The risk of additional mutations depends highly on the used mouse model, with
more genomically unstable tumors being more likely to acquire mutations via alter-
native mechanisms. This issue can be mitigated by either applying IM in genomically
stable models, or by combining targeted sequencing strategies with other sequenc-
ing modalities such as exome-sequencing19. Alternatively, RNA-sequencing-based
approaches17,20 such as IM-Fusion can be used for simultaneous identification of
transposon insertions and mutations, as a single RNA-sequencing dataset can be
used for insertion detection, variant calling, gene-fusion detection and differential
expression analyses.
Altogether, IM strategies are effective approaches for identifying candidate cancer
driver genes and potential mechanisms of therapy resistance. Moreover, when
combined with somatic engineering approaches, IM provides an especially powerful
method for identifying candidate cancer genes in specific genetic backgrounds and
rapidly validating these candidates in the same in vivo context. Besides this, deeper
sequencing and single-cell sequencing approaches21 may provide more insight into
the heterogeneity of IM-induced tumors and allow researchers to study clonal
evolution within these tumors. This type of approach – optionally combined with
multiplexed in vivo CRISPR approaches that permit studying interactions between
multiple cancer driver genes22,23 – may help determine how heterogeneous patient
tumors are likely to evolve over time and in response to specific treatments, enabling
the development of better treatment strategies.
8.3 Trade-offs in uncovering therapy resistance
mechanisms
Acquired therapy resistance is currently a major challenge in the clinic that limits
the effectiveness of many chemotherapy drugs and targeted therapies. In this work,
we aimed to identify resistance mechanisms to two different targeted therapies,
FGFR inhibition (FGFRi) in ILC (Chapter 6) and PARP inhibition (PARPi) in BRCA1-
deficient TNBC (Chapter 7). To do so, we transplanted donor tumors into multiple
syngeneic mice, which were subjected to treatment. By subsequently contrasting
therapy-resistant and -sensitive (i.e. vehicle-treated) tumors, this approach allowed
us to identify potential resistance mechanisms to both targeted treatments.
In Chapter 6, we focused on identifying FGFRi resistance mechanisms using inser-
tional mutagenesis, based on the premise that SB-induced tumors can acquire new
transposon insertions during treatment and in doing so become resistant to the
applied therapy24,25. One advantage of using IM for this purpose, is that potential
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resistance mechanisms are relatively easy to identify by using targeted sequencing
to reveal the locations of new insertions in resistant tumors. However, a limitation
of the approach is that the range of identifiable resistance mechanisms may be
limited by integration biases of the used transposon and by the types of mutations
that can be generated by transposon insertions (e.g. gene overexpression and gene
truncation, but not point mutations). Moreover, competing mutagenic processes
may result in additional mutations that may contribute to resistance but cannot be
detected by targeted insertion sequencing, as evidenced by the FGFR2 mutations that
we identified in RNA-sequencing data from several FGFRi-resistant ILC tumors.
In Chapter 7, we used genomic (copy number variation (CNV)-sequencing) and
transcriptomic (RNA-sequencing) approaches to identify potential PARPi resistance
mechanisms in BRCA2-deficient mammary tumors from KB2P mice. One of the main
challenges of this type of approach is that genomically unstable tumors (such as KB2P
tumors) are likely to contain many additional aberrations after treatment, of which
only a very small fraction is likely to be causally involved in treatment resistance. As
such, identifying potential resistance mechanisms requires additional prioritization
of mutations, either using computational algorithms or by integrating data from addi-
tional sequencing approaches, other experiments or external databases. In the KB2P
model, we addressed this issue by requiring genes to be frequently amplified/deleted
and to show a strong effect on expression, providing additional evidence that these
mutations have a functional effect. Additional evidence from a separate shRNA
screen was used to further validate our results, by providing orthogonal evidence
that candidate genes were indeed involved in resistance.
An alternative approach for identifying acquired resistance mechanisms involves
correction of copy number profiles of resistant tumors for events that were present
before treatment, and subsequent application of algorithms such as RUBIC26 or
GISTIC27 to identify recurrent copy number events that are acquired after treatment.
This would potentially allow us to identify DNA copy number alterations (CNAs) that
arose in response to treatment. The main advantage of this approach is that it may
restrict the number of potential candidate genes by focusing on the minimal regions
of recurrent CNAs. However, this approach requires a snapshot of the pre-treatment
copy number state for each tumor to avoid calling events that were already present
in the pre-treatment tumor samples. In our case, these samples were not available.
Moreover, it may be challenging to obtain representative pre-treatment samples
for each donor, due to differences in pre-treatment tumor fragments stemming
from intra-tumor heterogeneity. In addition, this approach assumes that the same
resistance mechanism occurs in each tumor, and it may therefore not have enough
statistical power in a population displaying heterogeneous resistance mechanisms.
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In essence, the main difference between our two resistance screens lies in their focus.
In the IM-based approach, we first used RNA-sequencing data to identify if any
known mechanisms could explain the observed resistance, allowing us to perform a
relatively focused analysis of this genome-wide dataset. We then used insertion-site
sequencing to identify novel resistance mechanisms in an unbiased fashion. Due to
the selective nature of the used transposon, this analysis identified a relatively short
list of novel mechanisms, which might not have been identified through genome-
wide analyses. In contrast, our analysis of the KB2P tumors was performed in a
genome-wide fashion and relied on additional data sources (such as the curated
list of DNA damage response (DDR) genes and the secondary shRNA screen) to
prioritize candidate genes. In this respect, IM-based approaches have the advantage
of being cleaner than a genome-wide analysis, at the risk of missing novel resistance
mechanisms that are not captured by the transposon system. On the other hand, the
sequencing approach has the advantage of potentially being more comprehensive
but runs the risk of missing mechanisms in the analysis stage, due to the added
complexity of the analysis, biases introduced by prior knowledge, and/or lack of
statistical power resulting from small sample size and heterogeneous resistance
mechanisms. As such, the choice of which approach to use likely depends on various
aspects of the used mouse model (such as its degree of genomic instability) and
pre-existing knowledge of potential resistance mechanisms.
Treatment resistance will most likely remain a substantial challenge for many anti-
cancer therapies in the foreseeable future. One particularly challenging aspect of
addressing therapy resistance is that it is essentially a race against evolution, in
which tumors are likely to develop new resistance mechanisms in response to any
applied therapies. As such, effective therapeutic strategies will need to be designed
to minimize or prevent the emergence of resistance, for example by targeting conver-
gent signaling pathways28 or changing treatment strategies (e.g. by employing drug
holidays29 or combination therapies30). However, testing different (combination)
treatments in different genetic backgrounds is likely to be prohibitively expensive
and time consuming, due to the sheer amount of possible combinations involved. As
such, we expect that computational models trained on existing experimental data
will become crucial in modeling how tumor cells and cell populations respond to
specific (combination) treatments, allowing us to predict which (combinations of)
anti-cancer drugs are most likely to be most effective in treating a given tumor and
preventing resistance.
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8.4 Advances in tumor sequencing technologies
For the studies described in this thesis, we have made substantial use of second-
generation sequencing technologies, which have greatly improved our ability to
perform in-depth genomic and transcriptomic characterization of cell populations.
However, one limitation of these technologies, is that they essentially reduce (cancer)
genomes into a large collection of very short sequence reads, which must be pieced
back together using a predefined reference genome to extract anything meaningful
from the data. The fact that these short sequencing reads do not allow de novo
assembly of cancer genomes inherently limits the power of our analyses. Moreover,
this fragmented snapshot is not extracted from individual cells, but from bulk
populations of thousands to millions of tumor cells, meaning that any derivation is
going to be an average blur of a population of cells, rather than a detailed picture of
all individual cells that captures all of their differences.
In this respect, one of the most exciting recent developments is the emergence of
single-cell sequencing technologies, which can be used to characterize the genomic
or transcriptomic state of individual cells31,32. This makes single-cell approaches
especially suitable for studying intra-tumor heterogeneity, which is considered to be
one of the main drivers of tumor progression, metastasis and escape from therapy33.
As such, single-cell RNA-sequencing approaches have frequently been used to identify
distinct populations of cells within tumors34–36 and to explore how these popula-
tions may be involved in tumor progression and therapy resistance37–39. Similarly,
single-cell CNV-sequencing and exome-sequencing approaches have been used to
track cancer evolution by deriving how distinct tumor subclones evolved during
tumor progression40,41. Limiting aspects of current single-cell technologies are low
sequencing depths and high costs due to the large numbers of cells that need to
be sequenced for a comprehensive analysis. However, with dropping sequencing
costs and the development of more cost-effective approaches, we expect that single-
cell sequencing will become an increasingly important pillar in studying tumor
heterogeneity and cancer evolution.
Besides this, third-generation sequencing approaches (e.g., Nanopore, PacBio) are
poised to further revolutionize sequencing analyses by providing much longer reads
(10,000-100,000 bp) than current (second-generation) technologies, which are
generally limited to reads of hundreds of base pairs. Increased read lengths provide
substantial benefits for many sequencing analyses, as longer reads are much easier
to stitch back together than short sequences, as demonstrated by de novo assemblies
based on long-read sequencing42. Similarly, identification of complex structural
variations in patient samples have been shown to benefit greatly from longer read
lengths, allowing Nanopore-based approaches to achieve substantial accuracy in
8.4 Advances in tumor sequencing technologies 291
identifying variants, even with relatively low sequencing depths43. Furthermore, in
RNA-sequencing based approaches, long-read sequencing has been used to identify
novel gene transcripts44 and quantify isoform expression45 more accurately than
current sequencing approaches.
Together, we expect that advances in single-cell and third-generation sequencing
will substantially increase our ability to detect more complex mutational events,
such as structural variants and alternative splicing, whilst simultaneously providing
detailed insight into the heterogeneous tumor environment. However, properly lever-
aging these technologies will also require the development of new computational
approaches for analyzing the produced data, as is evidenced by the widespread devel-
opment of software packages for the analysis of single-cell and long-read sequencing
data.
8.5 Increasing the reproducibility and accessibility
of sequencing data
To optimally exploit the full compendium of sequencing data that is currently being
generated, it will be important to generate and share sequencing datasets in a way
that they can be easily queried, integrated and visualized by fellow researchers.
One of the main challenges in this respect is the heterogeneity of many analyses,
which is fueled by lack of consensus on best practices for analyzing different types
of sequencing data. This has led to the development of many different variants of
sequencing analysis pipelines, which generally differ in their choice of software for
different steps of the analysis. As a result, these pipelines can produce considerably
different results, even when applied to the same datasets46–48, thus complicating the
integration of datasets from different research groups.
To establish a set of best practices, several efforts have been made to address this
issue by benchmarking different approaches on gold-standard datasets46–50. Ideally,
the results of these benchmarks will be used to develop templates for many standard
analyses in community projects (e.g. bcbio-nextgen*, Snakemake workflows†) and to
facilitate the sharing and democratization of sequencing pipelines. An important part
of these projects is the development of open-source workflow management systems
(e.g. Snakemake51, Nextflow52), which allow users to define abstract workflows
that can be shared and reused to analyze new datasets. Together with tools for
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Singularity54), these developments make it easier to develop workflows that can be
easily shared with, and applied by others, thus increasing the reproducibility and
uniformity of sequencing analyses.
Additionally, with the large amounts of data that are being generated, it is becoming
increasingly important to facilitate the deposition of these data into large central-
ized repositories, where they can be easily be integrated and analyzed by other
researchers. Unfortunately, processed datasets are rarely shared in this fashion,
as existing repositories (e.g. GEO55, ENA56) are generally restricted to specific
data types and therefore provide limited capabilities for integrating and visualizing
datasets from different sequencing modalities. Portals such as cBioportal57 are a
great step forward in this respect, as they provide basic functionality for querying
and visualizing different datasets without requiring specific computational exper-
tise. In future work, it will be important to expand these existing initiatives to
include many more public datasets, ideally upon publication of the corresponding
manuscripts. Besides this, we expect that integration with similar portals containing
data from non-human organisms (such as mouse models) will play an important role
in disseminating insights from these model systems and improve cross-pollination
with human sequencing efforts.
8.6 A future for mouse model systems?
Model systems have long been important cornerstones of cancer research, as they
provide renewable and manipulatable biological systems that can be used to for-
mulate and test hypotheses. Compared to other systems, mouse models have been
particularly useful as they provide a controlled and experimentally tractable in vivo
setting that remains relatively close to human biology. As a result, many different
types of mouse models of human cancer have been developed over the years, of
which we provided an overview in Chapter 1. These developments have given rise
to a vast collection of mouse models with different genetic backgrounds, mimicking
important aspects of many human cancer types58,59.
An important advantage of model systems such as mouse models, compared to hu-
man sequencing projects, is that they can provide unambiguous, causative evidence
of whether a given mutation is involved in tumorigenesis or therapy resistance.
For example, by introducing a mutation into a mouse model that does by itself
not develop tumors, we can unequivocally establish whether the added mutation
results in increased tumor formation60. Human sequencing projects are much more
limited in this respect, as without further validation these projects can generally only
provide correlative evidence61. As such, model systems play an important role in
8.6 A future for mouse model systems? 293
the follow-up of driver genes identified in these projects, by allowing us to validate
their role(s) in tumor formation and determine how they may affect other tumor
characteristics such as therapy response.
The utility of mouse models in cancer research will likely be enhanced by the
development of lentiviral and CRISPR-based somatic engineering approaches62,63,
which allow the rapid introduction of mutations into existing baseline mouse models
(Chapter 5). As such, these approaches can be used to speed-up the creation of
new mouse models containing specific mutations, greatly expanding the capacity to
further validate and characterize candidate driver genes. Moreover, by combining
vectors containing/targeting different driver genes, somatic engineering can also be
used to generate complex mouse models with different combinations of mutations,
enabling more detailed dissection of interactions between different driver genes and
how these influence tumor development and therapy response.
However, mouse models are not alone and face competition from human-based mod-
els. For instance, human tumor-derived organoid systems have recently gained much
popularity in cancer research by enabling efficient derivation of three-dimensional
(3D) cell culture models that maintain the genomic complexity of tumors more
faithfully than conventional cell line models64,65. For this reason, organoids have
been touted as an effective approach for generating in vitro models of patient tumors,
which can be sequenced and screened with anti-cancer drugs to identify mutations
and correlate these with therapy response66. Besides this, organoids can also be
manipulated using lentiviral and CRISPR-based somatic technologies, allowing vali-
dation of driver genes or mutations that are predicted to influence therapy response.
Combined with falling sequencing costs and increasing patient sequencing efforts,
these efforts in organoid models are poised to provide a wealth of data correlating
human tumor genotypes with drug response. Given enough data, this may sub-
stantially improve our ability to build computational models predicting a patient’s
therapy response, without requiring detailed modelling in (mouse) model systems.
Organoid-based approaches are however limited by the fact that they are grown
in a rather artificial in vitro environment, and as such do not faithfully reflect
the complexity of the tumor microenvironment and/or interactions with an active
immune system. As a result, (humanized) mouse models are much better suited for
studying the effects of immune-based therapies, which have gained much popularity
due to their unparalleled success in treating specific cancer types67–70. Besides this,
mouse models of de novo tumorigenesis provide opportunities for studying all stages
of tumor initiation, progression and metastasis, which is challenging to do with
models based on end-stage patient tumors. Finally, detailed in vivo characterization
is likely to remain important to gain insight into the role of specific drivers in
different stages of tumorigenesis, which can be used to design and develop novel
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therapies targeting driver-specific vulnerabilities. As such, we expect that mouse
model systems will continue to play an important role in cancer research. However,
to maximize their impact, studies should focus on exploiting the unique properties of
mouse models to complement patient- and organoid-based approaches, rather than
mimicking studies that are better performed in more human-like (in vitro) models.
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AAppendices
A.1 English summary
Cancer is a disease in which normal cells are deregulated by disruption of their
cellular processes, resulting in increased proliferation, survival and invasion of sur-
rounding tissues. This disruption is generally attributed to (epi)genetic alterations
in so-called driver genes, which provide cells with a selective growth advantage and
drive their malignant transformation. To improve cancer treatments, personalized
medicine approaches have aimed to identify exactly which mutations are driving
tumor development in a given patient and specifically target these mutations using
precision therapies. However, one of the main challenges of this approach is identi-
fying which mutations are true drivers, as tumors typically contain many additional
passenger mutations that do not actually contribute to tumor development. Besides
this, many patients often relapse after prolonged treatment due to the emergence of
acquired resistance, limiting the clinical effectiveness of targeted treatments.
To address these issues, it is crucial to (i) determine exactly which mutations are
driving the development of certain cancer types and (ii) identify potential resistance
mechanisms to targeted treatments. However, identifying driver genes in human
sequencing studies has been challenging, due to the large amounts of potential
drivers that are typically identified in these studies. Similarly, the identification of
resistance mechanisms is generally limited by lacking availability of pre- and post-
treatment tumor samples from patients, complicating the discovery of all potential
resistance mechanisms for a given treatment. Model systems such as mouse models
provide several complementary approaches for studying tumor development, by
enabling the development of renewable models resembling specific subtypes of
human cancer, which can then be studied in more detail to identify candidate
cancer genes and therapy resistance mechanisms. An overview of several of these
approaches is provided in Chapter 1.
In this thesis, we mainly focus on using genetically engineered mouse models to
identify candidate cancer genes and therapy resistance mechanisms in two different
types of breast cancer: invasive lobular carcinoma (ILC) and triple-negative breast
cancer (TNBC) (Chapter 2). ILC is a histological subtype of breast cancer that
accounts for 10-15% of all breast cancer cases and is characterized by mutations in
E-cadherin (encoded by the Cdh1 gene). Although ILCs generally show increased
expression of ERα, long-term outcomes of ILC are typically worse than other ER-
positive breast cancers, indicating that biological differences are influencing therapy
response. TNBCs account for another 10-17% of breast cancers and are characterized
by low expression of HER2 and the steroid hormone receptors ERα and PR. As such,
TNBCs cannot be treated with specialized hormone therapies, leaving chemotherapy
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as standard-of-care. Combined with the aggressive nature of these tumors, this
results in a relatively poor prognosis for patients with TNBC.
A common theme in both ILC and TNBC, is that they respond less favorably to
existing therapies than other breast cancer subtypes. As such, patients would benefit
from further research identifying which genes are driving the development of these
breast cancers, allowing the development of novel therapies targeting vulnerabilities
stemming from the identified drivers.
In Chapter 3, we aimed to identify potential driver genes of ILC by using Sleeping
Beauty (SB) transposon-based insertional mutagenesis (IM) to screen for candidate
cancer drivers in a mouse model with mammary-gland specific inactivation of Cdh1.
This showed that mice with combined loss of Cdh1 and activation of IM develop
tumors resembling human ILC, demonstrating the relevance of our model. Analysis
of the insertions in these tumors identified several known and novel drivers of
ILC, providing leads for the development of future therapies. Most notably, we
identified several recurrent and mutually exclusive SB transposon insertions in Myh9,
Ppp1r12a, Ppp1r12b and Trp53bp2, whose products have been implicated in the
regulation of the actin cytoskeleton. MYH9, PPP1R12B and TP53BP2 were also found
to be frequently aberrated in human tumors, indicating that this is a novel oncogenic
pathway in (human) ILC that might be exploited in future therapies.
One of the main challenges in the analysis of IM screens is that they can identify many
potential cancer genes, of which only a fraction is likely involved in tumorigenesis.
Additionally, the DNA-based approaches used to identify transposon insertions
and associated candidate genes do not provide much insight into how genes are
affected by the insertions. In Chapter 4, we addressed these issues by developing
an approach called IM-Fusion, which identifies transposon insertions from gene-
transposon fusions in RNA-sequencing data. Moreover, by combining insertion
detection with differential expression analysis, this approach is capable of providing
detailed insight into the effects of insertions on gene expression. To demonstrate
the utility of our approach, we applied IM-Fusion to two existing RNA-sequencing
datasets with matched DNA-based data. This demonstrated that IM-Fusion detects
transposon insertions and their true target genes more accurately than DNA-based
analyses.
In Chapter 5, we aimed to explore how the mutational landscape of BRCA1-deficient
TNBC is affected by the presence of several established driver genes (Myc, Met and
Rb1), in order to identify additional genes that collaborate with these established
drivers and may therefore be targetable in novel therapies. Our analyses showed that
BRCA1-deficient TNBCs with MYC overexpression exhibit a dramatically different
copy number landscape than TNBCs from other models, indicating that high MYC
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levels strongly affect the evolution of these tumors. By comparing recurrently
aberrated regions between mouse and human TNBCs, we identified Mcl1 as the
main driver gene in a locus that is specifically amplified in MYC-driven TNBC,
suggesting that MCL1 collaborates with MYC in TNBC development. Supporting this,
additional experiments in a BRCA1-deficient patient-derived xenograft (PDX) model
showed that MCL1 inhibition increases the effectiveness of the poly(ADP-ribose)
polymerase (PARP) inhibitor olaparib (which targets the BRCA-deficiency of these
tumors), underscoring the therapeutic potential of this combination treatment for
BRCA-deficient TNBC.
In the remaining chapters, we focused on identifying potential resistance mechanisms
to targeted treatments in ILC and TNBC.
First, in Chapter 6, we sought to explore the effects of FGFR inhibition in ILC, as
Fgfr2 was frequently activated by transposon insertions in our insertional mutage-
nesis screen (Chapter 3). To this end, we transplanted fragments of an ILC with
activated FGFR signaling into multiple recipient mice and treated these mice with the
FGFR inhibitor AZD4547. This showed that tumors initially regress upon treatment
with the inhibitor, but quickly become resistant to treatment. To identify potential
resistance mechanisms, we exploited the ongoing insertional mutagenesis in these
tumors to identify transposon insertions that were acquired during treatment and
may explain the observed resistance. Combined with a transcriptomic analysis of
these tumors, this approach identified several known and novel resistance mecha-
nisms. Notably, two novel resistance mechanisms were only identified by insertional
mutagenesis, demonstrating that IM is an effective tool for identifying resistance
mechanisms to targeted treatments in mice.
Next, in Chapter 7, we aimed to identify potential resistance mechanisms in BRCA2-
deficient breast cancer to PARP inhibition (PARPi), which specifically targets the
HR-deficiency of BRCA-deficient tumors. To do so, we performed in vitro PARPi
resistance screens in BRCA2-deficient mammary tumor cells. Besides this, we also
performed an in vivo analysis by transplanting pieces of BRCA2-deficient mammary
tumors into multiple recipient mice, treating these mice with PARPi until resistance
and subsequently contrasting the sensitive and resistant tumors. Strikingly, both
these analyses identified loss of poly(ADP-ribose) glycohydrolase (PARG) as a major
resistance mechanism. Further characterization showed that depletion of PARG
induces resistance by restoring PAR formation, rescuing controlled DNA replication
fork progression and promoting the recruitment of downstream DNA repair factors.
The potential relevance of PARG in clinical PARPi resistance is underscored by the
presence of PARG-negative clones in a subset of human TNBC and serous ovarian
cancers.
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Finally, in Chapter 8, we reflected on the methods and results presented in this
thesis and how they may be applied or extended in future work. Besides this, we
also consider several technological advances and important challenges that remain
to be addressed in the field.
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A.2 Nederlandse samenvatting
Kanker is een ziekte waarbij normale cellen worden gedereguleerd door verstoring
van hun cellulaire processen, wat resulteert in verhoogde proliferatie, overleving en
invasie van de omringende weefsels. Kanker wordt over het algemeen veroorzaakt
door mutaties in zogenaamde ‘driver-genen’, die cellen een selectief groeivoordeel
geven en hun kwaadaardige transformatie aansturen. Om kankerbehandelingen te
verbeteren, proberen onderzoekers en artsen precies te identificeren welke mutaties
in een bepaalde tumor aanwezig zijn om vervolgens gerichte antikankermedicijnen
toe te passen die op deze mutaties aangrijpen. Eén van de grootste problemen van
deze zogeheten ‘personalized medicine’ strategie is dat het lastig is om te bepalen
welke mutaties de echte ‘drivers’ zijn omdat de meeste tumoren grote aantallen
‘passenger’ mutaties bevatten die niet bijdragen aan de ontwikkeling van de tumor.
Daarnaast worden tumoren vaak resistent na langdurige behandelingen, waardoor
de klinische effectiviteit van veel gerichte antikankermedicijnen beperkt is.
Om deze tekortkomingen te verhelpen, is het cruciaal om (i) precies te bepalen
welke mutaties een rol spelen in de ontwikkeling van bepaalde kankertypes en (ii)
potentiële resistentiemechanismen voor bepaalde therapieën te identificeren. Het
identificeren van driver-genen in humane studies is echter nog steeds een uitdaging
vanwege de grote hoeveelheden potentiële driver-genen die worden geïdentificeerd
in deze studies. Daarnaast wordt de identificatie van alle mogelijke resistentiemech-
anismen bemoeilijkt door lage beschikbaarheid van biopten van tumoren voor en na
behandeling. Modelsystemen zoals muizen bieden verschillende complementaire
benaderingen voor het bestuderen van tumorontwikkeling omdat ze het mogelijk
maken om hernieuwbare modellen te genereren die veel aspecten van verschillende
menselijke kankersoorten bevatten. Deze modellen kunnen vervolgens worden
gebruikt om potentiële driver-genen te testen en verschillende mechanismen van
therapie resistentie te identificeren. Een overzicht van alle verschillende modelsyste-
men en hun toepassingen wordt gegeven in Hoofdstuk 1.
In dit proefschrift hebben we ons voornamelijk gericht op het gebruik van genetisch
gemodificeerde muizen om driver-genen en therapieresistentie-mechanismen te
identificeren in twee verschillende soorten borstkanker: invasief lobulair carcinoom
(ILC) en triple-negatieve borstkanker (TNBC) (Hoofdstuk 2). ILC is een histologisch
subtype van borstkanker dat verantwoordelijk is voor 10-15% van alle gevallen van
borstkanker. ILC wordt gekenmerkt door mutaties in E-cadherine. Hoewel ILCs
over het algemeen verhoogde expressie van ERα vertonen, zijn de overlevingskansen
voor ILC-patiënten doorgaans slechter dan voor patiënten met andere ER-positieve
borsttumoren, wat aangeeft dat biologische verschillen de therapiegevoeligheid beïn-
vloeden. TNBCs zijn verantwoordelijk voor 10-17% van alle gevallen van borstkanker
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en worden gekenmerkt door lage expressie van HER2 en de hormoonreceptoren
ERα en PR. TNBCs kunnen daarom niet worden behandeld met anti-hormonale
therapieën of geneesmiddelen tegen HER2, waardoor chemotherapie nog steeds
de standaardbehandeling vormt. Gecombineerd met de agressieve aard van deze
tumoren resulteert dit in een relatief slechte prognose voor patiënten met TNBC.
Een overeenkomst van ILCs en TNBCs is dat ze minder gunstig reageren op bestaande
therapieën dan andere soorten borstkanker. Het is daarom belangrijk om te onder-
zoeken welke driver-genen de ontwikkeling van deze borstkankersoorten stimuleren,
waardoor het mogelijk wordt om gerichte geneesmiddelen te ontwikkelen die speci-
fiek aangrijpen op kwetsbaarheden die deze driver-genen met zich meebrengen.
In Hoofdstuk 3 hebben wij het Sleeping Beauty (SB) transposon systeem gebruikt om
een insertiemutagenese (IM) screen uit te voeren in een muismodel met borstklier-
specifiek verlies van E-cadherine, teneinde mogelijke driver-genen van ILC te identi-
ficeren. Gezamenlijk verlies van E-cadherine en activering van het SB transposon
systeem leidde in muizen tot ontwikkeling van borsttumoren die leken op menselijke
ILCs, wat de relevantie van ons model ondersteunde. Analyse van de transposon-
inserties in deze tumoren leidde tot de identificatie van verschillende bekende en
nieuwe driver-genen, die mogelijk gebruikt kunnen worden om nieuwe therapieën
te ontwikkelen. Een opvallende ontdekking is dat vier van deze driver-genen (Myh9,
Ppp1r12a, Ppp1r12b en Trp53bp2) vaak voorkwamen maar nooit samen gemuteerd
waren, wat aangeeft dat ze waarschijnlijk een rol spelen in hetzelfde biologische
proces. Verder onderzoek wees uit dat alle vier de genen betrokken zijn bij de
regulatie van het actine cytoskelet in de tumorcellen. Drie van deze genen (MYH9,
PPP1R12B en TP53BP2) zijn ook vaak gemuteerd in borsttumoren bij de mens, wat
aangeeft dat dit nieuwe oncogene proces mogelijk een aangrijpingspunt vormt voor
de ontwikkeling van toekomstige therapieën.
Een van de belangrijkste uitdagingen bij het analyseren van insertiemutagenese
screens is dat de transposon-inserties veel potentiële kankergenen kunnen identi-
ficeren waarvan waarschijnlijk slechts een klein deel daadwerkelijk betrokken is
bij tumorontwikkeling. Bovendien geven de DNA-gebaseerde benaderingen die
vaak worden gebruikt om kandidaat-genen te identificeren, weinig inzicht in hoe
de expressie van genen wordt beïnvloed door de transposon-inserties, waardoor
biologisch inzicht in het effect van inserties wordt beperkt. In Hoofdstuk 4 hebben
wij daarom een nieuwe methode ontwikkeld, genaamd IM-Fusion, die deze proble-
men omzeilt door transposon-inserties te identificeren via detectie van fusies tussen
de transposons en de betrokken genen in RNA-sequencing data. Deze methode
verbetert de detectie van inserties door precies vast te stellen welke genen betrokken
zijn bij een fusie en daarnaast te testen op het effect van de insertie op genexpressie.
Om onze methode te toetsen, hebben we IM-Fusion toegepast op twee bestaande
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RNA-sequencing datasets van tumoren waarvoor ook DNA-sequencing datasets
beschikbaar waren. Onze vergelijking van IM-Fusion met de DNA-gebaseerde inser-
tie analyses liet zien dat IM-Fusion accurater is bij het detecteren van transposon-
inserties en de betrokken genen.
In Hoofdstuk 5 hebben we vervolgens onderzocht hoe BRCA1-gemuteerde TNBC
wordt beïnvloed door de aanwezigheid van verschillende bekende driver-genen
(Myc, Met en Rb1). We hebben gekeken of genetisch gemodificeerde muizen met
deze driver-genen gebruikt kunnen worden om genen te identificeren die collabor-
eren met een specifiek driver-gen in de ontwikkeling van BRCA1-gemuteerde TNBC.
Ons onderzoek liet zien dat tumoren met MYC-overexpressie een compleet ander
mutatieprofiel vertoonden dan andere tumoren, wat aangaf dat de evolutie van
deze tumoren sterk werd beïnvloed door de hoge MYC-activiteit. Door gemuteerde
regio’s in de muizentumoren te vergelijken met de gemuteerde regio’s in TNBCs van
patiënten, ontdekten we MCL1 als een belangrijke driver die specifiek geamplificeerd
is in MYC-gedreven TNBC, wat suggereert dat MCL1 samenwerkt met MYC in de
ontwikkeling van BRCA1-gemuteerde TNBC. Deze hypothese wordt verder onderste-
und door experimenten in een ‘patient-derived tumor xenograft’ muismodel voor
BRCA1-gemuteerde TNBC, die aantoonden dat MCL1 remming de effectiviteit van
de poly(ADP-ribose) polymerase (PARP) remmer olaparib (een remmer die specifiek
aangrijpt op de BRCA1 mutatie in deze tumoren) verhoogt. Dit geeft aan dat de
combinatie van PARP-remmers met MCL1-remmers mogelijk een kansrijke therapie is
voor patiënten met BRCA1-gemuteerde TNBC die niet goed reageren op behandeling
met alleen PARP-remmers.
In de resterende hoofdstukken hebben we ons gericht op het identificeren van
mogelijke resistentiemechanismen voor gerichte behandelingen in ILC en TNBC.
Naar aanleiding van onze insertiemutagenese screen in Hoofdstuk 3, onderzochten
we in Hoofdstuk 6 de effectiviteit van FGFR-remming in ILC, aangezien Fgfr2 vaak
werd geactiveerd door transposon-inserties in de tumoren. Om het effect van FGFR-
remming in deze tumoren te onderzoeken, transplanteerden we tumorfragmenten
van een ILC met geactiveerde FGFR-signalering in meerdere muizen, die vervolgens
werden behandeld met de FGFR-remmer AZD4547. Dit liet zien dat tumoren aan-
vankelijk goed reageerden op de behandeling, maar snel resistent werden tegen de
remmer. Om mogelijke resistentiemechanismen te identificeren, hebben we de ac-
tieve insertiemutagenese in deze tumoren gebruikt om nieuwe transposon-inserties
te identificeren die tijdens de behandeling optraden en mogelijk de waargenomen
resistentie kunnen verklaren. Combinatie van deze insertie-analyse met transcrip-
tomische analyse van dezelfde tumoren leidde tot de identificatie van verschillende
bekende en onbekende resistentiemechanismen. Een belangrijk punt is dat twee
resistentiemechanismen alleen werden geïdentificeerd via de insertie-analyse, wat
308 Appendix A Appendices
aantoont dat insertiemutagenese een effectief hulpmiddel is voor het identificeren
van resistentiemechanismen tegen gerichte behandelingen in muizen.
In Hoofdstuk 7 hebben we onderzocht hoe BRCA2-gemuteerde TNBCs resistentie
ontwikkelen tegen PARP-remmers (PARPi), een nieuwe klasse antikankermedicijnen
die specifiek aangrijpen op de HR-deficiëntie van BRCA-gemuteerde tumoren. Hier-
toe voerden we een tweetal in vitro PARPi-resistentie screens uit in BRCA2-deficiënte
borsttumorcellen. Daarnaast hebben we ook een in vivo analyse uitgevoerd door
tumorfragmenten van BRCA2-deficiënte borsttumoren te transplanteren in meerdere
muizen en deze muizen te behandelen met PARP-remmers, waarna we vervol-
gens de mutaties in PARPi-gevoelige en -resistente tumoren vergeleken. Opvallend
genoeg, identificeerden beide analyses het verlies van poly(ADP-ribose) glycohydro-
lase (PARG) als het belangrijkste PARPi-resistentiemechanisme in BRCA2-deficiënte
borsttumoren. Verdere experimenten toonden aan dat PARG-depletie PAR-vorming
herstelt en daarnaast de progressie van de DNA-replicatievork herstelt en de rekruter-
ing van DNA-reparatiefactoren bevordert. De klinische relevantie van PARG-verlies
als een resistentiemechanisme wordt verder ondersteund door de aanwezigheid van
PARG-negatieve cellen in een subset van humane TNBCs en eierstokkankers.
Ten slotte reflecteerden we in Hoofdstuk 8 op de methoden en resultaten die
in dit proefschrift worden gepresenteerd en hoe deze kunnen worden toegepast
of uitgebreid in toekomstig werk. Daarnaast beschreven we de implicaties van
verschillende technologische ontwikkelingen en belangrijke uitdagingen die nog
resteren voor de toekomst.
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